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POSTER SESSION
2901 
Atrial Fibrillation Therapies
Sunday, March 12, 2006, 9:00 a.m.-12:30 p.m.
Georgia World Congress Center, Hall B1
Presentation Hour: 10:00 a.m.-11:00 a.m.
2901-61 Prospective Randomized Comparison of Empiric 
Versus Targeted Pulmonary Vein Isolation on Atrial 
Fibrillation Control
Sanjay Dixit, Edward Gerstenfeld, David Callans, Joshua Cooper, David Lin, Andrea 
Russo, Vickas Patel, Ralph Verdino, Stephen Kimmel, Sarah Ratcliffe, Henry Hsia, 
Hemal Nayak, Simone Kutler, Erica Zado, Jian-Fang Ren, Francis Marchlinski, 
University of Pennsylvania Health System, Philadelphia, PA, Center for Clinical 
Epidemiology and Biostatistics, Philadelphia, PA
Background: Electrical isolation (EI) of pulmonary veins (PV) has been shown to be an 
effective therapy for atrial ﬁbrillation (AF). Most centers now perform empiric isolation 
of all PVs, however it is unclear if such an extensive ablation strategy is warranted. We 
hypothesized that EI of only arrhythmogenic PVs would be as efﬁcacious as EI of all PVs 
in achieving long-term AF control. 
Methods: Patients (pts) were randomized to undergo their 1st AF ablation procedure by 
targeting either arrhythmogenic or all PVs. We deﬁne arrhythmogenic PVs as initiating AF 
and / or atrial premature complexes spontaneously or with a standardized provocation 
protocol (isoproterenol - ISO, up to 20ug/min, cardioversion of pacing induced AF +/- 
ISO). EI (using 4mm, 8mm, or cool tip) was guided by a circular mapping catheter; the 
endpoint was entry and exit block persisting for ≥30 minutes. Pts were evaluated at 6 
weeks and 6 months with 4-week transtelephonic monitors preceding each visit and CT 
scan was performed at 3 months. Antiarrhythmic drug (AAD) use beyond 6 weeks was 
discouraged but was not required to be eliminated. 
Results: The population included 105 pts (age 57±9 years, 82 males). EI was achieved 
in 99% of all targeted PVs. 
All PVs 
(N=53)
Arrhythmogenic PVs 
(N=52)
AF Duration (months) 62 ± 54 61 ± 53
Paroxysmal AF 41 (77%) 36 (69%)
Veins Isolated / Pt (median) 4 3
Time for EI of PVs (min) 48 ± 27 46 ± 25
Acute Reconnection (≤30 min.) 49 / 185 (26%) 39 / 129 (30%)
Signiﬁcant Adverse Events 2 (4%) 0
Signiﬁcant (>70%) PV Stenosis 0 0
Long-Term AF Control on or off AAD at 6-
month visit 40 (75%) 37 (71%)
Freedom from AF off AAD at 6-month visit 28 (53%) 28 (54%)
p= NS for all comparisons
Conclusion: In a prospective randomized comparison to assess efﬁcacy after a single 
procedure, EI of arrhythmogenic PVs was as efﬁcacious as EI of all PVs in achieving 
control of AF with no signiﬁcant difference in procedure time or complication rates 
between the two techniques.
2901-62 Economic Analysis of Low Molecular Heparin 
Strategy Compared with Unfractionated Heparin 
Strategy for Cardioversion of Atrial Fibrillation Using 
Transesophageal Echocardiography: Results From the 
Acute II Study
Liping Zhao, Paul Kolm, Cheryl Lewis, Susan E. Jasper, Allan L. Klein, William S. 
Weintraub, Emory University, Atlanta, GA, Cleveland Clinic, Cleveland, OH
Background: The “Assessment of Cardioversion Using Transesophageal Echocardiography 
(ACUTE) II study compared use of low molecular heparin (LMWH) with unfractionated heparin 
(UFH) in patients with atrial ﬁbrillation, and showed similar clinical outcomes in the two groups. 
The present study explores the resource use and cost of the two strategies.
Methods: Between Dec.1999 and Dec.2004, 155 patients who were scheduled for TEE- 
guided chemical or electrical cardioversion were randomized to LMWH (n=76) versus 
UFH (n=79), and followed up for 5 weeks. Resources included initial and subsequent 
hospitalizations, outpatient diagnostic procedures and emergency room visits. Costs 
were derived from the UB-92 formulation of hospital bill and the Medicare fee schedule. 
All costs used 2001 as the base year.
Results: Overall, there were no signiﬁcant differences in safety outcomes between 
groups, including ischemic stroke, peripheral embolism, bleeding and death. LMWH 
group had shorter length of stay and more normal sinus rhythm at 5 weeks (p<0.05). 
Costs of initial and subsequent hospitalizations, outpatient procedures and emergency 
room visits were lower for patients randomized to LMWH, although the differences of 
costs for the latter two were not signiﬁcant. Total costs were signiﬁcantly lower for LMWH 
group (see Table).
Conclusion: In patients with AF undergoing TEE- guided cardioversion, use of LMWH as 
bridge therapy is a cost-saving strategy with similar clinical outcomes compared to UFH.
LMWH 
(n=76)
UFH 
(n=79)
Difference (LMWH-
UFH)
95% CI of the 
Difference
Initial hospitalization 
costs $4056.2 $5505.1 $1448.9 $638.0, $2565.8
Subsequent 
hospitalization costs $396.2 $1007.0 $610.8 $68.9, $2013.1
Outpatient procedure 
costs $60.0 $69.1 $9.1 -$8.4, $30.3
Emergency room visit 
costs $12.4 $29.8 $17.4 -$1.7, $45.9
Total costs $4524.8 $6611.0 $2086.2 $1025.8, $3774.2
2901-63 Transcatheter Patch Obliteration of the Left Atrial 
Appendage: Experimental Validation and Early Clinical 
Experience
Eleftherios B. Sideris, Savvas Toumanidis, Stylianos Rokas, Benjamin Macuil, Spyridon 
Moulopoulos, Department of Clinical Therapeutics, Medical School, University of 
Athens, Athens, Greece
Background: The left atrial appendage (LAA) is the most common site of thrombus formation 
in patients with atrial ﬁbrillation (AF). Left atrial appendage obliteration could prevent embolic 
strokes in patients unable to take adequate anti-coagulation. The transcatheter patch (TP) is 
a balloon deliverable device, adjustable for the size and shape of the appendage with simple 
balloon volume changes and unable to perforate since it is wireless.
Methods: The LAA appendage was obliterated by a transcatheter patch in 10 piglets, 
12-15 Kg. The TP was placed in the LAA appendage through the foramen ovale using a 
long sheath. Single balloon/patches without retention disk were used, inﬂated to 10-15 
mm. Preformed clot (PC) was placed on the patch in 6 animals, with the patch released in 
6 hours and surgical adhesive (SA) on the apical portion of the patch in 4, with the patch 
released in 30 minutes. Heparin was only given in the SA group. The procedure was 
performed under ﬂuoroscopy and echocardiography. Follow-up was performed in up to 3 
weeks and autopsied were obtained in all animals.
Five patients with AF and contra-indication to anti-coagulation had their LAA obliterated 
under trans-esophageal guidance and ﬂuoroscopy. The TPs were inﬂated to 18-25 mm 
and released in 30 minutes, using SA.
Results: The LAA was effectively occluded in all animals. All TPs were safely released. 
Follow-up was uneventful and in autopsy the LAA was occluded without thrombus; the 
patch was fully endothelialized in 2 weeks.
All patients had their atrial appendage well occluded and are doing well at the latest 
follow-up, on antiplatelet regiment only.
Conclusions: Transcatheter patch LAA obliteration is effective and safe in animals. Sixty 
minute patch release, using SA, appears safe. Early clinical experience is encouraging 
and larger feasibility studies are justiﬁed.
2901-64 Brain Natriuretic Peptide but Not CRP Predispose 
to Development of Atrial Fibrillation After Coronary 
Bypass Surgery
Nektarios D. Pilatis, Alexandros Anyfantakis, Panagiotis Iakovis, Dimitrios Degiannis, 
Constantinos Limas, Antigoni Haidaroglou, Dimitrios Palatianos, Dennis V. Cokkinos, 
Onassis Cardiac Surgery Center, Athens, Greece
Background: Atrial ﬁbrillation (AF) is recorded in 25-35% of patients (pts) undergoing 
coronary bypass surgery (CABG). Many mechanisms have been proposed for its 
occurrence. Increased diastolic pressure of the left ventricle and left atrium with dilation 
of the pulmonary veins, reﬂected by increased serum levels of brain natriuretic peptide 
(pre-BNP), may play a role, while an infammatory reaction has also been postulated. We 
prospectively investigated the association of pre-BNP and CRP with the development of 
postoperative (postop) AF. 
Methods: We assessed the clinical and laboratory variables of 140 pts (aged 66±9 years, 
131 men) undergoing CABG and measured pre-BNP and CRP levels preoperatively 
(preop) and 24 hours postop. Postop AF was deﬁned as the presence of this arrhythmia 
for 60 min or longer, requiring treatment. 
Results: Fifty two pts (37%) developed AF postop. They were older (68±8 vs 64±10, 
p=0.03) and received less frequently beta-blockers (57% vs 85%, p=0.001) than the 
nonAF pts. Preop pre-BNP levels were elevated in pts who developed postop AF (717 
pg/ml with 95%CI 430-1004 vs 393 pg/ml with 95%CI 328-459, p=0.011). Postop pre-
BNP levels were also signiﬁcantly higher than preop levels in both groups (980 pg/ml with 
95%CI 605-1355 in AF pts vs 727 pg/ml with 95%CI 588-866 in non-AF pts, p<0.001 for 
preop vs postop levels) and there was a strong trend of postop levels to be higher in AF 
pts (p=0.054 for postop levels between AF and non-AF). Pts in the highest quartile of pre-
BNP levels developed the arrhythmia more frequently than those in the lowest quartile 
(49% vs26%, p=0.048). Pre - and postop CRP levels were not associated with AF. 
Conclusions: Elevated serum levels of pre-BNP, signifying an increased diastolic 
pressure of the left ventricle and left atrium in the preop and postop period are associated 
with the development of post-CABG AF, while inﬂammation does not seem to play a role.
2901-65 New Transseptal Catheter Allows Left Atrial Access 
From any Venous Approach
Saibal Kar, Aamer H. Jamali, James Whiting, Brian Mann, Werner Hafelﬁnger, Neal 
Eigler, Cedars-Sinai Medical Center, Los Angeles, CA
Background: The development of newer interventional and electrophysiological 
procedures in the left heart mandates the need for safer and more ﬂexible transseptal 
catheterization systems. The traditional Brockenborough technique using a stiff trans-
septal needle has its limitations-it can only be done via the right femoral vein, and is often 
difﬁcult in patients with a distorted or enlarged atria.
Methods: The LaCross™ system (Savacor, Inc.) consists of an 8F Stabilizer Sheath that 
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spans the right atrium via both vena cavae. There is a window in the middle of its shaft. A 
curved tip guiding catheter contains an inner catheter with a ﬂexible and torquable shaft 
and a distal needle with exterior screw threads. These catheters are inserted into the 
Stabilizer exiting through the window in the right atrium. The system is directed towards 
the septum with ﬂuoroscopy or echocardiography. The septum is crossed by torquing the 
screw, and a stiff wire is advanced into the left atrium (LA). (ﬁg 1)
Results: Transseptal catheterization was performed in 9 dogs and 2 farm pigs via the 
left jugular vein. Access to the left atrium was successful via the left jugular vein in all 
11 animals. There were no complications. Once access was achieved in the LA, a larger 
sheath could be introduced over the stiff wire into the LA in all cases.
Conclusions: This new transseptal access system can be inserted via any tortuous 
central venous route. Early human testing results will be presented.
POSTER SESSION
2902 
Drug Eluting Stents: Mechanism Subset 
of Lesions IVUS
Sunday, March 12, 2006, 9:00 a.m.-12:30 p.m.
Georgia World Congress Center, Hall B1
Presentation Hour: 10:00 a.m.-11:00 a.m.
2902-66 Impact of Final Stent Dimensions on Long-Term Stent 
Patency Following ABT-578 Eluting Phosphorylcholine 
Coated Cobalt Chromium Alloy Stent Implantation: A 
Serial 3-D IVUS Study
Seung-Ho Hur, Akiyoshi Miyazawa, Ryota Sakurai, Masao Yamasaki, Yoichiro Hongo, 
William Wijns, Jean Fajadet, Martin B. Leon, David E. Kandzari, Paul G. Yock, Peter J. 
Fitzgerald, Yasuhiro Honda, Stanford University, Stanford, CA
Background: Stent underexpansion remains an important risk factor of restenosis 
following drug-eluting stent (DES) implantation. On the other hand, aggressive stent 
dilatation may result in increased vessel injury or procedural complications. The aim of 
this study was to assess the predictive minimum IVUS threshold of MSA for long-term 
stent patency following ABT-578 eluting, phosphorylcholine-coated, cobalt-chrominum 
alloy Driver™ stents (AES). 
Methods: From the ENDEVAVOR 2 and 3 trials, 210 AES with available serial (baseline 
and 8-month follow-up) IVUS examinations were analyzed. Baseline MSA and follow-
up minimum lumen area (MLA) were determined by 3-D IVUS analysis. According to 
previous physiological studies, long-term stent patency was deﬁned as MLA ≥3.0 mm2 
at follow-up. 
Results: Overall, neointimal volume index (volume/length) and %neointimal volume were 
1.26±0.87 mm3/mm and 17.2%, respectively. Follow-up MLA had a signiﬁcant positive 
correlation with baseline MSA (r=0.73, p<0.0001). The minimum IVUS threshold of 
baseline MSA for long-term stent patency was 6.0 mm2, determined based on the slope 
of the statistical curve between baseline MSA and follow-up stent patency rates (ﬁgure). 
Conclusions: In this statistical model, initial stent expansion accounted for up to 85% of 
AES patency at 8 months. Stent underexpansion should be avoided since smaller MSA 
below 6.0 mm2 can be associated with a steep decrease in follow-up AES patency.
2902-67 Nonuniform Strut Distribution Is Associated With More 
Neointimal Hyperplasia After ABT-578 Eluting Stent 
Implantation: A 3-D IVUS Analysis From the ENDEAVOR 
2 Trial
Takao Haasegawa, Katsuhisa Waseda, Junya Ako, Ryota Sakuirai, Yoichiro Hongo, 
William Wijns, Paul G. Yock, Yasuhiro Honda, Peter J. Fitzgerald, Stanford University, 
stanford, CA
Background: Differential local drug concentration due to nonuniform strut distribution 
(SD) may affect neointimal hyperplasia (NIH) following drug-eluting stent implantation. 
The aim of this study was to assess the impact of nonuniform SD on NIH in patients 
receiving ABT-578 eluting open-cell stents (AES).
Methods: In ENDEAVOR 2, 8-month 3-D IVUS was available in 85 de novo coronary 
lesions treated with single AES. On a cross-sectional image, nonuniform SD was deﬁned 
as interstrut angle (IA) >90° with a protractor centered on the stent. Volume index (volume/
length) was calculated for stent, lumen and neointima. % neointimal volume (NIV) was 
deﬁned as neointima/stent volume (%).
Results: Nonuniform SD was observed in 36% of patients. On a patient based analysis, 
patients with nonuniform SD showed a larger stent volume index (8.8±1.9 vs 7.3±1.9; 
p<0.001), NIV index (1.8±0.8 vs 1.1±0.7; p<0.001) and %NIV (21.1±10.4 vs 16.0±9.5; 
p=0.02) than patients with uniform SD. In the nonuniform SD patients, a segment based 
analysis showed similar results between the nonuniform vs uniform SD segments (table). 
Among the nonuniform SD segments, 79.5% of the maximum NI thickness biased toward 
the largest IA side.
Conclusions: Nonuniform SD can occur in more than one-third of open-cell stent 
implantations, and may be associated with less neointimal suppression following AES. 
These results may have an implication for the pharmacological and mechanical properties 
required for future drug-eluting stent designs.
Nonuniform SD patients Uniform SD 
patients p-valueNonuniform SD 
segments
Uniform SD 
segments
Stent volume index, 
mm3/mm 9.0±2.2* 8.6±1.8 7.3±1.9 <0.001
Lumen volume index, 
mm3/mm 6.6±2.0* 6.9±1.9 6.0±1.7 0.11
NIV index, mm3/mm 2.4±1.0† 1.8±0.8 1.1±0.7 <0.0001
%NIV, % 27.6±11.9† 20.5±10.5 16.0±9.5 0.04
*p=0.02, †p<0.0001 (Nonuniform SD segments vs Uniform SD segments)
2902-68 Procedural Results and Clinical Outcomes After Full 
Metal Jacket Drug-eluting Stent Implantation in Single 
Coronary Artery
Sundeep Mishra, Roswitha M. Wolfram, William W. Chu, Natalie Gevorkian, Zhenyi Xue, 
Rebecca Torguson, Augustus D. Pichard, Lowell F. Satler, William Suddath, Kenneth 
Kent, Ron Waksman, Washington Hospital Center, Washington, DC
Background: Lesion length and bare metal stent length correlates with higher incidences 
of major adverse cardiac events (MACE). The purpose of this study was to determine 
clinical outcome after full metal jacket (FMJ) of drug-eluting stent (DES) implantation in 
a single coronary artery.
Methods: We evaluated data of 99 consecutive patients treated with FMJ DES 
implantation deﬁned as ≥50 mm stented length (mean 63.3±13.2 mm, range 50-115mm) 
and a concurrent series of 466 patients with ≤24 mm DES length (mean18.4±3.8 mm, 
range 8-24 mm). Periprocedural, 1-, and 6-month clinical outcomes were compared 
between groups.
Results:Baseline clinical characteristics were mostly comparable between the groups. 
Procedural and in-hospital outcomes, including creatinine kinase-MB fraction (CK-MB) 
release were similar. Although the incidences of death and myocardial infarction (MI) at 
30 days and 6 months were comparable between groups, the combined end points of 
target lesion revascularization (TLR)-MACE at 6 months occurred more often in patients 
receiving ≥50 mm stent (Table). After adjusting for confounding factors in a multivariate 
model, only stent length was found to be a predictor of TLR-MACE.
Conclusions: FMJ DES implantation in diffuse coronary arteries is feasible and safe but 
stent length continues to correlate with higher revascularization rates.
Clinical Outcomes
Events ≥50mm (n=99 ) ≤ 24mm (n=466) p Value
In-hospital non Q-wave MI, n (%) 18 (18.6) 66 (14.5) 0.31
Death, n (%) at 30 days 1 (1.1) 5 (1.3) 1.00
Q- MI, n (%) at 30 days 1 (1.1) 2 (0.5) 0.46
TLR-MACE, n (%) at 30 days 5 (5.7) 7 (1.8) 0.05
Stent thrombosis, n (%) at 30 days 1 (1.0) 5 (1.1) 1.00
Death, n (%) at 6 months 3 (4.0) 10 (2.8) 0.48
Q-wave MI, n (%) at 6 months 2 (2.7) 3 (0.8) 0.21
TLR, n (%) at 6 months 5 (6.7) 5 (1.4) 0.02
TLR-MACE, n (%) at 6 months 9 (12.0) 18 (5.0) 0.03
 
2902-69 The Relation of High Ex Vivo Thrombogenic Potential 
to High Ischemic Risk in African American Women 
Undergoing Coronary Stenting
Kittane S. Vishnupriya, Kevin P. Bliden, Rolf P. Kreutz, Udaya S. Tantry, Paul A. Gurbel, 
Sinai Center for Thrombosis Research, Baltimore, MD
Background: We hypothesized that a high thrombogenic potential may contribute 
to the increased risk of post-PCI ischemic events reported in African Americans. 
Thrombelastography (TEG) is a point of care device that measures thrombogenic 
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potential by assessing platelet function, time to ﬁbrin generation, and maximum thrombin-
induced clot strength.
Methods: TEG was performed prior to anticoagulation in 240 consecutive patients 
undergoing elective PCI. Patients were followed for 6 months for the occurrence of 
ischemic events.
Results: African American (AA) patients had a higher thrombogenic index than 
Caucasian (C) patients (p=0.001) (Table). AA women had the highest thrombogenic index 
among all groups (p<0.001) and had the greatest clot strength (p < 0.0001). Ischemic 
events occurred most frequently in AA women [12/32 (38%)] vs. Caucasian women [11/60 
(18%), p = .04] and less commonly in C and AA men [15/132 (11%) and 2/31 (7%), 
respectively]. Multivariate analysis conﬁrmed the independent predictive value of these 
measurements.
Conclusions: Thrombogenic potential is inﬂuenced by ethnicity and gender. African 
American women exhibit the highest thrombogenic indices that strongly correlate with 
the greatest occurrence of ischemic events post-PCI. Identiﬁcation of thrombogenic 
potential as a new cardiovascular risk factor may lead to targeted and more intensiﬁed 
antithrombotic therapy in speciﬁc patients.
Thrombogenic Indices
AA C
Female 
(n=32)
Male 
(n=31) Total
Female 
(n=60)
Male 
(n=132) Total
P-value (AA 
vs.C)
Maximum Clot Strength 
(MA,mm) 73.5+/-4.9
66.6 
+/- 7.1
70 
+/-7.0 67.6+/-6.3
66.5+/-
6.4
66.9+/-
6.4 0.001
Time to Fibrin 
Generation (R, min.) 4.1+/-1.1
4.5+/-
1.5
4.3+/-
1.4 5.0+/-1.9 5.0+/-1.9 5.0+/- 0.01
Thrombogenic Index 
(relative Units) 3.7+/-1.4
2.3+/-
2.1 3+/-2 2.0 +/-2.6 1.8+/-2.4
1.9+/-
2.5 0.001
2902-70 Longitudinal Distribution of Neointimal Hyperplasia 
Within ABT-578 Eluting Phosphorylcholine-Coated 
Stents in De Novo Coronary Lesions
Ryota Sakurai, Yoichiro Hongo, William Wijns, Jean Fajadet, Richard E. Kuntz, Donald 
Cutlip, Jeffrey J. Popma, Peter Zimetbaum, Paul G. Yock, Peter J. Fitzgerald, Yasuhiro 
Honda, The ENDEAVOR 2 Trial Investigators, Stanford University, Stanford, CA
Background: Various distribution patterns of neointimal hyperplasia (NIH) have been 
reported with different types of drug-eluting stents. The aim of this study was to clarify the 
longitudinal NIH distribution within ABT-578 eluting, phosphorylcholine-coated, cobalt-
chromium alloy DriverTM stents (AES), compared to bare metal stents (BMS).
Methods: From 8-month 3-D intravascular ultrasound images in ENDEAVOR 2 (a 
prospective, multicenter, randomized trial comparing AES to BMS in de novo coronary 
lesions), 94 cases treated with a single 18-mm stent (AES 55; BMS 39) were enrolled. 
%NIH volume (%NIV) was deﬁned as NIH volume / stent volume x 100. The longitudinal 
NIH distribution was evaluated by comparing 18 subsegments (each 1 mm in length) over 
the stented segment.
Results: Overall, stent volume was not signiﬁcantly different between the 2 stent groups, 
and %NIV within the entire stent was signiﬁcantly less in AES than BMS (15.8±8.0 vs 
29.7±17.8%, p<0.0001). AES showed evenly inhibited %NIV at each subsegment (43-
56%) compared to the corresponding subsegment in BMS (p<0.001 for each). Both stents 
showed signiﬁcantly less %NIV in both proximal and distal stent segments than in the mid 
segments (p<0.001).
Conclusion: Compared to BMS, AES showed no predilection of NIH inhibition for location 
along the stented segment, having a similar NIH distribution pattern (diffuse but less NIH 
in both edges). This unique distribution pattern may play an important role in the safety as 
well as the effectiveness of AES.
2902-71 Delayed Strut Fracture of Sirolimus-eluting Stent 
(cypher®) and Related Restenosis: A Signiﬁcant 
Problem or an Occasional Observation?
Young Won Yoon, Bum-Kee Hong, Hyuck Moon Kwon, Se-Joong Lim, Sung-Ju Lee, 
Sung Woo Kwon, Jong Kwan Park, Jihyuck Rhee, Hyun-Seung Kim, Yongdong 
Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea
Background: In-stent restenosis after implantation of sirolimus-eluting stents (Cypher®) 
still occur in some cases and delayed stent strut fracture was recently suggested as a new 
potential mechanism. Bx Velocity® stent (Cordis), the platform of Cypher® stent was one 
of the popular stents in the past bare-metal stent era, but there was no reported delayed 
strut fracture so far. We experienced 14 delayed strut fracture cases of Cypher® stent at 
routine follow up coronary angiography and carefully reviewed each case.
Methods & Results: Mean age of the patients was 61.8±8.4 year and 9/14 cases were 
male patients. 11 cases showed complete strut disruption and the remaining 3 cases 
showed partial strut fracture conﬁrmed with IVUS. The mean length of the stent was 
29.4±4.9 mm and the mean diameter was 2.91 ± 0.16 mm. 9 cases (65%) were located at 
mid-LAD portion, 1 case was at prox-LCX portion and remaining 4 cases (28%) were at 
mid-RCA portion. The fractured sites were at the mid portion of the stents in all cases and 
12 cases (85.7%) were located angulated portion of coronary artery. The average inﬂation 
pressure was 12.6±1.2 atm and no adjuvant ballooning was performed in all cases. 6 
cases (43%) revealed focal angiographic restenosis just at the stent fracture site and TLR 
was performed in 5 cases (36%).
Conclusions: In our experience, long stent length and stenting at angulated portion 
showed increased tendency of delayed strut fracture. Although, the data regarding Cypher® 
stent fracture is limited so far and its exact mechanism is unknown, physicians should 
raise their consideration and further investigation should be performed in the future. The 
tendency to perform long stenting in DES era and structural stent characteristics alteration 
by drug carrier vehicle can be the possible mechanisms of Cypher® stent fracture.
2902-72 The Effects of a Diffusion Barrier on the Elution 
Characteristics of ABT-578 Via a Phosphorylcholine 
Matrix
Andrew J. Carter, Anastasia Brodeur, Erin Hasting, Lori Gibson, Robin Collingwood, 
Sarah Ross, Mark Johnson, Robert J. Melder, Borgess Medical Center, Kalamazoo, MI, 
Medtronic Vascular, Santa Rosa, CA
Background: Phosphorylcholine (PC) is used as a matrix for stent-based delivery of 
pharmaceutical compounds. The purpose of this study was to determine the effects of a 
PC diffusion barrier on the pharamacokinetics of drug elution from a strut-based coating 
of PC and ABT-578.
Methods: Balloon expandable cobalt alloy stents (Driver™, Medtronic Vascular) were 
coated with a thin layer of PC and ABT-578 (10 µg/mm) then a topcoat of PC varying 
thickness by weight from 15 to 200 µg per stent. One hundred seventy four ABT-578 
eluting stents with 15 µg topcoat (n = 90), 100 µg topcoat (n = 40) and 200 µg topcoat 
(n = 44) were implanted in the coronary arteries of 97 swine. Arterial tissue and stent 
pharmacokinetics were determined by HPLC analysis of drug content from samples 
obtained at various intervals between 0.5 to 28-days.
Results: The mean arterial ABT-578 tissue concentration (ng/mg) peaked at 1-day (25.92 
± 16.95) then gradually declined to 13.19 ± 7.87 at 7-days and 1.18 ± 0.64 at 28-days for 
the stents with 15 µg PC topcoat. Residual drug content on 6 of 6 (100%) of the 15 µg 
PC topcoat ABT-578 eluting stents was less than 5% of the initial drug load at 7-days as 
compared with 3 of 6 (50%) of the 100 µg and 0 of 6 of the 200 µg PC topcoat ABT-578 
eluting stents (p = 0.0025). The presence of a PC diffusion barrier delayed the time to 
drug depletion following a non-linear model of release kinetics (r2 ≥ 0.93, p ≤ 0.0001). 
The time to ≥ 95% drug depletion was extended from 7-days for 15 µg topcoat (mean 
residual 2.22 ± 1.86 %) to 14-days with the 200 µg topcoat (mean residual 4.07 ± 1.91%, 
p = 0.0004).
Conclusion: Phosphorylcholine serves as a suitable matrix for stent-based delivery of 
ABT-578. The elution of this lipophilic compound from a phosphorylcholine matrix is only 
modestly prolonged by the addition of a diffusion barrier.
2902-73 Determinants of Incomplete Neointimal Coverage 
Following Stenting in the Drug-eluting Stent Era: 
Intravascular Ultrasound And Angioscopic Study
Fusako Oshima, Jun-ichi Kotani, Masaki Awata, Shinsuke Nanto, Masaaki Uematsu, 
Takakazu Morozumi, Toshinari Onishi, Osamu Iida, Noriaki Ito, Hitoshi Minamiguchi, 
Kunihiro Akahori, Seiki Nagata, Kansai Rosai Hospital, Amagasaki, Japan
Background: Lack of neointimal coverage after stenting may result in poor outcomes. 
However, the determinants of the degree of neointimal coverage are poorly understood. 
Methods: To explore the determinants of neointimal coverage, we evaluated 62 stents 
(48 bare-metal stents, BMS; 14 sirolimus-eluting stents, SES) using angioscopy and 
intravascular ultrasound (IVUS) at follow-up (6±3 months). The degree of neointimal 
coverage was angioscopically classiﬁed to the two groups: (1) stent struts were completely 
embedded and invisible (complete coverage); (2) stent struts were not completely 
embedded and thus were visible (incomplete coverage). Following IVUS parameters were 
assessed: minimal stent area (MSA); % stent expansion (100 x MSA / external elastic 
membrane area at reference segment); and apposition between the stent and the vessel 
wall. Stent expansion≤40% was considered underexpansion. 
Results: Thirty-four complete and 28 incomplete coverage were identiﬁed. 
Underexpansion was seen in 48%, and all incomplete apposition (14%) was observed 
at the stent edge. The background demographics were similar in complete/incomplete 
coverage groups (age, gender, risk factors, vessel location, stent diameter and stent 
length) except for the stenting in the infract related artery (14% in incomplete versus 
44% in complete, P=0.0138) and the use of SES (43% in incomplete versus 6% in 
complete, P=0.0007). Underexpansion and incomplete apposition were more frequent 
in the incomplete coverage than in the complete coverage (85% versus 18%, P=0.0006; 
25% versus 0%, P=0.0161, respectively). Multivariate analysis showed SES implantation 
(coef.=0.53) and underexpansion (coef.=0.41) were strongly correlated with incomplete 
neointimal coverage after stenting (P=0.0001). 
Conclusion: Use of sirolimus-eluting stent and underexpansion of the stent were strongly 
associated with incomplete neointimal coverage after stenting. Interestingly, these 
determinants are compatible with the predictors of SES thrombosis previously reported.
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2902-74 Late and Very Late Stent Thrombosis in Patients With 
Drug-Eluting Stents
Peter Wenaweser, Cyrill Morger, Stephane Cook, Mario Togni, Michael Billinger, Bernhard 
Meier, Otto M. Hess, Stephan Windecker, University Hospital, Bern, Switzerland
Background: The phenomenon of late stent thrombosis (ST) has been encountered in 
the era of drug-eluting stents (DES). The purpose of the present study was to determine 
the incidence of late (>30 days) and very late (>1 year) ST in patients treated either with a 
sirolimus-eluting (SES, Cypher®) or a paclitaxel-eluting (PES, TAXUS®) stent.
Methods and Results: Between October 2002 and June 2005 a total of 3376 
consecutive patients (pts.) were treated with a DES (SES: n=2008, PES: n=1368). The 
overall incidence of ST in this period of time consisted of 1.5% (n=52: 33 early, 63.5%; 19 
late, 36.5%) angiographically proven ST after a median of 9 days (range 1 - 941). There 
was a trend to a lower incidence of ST overall in SES pts. (n=26, 1.3%) compared with 
PES pts. (n=26, 1.9%, p=0.16). The relative rate of early and late ST was comparable 
within the two DES groups: SES: 65% vs. 35%, PES: 62% vs. 38%, ns). Of the 19 late ST 
(SES n= 9, PES n=10), 9 occurred very late (47%) with a higher relative rate in SES than 
in PES (n=7, 27% vs. n=2, 8%, p=0.07). At the time of ST, 85% of pts. with early ST were 
on dual antiplatelet therapy, whereas only 58% with late ST (p=0.03). In pts. with very late 
ST, 2 had stopped any antiplatelet treatment, 4 took aspirin alone, and 3 were on dual 
antiplatelet therapy with aspirin and clopidogrel.
Clinical and procedural data at time of drug-eluting stent implantation were compared 
between pts. with early versus late ST and showed no signiﬁcant difference: acute 
coronary syndrome (70 vs. 79%, ns), multivessel disease (61 vs. 68%, ns), use of a 
GPIIb/IIIa inhibitor (44 vs. 17%, p=0.06), pre-treatment with clopidogrel (49 vs. 56%, ns), 
left ventricular ejection fraction (51 vs. 55%, ns), number of stent (1.27 vs. 1.33, ns), 
total stent length (22.1. vs. 22.9mm, ns), stent diameter (both 2.9 vs. 3.0mm) and stent 
implantation pressure (15.3 vs. 14.8bar, ns).
Conclusions: Stent thrombosis occurred in 1.5% of 3376 patients with DES. There was a 
trend to a higher overall incidence of ST in PES, and in contrast a trend to a higher relative 
rate of very late ST in SES. Very late ST occurred in most of the cases under single or 
dual antiplatelet therapy.
2902-75 Drug-eluting Stents for Elective Treatment of Left Main 
Lesions: Are the Results Different in High-Risk Patients 
for Cardiac Surgery: A Report From a Multicenter Registry
Philippe Garot, Thierry Lefèvre, Yves Louvard, Marc Silvestri, Olivier Darremont, Pierre 
Dumas, Marie-Claude Morice, Institut Cardiovasculaire Paris Sud, Quincy, France
Background : Left main stenting using DES has emerged as an alternative to cardiac 
surgery. However, whether the results of left main stenting using DES are different in 
high-risk patients for cardiac surgery is unknown.
Objectives : We sought to compare the results of DES for the treatment of left main lesions 
in high- (Euroscore≥6) vs. low-risk (Euroscore<6) patients for cardiac surgery.
Methods and results : A total of 316 patients treated by DES for unprotected left main 
lesion entered the present registry. Seventeen (n=17) additional patients were excluded 
from the present analysis because they presented with acute MI and/or shock. The clinical 
and procedural characteristics are described. 
Low-risk
Euroscore <6
N=197
High-risk
Euroscore≥6
N= 119
P
Euroscore 2.8±1.7 8.1±2.7 <0.0001
Estimated mortality rate by Euroscore 2.3±1.2% 12.9±14.3% <0.0001
Males 82% 66% 0.001
Age, y-o 64±10 77±7 <0.0001
Unstable angina 28% 46% 0.0001
Post-MI 4% 13% <0.001
Ejection fraction 64±9% 55±15% <0.0001
Distal left main stenting 79% 75% NS
Provisional T stenting 69% 75% NS
Final kissing PCI 77% 66% NS
PCI success, N (%) 99% 99% NS
Non Q-wave MI 3% 3% NS
Q-wave MI 0% 0% NS
In-hospital MACE 4% 5% NS
In-hospital death 1% 1% NS
6 Mo MACCE 11% 16% NS
6-Mo TVR 5% 5% NS
6-Mo death 3% 6% <0.05
6-Mo cardiac death 3% 4% NS
Conclusion : In-hospital outcome is similar in both low and high-risk patients for cardiac 
surgery electively treated by DES for unprotected left main lesion. At 6-month, the rate of 
death is higher in high-risk patients for cardiac surgery (but not the rate of cardiac death) 
reﬂecting worse baseline characteristics.
2902-76 Clinical Outcomes Following Percutaneous Coronary 
Intervention With Drug-eluting Stents in Octogenarians
Salah-Eddine Hassani, Roswitha Wolfram, Zhenyi Xue, Augusto Pichard, Neil 
J. Weissman, William O. Suddath, Lowell Satler, Kenneth Kent, Ron Waksman, 
Washington Hospital Center, Washington, DC
Background: The elderly population is at higher risk for percutaneous coronary 
intervention (PCI). We aimed to compare clinical outcomes of octogenarians versus 
patients <80 years after coronary drug-eluting stent (DES) implantation.
Methods: In-hospital, 30-day, and 6-month clinical outcomes were compared between 
339 octogenarians (84.4±4.8 yrs) and 2827 patients <80 years of age (62±10.2 yrs) after 
PCI with DES.
Results: Baseline characteristics revealed a higher prevalence of female gender 
(p<0.001), Caucasians (p=0.004), chronic renal failure (p<.001), heart failure (p<.001) 
and low ejection fraction (p=0.03) in the octogenarians. Patients <80 years of age were 
more likely to have a positive family history (p<.001), hyperlipidemia (p=0.006), smoking 
history, and obesity (p<.001, respectively). In-hospital outcomes were comparable for 
death, MI, and repeat revascularization, yet octogenarians had more acute renal failure 
(p=0.002) and hematoma (p=0.003). Outcomes at 6 months are in the Table. Multivariate 
analysis revealed cardiogenic shock, age, ST-MI at admission, and length of stay to be 
independent predictors of mortality at 6 months.
Conclusions: DES implantation in octogenarians is clinically safe and associated with a 
low rate of in-hospital events and TLR at 6 months. Octogenarians with acute coronary 
syndrome at presentation, however, do have a higher mortality risk due to their multiple 
co-morbidities.
Stable Angina Acute Coronary Syndrome
Events at 6-month 
(%)
Age ≥ 
80 y
Age < 
80 y p Value
Age ≥ 
80 y
Age < 
80 y p Value
Death 2(4.1) 9(1.5) 0.20 22(15) 39(3) <0.001
Q-wave MI 1(2) 7(1.2) 0.47 8(5) 12(1) <0.001
TLR 1(2) 16(3) - 2(1.3) 31(3) 0.62
TLR-MACE 4(8) 34(6) 0.52 25(17) 85(8) <0.001
 
2902-77 Safety and Efﬁcacy of Drug-eluting Stents for 
Percutaneous Revascularization of Internal Mammary 
Artery Grafts
Ashesh N. Buch, Natalie Gevorkian, Zhenyi Xue, Rebecca Torguson, Jana Founadjieva, 
Regina Deible, Lowell F. Satler, Kenneth M. Kent, Augusto D. Pichard, Ron Waksman, 
Washington Hospital Center, Washington, DC
Background: Drug-eluting stents (DES) reduce the need for repeat revascularization in 
native coronaries and vein grafts. This study examined the safety and efﬁcacy of DES for 
the treatment of lesions in the internal mammary artery (IMA) conduits and compares 
them with bare metal stents (BMS).
Methods: The records of 69 patients who underwent stenting of the IMA from 2001-2004 
were reviewed and analyzed. Of these, 30 patients were treated with DES (sirolimus - or 
paclitaxel-eluting stents) and 39 patients with BMS. The in-hospital and 6-month clinical 
outcomes were recorded and compared.
Results: Baseline characteristics were comparable between the two groups. Lesion 
location and characteristics were also similar except for a trend toward longer stent 
lengths and smaller diameters in the DES group. There was no late thrombosis in either 
group. The in-hospital, 1- and 6-month outcomes were similar. (Table) 
Parameter, %(n) BMS (n=39) DES (n=30) p value
Clinical characteristics
Unstable angina 63 (25) 60 (18) 0.814
Diabetes mellitus 42 (16) 53 (16) 0.397
Lesion Location
Ostium 15 (6) 10 (3) 0.72
Shaft 35 (14) 20 (6) 0.19
Anastomosis 50 (20) 70 (21) 0.14
Stent length 14.8 ± 3.5 20.2 ± 7.7 0.255
Stent diameter 2.7 ± 0.25 2.7 ± 0.22 0.935
6-month outcomes
Death 5.1 (2) 6.7 (2) 1.0
Q wave MI 0 3.3 (1) 0.43
Non-Q wave MI 5.1 (2) 1.3 (4) 0.39
TLR 10.26 (4) 3.33 (1) 0.38
TLR-MACE 15.38 (6) 10 (3) 0.72
Conclusions: DES implantation in IMA appears safe and associated with low rates of 
recurrences and comparable outcomes to BMS.
2902-78 Paclitaxel-eluting Stent Implantation (Taxus) Compared 
With Maximally Optimized Intracoronary β-irradiation 
Using a Rhenium-188 Filled Balloon Catheter for 
Treatment of In-stent Restenoses
Jochen Wöhrle, Thorsten Nusser, Matthias Kochs, Sven Reske, Vinzenz Hombach, 
Bernd Krause, University of Ulm, Ulm, Germany
Background: We compared the efﬁcacy of paclitaxel-eluting (Taxus, BostonScientiﬁc) stent 
implantation with maximally optimized rhenium-brachytherapy for treatment of in-stent 
restenosis in native coronary arteries. Optimization of rhenium brachytherapy included 
a dose increase to 30Gy in 0.5mm tissue depth and a prolongation of the irradiated 
segment which exceeded the traumatized segment by 7.5mm on both sides.
Methods: We included 100 patients with in-stent restenosis in a native coronary artery, 50 
patients in each group. Patients were included during the same study period. Combined 
antiplatelet therapy was given for 12 months. Patients were scheduled for angiographic 6 
months` follow-up. We separately analyzed the target lesion, the proximal and distal 5mm 
segment as well as the total segment.
Results: Diabetes mellitus was present in the Taxus-group (T) in 33% and in the 
Rhenium group (R) in 23%. Lesion length was T/R 11.6±5.1/14.9±6.4mm. Irradiation 
dose was successfully applied in 3.8±2.9 fractions. Maximal inﬂation pressure was 
T/R 17.6±2.6/16.6±2.7atm. At the target lesion reference diameter pre PCI was 
T/R 2.76±0.52/2.60±0.56mm, MLD was pre T/R 0.51±0.22/0.59±0.31mm , post 
2.70±0.40/1.92±0.42mm (p<0.001) and at follow-up 2.48±0.71/1.80±0.72mm (p<0.002). 
Late loss and late loss index at the target lesion were for T/R 0.22±0.53/0.12±0.49mm 
and 0.11±0.31/0.10±0.41, and at the total segment T/R 0.22±0.53/0.16±0.50mm 
and 0.11±0.31/0.14±0.44, respectively. Late loss of the proximal segment was 
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0.23±0.66/0.11±0.36mm and of the distal segment T/R -0.07±0.39/0.04±0.47mm. 
Diameter stenosis at the target lesion was T/R pre 80.9±6.6/77.3±11.2%, post 
13.6±9.3/28.1±8.9% (p<0.001) and at follow-up 17.6±20.4/36.6±20.8% (p<0.002). Binary 
restenosis rate for the total vessel was T/R 8.7%/20.0%.
Conclusions: Late loss and late loss index were statistically not different between both 
groups. Nevertheless, paclitaxel-eluting stent implantation provides a signiﬁcant larger 
acute gain and therefore a lower binary restenosis rate for the total vessel segment 
including edge effects compared with maximally optimized rhenium-188 brachytherapy.
2902-79 The Changing Proﬁle of Patients and Lesions 
Undergoing Percutaneous Coronary Intervention: 
Before and After the Introduction of Drug-eluting Stents
Abdul M. Sheikh, Ziyad Ghazzal, John S. Douglas, Henry A. Liberman, Viola Vaccarino, 
Emir Veledar, Emory University School of Medicine, Atlanta, GA
Background: This study seeks to examine the changing proﬁle in patients and lesions 
undergoing percutaneous coronary intervention (PCI) over the past six years and 
compares the eras before and after the introduction of drug-eluting stents (DES).
Methods: From 1999 to 2005, 10, 929 patients and 17, 290 lesions were treated at 
Emory University. Patients were divided into two groups: those treated before the routine 
use of DES (1999-2002) and after the routine use of DES (2003-2005).
Results: We observed no statistically signiﬁcant change in the mean patient age (62.8 
vs. 63 years, p=NS) and proportion of males (70.2% vs. 69.4%, p=NS) between the two 
time periods. The prevalence of hyperlipidemia, renal failure, and chronic obstructive lung 
disease was also similar. However, more diabetics (28.3% vs. 32.2%, p=0.002) and patients 
with hypertension (70.4% vs. 78.1%, p=0.0001) underwent PCI after the routine use of 
DES. Angiographically, a signiﬁcantly higher percentage of lesions longer than 20 mm 
had PCI attempted after the introduction of DES than before (18.9% vs. 9.6%, p=0.0001). 
Similarly, after the introduction of DES compared with before, more PCIs were attempted in 
vessels smaller than 3 mm in diameter (66.7% vs. 61.0%, p=0.001). There was a tendency 
towards more interventions attempted in total occlusions (11.3% vs. 9.88%, p=0.0979) and 
saphenous vein grafts (5.1% vs. 4.5%, p=0.112). There was no difference in the proportion 
of patients undergoing multivessel PCI (37.8% vs. 36.4%, p=0.33).
Conclusions: Since the introduction of drug-eluting stents there has been a signiﬁcant 
increase in lesions attempted percutaneously that previously carried a high risk of 
restenosis, speciﬁcally longer lesions, smaller vessels, lesions in diabetics, and a 
tendency to intervene more in total occlusions and saphenous vein grafts.
2902-80 6-Month Clinical Outcome After Implantation of 
Sirolimus-eluting Stent in Bifurcation Lesions: 
Comparison of Simple Versus Complex Strategy; 
Preliminary Results From the j-Cypher Registry
Toshihiro Tamura, on behalf of the j-Cypher Registry Investigators, Kazuaki Mitsudo, 
Takeshi Kimura, Takeshi Morimoto, Kazushige Kadota, Takaaki Isshiki, Masaru Tanaka, 
Yukio Kazatani, Akira Miura, Hitoshi Nakashima, Ryozo Tatami, Kazuo Hazi, Yoshiharu 
Murata, Etsuo Ohta, Naoko Okamoto, Hiromi Yoshida, Kyoto University Hospital, Kyoto, 
Japan
Background:Although various approaches using Sirolimus-eluting stents(SES) 
in coronary bifurcations have been proposed, the optimal strategy has not been 
established.
Methods:Design of the j-Cypher Registry was multi-center prospective enrollment of 
consecutive patients receiving SES from 40 centers in Japan. From September 2004 to 
September 2005, 6-month follow-up data was available in 2022 patients. Among them, 
we identiﬁed 317 patients(346 lesions) who were treated with SES in bifurcation lesions 
including acute myocardial infarction and left main coronary artery disease. Bifurcation 
lesions are classiﬁed according to the angulation of the bifurcation and plaque burden. 
143 lesions(41.3%) were true bifurcations. 295 patients were treated with provisional 
side branch stenting and 22 patients were elective stenting. We divided into simple 
strategy(stenting only main branch: group S) and complex strategy(stenting main and 
side branch: group C). Two strategies were selected according to the operators’ discretion. 
We compared 6-month clinical outcome of both strategies.
Results:Because only 17 patients(5.8%) among those who were treated with provisional 
stenting of the side branch crossed to the group C, 278 patients(with 306 bifurcations) 
were included in group S and 39 patients(with 40 bifurcations) in group C. 5 methods of 
two stenting were used: T-stenting(60%), Cullote stenting(27.5%), Crush stenting(5%), 
Touching stenting(5%) and Kissing stenting(2.5%). No subacute stent thrombosis occurred 
in both groups. Fluoroscopic time was longer in groupC(26.8±15.8min vs 36.0±16.7min, 
p=0.0008). There were no signiﬁcant differences between group S and group C with 
regard to the incidence of death(4.0% vs 7.7%, p=0.39), myocardial infarction(2.2% vs 
2.6%, p=0.99), target lesion revascularization(0.4% vs 2.6%, p=0.23) and cumulative 
major adverse cardiac events(8.6% vs 15.4%, p=0.29) at 6-month.
Conclusions:For SES placement in bifurcation lesions, most cases were performed stenting 
only main branch strategy and only few cases crossed to stenting both branches. There were 
no signiﬁcant differences between two groups regarding 6-month clinical outcome.
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2903-81 Characteristics of Patients With Acute Myocardial 
Infarction Transferred to Tertiary Care Centers With 
Revascularization Capabilities
Jeffrey S. Berger, Nicholas Wanahita, Timm Dahlin, David L. Brown, State University of 
New York-Stony Brook, Stony Brook, NY, Duke University, Durham, NC
Background: The standard of care for the treatment of acute myocardial infarction (AMI) 
is to transport the patient to the nearest acute-care hospital for reperfusion therapy. 
However, most hospitals in the United States (US) lack the capability to perform surgical 
or percutaneous revascularization and many high-risk AMI patients have contraindications 
to thrombolytic therapy, fail to reperfuse pharmacologically, or are hemodynamically 
unstable and therefore require non-pharmacologic revascularization. Transfer of high-
risk AMI patients may represent an effective strategy for those presenting to a hospital 
without revascularization capabilities. The objective of this study was to compare the 
characteristics and outcomes of AMI patients who were and were not transferred from 
non-revascularization hospitals to those with revascularization capabilities.
Methods: Data from the Centers for Medicare and Medicaid Services from 2001-2003 for 
all US patients above age 64 with a principal diagnosis of AMI was evaluated.
Results: Among 399,775 AMI patients admitted to non-revascularization hospitals, 
141,283 (35%) were transferred to a revascularization facility. Patients with increasing 
age were less likely to be transferred (P<0.001). Females were less likely to be transferred 
(OR 0.84 95% CI 0.83-0.86) than males. Compared to Whites, African Americans and 
Hispanics were 31% and 47% less likely to be transferred (P<0.001). Independent 
clinical predictors of being transferred were anterior MI, ventricular ﬁbrillation, prior PCI, 
tobacco use and hyperlipidemia. Independent clinical predictors of not being transferred 
were congestive heart failure, cardiogenic shock, cardiac arrest, acute and chronic renal 
failure and Alzheimer’s disease. The predicted and actual mortality among patients not 
transferred was 15.2% and 18.5%, respectively. For patients transferred, the actual and 
predicted mortality was 8.9% and 8.7%, respectively.
Conclusions: In the US, patients over age 64 admitted with AMI to non- revascularization 
hospitals and subsequently transferred were at lower risk and therefore had improved 
survival compared to those who remain in non-revascularization facilities.
2903-82 Moderate Mitral Regurgitation Is Associated With 
Long-Term Prognosis in Patients With Coronary Artery 
Diseases Undergone Revascularization
Neiko Ozasa, Takeshi Morimoto, Satoshi Shizuta, Yutaka Furukawa, Ryoji Taniguchi, 
Masanao Toma, Yoshisumi Haruna, Mitsuru Abe, Yoshihisa Nakagawa, Toshihiro 
Tamura, Natsuhiko Ehara, Naritatsu Saito, Takahiro Doi, Akinori Takizawa, Mitsuomi 
Shimamoto, Tomoyuki Murakami, Akira Yoshida, Hiroyuki Nakajima, Shigeo Matsui, 
Yukiko Imai, Satoshi Teramukai, Masanori Fukushima, Toru Kita, Takeshi Kimura, 
on behalf of the CREDO-Kyoto Investigators, Kyoto University Graduate School of 
Medicine, Kyoto, Japan, Division of Cardiology, Kobe General Hospital, Kobe, Japan
Background: Outcome of patients undergoing revascularization for coronary artery 
diseases with moderate mitral regurgitation (MR) were not well scrutinized.
Methods: We conducted retrospective cohort study of 5978 patients who had coronary 
artery diseases and underwent ﬁrst PCI or CABG between January 2000 and December 
2002 at 31 hospitals in Japan. Patients who had concurrent surgical procedure at CABG 
or severe MR were excluded. All-cause mortality was evaluated for up to 5 years.
Results: Doppler echocardiography was performed in 4713 patients (78.8%) at baseline. 
Among the 4713 patients, PCI was performed in 3423 patients and CABG was performed 
in 1110 patients. Three year survival with or without moderate MR was 84.4% and 94.3%, 
respectively (log-rank test p<0.001, ﬁgure1). Moderate MR was associated with lower 
survival rate at 3 years in both PCI group (MR+ 81.8% vs. MR- 93.3%, p<0.0001) and 
CABG group (MR+ 79.5% vs. MR- 92.1%, p<0.01). After adjustment for revascularization 
methods, age, the New York Heart Association classiﬁcation, atrial ﬁbrillation, diabetes, 
serum creatinine, and history of cancer, the moderate MR was associated with increased 
hazard risk of 1.6 for all-cause mortality (p=0.03, 95% CI 1.05-2.37).
Conclusions: Mitral regurgitation was associated with lower all-cause mortality in 
patients with coronary artery diseases even when the regurgitant degree was moderate. 
Poor prognosis associated with moderate MR was independent to the modes of 
revascularization.
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2903-83 Comorbidity and Outcome After Percutaneous 
Coronary Interventions
Mandeep Singh, Charanjit Rihal, Veronique Roger, Ryan Lennon, John Spertus, Arshad 
Jahangir, David Holmes, Jr., Mayo Clinic, Rochester, MN, Mid America Heart Institute, 
Kansas City, MO
Background: Current risk assessment for percutaneous coronary intervention (PCI) 
lack systematic inclusion of comorbid conditions. We evaluated whether adding comorbid 
conditions can improve the prediction by a currently available model and whether long-
term mortality after PCI can also be determined.
Methods: We reviewed the records of 9,032 PCIs (7,659 patients) performed at Mayo 
Clinic between January 1, 1999, and June 30, 2004, and noted the Mayo Clinic Risk 
Score (MCRS) and the coronary artery disease (CAD)-speciﬁc index for determination of 
comorbid conditions. The MCRS comprises of 8 variables (age, shock, NYHA>=3 CHF, 
renal disease, non-elective interventions, thrombus, left main disease, and multivessel 
disease), and used weighted integers for risk categorization of the patients undergoing 
PCI. The CAD -speciﬁc index assigns weights to individual diseases according to their 
prognostic signiﬁcance. The range of the index was from 0 to 21. We grouped the 
comorbidities into 3 convenient groups with CAD-speciﬁc index of 0-1, 2-3, or 4 or more.
Results: For the cohort, the mean MCRS score was 6.5±2.9. The CAD-speciﬁc index was 
0 or 1 in 46%, 2 or 3 in 30%, and 4 or higher in 23%. The rate of in-hospital major adverse 
cardiovascular events (MACE) increased with higher MCRS and CAD-speciﬁc index 
(Cochran-Armitage test, P<.001 for both models). The c-statistic for the MCRS for in-
hospital MACE was 0.78; adding the CAD-speciﬁc index did not improve its discriminatory 
ability for in-hospital MACE (c-statistic=0.78; likelihood ratio test, P=.29). A total of 707 
postdismissal deaths occurred after 7,253 successful procedures. The c-statistic for all-
cause mortality was 0.69 for the MCRS model alone and 0.75 for the MCRS and CAD-
speciﬁc indices together (likelihood ratio test, P<.001), indicating signiﬁcant improvement 
in the discriminatory ability.
Conclusions: Addition of comorbid conditions to the determinants of in-hospital 
complications adds signiﬁcant prognostic information for postdismissal mortality.Such 
health-status measures should be included in future risk stratiﬁcation models that predict 
long-term mortality after PCI.
2903-84 Impact of Operator Volume on Mortality Following 
Percutaneous Coronary Intervention: A Report From 
the Combined 2000-2001 New York State Angioplasty 
Registries
Christopher L.F. Gade, Dmitriy N. Feldman, Alexander J. Slotwiner, Srihari S. Naidu, 
Manish Parikh, Mun K. Hong, Geoffrey Bergman, S. Chiu Wong, Robert M. Minutello, 
NY Presbyterian Hospital-Cornell Medical Center, New York, NY
Background: Previous data showed a signiﬁcant relationship between percutaneous 
coronary intervention (PCI) operator volume and outcomes. Outcomes improved as case 
volume increased. We examined this relationship with more recent large registry data.
Methods: Using the 2000-2001 NY State PCI Database, (n=82,140), we examined the 
effect of PCI operator volume on in-hospital mortality and major adverse cardiovascular 
events (MACE), deﬁned as emergent CABG, MI or CVA. We divided operator volume 
into quartiles: less than 75 procedures per year, 75-150 procedures per year, 151-300 
procedures per year and greater than 300 procedures per year. We analyzed baseline 
characteristic and outcome differences among quartiles.
Results: (see table) There were signiﬁcant differences in co-morbidity among quartiles 
with a higher percentage of acutely ill patients in the lowest volume operator quartile. 
Low volume operators performed a higher percentage of emergent cases (deﬁned as 
such when at least one of the following was present: MI within 24 hours, cardiac arrest, 
shock or thrombolytic use). There were signiﬁcant, inverse relationships between operator 
volume and mortality, and between operator volume and MACE. However, when mortality 
was adjusted using propensity score analysis, this relationship lost signiﬁcance.
Conclusions: In the modern era, populations treated by lower volume operators may 
have more acute illness. Risk adjusted mortality rates are similar across operator volume 
categories.
Demographics and Outcomes by Operator Volume Quartile
<75 
cases/
year
75-150 
cases/year
151-300 
cases/year
>300 
cases/
year
p 
value
Age (years) 63.1 63.7 64.1 64.7 <.001
Male sex (%) 67.2 67.4 67.9 69.2 <.001
Diabetes Mellitus (%) 26.6 24.1 25.5 26.7 .009
Mean LV Ejection Fraction (%) 51.6 52.2 51.6 52.1 <.001
Chronic Renal Failure (%) 2.1 2.6 2.5 2.5 .135
Multivessel Disease (%) 40.3 43.7 46.7 50.0 <.001
Emergent Cases (%) 16.2 13.7 13.8 11.9 <.001
Mace(%) 1.3 1.2 1.2 0.9 <.001
Death(%) 0.9 0.7 0.8 0.6 .014
 
2903-85 Baseline Thrombocytopenia Predicts In-Hospital 
Adverse Cardiac Events in Patients Undergoing 
Percutaneous Coronary Intervention
Christopher B. Overgaard, Alan W. Barolet, John R. Ross, Douglas J. Ing, Peter H. 
Seidelin, Karen Mackie, Eric M. Horlick, Paul A. Daly, Leonard Schwartz, Vladimir 
Dzavik, University Health Network, University of Toronto, Toronto, ON, Canada
Background: Mild thrombocytopenia (TP) at baseline in patients undergoing 
percutaneous coronary intervention (PCI) is not uncommon. Whether TP has any impact 
on clinical outcome of patients undergoing PCI is unknown. Our aim was to determine 
if the presence of TP at baseline impacts on the development of major adverse cardiac 
events (MACE) in patients undergoing PCI at our institution.
Methods: From 04/00 until 03/05, 9870 PCI procedures were performed at the University 
Health Network, a tertiary PCI center in Toronto, Canada. A baseline platelet count was 
recorded in 8510 cases. Patients with a platelet count <150x109/L were assigned to the 
TP group, and those with a normal platelet count to the NP group. Baseline clinical and 
angiographic variables, as well as procedural and in-hospital outcome variables were 
entered prospectively into our PCI registry. Multivariable analysis was performed using 
logistic regression.
Results: TP patients (n=578) were older (TP 66±11 years vs. NP 63±12 years, 
p<0.0001) and more likely to be male (29% vs. 16%, p<0.0001), have diabetes (33% vs. 
28%, p=0.006), 3-vessel or left main disease (43% vs. 29%, p<0.0001), grade 3 or 4 LV 
function (26% vs. 17%, p<0.0001), lower creatinine clearance (73±35 vs. 85±36 ml/min, 
p<0.0001), and prior CABG (27% vs. 16%, p<0.0001). The rate of in-hospital MACE was 
higher in the TP group (7.5% vs. 3.2%, p<0.0001), in part due to a higher death rate (4% 
vs. 1%, p<0.0001). The higher MACE rate was observed in elective patients (TP 3.8% vs. 
NP 2.0%, p=0.045) as well as those undergoing PCI for non-elective indications (10.5% 
vs. 4.5%, p<0.0001). There were no differences in bleeding complications between the 
groups. TP was independently associated with MACE (p=0.005), emergent indication for 
PCI (p<0.0001), PCI of a Type C lesion (p<0.0001), creatinine clearance <60 ml/min 
(p<0.0001), recent MI (p=0.0005), and grade 3 or 4 LV function (p=0.006).
Conclusions: Baseline TP is an independent predictor of in-hospital MACE in patients 
undergoing PCI for elective and non-elective indications. This ﬁnding may help clinicians 
identify patients at higher risk for adverse outcomes in this population.
2903-86 Predictors of Length of Hospital Stay After 
Contemporary Percutaneous Coronary Intervention
Noah J. Jones, Dean E. Smith, Eva Kline Rogers, Sanjaya Khanal, Richard McNamara, 
Thomas LaLonde, Michael J. O’Donnell, Kirit Patel, David Share, Mauro Moscucci, 
University of Michigan, Ann Arbor, MI
Background: Post-procedure length of stay (LOS) is an important determinant of medical 
costs of Percutaneous Coronary Intervention (PCI). There are currently no predictive 
models of LOS following contemporary PCI. We sought to develop predictive models of 
LOS following PCI.
Methods: Data on 86,097 patients were collected in a regional consortium between Jan. 
1998 and Dec. 2004 (Blue Cross Blue Shield of Michigan Cardiovascular Consortium). 
Predictors of log-transformed LOS were identiﬁed using parsimonious multiple linear 
regression modeling. Variables evaluated in sequence included pre-procedure (model 
I), pre-procedure and intra-procedure (model II), pre-procedure and intra-procedure 
variables and post-procedure outcomes (model III).
Results: In this large dataset, demographic and historic factors alone explained 33% of 
variability in post-procedure LOS (R2= 0.33). The addition of procedural variables added 
little to the explained variability (R2=0.34). Variables signiﬁcantly (p<0.001) related to 
longer LOS in the ﬁrst two models included female gender, advanced age, CHF, COPD, 
DM, history of GI bleed, PVD, night time and weekend admission, urgent or emergent 
procedure, creatinine ≥ 2 mg/dl, ejection fraction < 40%, MI within 24 hrs, any MI 
preceding the procedure, pre-procedure nitroglycerin, pre-procedure heparin, and intra 
aortic balloon pump use. In a combined third model incorporating the above variables 
plus post procedure and outcome variables the explained variation in LOS increased to 
56% (adjusted R2=0.56). All the previously listed variables were signiﬁcant in this model 
(p<0.001). In this third model, post-procedure heparin or low molecular weight heparin, 
stroke, emergency and non-emergency CABG, contrast nephropathy, arrhythmias, 
MI, angina, pulmonary edema, loss of limb (all p<0.0001), no reﬂow (p=0.0005), and 
acute closure (p=0.001) were post-procedure and outcomes variables independently 
associated with longer LOS.
Conclusions: These prediction models identify factors responsible for prolonging LOS 
after PCI, and can be used to provide risk-adjusted LOS and to identify targets for quality 
improvement and cost reduction efforts.
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2903-87 Ostial Stenosis in Coronary Artery Bypass Grafts With 
Symmetry Connectors
Abdul Rashid, N. Paul Ayers, Eliot Schechter, Jorge F. Saucedo, Mohammad K. Ghani, 
Thomas A. Hennebry, The University of Oklahoma, Oklahoma City, OK, Veterans Affairs 
Medical Center, Oklahoma City, OK
Background: The Symmetry connector was developed to obviate the need of cross 
clamping aorta and provide early achievement of proximal anastomosis in patients 
undergoing coronary artery bypass graft (CABG). There is little data for long term 
outcome with Symmetry connectors.
Methods: We studied consecutive 251 patients from Jan 2002 to Oct 2004 at Veteran 
Affairs Medical Center who underwent CABG. There were 128 patients in group I who had 
proximal Symmetry anastomoses (51%) and 123 patients in Group II, who had proximal 
hand-sewn anastomoses (49%) served as controls. Chi-square tests, univariate and 
multivariate tests were applied where appropriate.
Results: At follow up a total of 17/128 (13.2%) patients presented with graft occlusion at 
the ostium in Group I as compared to 2/123 (1.6%) patients in Group II {p = 0.0004, odds 
ratio [OR]: 9.37} in average of 8 months (rage; 0.5 to 18 months). At angiography, a total of 
51 saphenous vein grafts were found to have occlusion (n = 22) or stenosis >60% (n = 29) 
and were treated with angioplasty or stenting. Six of 17 patients re-admitted with chest 
pain and found to have stenosis at the previously treated connector site in average of 45 
days. These patients were treated with angioplasty and stents during this time.
Conclusions: In conclusion, patients with coronary artery bypass graft with Symmetry 
connector present early with high frequency of graft stenosis at connector site.
2903-88 The Association Between Stent Deployment Pressure 
and In-Hospital Complications of Contemporary PCI: 
Insights From a Large Multicenter Registry
Hitinder Gurm, Dean Smith, Michael O’Donnell, Kirit Patel, Sanjaya Khanal, Thomas 
Lalonde, Richard McNamara, David Share, Mauro Moscucci, for The Blue Cross Blue 
Shield of Michigan Cardiovascular Consortium (BMC2), University of Michigan Medical 
Center, Ann Arbor, MI
Background: Current data and manufacturers’ guidelines recommend stent deployment 
at high inﬂation pressures. There are limited data on current practice patterns and clinical 
impact of variations in stent deployment pressures.
Methods: We evaluated the relationship between stent deployment pressure and 
outcome of 26,768 patients who underwent PCI between 8/2003 and 12/2004 in a large 
regional consortium (Blue Cross Blue Shield of Michigan Cardiovascular Consortium). 
The primary outcome was in-hospital major adverse cardiovascular events (MACE) 
deﬁned as a composite of death, MI, stroke, any CABG or target lesion revascularization, 
and in-hospital sub-acute stent thrombosis. Hierarchical modeling was used to adjust for 
clustering and for differences in patient characteristics.
Results: While the majority of stents were deployed at high pressure, 15% were deployed 
at < 12 atmospheres and ~ 5% were deployed at < 10 atmospheres. There was a U 
shaped relationship between complications and deployment pressure, with the worse 
outcome in the low pressure group. After multivariable adjustment, a deployment pressure 
of < 10 atmospheres remained a signiﬁcant predictor of MACE ( P = 0.011).
Conclusion: Patients undergoing stent deployment at low pressure appear to be at an 
increased risk of MACE. While the majority of stents are deployed at appropriate pressure, 
our data highlight the need for improvement in technique in a small but signiﬁcant 
subgroup of patients undergoing coronary stenting. 
Deployment pressure < 10 atm 10-12 atm
12-14 
atm 14-16 atm > 16 atm P
n(%) 1470(5.4%)
2856
(10.6%)
5645
(21.1%)
11462 
(42.8%)
5335 
(19.9%)
In hospital Death 29 (1.9%)
36
(1.2%)
48
(0.8%)
104
(0.9%)
258
(0.8%) 0.0002
Unplanned CABG 13 (0.88%)
12
(0.42%)
14 
(0.25%)
22
(0.19%)
17
(0.32%) <0.0001
Sub acute stent 
thrombosis
5
(0.34%)
7
(0.25%)
12 
(0.21%)
29
(0.25%)
20
(0.37%) 0.51
MACE 76 (5.17%)
95 
(3.33%)
181
(3.21%)
380
(3.32%)
211 
(3.96%) 0.0012
 
2903-117 Twenty-ﬁve Year Trends in Gender Disaparities in the 
Thirty-Day Mortality Following Percutaneous Coronary 
Interventions at Mayo Clinic
Mandeep Singh, Veronique Roger, Charanjit Rihal, Ryan Lennon, David Holmes, Jr., 
Malcolm Bell, Regina Herges, Bernard Gersh, Mayo Clinic, Rochester, MN
Objective: To compare 30-day mortality rates among women and men undergoing 
percutaneous coronary interventions (PCI) in the last 25 years and determine whether 
differences in rates between men and women have changed.
Methods: We evaluated 30-day mortality on a consecutive series of 18885 unique 
patients undergoing PCI at Mayo Clinic, Rochester. For patients with multiple PCIs, only 
the initial procedure was included. Two cohorts were analyzed: patients seen between 
1979 and 1995 (n = 7904, 28% women) and those treated between 1996 and 2004 (n = 
10981, 31% women).
Results: Women were older than men (69±12 vs. 64±12 years) and more had class III 
or IV angina (61% vs. 53%), heart failure (12% vs. 8%), diabetes mellitus (26% vs. 19%), 
hypertension (69% vs. 55%), and hypercholesterolemia (68% vs. 58%; all p<0.001). 
Overall, the PCI was successful in 89% of women and 90% men with an in-hospital 
mortality rate of 3.0% and 2.1%, respectively (P<0.001). Signiﬁcant reductions in 30-
day mortality from the early to late eras were observed in men (2.8% to 2.2%; p=0.04) 
and women (4.4% to 2.9%; p=0.003). The multivariate odds ratio of 30-day mortality for 
women vs men was 1.24 (95% CI 0.91, 1.62; p=0.10) for the early group and 0.94 (95% 
CI 0.82, 1.22; p=0.65) for the late group. The difference in odds ratios was not signiﬁcantly 
different (p=0.12).
Conclusions: Thirty day mortality rates between both genders have decreased over time. 
After risk-adjustment, women have similar mortality rates during the index hospital stay 
in both the eras.
2903-118 Interventional Operator Does Not Predict Hospital Cost 
After Clinical and Angiographic Case-Mix Correction
William B. Hillegass, Silvio E. Papapietro, Brigitta C. Brott, Paul R. Myers, Greg 
D. Chapman, Kalgi A. Modi, Vijay K. Misra, University of Alabama at Birmingham, 
Birmigham, AL
Background: The validity of cost-proﬁling cardiovascular interventionalists without case-
mix adjustment is uncertain.
Methods: Clinical, core lab angiographic, and hospital cost data were prospectively 
collected on 1329 consecutive hospitalizations involving percutaneous coronary 
intervention in 1154 patients. Variable and apportioned ﬁxed costs were measured from 
an individual patient resource-use cost-accounting system. Mean cost for the 8 operators 
at a hybrid university-private practice were compared. After derivation of a multivariate 
regression model to predict hospital cost, operator was introduced into the model. A 
second model deleting operator modiﬁable variables was also examined.
Results: 
Volume and Cost by Operator
Operators Number Mean Cost + s.d. Median Cost
1 227 (17.1) 11,450 + 7,192 9,696
2 199 (15.0) 12,850 + 7,381 10,986
3 182 (13.7) 14,867 + 11,296 11,723
4 170 (12.8) 13,713 + 9,743 11,175
5 164 (12.4) 12,267 + 10,555 9,637
6 130 (9.8) 11,360 + 6,030 10,337
7 129 (9.7) 12,815 + 8,951 10,555
8 128 (9.6) 9,494 + 4,269 8,323
By ANOVA, patients treated by operator 3 and 4 had signiﬁcantly higher hospital costs and 
operator 8 had lower cost. In the multivariate model considering the only 12 signiﬁcant, 
independent clinical, angiographic, and procedural predictors of cost, operator was not a 
signiﬁcant, independent predictor of hospital cost. When potentially modiﬁable operater 
determined procedural predictors (stent number, lesion number treated, and IIb/IIIa use) were 
deleted from the model, operator was still not a signiﬁcant, independent predictor of cost.
Conclusion: Controlling for detailed clinical and angiographic patient characteristics 
eliminated the apparent signiﬁcant cost variability between operators. Cost-proﬁling 
without case-mix correction is inappropriate.
2903-119 Long-Term Survival Advantage of Coronary Artery 
Bypass Grafting (CABG) Over Percutaneous Coronary 
Intervention (PCI ) in the Real World Clinical Practice: Is 
It Real?
Takeshi Kimura, Satoshi Shizuta, Natsuhiko Ehara, Ryoji Taniguchi, Yoshisumi Haruna, 
Masanao Toma, Toshihiro Tamura, Mitsuru Abe, Yutaka Furukawa, Yoshihisa Nakagawa, 
Masakiyo Nobuyoshi, Hitoshi Okabayashi, Kazuaki Mitsudo, Tatsuhiko Komiya, Hisao 
Ogawa, Michio Kawasuji, Hiromi Yoshida, Emi Takinami, Yukiko Imai, Satoshi Teramukai, 
Masanori Fukushima, Masashi Komeda, Toru Kita, for the CRED0-Kyoto Investigators, 
Kyoto University Graduate School of Medicine, Kyoto, Japan
Background: A recent report from two very large registries suggested long-term survival 
advantage of CABG over PCI. However, there remains the possibility that observational 
studies may fail to identify all potential confounders.
Methods: CREDO-Kyoto is a multi-center registry in patients ( pts ) undergoing ﬁrst PCI 
or CABG between Jan. 2000 and Dec. 2002. Detailed in-hospital and follow-up data were 
collected from the hospital charts by independent clinical research coordinators. Among 5996 
pts enrolled in the registry, 3392 ( PCI 2460 ( 85% stent use ), CABG 932 ( 36% off-pump )) 
pts were identiﬁed to have multi-vessel disease excluding pts with left main disease.
Results: Crude survival rate at 3 years ( follow-up interval 893 ± 443 days ) was not 
signiﬁcantly different between the two groups ( PCI 90.8% vs. CABG 92.9% : p= 0.19 ). 
Using 19 factors associated with all-cause mortality by univariate analysis, multivariate 
Cox model was created. In addition to the well-established risk factors, several other 
factors such as anemia, malignancy, atrial ﬁbrillation ( Af ), and valvular heart disease ( 
VHD ) that were not measured in the previous report were identiﬁed to be independent 
predictors of mortality ; R.R. ( 95% C.I. ) P value ; s-Creatinine > 1.2 mg/dl 1.61 ( 1.4 - 1.85 
) < 0.0001 ; Malignancy 1.49 ( 1.24 - 1.77 ) < 0.0001 ; Heart failure 1.37 ( 1.18 - 1.58 ) < 
0.0001 ; Hemoglobin < 12.0g/dl 1.35 ( 1.17 - 1.55 ) < 0.0001) ; Age > 70 1.31( 1.14 - 1.52 
) 0.0002 ; Extra-cardiac vascular disease : 1.22 ( 1.06 - 1.39 ) 0.006 ; VHD 1.32 ( 1.05 
- 1.64 ) 0.02 ; Af 1.28 ( 1.04 - 1.55 ) 0.02.
Despite identiﬁcation of novel predictors of all-cause mortality, when mode of 
revascularization was incorporated into this model, the long-term risk of death after 
CABG relative to PCI was 0.83 ( 95% CI. 0.71 - 0.97 ; p= 0.02 ). However, when combined 
cardiovascular death, MI, and stroke was used as an endpoint, beneﬁt of CABG over PCI 
was no more apparent ( R.R. 0.98 ( 0.85 - 1.12 ) p= 0.74 )
Conclusions: Even after careful adjustment of baseline characteristics, CABG was still 
shown to have survival advantage over PCI by standard multivariate analysis. However, 
there remains the possibility of presence of unmeasured confounders inﬂuencing all-
cause mortality.
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2903-120 Expected Reduction in CABG Referral in the Drug-
Eluting Stent Era
Frédéric Poulin, Jean-François Gobeil, Stéphane Rinfret, Montreal University Health 
Center, Montréal, PQ, Canada
Background: Drug-eluting stents (DES) dramatically reduce restenosis compared 
to bare-metal stents, and may promote percutaneous rather than surgical strategy for 
multivessel coronary disease in the near future. The aim of our study was to quantify this 
potential uptake from coronary artery bypass graft surgery (CABG) in the DES era.
Methods: Clinical data and outcomes of consecutive patients who underwent CABG 
without concomitant surgery in a large Canadian tertiary hospital prior to the introduction 
of DES were collected. Two interventional cardiologists independently reviewed coronary 
angiographies and had to agree on feasibility of percutaneous treatment. We excluded 
patients with signiﬁcant (>50%) left main disease, chronic total occlusion, and predeﬁned 
high-risk lesions, including ostial left anterior descending (LAD) or left circumﬂex (LCX) 
lesions and high-risk or multiple (> 2) bifurcating lesions. Complete revascularization had 
to be achieved for a patient to be shifted from the CABG population to the percutaneous 
approach. The virtual planned procedure was described for eligible patients
Results: From January to September 2003, 194 CABG procedures were reviewed. 
The mean age of patients was 65.3 ± 9.0 years, 78.9% were male, and 34.5% had 
diabetes. The majority of patients (79.3%) had three vessels disease and 23.7% had a 
ejection fraction (EF) lower than 0.40. The median postoperative stay was 6 days. Death, 
postoperative myocardial infarction and stroke occurred in 4.6%, 5.2% and 4.1% of 
patients, respectively. Among the 194 candidates, only 20 (10.3%) were deemed eligible 
for DES instead of surgery. The main reasons to favor CABG were: chronic total occlusion 
(57.5%), left main disease (28.2%), high-risk or multiple bifurcation lesions (14.9%) and 
ostial LAD or LCX lesions (12.1%). The mean number of stents per patient would have 
been 3.6 with a mean total length of 80.6 mm and a mean diameter of 2.9mm.
Conclusions: DES are expected to have a low impact on overall revascularization 
strategies, with about a 10% uptake from traditional CABG surgery. Chronic total 
occlusions and other anatomic limitations will remain central in the decision to refer for 
surgical revascularization
2903-121 Predictors of Hospital Cost in Percutaneous Coronary 
Intervention
William B. Hillegass, Greg D. Chapman, P. Robert Myers, Kalgi A. Modi, Silvio 
Papapietro, Vijay K. Misra, Brigitta C. Brott, University of Alabama at Birmingham, 
Birmingham, AL
Background: Understanding characteristics driving the cost of percutaneous coronary 
intervention may guide new approaches to managing cost without compromising 
effectiveness.
Methods: Clinical, core angiographic, and cost data were prospectively collected on 
1329 consecutive hospitalizations involving percutaneous coronary intervention in 1154 
patients. Variable and apportioned ﬁxed costs were measured from an individual patient 
resource-use cost-accounting system. Hypothesized predictors of cost were examined in 
univariate and step-wise multivariate regression analysis.
Results: The mean age was 60+13 with 35% women. Indication for intervention: acute 
ST-segment elevation MI 14.7%, post-MI 18.7%, unstable angina 34.9%, stable angina 
26.9%, and silent ischemia 4.3%. Diabetes was present in 36.4%, prior CABG 12.5%, 
and cardiogenic shock 3.1%. Mean and median hospital cost were $12,525 + 8,891and 
$10,235 respectively. In step-wise multivariate regression analysis the signiﬁcant 
independent predictors of hospital cost included clinical, angiographic, and procedural 
factors. 
Predictor, z-statistic, incremental $
Stent number 6.2 1611/stent
Cardiogenic shock 5.3 8456
IABP support 5.1 9221
Pre-hematocrit -5.1 -238/Hct point
Lesion number treated 4.0 1924/lesion
Diabetes mellitus 4.0 2083
Prior CABG 3.5 2450
Heavy lesion calciﬁcation 2.7 3934
Pre-TIMI 0 ﬂow in target vessel 2.7 1930
Stable Angina -2.6 -1518
Target vessel calciﬁcation 2.2 1786
IIb/IIIa antagonist use 2.1 1086
After adjusting for these variables, age, gender, and operator were not signiﬁcant 
independent predictors of cost.
Conclusions: Few of the 12 signiﬁcant, independent cost predictors are modiﬁable. Cost 
will be reduced only if strategies can be developed to reduce the number of stents used, 
lesions treated, and frequency of IIb/IIIa use without compromising outcome, unless 
acquisition costs decrease.
2903-122 1,018 Percutaneous Coronary Interventions Without On-
Site Cardiac Surgery: Procedural Success and Safety
Henry H. Ting, Ganesh Raveendran, Charanjit S. Rihal, Katherine L. Boutchee, Ryan J. 
Lennon, Mandeep Singh, Douglas L. Wood, David R. Holmes, Mayo Clinic, Rochester, MN
Background: Performing percutaneous coronary interventions (PCI) without on-site 
cardiac surgery remains controversial. We evaluated outcomes in 1,018 PCI procedures 
performed without on-site cardiac surgery.
Methods: Immanuel St. Josephs Hospital (ISJ) is located 85 miles from Mayo Clinic, 
the nearest center with on-site cardiac surgery. All components of the Mayo Clinic PCI 
program were replicated at ISJ, including a telemedicine system to enable real-time 
consultation with interventional cardiology and cardiac surgical colleagues. PCI cases at 
ISJ were matched 1:1 with cases at Mayo Clinic using a clinical propensity score for risk.
Results: From March 1999 to August 2005, 1018 PCI procedures were performed at ISJ, 
including 726 elective PCI and 292 primary PCI for ST elevation myocardial infarction 
(STEMI). Procedural success deﬁned as residual stenosis <20% without in-hospital 
death, any myocardial infarction (MI), or target vessel revascularization (TVR) was 
achieved in 92% (95% CI 89% - 94%) of elective PCI and 90% (95% CI 86%-93%) of 
primary PCI. No patients required transfer to another facility for emergent cardiac surgery 
from a procedure related complication.
Conclusions: Elective and Primary PCI for STEMI can be performed with safety and 
efﬁcacy at a community hospital without cardiac surgical capability by following rigorous 
standards for training of staff, maintenance of skills and volumes, and case selection.
Outcome
Elective PCI 
Mayo Clinic 
(n=726)
Elective PCI 
ISJ (n=726) P
Primary PCI 
Mayo Clinic 
(n=292)
Primary PCI 
ISJ (n=292) P
Procedural 
Success 640 (88%) 666 (92%) 0.02 247 (85%) 263 (90%) 0.04
In-hospital death 1 (0.1%) 4 (1%) 0.2 7 (2%) 10 (3%) 0.4
In-hospital MI 26 (4%) 18 (2%) 0.2 6 (2%) 6 (2%) 1.0
In-hospital TVR 5 (1%) 16 (2%) 0.01 12 (4%) 7 (2%) 0.25
In-hospital death, 
MI, or TVR 30 (4%) 35 (5%) 0.5 22 (8%) 19 (7%) 0.6
ORAL CONTRIBUTIONS
2801 
Drug Eluting Stents Unresolved Issues
Sunday, March 12, 2006, 10:30 a.m.-Noon
Georgia World Congress Center, Room C207
10:30 a.m.
2801-3 Late Stent Thrombosis in Sirolimus-Eluting Versus Bare 
Metal Stents in 4 Randomized Clinical Trials With 3-Year 
Follow-Up
Giora Weisz, Jeffrey W. Moses, J. Schofer, Marie-claude Morice, Erick Schampaert, 
Patrick Wang, Martin B. Leon, Cardiovascular Research Foundation, New York, NY, Center 
for Interventional Vascular Therapy, Columbia University Medical Center, New York, NY
Background: The standard deﬁnition of stent thrombosis (ST) requires indisputable 
evidence that may underestimate the true frequency of ST. We applied a more liberal 
deﬁnition of ST, using a revised classiﬁcation, and re-analyzed ST from 4 sirolimus-eluting 
stent (SES) vs. control bare metal stent (CS) studies. 
Methods: All adverse events from procedure to 3yr follow-up (FU) from SIRIUS, E-
SIRIUS, C-SIRIUS, RAVEL were blindly re-adjudicated. These studies included simple 
and intermediate complexity lesions and pts received dual antiplatelet therapy for 2-3 
mos. Deﬁnitions for ST were: Early ST (≤30d) - angiographic documentation of target 
vessel (TV) occlusion or any cardiac death or MI within 30 days. Deﬁnite late (≥31d) ST 
required MI attributed to the TV and angiographic documentation of thrombus. Possible 
and cannot exclude late ST were MI or sudden cardiac death, respectively, attributable to 
the TV, without other identiﬁable “culprit” lesions or interim intervention.
Results: 878 pts were treated with SES and 870 with CS. 
p=ns for all SES vs. CS comparisons
Thrombosis 
Adjudication
Early ST Late ST All ST
0-30 
days
31-365 
days
1-2 
years
2-3 
years 0-3 years
SES CS SES CS SES CS SES CS SES CS
Deﬁnite 4 (0.5%) 1 (0.1%) 1 (0.1%) 4 (0.5%) 2 (0.2%) 0 2 (0.2%) 0 9 (1.0%) 5 (0.6%)
Possible - - 1 (0.1%) 3 (0.3%) 0 1 (0.1%) 0 0 1 (0.1%) 4 (0.5%)
Cannot exclude - - 1 (0.1%) 3 (0.3%) 1 (0.1%) 2 (0.2%) 3 (0.3%) 0 5 (0.6%) 5 (0.6%)
All events 4 (0.5%) 1 (0.1%) 3 (0.3%) 10 (1.1%) 3 (0.3%) 3 (0.3%) 5 (0.6%) 0 15 (1.7%) 14 (1.6%)
Conclusions: 1. Combined SES + CS ST rates @ 3 yrs are doubled with liberal deﬁnitions 
(from 0.8% to 1.7%). 2. There are no signiﬁcant differences in ST rates between SES and 
CS, at all time points, irrespective of ST deﬁnitions. 3. After 1 year, late ST events are still 
observed, comprising 29% of all ST using standard deﬁnitions, and 38% using liberal 
deﬁnition. Thus, a comprehensive analysis of ST requires both late follow-up (>1yr) and 
attention to speciﬁc ST deﬁnitions.
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10:42 a.m.
2801-4 Intravascular Ultrasound in Very Late DES-Stent 
Thrombosis
Stephane Cook, Peter Wenaweser, Mario Togni, Michael Billinger, Bernhard Meier, Otto 
M. Hess, Stephan Windecker, Swiss Cardiovascular Center Bern, University Hospital, 
Bern, Switzerland
Background. Late stent thrombosis after drug eluting stents (DES) has been reported 
up to 442 days after implantation. Although in some cases stent thrombosis seems to 
have been closely related to aspirin and/or clopidogrel discontinuation, other cases were 
not correlated with antiplatelets therapy, which suggests the presence of local triggers 
in these patients. DES have been associated with delayed healing and polymer related 
hypersensitivity reactions, as well as the use of longer stents and shorter diameters.
Objective and Methods. To gain further insight into its pathophysiology, we performed 
intravascular ultrasound (IVUS) in 10 patients (100% male, age 62+/-12 years old) 
undergoing coronary interventions for (very) late stent thrombosis (ST) after DES-
implantation (533±280 days) and compared these ﬁndings to IVUS obtained in 198 all-
comers who did not experience ST after more than 12 months. Intravascular ultrasound 
imaging was performed in the ST-segment (50%LAD, 10%RCX, 40%RCA) using 
motorized pullback (0.5 mm/s). Images were analyzed ofﬂine at an independent core 
laboratory. Stent expansion was its minimum cross-sectional area (MSA) divided by 
reference lumen area. Stent malapposition was deﬁned as a lack of contact between any 
strut and the vessel wall.
Results. All IVUS analyzed from ST group demonstrated potential local trigger. Total stent 
length (7 SES, 3 PES) was twice as long as in controls (36.1±20.6 vs. 18.8±9.4mm, 
p<0.001). MSA (5.5±1.7mm2 vs. 6.5±1.9mm2, p<0.05) and stent expansion rate 
(0.58±0.25 vs. 0.81±0.17, p<0.001) were signiﬁcantly smaller in the ST group than in 
the control patients. Underexpansion was due to calciﬁed lesion with calcium arc of 360° 
in 40% of ST. Rate of incomplete stent apposition (ISA) was signiﬁcantly greater in the 
ST group (50%, p=0.03). In 4/5 cases, ISA was associated with images considered as 
hypersensitivity reaction by others.
Conclusion. Stent underexpansion, incomplete stent apposition and long stent length 
are associated with (very) late stent thrombosis after successful DES implantation.
10:54 a.m.
2801-5 Genomic Analysis of Human Atherectomy Specimens 
Predicts Superior Performance of Sirolimus Eluting 
Stents
Euan Ashley, Rossella Ferrara, Jennifer Y. King, Xuanmin He, Ulrich Gerckens, Aditya 
Vailaya, Allan Kuchinsky, Angela Soito, Raymond Tabibiazar, Joshua Spin, John B. 
Simpson, Eberhard Grube, Thomas Quertermous, Stanford University, Stanford, CA
Background: Recent studies suggest a small but consistent beneﬁt of sirolimus over 
paclitaxel for inhibition of in-stent restenosis (ISR).
Methods: We set out to describe the unique transcriptional signature of ISR and to 
use this as a tool to predict the efﬁcacy of current and future anti-restenosis agents. 
Specimens (n=70) were acquired from patients undergoing coronary atherectomy. 
RNA was isolated, reverse transcribed, ﬂuorescent dye-labeled and hybridized to 22k 
oligonucleotide microarrays. The mean transcriptional proﬁle of de novo lesions was 
subtracted from that of ISR lesions to yield the unique transcriptional signature of ISR. 
Separately, a series of gene interaction networks were developed from Medline using 
a natural language parsing algorithm and the keywords ‘sirolimus’ and ‘paclitaxel’. We 
overlaid the transcriptional proﬁle of ISR on these networks.
Results: As expected, sirolimus networks were larger (818 vs 611 nodes, 3690 vs 
1862 associations). However, the mean signiﬁcance level for differentially regulated 
genes within the sirolimus network was also higher than for paclitaxel (Figure, p=0.01). 
This overabundance implies a more fundamental role for sirolimus in inhibiting the key 
transcriptional processes of ISR.
Conclusions: Genomic analysis predicts superior performance of sirolimus over 
paclitaxel as an elution agent for the inhibition of ISR. This novel approach may enhance 
future identiﬁcation of agents more speciﬁc for the molecular processes of ISR.
 
11:06 a.m.
2801-6 Does C-reactive Protein Predict Outcomes of Patients 
With Stable Angina and Acute Coronary Syndrome Who 
Are Undergoing Percutaneous Coronary Intervention 
With Drug-Eluting Stents?
Roswitha M. Wolfram, Ashesh N. Buch, Zhenyi Xue, Augusto D. Pichard, William 
Suddath, Lowell Satler, Kenneth M. Kent, Ron Waksman, Washington Hospital Center, 
Washington, DC
Background: Elevated high sensitive (hs) C-reactive protein (CRP) is associated with an 
increased risk of adverse cardiac events after percutaneous coronary intervention (PCI) 
with bare metal stents (BMS). We aimed to determine the impact of elevated baseline hs-
CRP in patients undergoing contemporary PCI including drug-eluting stents (DES) plus 
statin and clopidogrel pharmacotherapy.
Methods: 479 stable angina (SA)- and 482 acute coronary syndrome (ACS) patients 
treated with contemporary PCI were stratiﬁed according to their baseline hs-CRP. 
Outcomes were compared.
Results: SA patients were divided into 3 groups: CRP 1 mg/l; CRP 1-3 mg/l; and CRP 
>3mg/l. Baseline characteristics were similar except for higher body mass index (BMI), 
lower left ventricular ejection fraction (LEVF), more diabetes, and smoking with CRP 
>3mg/l (p<0.001, p=0.008, respectively). Procedural success, in-hospital complications, 
and 6-month events were similar in all groups (Table). ACS patients were divided into a 
CRP <12mg/l group and compared to a CRP >12mg/l group. Baseline characteristics 
showed lower LVEF and more smokers in CRP >12mg/l patients (p=0.002, p<0.001) but 
overall more cardiovascular risk factors in patients with CRP <12mg/l. As in stable angina 
patients, all outcomes were comparable (Table).
Conclusion: In contemporary PCI utilizing DES, clopidogrel, and aggressive statin 
therapy, elevated baseline hs-CRP is no longer associated with an increased risk of 
adverse cardiac events. 
CRP <1
(n = 
123)
CRP 
1-3
(n = 
162)
CRP >3
(n= 194)
p 
Value
CRP 
<12
(n = 
398)
CRP 
>12
(n= 84)
p Value
hs-CRP at baseline mg/l 0.6 ± 0.3
1.8 ± 
0.5
18.7 ± 
44.4 <.001
3.0 ± 
2.7
63 ± 
122 <.001
Major in-hospital 
complication 1(0.8%)
1 
(0.6%) 2 (1%) 1.00 1(0.3%) 1 (1%) 0.32
30 days
Death 0 0 2 (1%) 0.34 0 1 (1%) 0.18
Q-wave MI 0 0 0 ... 2 (0.6%) 0 1.00
TLR-MACE 0 0 2 (1%) 0.34 2 (0.6%) 2 (3%) 0.15
6 months
Death 1(1%) 1(1%) 4 (4%) 0.45 4 (2%) 1 (2%) 1.00
Q-wave MI 2 (2%) 0 1 (1%) 0.28 3 (1.5%) 0 1.00
TLR 1 (1%) 1 (1%) 1 (1%) 1.00 5 (2.5%) 1 (2%) 1.00
TLR-MACE 7 (8%) 2 (2%) 6 (5%) 0.12 12 (6%) 2 (4%) 0.74
11:18 a.m.
2801-7 Detailed Angiographic and Clinical Analysis of 
Sidebranch Patency Following Placement of Multiple, 
Long (18 mm) Overlapped and Nonoverlapped Cypher 
Stents
Jeffrey J. Popma, Dean J. Kereiakes, Ilie Barb, Campbell Rogers, David Snead, Patrick 
Wang, Michael Jonas, Martin Leon, Jeffrey Moses, Brigham and Women’s Hospital, 
Boston, MA
Background. Higher MI rates are found with treatment of diffuse disease with bare metal 
stents (BMS), often attributable to sidebranch (SB) narrowing.
Objective. To compare the angiographic/clinical outcomes after multiple BMS and 
sirolimus-eluting stents (SES).
Methods. 271 pts enrolled in the SIRIUS, E/C SIRIUS, and DIRECT treated with 
multiple (> 2), long (>18 mm) BMS (N=112) or SES (M=159) were identiﬁed. Stents 
were overlapped > 1 mm in 244 (90%) pts. SB analysis was performed in 233 patients 
(BMS=94; SES=139). SB were classiﬁed as occlusion (TIMI 0,1), reduced ﬂow (TIMI <3), 
or compromise (> 70% stenosis).
Results. Diabetes was common (30%). Lesion (21 mm) and stent (39.5 mm) lengths 
and RVDs (2.74 mm) were similar in both groups. 364 SB were identiﬁed within the stent 
(91%), in the overlap zone (7%), or outside the stent (2%). The SB diameter was 1.38 
mm in BMS and 1.30 mm in SES. The number of SBs per pt were similar (BMS, 1.64; 
SES, 1.51). 
Control, % CYPHER, % P value
SB Occlusion / SB Reduced Flow 11.0 / 19.5 5.3 / 13.9 0.048 / 0.20
SB Compromise 13.6 11.2 0.507
30-day MACE / CPK MB > 8x N 3.6 / 3.6 1.3 / 0 0.24 / 0.03
9-month MACE 37.8 7.6 < 0.0001
A nonsigniﬁcant reduction in SB reduced ﬂow was noted in overlapped SES (10.5%) 
compared with overlapped BMS (25%). Most SB events occurred during stent deployment. 
The occurrence of MI was associated with the occurrence of SB occlusion (p=0.004) or 
SB reduced ﬂow (p=0.004).
Conclusions. 1. SB patency is an important determinant of MI in pts treated with 
multiple long stents. 2. Compared with BMS, treatment with multiple, long SES had less 
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SB occlusion with similar rates of reduced SB ﬂow. 3. Late clinical outcome is markedly 
improved with the use of SES.
11:30 a.m.
2801-8 The Magnitude of Neointimal Hyperplasia as a 
Mechanism of In-stent Restenosis in Diabetes Mellitus 
After Sirolimus Eluting Stent Implantation: A Volumetric 
Intravascular Ultrasound Study
Koichi Sano, Stephane Carlier, Gary S. Mintz, Kenichi Fujii, Jose Costa, Masashi 
Kimura, Kaoru Tanaka, George D. Dangas, Roxana Mehran, Issam Moussa, Edward 
M. Kreps, Michael B. Collins, Gregg W. Stone, Jeffrey W. Moses, Martin B. Leon, 
Cardiovascular Research Foundation, New York, NY
Background: Diabetes mellitus (DM) as a risk factor for restenosis in the drug eluting 
stent era is still a matter of debate; in particular, the impact of DM on the in-stent 
restenosis (ISR) patterns is unknown.
Methods&Results: Using intravascular ultrasound (IVUS), we identiﬁed 49 ISR lesions (22 
lesions in 17 pts with DM and 27 lesions in 25 pts without DM) after sirolimus-eluting stent 
(SES) implantation. Stent areas tended to be smaller in DM pts (Table). Importantly, at follow-
up, the minimum lumen areas (MLA), %IH (intimal hyperplasia [IH]/stent area) at MLA, the 
lengths of the ISR lesion (IH-containing length of the stent with a MLA<4.0mm2), net volume 
obstruction, and neointima free stent length were similar in DM and non-DM pts.
Conclusion: Despite smaller stents, neointima growth patterns in restenotic SES were 
almost identical in DM and non-DM pts. Thus, post-SES implantation, the neointimal 
hyperplasia response does not appear to be more aggressive in DM pts than in non-DM 
pts. This IVUS analysis indicates that SES has lessened the importance of DM as a risk 
factor for ISR after stent implantation. 
DM
(n=21)
Non-DM
(n=26) p Value
Minimum lumen area (MLA, mm2) 2.7±1.0 2.8±1.0 0.6
Stent area at MLA (mm2) 5.0±1.6 5.9±2.0 0.1
%IH at MLA 45.7±14.0 50.9±13.1 0.2
Proximal reference vessel area (mm2) 11.7±3.3 15.1±6.9 0.2
Distal reference vessel area (mm2) 8.0±3.8 8.7±5.0 0.6
Stent length (mm) 43.7±18.3 38.6±20.6 0.4
Average stent area (mm2) 5.8±1.7 6.3±2.0 0.4
Net volume obstruction (%) 9.0±6.7 11.8±6.8 0.2
ISR length (mm) 6.0±5.1 6.1±5.7 0.9
Neointima free stent length (mm) 27.8±17.8 21.4±13.9 0.2
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2904-61 Construct Validation of Virtual Reality Simulation for 
Carotid Artery Stenting
Amar D. Patel, William J. Nicholson, Christopher U. Cates, From the Emory Angiographic 
Simulation Training (EAST) Center, Emory University, Atlanta, GA
Background: As a result of the high complexity and risk associated with percutaneous 
endovascular procedures such as carotid artery stenting (CS), virtual reality (VR) 
simulation training is recommended as an approach to instruct novices and to evaluate 
the psychomotor components of a procedure ex vivo. We assessed the ability of the 
Vascular Interventional System Trainer (VIST) VR simulator to detect differences in novice 
(NP) and expert (EP) physicians performing CS.
Methods: The performance of 22 NP (mean <2 CS total cases) was compared to 8 EP 
(mean >150 CS total cases) performing simulated right CS. All subjects were participants 
in a formalized didactic training course for CS that involved performing 1 supervised, 
mentored simulation after didactic training. A supervised, but unmentored simulated 
CS case was subsequently performed with measures of performance recorded by the 
simulator.
Results: EP made fewer errors involving catheter handling, guidewire use, and use of 
the embolic protection device. Also, EP performed the procedure faster and used less 
ﬂuoroscopy than NP. There were no differences in stent or balloon sizing relative to 
the lesion or vessel between the groups. No difference in the stent deployment errors 
between the 2 groups was observed. Overall, EP made far fewer total errors compared 
to NP (See table below).
Conclusion: The VIST VR simulator is capable of differentiating both NP and EP 
who perform CS based on both static and dynamic measures of operator technical 
performance.
2904-62 Interventional Vascular Simulation Is Mostly Beneﬁcial 
for Training of Fellows and Teaching the Use of New 
Devices and Procedures
Giora Weisz, William Gray, Lisa Hathaway, Patricia Knipper, Chad Bertling, Michelle 
Gong, Gregg W. Stone, Martin B. Leon, Cardiovascular Research Foundation, New York, 
NY, Columbia University Medical Center, New York, NY
Introduction: Interventional Vascular Simulation (IVS) is an emerging technology in 
simulation-based medical education, although its full role has not been established yet. 
We report the assessment of IVS throughout various training categories as evaluated by 
a large group of interventional cardiologists.
Methods: During TCT 2004, attendees could participate in hands-on introductory sessions 
on 23 simulators made by 6 different manufacturers (CATHI, Immersion Medical, Medical 
Simulation Corporation, Mentice, Simbionix, Xitact) that simulated coronary, carotid, and 
renal interventions. At the end of the session, participants evaluated the simulators and 
educational sessions, and graded IVS as a training tool.
Results: A total of 379 interventional cardiologists ﬁlled the evaluation form, of whom 75% 
were attending physicians, with mean experience of 8 years of interventional practice, 
and mean of 200 interventions per year. The Table summarizes the evaluation of IVS. 
Values are given on a scale of 1-5 (5=best, 1=worst)
Grading (range)
TCT simulation session rating 4.23 (4, 5)
Resemblance of simulation to actual cases 3.69 (3, 4)
Current technology status 3.77 (3, 4)
Beneﬁt for fellows in cardiology 4.35 (4, 5)
Beneﬁt for fellows in interventional cardiology 4.46 (4, 5)
Beneﬁt to experienced interventionalists 3.83 (3, 5)
Beneﬁt for training for new device/procedure 4.44 (4, 5)
Beneﬁt to patients 3.82 (3, 5)
Objectivity in credentialing process 3.73 (3, 4)
A total of 92.2% of the fellows and 95.3% of the attending physicians believed that 
simulator training should be implemented prior to training on patients.
Conclusions: As evaluated by large cohort of interventional cardiologists, IVS may 
provide the largest beneﬁt for fellows in training and for guiding the use of new devices 
and procedures. The current technology status and resemblance of IVS to actual cases 
were rated as fair. Further studies are needed to validate the beneﬁt of IVS for training 
and credentialing.
2904-63 Correlation of Static and Dynamic Measures of 
Performance During Simulated Carotid Angiography
Amar D. Patel, Reza Fazel, William J. Nicholson, Tarek Helmy, Christopher U. Cates, 
From the Emory Angiographic Simulation Training (EAST) Center, Emory University, 
Atlanta, GA
Background: The use of high-ﬁdelity virtual reality simulators in the performance 
assessment of complex percutaneous endovascular procedures is emerging. Operator 
technical performance during virtual reality simulation can be assessed using static (not 
directly dependent on the operator and the environment) and/or dynamic (operator and 
environment dependent) measures of performance (metrics). We sought to determine the 
correlation between the static and dynamic metrics of physicians performing simulated 
carotid angiography (CA) using the Vascular Interventional System Trainer (VIST, Mentice 
AB, Gothenburg, Sweden).
Methods: 79 experienced endovascular physicians with limited CA experience 
(mean=65 total cases) performed 230 simulated CA cases within the constructs of the 
Emory NeuroAnantomy Carotid Training Course. Prior to performing these simulations, 
all participants were given formalized didactic training followed by 1 supervised and 
mentored instruction on performing simulated CA. Supervised, but unmentored simulated 
CA cases were then performed with static (procedure time (PT), ﬂuoroscopy time (FT), 
and contrast volume (CV)) and dynamic (catheter vessel errors, catheter movement 
errors) metrics recorded by the simulator.
Results: Multivariate linear regression adjusting for physician subspecialty and prior 
peripheral procedure experience showed that PT was directly proportional to the number 
of catheter-related handling errors (correlation coefﬁcient (R) = 0.0088; p<0.0003). There 
was no signiﬁcant association between FT and the number of catheter errors (R = -0.0014; 
p = 0.54). CV paradoxically showed an inverse correlation, in that as the amount of CV 
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increased, the number of catheter-related errors decreased (R = -0.052; p = 0.007).
Conclusions: Static measures of performance such as FT and CV do not predict the 
number of dynamic metric errors and, therefore, true operator procedural performance. 
PT was the only static metric that correlated with operator performance. Dynamic metrics 
of performance should be used as measures of performance when assessing operator 
technical skill.
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2905-64 Treatment of Calciﬁc Aortic Stenosis With the Edwards 
Percutaneous Heart Valve: Mid-Term Follow-Up From 
the Initial Feasibility Studies
Helene Eltchaninoff, Christophe Tron, Vasilis Babaliaros, Fabrice Bauer, Carla Agatiello, 
Sydney Tapiero, Deborah Nercolini, Alain Cribier, Charles Nicolle Hospital, Rouen, France
Background: We developed a percutaneous heart valve (PHV) made of equine pericardium 
valve sutured in a balloon-expandable, stainless-steel stent to treat inoperable patients 
with aortic stenosis. The aim of our study was to assess the feasibility, safety, efﬁcacy and 
durability of percutaneous heart valve (PHV) implantation in the aortic position.
Methods: 37 patients (aortic valve area <0.7cm2, class IV NYHA, and severe 
comorbidities) were recruited after formally declined for surgical valve replacement. A 
PHV mounted on a delivery balloon was implanted by retrograde or antegrade trans-
septal approach. Clinical and echocardiographic outcomes were assessed serially.
Results: Twenty-seven patients were implanted successfully (23 antegrade, 4 retrograde) 
in the subcoronary position with improvement in valve area (0.60±0.11 cm2 to 1.70±0.10 
cm2, p<0.0001) and transvalvular gradient (37±13 mmHg to 9±2 mmHg, p<0.0001). 
Paravalvular aortic regurgitation was grade 0-1 (n=10), grade 2 (n=12), and grade 3 
(n=5). One week post-procedure, improvement in left ventricular function (45±18% to 
53±14%, p=0.02) was most pronounced in patients with ejection fraction <50% (35±10% 
to 50±16%, p<0.0001). Thirty-day major adverse events after successful implantation 
were 26% (pericardial tamponade, stroke, arrhythmia, sepsis and one death unexplained 
at autopsy). Eleven patients are currently alive with follow-up of 6 months (n=2), 7 months 
(n=3), 8 months (n=1), 9 months (n=2), 20 months (n=1) and 24 months (n=2). All patients 
experienced amelioration of symptoms (>90% class I or II NYHA). PHV function remained 
unchanged during follow-up, and no deaths were device-related.
Conclusions: With continued advances, PHV implantation should become a treatment 
for select patients with degenerative aortic stenosis.
2905-65 Crossing Coronary Arteries With the Carillon™ Mitral 
Contour System in Healthy Canines
Richard Van Bibber, Garrett Beget, David Reuter, Cardiac Dimensions, Inc., Kirkland, WA
Background: The Carillon™ Mitral Contour System is a percutaneous mitral valve therapy 
for patients with mitral valve regurgitation secondary to dilated cardiomyopathy. The 
Carillon™ is a permanent coronary venous implant. Coronary arteries sometimes cross 
the veins in the implant target zone. The effect of the Carillon™ on arterial dimensions 
and blood ﬂow will help determine the optimal implant strategy.
Methods: 12 healthy canines were implanted with the Carillon™ and survived for 6 weeks. 
Arteries were crossed in every dog. Mitral annular diameter was measured with transthoracic 
echocardiography. The impact of the Carillon™ on crossing arteries was assessed with 
angiography, intravascular ultrasound and fractional ﬂow reserve (FFR). Coronary artery 
stents (Guidant Corp.) were used to correct ﬂow defects caused by the implant.
Results: Mitral annular diameter was reduced acutely and chronically. 15 coronary 
arteries were crossed. 10 of the 12 dogs had no signiﬁcant arterial defects following 
implantation or 6 weeks later. In 2 dogs, each with an artery crossing under the Carillon™, 
ﬂow defects were detected at implant. Coronary stents resolved the ﬂow defects.
Conclusions: 1) Arterial defects occurred in only 2 of 15 arteries. 2) If there was no 
arterial defect observed acutely following Carillon™ implantation, none developed 
chronically regardless of whether the artery crossed over or under the implant. 3) Acute 
arterial defects can be corrected by recapturing the implant or with stents.
Data From Animals Without Stents (n=10, mean +/- SEM)
Post-Implant Chronic(Six Weeks)
TIMI Flow in Crossed Arteries 3 3
FFR 0.97 ± 0.01 0.96 ± 0.01
Arterial Lumen Diameter (% Change from Baseline) -8 ± 3 0 ± 3
Mitral Annular Diameter (% Reduction from Baseline) 20 ± 2 13 ± 2
 
2905-66 Annular Function in Patients Undergoing Mitral Valve 
Repair: Is Annuloplasty Always Needed?
Francesco Maisano, Ottavio Alﬁeri, San Raffaele Scientiﬁc Institute, MIlano, Italy
Background: Surgical mitral valve reconstruction is performed by combination of leaﬂet 
and annular repair. Since annuloplasty has shown to improve durability of repair, it is usually 
carried out regardless the actual presence of an annular dilatation or dysfunction. With 
the advent of transcatheter leaﬂet repair, identiﬁcation of patients with preserved annular 
function is becoming critical. We retrospectively analysed a series of patients undergoing 
mitral valve repair, to identify those individuals with preserved annular function.
Methods: Preoperative echo data regarding 82 pts undergoing mitral repair for degenerative 
regurgitation with the use of annuloplasty ring were prospectively collected, including mitral 
annulus systolic intercommissural (CC) and septo-lateral (SL) dimensions, and the length 
of the anterior (AL) and posterior (PL) leaﬂets. The ratio of SL/AL was used to measure 
annular dilatation (SL/AL >1.4). Following mitral repair, the ratio between the preoperative 
CC distance and the size of the implanted annular prosthesis (CC/SR) was used to identify 
pts with preserved annular function, who did not need annular remodelling.
Results: All patients underwent successfull mitral repair. Mean preoperative CC dimension 
was 46±5.8 mm, SL was 42±5.3 mm, AL was 31±5.3 mm and PL was 21±5.8mm. The 
mean SL/AL ratio was 1.67±0.35. Mean implanted prosthesis size (SR) was 34±3.2 
mm, with a mean CC/SR ratio of 1.34±0.14. In 16 pts (19%), the CC/SR ratio was lower 
than 1.2, indicating a minimal remodelling obtained by annuloplasty and suggesting the 
presence of preserved annular function. CC/SR ratio <1.2 was more frequently observed 
in patients with SL/AL ratio lower than 1.4 (p=0.009).
Conclusions: In current surgical candidates, annular function is preserved in less than 
20% of the population. The ratio between annular and leaﬂet size is a good indicator of 
annular function. In this subgroup of patients, an isolated leaﬂet repair may be indicated. 
Further studies are needed to identify the incidence of annular dysfunction in non surgical 
candidates, who could possibly be candidate for a earlier percutaneous intervention.
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2906-67 What Is the Best Quantitative Surrogate of Target 
Lesion Revascularization? An Angiographic and 
Volumetric Intravascular Ultrasound Meta-analysis 
From the Taxus IV, V, and VI Trials
Gary Mintz, Neil J. Weissman, Jeffery Popma, Keith Dawkins, Eberhard Grube, Stephen 
Ellis, Devin Katz-Sawyer, Peter Lam, Joerg Koglin, Gregg W. Stone, Washington 
Hospital Center, Washington, DC, Cardiovascular Research Foundation, New York, NY
Background: The efﬁcacy of anti-restenosis drug-eluting stents can be assessed 
clinically or using methods such as quantitative coronary angiography (QCA) or 
intravascular ultrasound (IVUS). While clinical outcomes are ultimately the most 
meaningful, quantitative surrogates have the advantage of reducing sample sizes and 
providing mechanistic insights.
Methods: To determine the best quantitative surrogate for 9-month target lesion 
revascularization (TLR), we performed a meta-analysis of 547 patients with paired QCA 
and IVUS data from TAXUS IV, V, and VI. QCA parameters included in-segment diameter 
stenosis (DS) and in-segment late loss (LL). Volumetric IVUS parameters included % in-
stent intimal hyperplasia (%IH; volume divided by stent volume) and minimum lumen area 
(MLA). The receiver operating characteristics (ROC) method using c-statistics was used 
to assess the correlation of each surrogate endpoint to predict TLR.
Results: As shown in the Table, all 4 quantitative measures demonstrated signiﬁcant 
(p<0.0001) anti-restenosic efﬁcacy of TAXUS stent implantation. However, the two QCA 
parameters were better than the two IVUS parameters as surrogates for TLR. In particular, 
QCA DS (c=0.959) correlated best with TLR, even better than late loss (c=0.907).
Conclusion: While detailed IVUS analyses can provide mechanistic insights distinct from 
those obtained clinically or angiographically, QCA parameters are better surrogates for 
angiographically-driven outcomes (TLR) than IVUS. 
c-statistic
Overall BMS TAXUS Overall BMS TAXUS
In-Segment %DS 33.5±17.9 (547)
39.3±18.0 
(263)
28.1±16.1 
(284) 0.959 0.923 0.988
In-Segment LL 
(mm)
0.42±0.54 
(547)
0.60±0.53 
(263)
0.25±0.49 
(284) 0.907 0.820 0.976
In-Stent %IH 21.2±16.3 (547)
31.1±14.5 
(263)
12.1±11.8 
(284) 0.771 0.772 0.748
MLA (mm2) 4.85±2.19 (546)
4.39±2.21 
(262)
5.28±2.08 
(284) 0.678 0.640 0.714
 
2906-68 Assessing Drug-eluting Stent Expansion: Lessons 
Learned From Intravacular Ultrasound
Jose de Ribamar Costa, Jr., Gary S. Mintz, Stephane G. Carlier, Kenichi Fujii, 
Masashi Kimura, Koichi Sano, Kaoru Tanaka, Yingbo Na, Joanna Lui, Sinan Biro, 
Celia Castellanos, George Dangas, Edwards M. Krepps, Michael Collins, Issam 
Moussa, Gregg W. Stone, Jeffrey W. Moses, Martin B. Leon, Cardiovascular Research 
Foundation, New York, NY, Columbia University Medical Center, New York, NY
Backgound: Despite the effectiveness of drug-eluting stents (DES), stent expansion 
remains an important predictor of restenosis and subacute thrombosis. Compliance 
charts were developed to guide stent size selection and predict ﬁnal minimum stent 
diameter (MSD) and area (MSA). We assessed the relation between the MSD and MSA 
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measured by intravascular ultrasound (IVUS) vs. that predicted by the manufacturers’ 
compliance charts of the 2 currently US-approved DES. 
Methods: We enrolled 200 pts with de novo coronary lesions treated with a single, 
>2.5mm Cypher® (SES, 133 pts) or Taxus® (PES, 67 pts) under IVUS guidance without 
post-dilation. 
Results: Overall, stents achieved only 75±10% of the predicted MSD and 66±17% 
of the predicted MSA. 98% of all stents failed to achieve the predicted MSD, and only 
0.3% achieved the expected MSA. Furthermore, 24% of SES and 28% of PES did not 
achieve a ﬁnal MSA of 5mm2, a consistent predictor of DES failure. Lesion morphology, 
arc of calcium, stent and lesion length, and reference vessel size did not affect DES 
expansion. Small diameter SES (2.5mm), when deployed at pressures <15atm achieve 
worse expansion than PES (56% vs. 83%, p<0.001). For the other sizes and pressures 
there were no differences between SES and PES. 
Conclusions: (1) Compliance charts fail to predict the MSD and MSA. (2) An important 
percentage of DES fail to achieve even minimum standards of stent expansion 
(MSA=5.0mm2). (3) Post-dilation should be performed more often to optimize DES 
deployment for 2.5 mm SES.
2906-69 Incidence and Impact of Plaque Prolapse After Drug-
eluting Stents in the Diabetic Patients: A 3D Volumetric 
Intravascular Ultrasound Study
Hideki Futamatsu, Marco A. Costa, Pilar Jimenez-Quevedo, Dominick J. Angiolillo, 
Cecilia Corros, Kino Morikawa-Futamatsu, Fernando Alfonso, Julie Jiang, Pavel 
Cervinka, Rosana Hernandez-Antolin, Carlos Macaya, Theodore A. Bass, Manel 
Sabaté, Cardiovascular Imaging Core Laboratories, University of Florida, Jacksonville, 
FL, Cardiovascular Institute, San Carlos University Hospital, Madrid, Spain
Background: Plaque prolapse (PP) has been observed in up to 22% of patients treated 
with bare metal stents. PP may be more frequent in diabetic patients because of their 
larger atherosclerotic burden. The incidence of PP following drug-eluting stent (DES) 
implantation and its clinical impact is unknown. This study evaluated the PP phenomenon 
after bare metal and DES implantation in diabetic patients using 3D volumetric 
intravascular ultrasound (IVUS).
Methods: IVUS was performed post-intervention and at 9-months follow-up in 169 
diabetic patients with 207 lesions treated with bare BX-Velocity stent (BMS, n=60), 
Sirolimus-eluting BX-Velocity stents (SES, n=74), and Paclitaxel-eluting stent (PES, 
n=73). IVUS data at the sites of PP were compared with the other regions of the stented 
segment in each lesion.
Results: Baseline characteristics were similar between groups. There were 39 sites of 
PP (BMS=11, SES=11, PES=17) in 32 stented segments of 207 (15.5%) lesions. The 
incidence of PP was similar in all populations (BMS vs. SES vs. PES; 16.7% vs. 12.2% 
vs. 19.2%). There were no stent thrombosis associated with PP. PP were more frequent 
in the right coronary artery (RCA vs. others: 68.8% vs. 31.2%, P<0.05). Post-procedure 
PP volume was 3.23mm3 in SES, 5.25mm3 in PES and 1.67mm3 in BMS. After 9 months, 
changes in plaque volume (follow-up - post) at PP was signiﬁcantly different between 
SES vs. BMS (p=0.009) and SES vs. PES (p=0.04) (SES=-0.82mm3; PES=+4.99mm3; 
BMS=+8.2 mm3). There were no differences in mean plaque areas at 9-months between 
the sites with and without PP (SES= 0.55mm2 vs. 0.77mm2, PES= 1.8mm2 vs. 1.53mm2, 
BMS= 3.28mm2 vs. 3.24mm2, respectively). Restenosis was observed in 44% of BMS 
patienst with PP vs.27.5% in those without PP.
Conclusions: A high incidence of PP was observed after implantation of new generation 
tubular stents in diabetic patients. DES were not associated with increased risk of PP. 
There was a increase in PP volume in both BMS and PES but not after SES. PP appears 
to be a benign phenomenon, as it was not associated with higher risk of thrombosis and 
did not elicited an increased neointimal proliferation when compared to segments without 
PP in each group.
2906-70 Is Stent Underexpansion the Main Cause of In-stent 
Restenosis After Sirolimus-eluting Stent Implantation?: 
An Intravascular Ultrasound Study
Byoung-Keuk Kim, Sungjin Oh, Dong Woon Jeon, Kyung Heui Kim, Yong Sun Moon, 
Kyung Jin Park, Joo Young Yang, National Health Insurance Corporation Ilsan Hospital, 
Koyang-shi, South Korea
Background: Intravascular ultrasound(IVUS) is useful in assessing the causes of in-
stent restenosis(ISR) after sirolimus-eluting stent(SES) implantation. We used IVUS to 
evaluate the causes of ISR after SES implantation.
Methods: Between March 2003 and November 2004, a total of 332 patients(pts) with 
437 lesions were treated with 520 SESs in our institute. 17 pts out of them had ISR in 18 
lesions(3.4%), and IVUS assessment was applicable to 13 lesions of them. We described 
the patterns of ISR and sought to ﬁnd the possible causes of ISR after SES implantation 
with the aid of IVUS analysis.
Results: 17pts with ISR were: male 53%, diabetics 18%, and age 66 ± 9 years. Pre-
procedural mean reference vessel diameter(RVD) was 2.83±0.34 mm and lesion 
length(LL) was 37.4 ± 17.5 mm. In 9 lesions(50%), overlapping of 2 SESs was required 
for full lesion coverage of diffuse long lesion. The pattern of ISR in 17 lesions(94%) 
was focal(gap; 1, margin; 2, body; 12, multifocal; 2 lesions). Diffuse ISR was noted 
in 1 lesion(restenotic LL; 14.5 mm). Analyzing IVUS-applicable 13 lesions, stent 
underexpansion [minimal stent CSA < 5 mm2 in non-small artery or minimal stent CSA 
< 4.5 mm2 in small vessel artery(RVD< 2.8 mm)] was observed in 7 lesions(54%), and 2 
lesions of them were chronic total occlusion. Stent fracture or stent discontinuity (absence 
of stent struts on IVUS at restenotic lesion) was identiﬁed in 3 lesions(23%)[one lesion 
of them was a gap between 2 different SESs, not overlapped on IVUS]. Proximal edge 
restenosis was shown in 2 lesions; one lesion was related to residual dissection after the 
procedure, the other to balloon trauma outside the stent. Except for edge ISR related to 
local injury, stent underexpansion(7 of 11 lesions, 64%) was the most common IVUS 
ﬁnding of intra-stent ISR.
Conclusions: The common IVUS ﬁndings in SES restenosis in our study group are stent 
underexpansion, stent fracture, and edge restenosis related to local injury. In cases of 
intra-stent ISR(with the exception of edge restenosis), stent underexpansion was more 
related to coronary restenosis. Therefore, this study suggests that IVUS is required to 
assess adequate expansion of stent and to prevent ISR.
2906-71 Neo-intimal Coverage Following Sirolimus-Eluting 
Stent Implantation Under the Current Dual Anti-platelet 
Therapy: An Angioscopic Study
Jun-ichi Kotani, Masaki Awata, Shinsuke Nanto, Masaaki Uematsu, Takakazu Morozumi, 
Toshinari Onishi, Osamu Iida, Noriaki Ito, Fusako Oshima, Hitoshi Minamiguchi, 
Kunihiro Akahori, Seiki Nagata, Kansai Rosai Hospital, Amagasaki, Japan
Background:Neo-intimal covering after stent implantation is not well understood, 
particularly after the recently emerged drug eluting stents (DES). 
Methods: To assess the intimal covering following DES as well as bare metal stents (BMS), 
we studied 37 stents (15 DES and 22 BMS) using angioscopy. The patients received both 
aspirin (100 mg) and ticlopidine (200 mg) every day until follow-up. The degree of neo-
intimal covering and the existence of thrombi were evaluated. Intimal covering was graded 
as: grade 0 = struts were exposed similarly to the time of implantation; grade 1 = struts 
were covered, but not embedded; grade 2 = struts were embedded by the neo-intima; and 
grade 3 = struts were fully embedded and invisible by angioscopy. 
Results: There was no difference in follow-up duration between the two groups (132±48 
days in BMS vs 116±47 days in DES; P=0.3). See ﬁgure for the grades. White thrombi 
were seen in one BMS, and mural red thrombi were seen in 5 DES and 2 BMS (P=0.14). 
Conclusion: Given similar long-term anti-platelet drug administration, all struts of bare-
metal stents were completely embedded by the neo-intima, but not those of sirolimus-
eluting stent (13.3%); 20% of struts were still exposed.
2906-72 Angioscopic Evaluation of Neointimal Coverage 
Following Treatment of In-Stent Restenosis: 
Comparison Between Brachytherapy, Drug-eluting 
Stent Implantation and Balloon Angioplasty
Jun-ichi Kotani, Masaki Awata, Shinsuke Nanto, Masaaki Uematsu, Takakazu Morozumi, 
Toshinari Onishi, Osamu Iida, Noriaki Ito, Fusako Oshima, Hitoshi Minamiguchi, 
Hirokuni Akahori, Seiki Nagata, Kansai Rosai Hospital, Amagasaki, Japan
Background: The pattern and magnitude of neointimal coverage following treatment 
of in-stent restenosis (ISR) are little known. The aim of this study was to compare the 
angioscopic ﬁndings following different strategies for ISR. 
Methods: Follow-up (7.5±3.0 months) angioscopy was performed in 44 stented segments 
that had been treated for ISR by vascular brachytherapy using beta-ray (VBT; n=14), 
drug-eluting stent (DES) implantation (n=11), and cutting/regular balloon angioplasty 
(n=19). The study focused on neointimal coverage and existence of thrombus. Intimal 
coverage over the stent was graded as follows: grade 0 = struts were exposed similarly 
to the time of implantation; grade 1 = struts were covered, but not embedded; grade 2 
= struts were embedded by the neointima; grade 3 = struts were fully embedded and 
invisible by angioscopy. 
Results: No white thrombus was identiﬁed but red mural thrombi were detected in 28.6% of 
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VBT, 15.8% of balloon angioplasty and 18.2% of DES (P=0.7). Complete neointimal coverage 
(grades 2/3) was seen in 89.5% of balloon angioplasty as compared to 43.9% of VBT and 
28.2% of DES (ﬁgure). Conclusion: Angioscopic assessment of neointimal coverage 
following in-stent restenosis treatment was dependent on the treatment strategies.
 
2906-73 Optical Coherence Tomographic Analysis of Neointimal 
Stent Coverage in Sirolimus-eluting Stent, Compared 
With Bare Metal Stent
Tatsuya Ito, Mitsuyasu Terashima, Yoshihiro Takeda, Osamu Katoh, Tetsuo Matsubara, 
Etsuo Tsuchikane, Mariko Ehara, Yoshihisa Kinoshita, Kenya Nasu, Jean-Francois 
Surmely, Nobuyoshi Tanaka, Akira Murata, Hiroshi Fujita, Koyo Sato, Takahiko Suzuki, 
Toyohashi Heart Center, Toyohashi, Japan
Background: Optical coherence tomography (OCT) is a high-resolution (about 10 µm), 
catheter based imaging modality. The aim of this study was to analyze the time course 
of neointimal coverage of Sirolimus-Eluting Stent (SES) with this new imaging modality, 
compared with bare metal stent (BMS).
Methods: Using OCT, 12 SES and 5 BMS were evaluated at 2-month follow-up, and 
11 SES and 9 BMS were at 8-month follow-up. OCT images of all stents were obtained 
by pulling back OCT optical ﬁber automatically at 1.0mm per second, and analyzed 
at intervals of 1mm. Every observed strut was classiﬁed into either covered (C-S) or 
uncovered (UC-S). Neointimal thickness (NIT) was measured at the site of covered stent 
strut, and mean and maximal neointimal thicknesses in each stents were obtained.
Results: Results are shown in Table. At both 2- and 8-month follow-up, mean and 
maximal NIT in SES were signiﬁcantly less than in BMS (At 2-month: p < 0.01, p < 0.01, at 
8-month: p < 0.01, p < 0.01, respectively). Beside, mean and maximal NIT were increased 
signiﬁcantly from 2-month to 8-month follow-up in both groups. Percentage of UC-S was 
higher in SES compared to BMS (at 8-month, p = 0.029).
Conclusions: According to OCT analysis, neointimal formation in SES was signiﬁcantly 
less than in BMS. At 8-month follow-up, frequency of uncovered stent struts in SES was 
still higher than in BMS. These ﬁndings could possibly explain the occurrence of late 
thrombosis in SES.
DES 2M DES 8M BMS 2M BMS 8M
mean NIT (mm) 0.05 ± 0.03 0.09 ± 0.04 0.17 ± 0.03 0.43 ± 0.18
maximal NIT (mm) 0.27 ± 0.09 0.41 ± 0.09 0.59 ± 0.07 1.08 ± 0.37
UC-S (%) 12.1 ± 10.9 5.2 ± 5.6 5.1 ± 6.0 0.7 ± 0.9
C-S (%) 87.9 ± 10.9 94.8 ± 5.6 94.9 ± 6.0 99.3 ± 0.9
 
2906-74 The Importance of Calcium in Ruptured Saphenous 
Vein Graft Plaques: An Intravascular Ultrasound 
Analysis
Aleksandra Michalek, Gary S. Mintz, Jerzy Pregowski, Pawel Tyczynski, Sang-Wook 
Kim, Salah-Eddine Hassani, Szymon Bieganski, Li Lu, Witold Pikto-Pietkiewicz, Tomasz 
Pasierski, Neil J. Weissman, Cardiovascular Research Institute/Medstar Research Institute, 
Washington Hospital Center, Washington, DC, Miedzyleski Hospital, Warsaw, Poland
The relationship of patterns of saphenous vein graft (SVG) calciﬁcation to plaque instability 
has not been studied. Methods. To determine the relationship of calcium to SVG plaque 
ruptures, we analyzed 95 IVUS-identiﬁed ruptured SVG plaques and compared them with 
81 matched non-ruptured SVG plaques. IVUS analysis included 10mm long segments 
centered on the minimum lumen area; the length and number of calcium deposits 
was assessed and the arc of calcium was measured every 0.5mm. Results. 40 SVG 
ruptured plaques and 33 non-ruptured plaques contained calcium. Ruptured plaques had 
smaller arcs and shorter lengths of individual calcium deposit than control plaques. The 
distribution of superﬁcial vs deep calcium was similar between the two groups, although 
the deep calcium deposits were smaller in ruptured than in control SVG plaques. Within the 
ruptured plaque group, we then analyzed calcium deposits seen in the same image slice 
as the ruptured cavity and compared these deposits to the proximal and distal references. 
The arc of lesion calcium was signiﬁcantly smaller (40.0±28.9º vs 54.9±28.45º, p<0.001) 
and the length was signiﬁcantly shorter (1.89±1.3 vs 2.34±1.4mm, p=0.046) than calcium 
seen in the reference segments. Conclusion. Ruptured SVG plaques are associated with 
smaller and shorter calcium deposits. This ﬁnding is similar to what has been reported 
in native coronary arteries and suggests that the presence of small pieces of calcium 
impacts on plaque instability even in SVG lesions. 
Ruptured SVG 
plaques
Non-ruptured SVG 
plaques p
Number of calcium deposits/
plaque 2.15 1.93 0.43
Arc of calcium deposits 48.3±29.4º 63.1±42.1º 0.019
Length of calcium deposits 2.1±1.4mm 3.4±2.5mm <0.001
Deep/superﬁcial calcium (%) 38.4%/61.6% 38.5%/61.5% 1.0
Arc of deep Ca deposits 36.3±17.0º 54.1±33.9º 0.011
Length of deep deposits 1.8±1.4mm 3.4±2.5mm 0.003
Arc of superﬁcial deposits 55.7±33.0º 68.7±46.0º 0.12
Length of superﬁcial deposits 2.3±1.3mm 3.5±2.5mm 0.005
 
2906-75 Relationship Between Stent Apposition Pattern 
and Neointimal Coverage after Sirolimus-Eluting 
Stent Implantation: Analysis by Optical Coherence 
Tomography Imaging
Mitsuyasu Terashima, Tatsuya Ito, Osamu Katoh, Tetsuo Matsubara, Etsuo Tsuchikane, 
Mariko Ehara, Yoshihisa Kinoshita, Tomomichi Suzuki, Yoshihiro Takeda, Kenya Nasu, 
Jean-Francois Surmely, Nobuyoshi Tanaka, Akira Murata, Takahiko Suzuki, Toyohashi 
Heart Center, Toyohashi, Japan
Background: Previous animal study reported that the severity of vessel wall injury induced 
by stent implantation is related to the magnitude of resulting neointimal proliferation. The 
aim of this study is to analyze the relationship between apposition patterns of Sirolimus-
Eluting Stent (SES) strut to vessel wall and neointimal coverage of strut using optical 
coherence tomography (OCT).
Methods: Using OCT, 1264 struts of 12 SES in 10 patients at 2-month follow-up were 
evaluated. All OCT images were obtained by pulling back OCT optical ﬁber automatically 
at 1.0mm per second, and analyzed at intervals of 1mm. Every observed strut was 
classiﬁed into either covered or uncovered. Neointimal thickness (NIT) was also 
measured at the site of covered stent strut. Apposition patterns of stent strut to vessel 
wall were classiﬁed into 3 groups: A+: apposition with indentation, A-: apposition without 
indentation, or incomplete apposition (ﬁgure). Rate of stent coverage and mean NIT were 
compared between A+ struts and A- struts.
Results: A+ was found in 651struts, A- in 611struts, and incomplete apposition in 2 
struts. Rate of stent strut coverage in A+ was higher than that in A- (97.5% vs 71.4%, 
p<0.05). There was no difference in mean NIT between A+ and A- (0.1 ± 0.04mm vs 
0.06 ± 0.03mm).
Conclusions: This OCT analysis showed that apposition patterns of SES strut to vessel 
wall were related to neointimal coverage of stent strut. Tight apposition of strut to vessel 
wall would lead to favorable neointimal stent coverage.
 
2906-76 Phasic Patterns of Intramyocardial Coronary 
Artery Flow Velocity in Patients With takotsubo 
Cardiomyopathy as Assessed With Doppler Flow Wire
Hiroshi Yamaguchi, Shinichiro Toyoshima, Takashi Kuwahata, Yuko Furusho, Kazuaki 
Kiyonaga, Yoshifumi Toyama, Nanpuh Hospital, Kagoshima, Japan
Impaired coronary circulation in takotsubo cardiomyopathy remains unknown. The aim of 
this study was to investigate the phasic ﬂow velocity patterns in septal coronary arteries in 
the ventricular septum with myocardial damages and clarify characteristics. 
Methods and Results: In ten patients (mean age, 72±8 years; 2 males, 8 females) 
with takotsubo cardiomyopathy, phasic patterns (average peak velocity: APV and ratio 
of diastolic to systolic APV: DSVR) of the coronary ﬂow velocity in septal arteries and 
coronary ﬂow reserve (CFR), using 0.014 inch Doppler ﬂow wire, were examined in both 
the acute (2.3±1.9 days) and the convalescent stage (33±9 days). Severe left ventricular 
dysfunction was present on admission (ejection fraction, 38±9 %) and rapidly improved 
in all patients (ejection fraction at four weeks, 60±11 % P<0.01). In all patients, systolic 
reversal and “dip and dome” phasic pattern in the diastole were detected in acute phase 
and disappeared in the convalescent phase. Accordingly, APV, DSVR and CFR improved 
from 17± 6cm/sec, 7.5±2.6 and 1.9±0.3 in the acute phase to 26±11 cm/sec (p<0.05), 
2.1±0.6 (p<0.05) and 2.7±0.5 (p<0.01) respectively, in the convalescent phase. 
Conclusions: The systolic reversal and “dip and dome” diastolic phasic pattern in the 
intramyocardial coronary artery ﬂow velocity and decreased CFR are characteristics in 
“takotsubo cardiomyopathy” and may be caused by transient coronary microvascular 
abnormalities.
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Left Main Disease Intervention
Sunday, March 12, 2006, 1:30 p.m.-5:00 p.m.
Georgia World Congress Center, Hall B1
Presentation Hour: 2:30 p.m.-3:30 p.m.
2907-77 Drug Eluting Stent Implantation Versus Bypass 
Surgery in Unprotected Left Stenosis: A Single Center 
Experience
Alaide Chieffo, Nuccia Morici, Francesco Maisano, Matteo Montorfano, Flavio 
Airoldi, Mauro Carlino, Gloria Melzi, Iassen Michev, Ottavio Alﬁeri, Antonio Colombo, 
Interventional Cardiology Unit, San Raffaele Hospital, Milan, Italy, Cardiac Surgery Unit, 
San Raffaele Hospital, Milan, Italy
Background: Improvements in results with drug-eluting stent (DES) extend their usage 
in unprotected left main (LMCA) stenosis. 
Methods: All patients with LMCA stenosis treated with PCI with DES implantation or 
by-pass surgery in our Center between March 2002 and July 2004 were analyzed. The 
primary clinical end point was the cumulative occurrence, during hospitalization and at 
one year, of major adverse cardiac and cerebrovascular events (MACCE) deﬁned as 
death, myocardial infarction, cerebrovascular events and taget vessel revascularization. 
The secondary end-point was the cumulative occurrence of death, myocardial infarction 
and cerebrovascular events. Adjustment for the propensity score, which takes into account 
differences in baseline and lesion characteristics was performed. 
Results: Two-hundred and forty-nine patients have been treated: 142 with by-pass 
surgery (CABG) and 107 with PCI with DES implantation (PCI). Patients treated with PCI 
were younger (63.6±10.3 vs. 67.5±9.7 years; p=0.002), less frequently had hypertension 
(58.8% vs. 76.0%; p= 0.006) and renal failure (1.9% vs 8.4%; p= 0.02) but more often 
presented with unstable angina (31.8% vs. 21.8%; p=0.08). At one year, there was no 
difference in the occurrence of MACCE in PCI vs CABG both at the unadjusted (OR= 
0.675; 95% CI= 0.371-1.189; p= 0.1891) and at the adjusted analysis (OR= 0.568; 
95% CI= 0.229-1.344; p= 0.2266). Conversely, there was advantage of PCI compared 
to CABG in the occurrence of MACCE without revascularization both at the unadjusted 
(OR= 0.300; CI 95%= 0.102-0.617; p= 0.0004) and adjusted analysis (OR= 0.385; 95% 
CI= 0.180-0.819; p= 0.01).
Conclusions: At one year, PCI with DES for LMCA seems to offer the same degree of 
protection against death, stroke, myocardial infarction to by-pass surgery.
2907-78 Predictors of Death After Unprotected Left Main 
Stenting. Insights From the Left Main TAXUS Registry
Véronique Decalf, Thierry Lefevre, Marc Silvestri, Oliver Darremont, Yves Louvard, 
Jean-Louis Leymarie, Philippe Garot, Thierry Unterseeh, Pierre Dumas, Oscar Tavolaro, 
Marie-Claude Morice, Institut Cardiovasculaire Paris Sud, Massy, France
Background: For many years, CABG has remained the gold standard treatment of 
unprotected left main (LM) stenosis. DES have now emerged as an alternative to cardiac 
surgery for the treatment of LM stenosis.
Methods and Results: We sought to determine the predictors of death at 6-8 months 
after unprotected left main stenting in a large cohort of 212 consecutive Pts with de novo 
LM stenosis prospectively included from May 2003 to June 2005 after informed consent 
in a pilot feasibility study using the Taxus stent. During this period, 9 Pt died (4.3%), 1 AT 
during the procedure, 1 due to severe groin hematoma at day 2, 2 sudden deaths at day 8 
and at 2 months, 2 during dialysis, 1 Pulmonary oedema and 1 Hemorrhage at 2 months, 
1 Pulmonary infection at 4 months, 1 Stroke at 5 months, 1 Cancer at 7 months.
By univariate analysis predictorS of death were as follows: 
Death
N=9
Non death
N=203 p
Age, years 74.9 ± 11.3 68.3 ± 11.3 0.088
Euroscore 6.6 ± 2.2 4.6 ± 3.4 0.091
3-vessel disease (%) 57 26 0.097
Diabetes (%) 89 26 0.006
Dialysis (%) 22 0.5 <0.001
Conclusion: Patients who died after unprotected left main stenting had a trend toward 
less favourable clinical and angiographic characteristics (older pts with higher Euroscore 
and 3 vessel disease). However, the only signiﬁcant predictors of death were diabetes 
and chronic renal failure on dialysis.
2907-79 Are the Results of Drug-Eluting Stents for the Elective 
Treatment of Unprotected Left Main Lesions Different in 
Diabetics?
Philippe Garot, Thierry Lefèvre, Yves Louvard, Marc Silvestri, Olivier Darremont, Pierre 
Dumas, Marie-Claude Morice, Institut Cardiovasculaire Paris Sud, Quincy, France
Background : Left main (LM) stenting using DES has emerged as an alternative to 
cardiac surgery. However, whether the results of elective LM stenting using DES are 
different in diabetics is unknown.
Objectives : To determine the results of elective LM stenting using DES in diabetics.
Methods and results : Using the data of a French multicenter registry including 325 pts 
electively treated by DES for unprotected LM lesion, we sought to compare the results 
of PCI and outcomes in diabetics (n=90) vs. non diabetics (n=235). Seventeen (n=17) 
pts presenting with acute MI and/or shock were excluded from the present analysis. The 
procedural characteristics and outcomes are described. 
Diabetics
N= 90
Non diabetics
N= 235 P
Euroscore 5.0±3.2 4.7±3.4 NS
Males 76% 76% NS
Age, y-o 69±10 69±12 NS
Hypertension 73% 60% <0.05
Unstable angina 34% 35% NS
Post-MI 4% 8% NS
Ejection fraction 60±12% 61±13% NS
Distal left main stenting 76% 76% NS
Provisional T stenting 64% 66% NS
Distal LM ‘’T’’ shape 33% 26% <0.05
PCI success, N (%) 100% 98% NS
Non Q-wave MI 3% 2% NS
Q-wave MI 0% 0% NS
In-hospital MACE 7% 3% <0.05
In-hospital death 2% <1% 0.07
6-Mo MACCE/TVR 23% 5% <0.001
6-Mo TVR 5% 3% <0.05
6-Mo death 11% 2% <0.0001
6-Mo cardiac death 8% <1% <0.0001
  Despite high PCI success rates in diabetics (similar to that of non diabetics), diabetics 
had, compared to non-diabetics, higher rates of MACE during hospital stay and higher 
rates of MACE, TVR and death at 6-Mo.
2907-80 Distal Versus Non Distal Left Main Stenting. Results 
From the French Taxus Pilot Study
Prakash Pillay, Thierry Lefevre, Olivier Darremont, Marc Silvestri, Marie-Claude 
Morice, Yves Louvard, Jean-Louis Leymarie, Véronique Decalf, Philippe Garot, Thierry 
Unterseeh, Pierre Dumas, Institut Cardiovasculaire Paris Sud, Massy, France
PCI to the distal LM is the most technically challenging subset of LM revascularization. 
Between 03/03 and 01/05, 216 pts were included in the Left Main Taxus pilot study at 
4 French centres with a large experience of LM stenting. We examined the data for 
differences in the results of procedures performed on de novo lesions of the distal LM vs 
ostial/ proximal and mid shaft LM using the Paclitaxel eluting stent(s).
The prescribed strategy was for stenting the distal LM and main branch followed by 
provisional T stenting of the side branch. All pts received clopidogrel and aspirin before and 
for at least 6 months post procedure. Scheduled clinical follow-up was at 1, 6 and 12 months 
post index procedure. Angiographic follow-up was recommended at 4 to 6 months.
Left main lesion was distal in 74% of cases and non distal in 26%. The majority of distal 
lesions were Y type (60%). A provisional side branch T stent strategy was used in the 
majority of cases (94%) and a second stent was used to treat the side branch in 37%. 
Final kissing balloon inﬂation was performed in 96%.
Results 
Item Non Distal56pts
Distal
160 pts P value
Age, years 67.4+10.5 69.1+11.6 NS
Euroscore 4.9+3.7 4.7+3.3 NS
DM, % 25.0 29.4 NS
Unstable angina, % 26.8 33.1 NS
LVEF, % 62.1 60.0 NS
Procedural Duration, min 49.0+31.5 60.7+32.0 <0.05
Contrast media, ml 169+133 216+152 NS
Acute ST, % 0.0 0.6 NS
Subacute ST, % 0.0 0.6 NS
Emergency CABG, % 1.8 0.0 NS
Death/cardiac death, % (6-8 months) 1.8/1.8 5.0/2.5 NS
Restenosis LM, % (6-8 months) 2.9 7.6 NS
TVR, % (6-8 months) 1.8 3.9 NS
Total MACE % (6-8 months) 7.1 10.6 NS
Despite longer procedural times and a trend for a higher volume of contrast media used 
when treating distal compared to non distal left main lesions, PCI can be safely and 
effectively performed with the TAXUS stent using a strategy of main branch stenting 
followed by provisional side branch T-stenting. The non signiﬁcant higher risk of restenosis 
and TVR observed for distal left main can be explained by the simple fact that there is two 
lesions to treat instead of one.
2907-81 Unprotected Left Main PCI: Bare Metal Stent Versus 
Drug Eluting Stent Randomized Study
Andrejs Erglis, Inga Narbute, Indulis Kumsars, Sanda Jegere, Iveta Mintale, Ilja Zakke, 
Uldis Strazdins, Andris Saltups, Latvian Centre of Cardiology, P. Stradins Clinical 
University Hospital, Riga, Latvia, Cabrini Medical Centre and Monash Medical Centre, 
Melbourne, Australia
Background: In an effort to ﬁnd the optimal intervention for LM disease we randomized 
bare metal stent (BMS) or drug eluting stent (DES) for unprotected LM IVUS guided PCI.
Purpose:
• compare safety and efﬁcacy of BMS and DES for unprotected LM 
• evaluate intra-hospital outcome
• evaluate 6 months clinical, angiographic and IVUS outcome
Methods: Between January 2002 and September 2005 - 180 consecutive patients with 
unprotected LM disease underwent PCI in our center, 108 of them randomized to BMS 
(n=53) or DES (n=55). In randomized cohort (n=108) all interventions were IVUS guided 
and underwent cutting balloon (CB) pretreatment before stenting.
Results: In both cohorts baseline clinical characteristics were comparable, diabetes 
mellitus was more frequent in DES group (8% vs 3% p=0.29).
Procedural success - 99%. Distal LM intervention - 78%. No intrahospital MACEs. Mean 
hospitalization time 3.3 days.
Six months follow-up is performed for 65% patients. One non-cardiac and one cardiac 
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death obtained. Angiographic binary restenosis was obtained in 7 (4 in BMS and 3 in 
DES), TLR in 4 (all BMS) and TVR in 4 (2 in BMS and 2 in DES) cases.
IVUS results. 
DES group BMS group P values
MLD post PCI, mm 3.25±0.26 3.29±0.33 0.614
MLD at f-up, mm 3.05±0.31 2.98±0.51 0.469
MLD late loss, mm 0.20±0.14 0.41±0.28 0.002
MSA post PCI, mm2 8.64±1.32 9.13±1.49 0.148
MSA at f-up, mm2 7.62±1.48 7.58±2.39 0.936
MSA late loss, mm2 0.88±0.56 1.84±1.17 0.001
Intima volume, mm3 13.13±13.87 22.03±14.79 0.007
Conclusions:
Left main PCI was safe and effective with excellent immediate and mid-term result in 
both groups. IVUS guidance and CB pretreatment may be effective strategy to obtain 
better result.
However, IVUS follow-up results conﬁrm statistically signiﬁcant beneﬁt after DES 
implantations in the unprotected LM lesions in all measured dimensions over BMS.
2907-82 Drug-Eluting Stent Implantation in Unprotected Left 
Main: One Year Outcome
Alaide Chieffo, Nuccia Morici, Giuseppe Sangiorgi, Matteo Montorfano, Mauro Carlino, 
Flavio Airoldi, Tiziana Aranzulla, Gloria Melzi, John Cosgrave, Antonio Colombo, 
Interventional Cardiology Unit, San Raffaele Hospital, Milan, Italy
Background: The long-term safety and efﬁcacy of drug-eluting stent (DES) implantation 
in the treatment of unprotected left main (ULM) lesions is still a matter of debate.
Methods: Primary end-point of the study was 1 year major adverse cardiac event (MACE) 
deﬁned as the occurrence of any of the followings:cardiac death, myocardial infarction 
(MI), target lesion revascularization (TLR) and target vessel revascularization (TVR). All 
consecutive patients (pts) who had sirolimus (SES, Cypher, Cordis, Johnson and Johnson 
Company, Warren, NJ) or paclitaxel-eluting stent (PES, Taxus, Boston Scientiﬁc, Natick, 
MA) electively implanted in de novo lesions on ULM were analyzed. 
Results: A total of 107 pts were treated:52 with PES and 55 with SES. Twenty (18.7%) 
patients were diabetics, 34 (31.7%) unstable angina, mean age 63.6±10.3 years, EF 
52.0±10. High mortality risk scores (Euroscore >6 and/or Parsonnet >15) were present 
in 43 (40%) of the patients. Eighty-seven (81.3%) patients had distal left main lesions: 
77 bifurcation and 10 trifurcation. Both branches were stented in 64 (73.6%) pts: 
crushing technique was performed in 38 (59%) of them. Reference vessel diameter 
was 3.3±0.68mm. Procedural success was achieved in all pts. During hospitalization 10 
(9.3%) patients had non-Q wave MI. None of the patient had Q wave myocardial infarction 
(MI), died or had CABG. At 1 year, 1 patient had thrombosis with MI at 3 months, 3 (2.8%) 
patients died. One patient died after discontinuing antiplatelet therapy 53 days after the 
procedure because of acute pancreatitis, 1 died as a result of pulmonary edema (this 
patient had severe aortic and mitral regurgitation, and stent patency was demonstrated 20 
days before death), and 1 died of complications related to elective CABG. TLR occurred 
in 17 (15.8 %) pts (12 re-PCI and 5 CABG), TVR in 21 (19.1%). Angiographic follow-up 
performed in 89 (84%) pts showed restenosis in 16 pts (17.9%); all restenosis occurred in 
pts with treatment of distal left main and were focal.
Conclusions In this early experience with DES in ULM we can state that this procedure 
appears safe with favourable and improved clinical results maintained at one year clinical 
follow-up.
2907-83 Unprotected Left Main Stenting With Drug-eluting 
Stents: Midterm Follow-Up
Elizabeth Saylors, Frances Wood, Joel Schneider, R. Lee Jobe, Tift Mann, Wake Heart 
and Vascular Associates, Raleigh, NC
Background. The low incidence of restenosis after drug-eluting stent deployment has 
made unprotected left main stenting (ULMS) a possible therapeutic option. Several 
studies have shown a low in-hospital complication rate with ULMS, but the long-term 
outlook remains uncertain. Our experience with ULMS was reviewed.
Methods. ULMS was perfomed in 92 patients who refused or were excluded from surgery 
(mean age 69, mean Euroscore 5.5%) from June 2003 to August 2005. Patients were 
subdivided according to lesion location. Disease was conﬁned to the ostium or main stem 
in group A (28 patients) and involved the bifurcation in group B (64 pts). The technique 
in group B included stent deployment in the main branch with provisional sidebranch 
stenting in 46 (72%), V stents in 14 (22%), and crush technique in 4 (6%). Study endpoints 
were cardiac death, MI, and TVR.
Results. Primary procedural success was 96% in group A (1 MI) and 94% in group B (2 
MI, 1 urgent TVR). One patient died early at an outside hospital of stent thrombosis after 
discontinuation of plavix. Mean follow-up was 8 ± .5 months (6 to 26 months). There were 
2 cardiac deaths in group A(7%) and 3 in group B(5%) during the follow-up period. Event-
free survival is shown in the Kaplan-Meier curve below.
Conclusion. Procedural success with ULMS was high and midterm event-free survival 
acceptable in this high surgical risk group. However, late events and mortality remain a 
concern and caution is urged in performing ULMS pending the results of prospective, 
randomized trials.
2907-84 Shotgun Stenting of Left Main Bifurcation Stenosis
Anjan K. Siotia, Allison C. Morton, Julian P. Gunn, Northern General Hospital, Shefﬁeld, 
United Kingdom
Background: There is no single, widely accepted interventional technique for treating left 
main stem (LMS) bifurcation stenosis. We performed a prospective, safety and feasibility 
study of treating such lesions with the ‘shotgun’ (‘kissing’) stent technique (ﬁg 1).
Methods: 30 consecutive patients with LMS bifurcation stenosis were treated using 
a shotgun technique. Drug-eluting stents (Taxus, Boston Scientiﬁc, Natick, MA) were 
used when technically feasible (28/30 cases). Balloon counterpulsation was used in 3 
patients and 25 received abciximab. All patients are scheduled for 6 month clinical and 
angiographic follow-up.
Results: Mean age was 63 years, 19 were male, 26 were elective, 3 urgent and 1 
emergency. The procedure was successful in all cases. There was 1 in-hospital death (a 
65y old man with anterior myocardial infarction, LMS, LAD and OM stenoses, recurrent 
ventricular ﬁbrillation (VF), ejection fraction 40% and bronchopneumonia who had been 
turned down for CABG). After successful PCI, he could not be resuscitated after a third 
episode of VF. There was no other major adverse event. 18 follow-up angiograms have 
been performed so far and 2 patients (11%) required target lesion revascularisation for 
restenosis. At follow up of 8±3.4 months, the remaining 27 patients remained well and 
free of angina.
Conclusions: The shotgun technique for treating bifurcation disease of the LMS is safe 
and feasible. Medium term results are good.
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2908-85 Mid-Term Angiographic Follow-Up of De Novo Coronary 
Bifurcation Lesions Treated With the Nitinol Self-
expanding Biolimus A9-Eluting Stent: Results From the 
Prospective, Multicenter Axxess Trial
Ricardo A. Costa, Alexandra Lansky, Alexandre Abizaid, Ralph Muller, Roxana Mehran, 
Ecaterina Cristea, Maria Corral, Ken Mori, Ramona Pop, Brett Trauthen, Stefan Verheye, 
Franz J. Neumann, Fausto Feres, Dougal McLean, Eberhard Grube, Cardiovascular 
Research Foundation, New York, NY, Siegburg Heart Center, Siegburg, Germany
Background: The AXXESS Plus Biolimus-A9-coated stent (DEVAX, Inc) is a novel technology 
for bifurcation lesions based on a nickel-titanium self-expanding conical stent platform that 
permits deployment across the carina of a bifurcation while providing easy access to the distal 
the main vessel (MV) concurrent with the ostium of the side branch (SB). 
Methods: Inclusion criteria were lesions >50% DS within 5mm of a bifurcation in vessels 
2.5-4.0mm in diameter in the MV and ≥2.25mm in the SB. The primary endpoint was 
in-stent late loss at 6 mo. angio FU. Procedural success was <50% residual DS of the 
target lesion without in-hospital MACE - death, MI, or TLR, using any combination of 
percutaneous devices. 
Results: 136 pts were enrolled at 13 clinical sites. Treatment modality was performed as 
follow: 19.1% had AXXESS stent only; 27.9% had AXXESS stent + stent in the distal MV; 
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12.5% had AXXESS stent + stent in the SB only; and the majority (40%) had AXXESS 
stent + stents in the distal MV and SB. (Additional stents were sirolimus-eluting stent.) 
Procedural success was achieved in 94.9% (3 pts had in-hospital MI and 4 pts had ﬁnal 
residual DS >50% in the SB). Angio FU at 6 months was completed in 126 pts (92.6%). 
QCA results are shown in the Table. Overall bifurcation restenosis (MV ± SB) was 23%. 
Conclusions: The AXXESS stent showed high procedural success rate and excellent 6 
months angiographic results (late loss 0.09mm and stent restenosis 7.1%) in this complex 
lesion subset. A larger effectiveness trial is planned. 
MV SB
Lesion length, mm 16.28±7.44 7.43±3.90
Pre Reference diameter, mm 2.86±0.35 2.34±0.32
Pre MLD, mm 0.78±0.30 0.88±0.39
Pre %DS 72.9±9.4 62.2±17.0
Final MLD (in-stent) 2.83±0.45 2.02±0.53
Final %DS (in-stent) 4.7±11.37 17.2±20.5
FU MLD (in-stent) 2.74±0.60 -
FU %DS (in-stent) 5.3±18.9 -
Late loss, mm
In-stent (*AXXESS only) 0.09±0.56* 0.31±0.49
In-lesion 0.23±0.49 0.22±0.46
Restenosis, %
In-stent (*AXXESS stent only) 4.8 (6/126)* 9.2 (6/65)
In-stent - AXXESS+distal stent 7.1 (9/126) -
In-lesion 11.9 (15/126) 14.3 (18/126)
SB stent (n=65)
2908-86 Cypher & Bifurcation Stenting: How Damaged Are the 
Polymer and Stent Structure?
Yoshihisa Kinoshita, Osamu Katoh, Tetsuo Matsubara, Jean-Francois Surmely, Takahiko 
Suzuki, Toyohashi Heart Center, Toyohashi, Aichi, Japan
Background: Report using the Cypher stent for bifurcating stenting (BS) have not 
considered the damage done to the polymer or stent structure.
Methods: We deployed Cypher stents in a polyvinyl alcohol “phantom” vessel with 3.0mm 
diameter main branch (MB) and 2.5mm side-branch (SB). Kissing-balloon dilatation 
was then performed using 3.0/2.5mm balloons in the MB and SB, and stent-structure 
observed with an optical microscope (OM), multi-slice computed tomography and IVUS. 
An electron microscope was used to observe polymer damage. BS strategy entailed 
culottes-stenting, conventional crush-stenting, reverse crush-stenting, and, a technique 
devised by ourselves, “ﬂower-stenting”, whereby the proximal side of the stent ﬂares out 
like petals (Fig. 1).
Results: OM and IVUS showed all techniques gave ample dilatation of 2.5-3.0mm at 
the SB ostium, but only ﬂower-stenting gave adequate coverage there. Conventional and 
reverse crush techniques resulted in considerable strut protrusion into the MB (Fig 2). 
Crush-stenting also caused severe polymer damage, including circumferential damage to 
the struts in the MB (Fig. 3). Damage was less with the ﬂower and culottes methods.
Conclusions: The “ﬂower-stenting” technique or special BS drug-eluting stents may be 
superior to existing techniques.
 
2908-87 Bifurcation Angle Is an Independent Predictor of 
Outcome After Crush Stenting of Coronary Bifurcation 
Lesions
Vladimir Dzavik, Paul Daly, Douglas Ing, Erick Horlick, Rajesh Kharbanda, Alan Barolet, 
Sanh Bui, Karen Mackie, John Ross, Leonard Schwartz, Peter H. Seidelin, University 
Health Network, University of Toronto, Toronto, ON, Canada
Background: Crush stenting (CS) is an effective technique for percutaneous coronary 
intervention (PCI) of complex Y type bifurcation lesions. We hypothesized that the angle 
between the side branch and proximal main vessel (bifurcation angle = BA) may affect 
the outcome of CS of bifurcation lesions. We thus undertook to study this hypothesis and 
secondly to determine the independent predictors of long-term outcome after CS PCI.
Methods: Of the 538 PCI cases involving a bifurcation with a side-branch diameter 
≥2.0 mm (18.9% of all cases) performed in the University Health Network Interventional 
Cardiology Program (Toronto Canada) between 11/03 and 03/05, 133 were performed 
utilizing CS (n=56), balloon CS (n=71) or reverse CS (n=6). Patients were divided into 
2 groups utilizing the median BA as the cut point. Multivariable analysis was performed 
using stepwise regression.
Results: The median BA of the 133 patients was 50° (Grp 1 = BA<50°, Grp 2 = BA≥50°). 
Patients received a loading dose of clopidogrel, which was then routinely prescribed for 
1 year, and 93.2% were treated with a glycoprotein IIb/IIIa inhibitor. Grp 2 patients were 
more likely to be women (33% vs. 15%, p=0.02), have a prior PCI (26% vs. 12%. p=0.05) 
and prior CABG (15 vs. 5%, p=0.05). Procedural success was 98.5% in Grp 1 and 95.4% 
in Grp 2 (p=ns). Two patients in Grp 2 had an acute stent thrombosis and 1 patient in 
Grp 2 died in-hospital. During a follow-up period up to 648 days, 1 patient (1.5%) in 
Grp 1 and 4 (6.1%) in Grp 2 died (p=ns). MACE (death, MI, TLR, CABG) was observed 
more frequently in Grp 2 (22.7% vs. 6.2%, p=0.007). BA≥50° (p=0.004), no ﬁnal kissing 
balloon inﬂation (p=0.012) and lower creatinine clearance (p=0.031) were independent 
predictors of MACE.
Conclusions: The ﬁnding of BA≥50° as a predictor of MACE after PCI of bifurcation 
lesions utilizing CS techniques that is independent of no ﬁnal kissing balloon inﬂation 
and poor renal function, known predictors of adverse outcome, is novel. An acute angle 
between the main vessel and the stented side-branch confers a setting of increased 
turbulent ﬂow that may have untoward consequences with respect to thrombosis and 
possibly as a stimulus for cell proliferation. Further study is warranted.
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2909-88 Topical Lubrication to Facilitate Stent Delivery After 
Initial Failure of Stent Placement: Acute Results and 
Long-Term Outcomes
Alok Singh, Mark Awar, Adeeb Ahmed, Paul Walinsky, David L. Fischman, Michael P. 
Savage, Thomas Jefferson University Hospital, Philadelphia, PA
Objective: Failure to deliver stents to target lesions is encountered in up to 4% of 
percutaneous coronary interventions (PCI). The goal of this study was to assess the utility 
of topical lubrication to aid stent delivery in challenging anatomy and it’s effects on long-
term clinical outcome.
Methods: We evaluated the effectiveness of topically applied lubrication to facilitate 
stent delivery after failed stent placement in 20 (2.5%) out of 813 consecutive patients 
undergoing PCI. Initial attempts at stent delivery failed despite balloon predilatation and use 
of moderate-to-stiff guidewires in all patients. The lubricious solution used was RotaGlide 
(Boston Scientiﬁc, Maple Grove, MN), a phospholipid emulsion originally designed to 
reduce catheter friction during rotational atherectomy. Following unsuccessful delivery, 
stents were removed from the guiding catheters, topically saturated with RotaGlide using 
a 20 ml syringe, and deployment immediately reattempted. Procedural efﬁcacy and long-
term clinical outcomes were assessed.
Results: The study population included 15 men and 5 women with a mean age of 69 + 10 
years. Target vessels included 10 LCX, 8 RCA and 2 LAD. The lesions were complex with 
ACC/AHA class B2 or C in all 20 (100%), tortuosity in 17 (85%), calciﬁcation in 13 (65%), 
and diffuse disease in 10 (50%). Stent types included Cypher (11), Taxus (6) and bare-
metal (3). RotaGlide lubricated stents were successfully deployed in the target lesions in 
17 of the 20 patients (85%). The remaining 3 patients were treated by balloon angioplasty 
alone. Patients were followed 19.5 + 3.2 months after their index procedure. There were 
no periprocedural complications or subacute stent thromboses. Of the 14 patients with 
drug eluting stents (9 Cypher, 5 Taxus), none had clinical restenosis or target vessel 
revascularization. Target lesion revascularization secondary to restenosis was required 
in 1 of 3 patients treated with bare-metal stents. One patient died 4 months after PCI due 
to noncardiac cause (sepsis).
Conclusion: Topical lubrication with RotaGlide is a simple and effective aid for stent delivery 
in complex lesions. RotaGlide appears safe and biocompatible with drug eluting stents.
2909-117 Randomized Double-Blind Placebo-controlled 
Pilot Study of the Safety and Efﬁcacy of Short-
Term Cyclooxygenase-2 Inhibition Before Elective 
Percutaneous Coronary Intervention
Francesco Pelliccia, Antonino Granatelli, Vincenzo Pasceri, Christian Pristipino, Giulio 
Speciale, Adriana Roncella, Giuseppe Mercuro, Giuseppe Richichi, San Filippo Neri 
Hospital, Rome, Italy, University of Cagliari, Cagliari, Italy
Background: Inﬂammation can play a role in the pathophysiology of small myocardial 
infarctions after percutaneous coronary intervention (PCI), and experimental studies 
have shown that the degree of myonecrosis can be reduced by antiﬂogistic agents such 
as cyclooxygenase-2 (COX-2) inhibition. However, reasons for concern about long-term 
cardiovascular safety of COX-2 inhibitors are limiting their use in cardiac patients. Aim of 
this study was to verify in a randomized study if short-term COX-2 inhibition before PCI is 
safe and has any protective effects.
Methods: Fifty patients with stable angina (32 men, age: 55+13 years) scheduled for 
elective coronary intervention entered a randomized, double-blind, placebo-controlled 
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pilot trial. For 5 days prior to the procedure, 25 pts were assigned to receive celecoxib 
(200 mg b.i.d) and 25 pts had placebo. Creatine kinase-MB, troponin-I and myoglobin 
levels were measured at baseline and at 8 and 24 hours post procedure.
Results: Comparison between the two groups did not show any difference in age, sex, 
risk factors, cardiac function, and extension of coronary artery disease. Also, there was 
no difference in any technical aspect of PCI. Detection of markers of myocardial injury 
above the upper normal limit was signiﬁcantly lower in the celecoxib vs placebo group: 
12% vs 35% for creatine kinase-MB (p=0.001), 20% vs 48% for troponin-I (p=0.0004) 
and 22% vs 51% for myoglobin (p=0.0005). Myocardial infarction by creatine kinase-MB 
determination was less commonly seen after PCI in the celecoxib than in the placebo-
group (5% vs 18%, p=0.025). Postprocedural peak levels of creatine kinase-MB (2.9+18 
vs 7.5+18 ng/mL, p=0.0002) were also signiﬁcantly lower in the celecoxib vs placebo 
group. No signiﬁcant side effect was reported by the two groups of patients.
Conclusions: Pretreatment with celecoxib 200 mg b.i.d. for 5 days signiﬁcantly reduced 
procedural myocardial injury in elective PCI. These ﬁndings indicate that the antiﬂogistic 
action of COX-2 inhibition may provide a friendly protection to ischemic cardiomyocytes. A 
multicentre randomized study is now ongoing and complete results will be available by 2006.
2909-118 Delayed Thrombin-induced Platelet-ﬁbrin Clot 
Generation by Clopidogrel: A New Dose-related Effect 
Demonstrated by Thrombelastography in Patients 
Undergoing Coronary Artery Stenting
Paul A. Gurbel, Kevin Bliden, Kirk Guyer, Nikhil Aggarwal, Udaya Tantry, Sinai Center for 
Thrombosis Research, Baltimore, MD, Indiana University at South Bend, South Bend, IN
Background: Thrombin generation is dependent on platelet activation and clopidogrel 
reduces platelet activation in patients undergoing stenting. However, the effect of the 
clopidogrel loading dose on the rate of thrombin-induced platelet-ﬁbrin clot formation is 
unknown in this patient population.
Methods: Using thrombelastography we measured the time to platelet-ﬁbrin clot formation 
(R), a marker of the speed of thrombin generation, in 120 patients undergoing elective 
coronary artery stenting treated with standard and high loading doses of clopidogrel. 
Platelet reactivity to adenosine diphosphate (ADP) by light transmittance aggregometry 
(LTA) was determined simultaneously. Measurements were made immediately before and 
at 24 hours after clopidogrel treatment.
Results: Clopidogrel produced a prolongation in R (4.4 ± 1.4 min. pre vs. 5.4 ± 1.7 min. 
post, p< 0.001) that directly correlated with the change in platelet aggregation (r = 0.65, 
p<0.0001). Prolongation in R was greatest in patients treated with a high loading dose 
(p=0.004).
Conclusions: Delayed thrombin-induced platelet-ﬁbrin clot formation as measured by 
TEG is a newly reported dose-related effect of clopidogrel that contributes to the overall 
antithrombotic properties of the drug in patients undergoing stenting. This effect was 
more marked in patients loaded with 600 mg, lending further mechanistic support for 
this dose of clopidogrel as a more effective antithrombotic regimen than the standard 
300 mg dose.
Platelet Aggregation and Time To Platelet-Fibrin Clot Formation
Total 
Group 
(n=120)
300 mg 
Clopidogrel 
(n=73)
600 mg 
Clopidogel 
(n=47)
p-value
(300mg vs 
600 mg)
Absolute Change in Platelet 
Aggregation (5uM ADP,%) 21.0 ± 1.6 16.4 ± 1.8 26.2 ± 1.6 0.002
Absolute Change in Platelet 
Aggregation (20uM ADP,%) 17.8 ± 1.7 13.6 ± 1.5 22.7 ± 1.8 0.003
Absolute Change in Time to 
Platelet-Fibrin Clot Formation 
(min)
0.91 ± 
0.17 0.73 ± 0.15 1.42 ± 0.14 0.01
2909-119 Telomeres Shortening in Patients With Coronary Artery 
Disease Is Due to the Reduced Telomerase Activity 
Depending on the Severity of the Disease
Marco L. Rossi, Nicola Marziliano, Elena Corrada, Dennis Zavalloni Parenti, Guido Belli, 
Gabriele Gasparini, Paolo Pagnotta, Patrizia Presbitero, Istituto Clinico Humanitas, 
Rozzano-Milan, Italy, IRCCS Policlinico San Matteo, Pavia, Italy
Background: Short telomeres have been documented in coronary artery disease 
(CAD). The telomerase (TERT) controls telomeres’ length and telomeres shortening is 
accelerated in cells with low TERT activity. Patients with CAD have shorter telomeres 
length in circulating leukocytes than controls. We wanted to clarify whether telomeres 
shortening in leukocytes of patients with CAD is due to an increased cell turnover or a 
consequence of low TERT activity or a primary genetic abnormality by investigating the 
telomeres length and the TERT activity.
Methods: We enrolled consecutively 20 patients with single, 20 with two and 20 with 
three coronary vessels disease underwent coronary angiography for CAD and 20 patients 
without CAD underwent coronary angiography for screening before valvular surgery. 
There were not differences for demograﬁc, clinical and angiographic characteristics. 
Telomeres length was assessed by quantitative PCR (Q-PCR) and TERT activity by 
TRAP-EZ chemistry.
Results: The mean telomeres length and TERT activity were signiﬁcantly lower in patients 
with three coronary vessels disease Vs patients with single or two vessels disease and 
without CAD (see table).
Conclusion: Telomeres shortening may be due to a reduction in TERT activity rather than 
the increased cell turnover due to inﬂammatory processes: a reduction in the activity of 
this enzyme might render more susceptible to atherosclerotic risk factors. 
Telomeres mean length (kb) TERT Activity (Arbitrary Units)
Single-Vessel 12.6 ± 0.4 66.7 ± 5.1
Di-Vessel 10.6 ± 0.5 54.1 ± 3.3
Tri-vessel 7.2 ± 0.7 * 42.4 ± 4.2 *
Controls 15.8 ± 0.4 73.7 ± 3.4
* p<0.001
2909-120 Is Platelet Hyper-reactivity in Patients With Subacute 
Stent Thrombosis the Consequence Rather Than the 
Cause of the Acute Thrombotic Event?
Eli I. Lev, Carlos L. Alviar, Erdinc M. Arikan, Bijal P. Dave, Juan Granada, Timothy 
DeLao, Kelly Maresh, Neal S. Kleiman, The Methodist Hospital, Houston, TX
Background: Recent data suggest that patients (pts) with subacute stent thrombosis 
(SAT) have increased platelet reactivity. However, it is not known whether this ﬁnding 
results from the acute presentation or from pre-existing tendencies toward higher 
reactivity. Our aim was to compare platelet reactivity in pts with SAT and pts with ST 
elevation acute myocardial infarction (AMI) not related to stenting.
Methods: We identiﬁed 12 pts with SAT (≤30 dys of stenting), 16 pts with ST elevation 
AMI treated with primary PCI and 16 pts with uncomplicated elective stenting (control 
group). All pts were treated with aspirin and clopidogrel. Platelet function was evaluated 
3.7±0.9 dys after the latest intervention (SAT group), 2.8±0.7 dys after primary PCI (AMI 
group) and 3.4±0.8 mo after stenting (control group). Platelet reactivity was evaluated by 
aggregation in response to 5 and 20 µM ADP and 1.5 mM arachidonic acid (AA), and ﬂow 
cytometry determined P-Selectin expression and PAC-1 binding.
Results: There were no differences in baseline clinical characteristics (overall mean age 
62.4±9.3 yrs, 38.6% women). There were no signiﬁcant differences between the SAT and 
AMI groups in any of the platelet assays. However, both these groups differed from the 
control group (Table).
Conclusions: Compared with AMI pts, SAT pts, receiving aspirin and clopidogrel, do 
not appear to have increased platelet reactivity. Previous data indicating platelet hyper-
reactivity in SAT pts, may have been related to the AMI presentation.
Platelet reactivity among the three groups
SAT 
Group 
(n=12)
AMI 
Group 
(n=16)
Control 
Group 
(n=16)
P Value for SAT 
vs. Control
P value for AMI 
vs. control
Mean AA 
Aggregation (%) 13.2±5.8 15.1±4.6 10.7±2.7 0.1 0.02
Mean 5 µM ADP 
Aggregation (%) 47.7±17.5 46.9±14.1 38.3±9.8 0.06 0.05
Mean 20 µM ADP 
Aggregation (%) 65.7±14.1 65.2±10.9 57.1±11.9 0.07 0.05
PAC-1 binding 
(MFI) 4.1±2.2 3.9±1.7 3.2±1.4 0.09 0.1
P-Selectin 
expression (MFI) 11.3±3.3 11.5±4.9 8.4±4.1 0.01 0.01
 
2909-121 First in Man: Coronary Sinus Narrowing With a Reducer 
Stent - A Possible Alternative Percutaneous Treatment 
for Patients With Refractory Angina
Shmuel Banai, Gad Keren, Horst Sievert, Ashok Seth, Shmuel Ben Muvhar, Ajay M. 
Naik, Aharon Medina, Praveen Chandra, Hethal Shah, Keyur H. Parikh, Sourasky Tel 
Aviv Medical Center, Tel Aviv, Israel
Increased Coronary Sinus (CS) pressure redistributes collateral blood ﬂow into ischemic 
territories of the myocardium, reduces ischemic damage and infarct size. CS narrowing 
might offer an alternative treatment for patients with refractory angina who are not 
candidates for revascularization. The CS Reducer is a percutaneous implantable stent-
like device, designed to establish CS narrowing and to elevate CS pressure. The Reducer 
is a stainless steel mesh, balloon expandable stent. After implantation it has an hourglass 
shape with a diameter of 3.0 mm at its center and 8-12 mm at both ends. In a pre-
clinical experiment, implantation of the Reducer was safe and associated with reduced 
mortality and improved ischemic and cardiac functional parameters. To evaluate the CS 
Reducer as a potential alternative therapy for patients with refractory angina who are not 
candidates for revascularization a First in Man multi center, prospective, non-randomized, 
single-arm, safety and feasibility study was conducted.
Coronary sinus Reducers were implanted in 15 patients with CCS angina class III, 
objective evidence of reversible myocardial ischemia, and EF>30%. Follow up at 1, 3 
and 6 months included CT angiography, stress echo, thallium SPECT, and angina/QOL 
questionnaire.
Results: All the patients tolerated the procedure well. Immediate procedural and peri-
procedural success rate was 100%. All patients were discharged 2 days after implantation. 
During a follow up period of 1-6 months no MACE was recorded. There was no evidence 
of migration of the device, thrombosis or occlusion of the CS. Following implantation of 
the CS Reducer: angina class, quality of life, and exercise tolerance have improved. The 
complete 6 months follow up evaluation including: clinical, quality of life, CT angio, stress 
echo, and myocardial perfusion data will be presented.
Conclusions: Implantation of the CS Reducer is feasible and safe, and may present 
a novel effective tool to treat patients with refractory angina who are not candidates for 
revascularization.
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2909-122 Clinical Beneﬁt of Pre-treatment With High Dose 
of Clopidogrel Before Percutaneous Coronary 
Intervention Is Associated With Lower Procedural 
Levels of P-selectin. Results From the Armyda-2 
(Antiplatelet therapy for Reduction of MYocardial 
Damage during Angioplasty): Select Substudy
Giuseppe Patti, Massimo Chello, Diego Colonna, Andrea D’Ambrosio, Vincenzo Pasceri, 
Leonardo Lassandro Pepe, Laura Gatto, Fabio Cacciapaglia, Giordano Dicuonzo, Elvio 
Covino, Germano Di Sciascio, Department of Cardiovascular Sciences, Campus Bio-
Medico University, Rome, Italy
Background: ARMYDA-2 trial has demonstrated that pre-treatment with a 600 mg 
loading dose of clopidogrel given 4 to 8 hours before intervention signiﬁcantly reduces 
the occurrence of procedural myocardial infarction in patients (pts) undergoing coronary 
stenting, as compared with the conventional 300 mg dose. Other biological mechanisms 
(in addition to a stronger platelet inhibition) responsible of this protective effect are not 
completely characterized.
Methods: Measurement of soluble P-selectin was obtained in a subgroup of 84 from 255 
pts enrolled in ARMYDA-2 trial: 41 pts belonged to 600 mg and 43 to 300 mg loading 
dose of clopidogrel. Blood samples were drawn before randomization (4 to 8 hours before 
procedure), at the time of intervention and at 8 and 24 hours after the procedure.
Results: Reduction of procedural myocardial injury after pre-treatment with 600 mg 
loading dose was conﬁrmed. Baseline P-selectin values were similar in the 2 arms (600 
mg: 92±9 ng/mL; 300 mg: 90±10 ng/mL; P=0.69), whereas at the time of intervention they 
were signiﬁcantly lower in pts of the 600 mg group (50±13 vs. 58±15 ng/mL; P=0.048). 
There was no difference in P-selectin levels at follow-up determinations (8 hours: 47±11 
vs. 50±13 ng/mL; P=0.26; 24 hours: 43±11 vs. 46±10 ng/mL; P=0.25).
Conclusions: In pts undergoing percutaneous intervention, the reduction of procedural 
myocardial injury after pre-treatment with 600 mg dose of clopidogrel 4 to 8 hours pre-
intervention causes a more pronounced decrease of P-selectin levels at the time of the 
procedure vs the 300 mg dose. These results suggest that clinical beneﬁt of a higher 
clopidogrel loading regimen may include an attenuation of linking mechanisms between 
thrombosis and inﬂammation, in particular of P-selectin-dependent platelet-leukocyte-
endothelium interactions.
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2910-61 Transcatheter Closure of Patent Foramen Ovale to 
Prevent Recurrent Stroke: Initial U.S. Experience With 
the Cardia PFO Closure Device
Michael P. Savage, David L. Fischman, Babu Jasti, Michael Mooney, Adam Greenbaum, 
Daniel Turner, for the Cardia Trial Investigators, Thomas Jefferson University Hospital, 
Philadelphia, PA
Background: Transcatheter devices designed to close patent foramen ovale (PFO) 
continue to evolve. In this prospective multicenter study, we assessed the initial U.S. 
experience with the Cardia PFO closure device for the prevention of recurrent stroke in 
patients with PFO.
Methods: The study was a prospective registry of 90 patients conducted at 22 clinical 
sites. Entry required the following: (1) Age 18 to 65 years; (2) One or more documented 
embolic events with sudden neurological deﬁcit and CT/MRI evidence of cerebral 
infarction; (3) PFO between 1 and 20 mm in diameter documented by TEE; (4) Absence of 
other manifest causes of cerebral thromboembolism. All procedures were performed with 
the generation III Cardia PFO closure device, a self-expanding double umbrella design 
consisting of polyvinyl alcohol sails and nitinol arms. PFO closure was performed with 
ﬂuoroscopic and echocardiographic guidance. Patients were prescribed aspirin 325 mg 
and clopidogrel 75 mg daily for 6 months. Procedural success and late clinical outcomes 
were assessed.
Results: The study population consisted of 40 men and 50 women with a mean age of 
47+12 years. Twenty patients had a history of multiple embolic events. PFO closure was 
successful in 89 of the 90 patients (98.9%). One patient had unsuccessful closure with 
device embolization (retrieved by catheter snare without sequelae). There were no other 
major procedural complications. Post procedure follow-up was available at a mean of 
12+ 6 months. Recurrent stroke occurred in one patient (1.1%) who was noncompliant 
with the prescribed antiplatelet regimen. Transient ischemic attacks were reported in two 
additional patients (2.2%). Two patients (2.2%) died during follow up from causes not 
device related.
Conclusions: (1) The Cardia PFO closure device is effective in sealing PFO, with a high 
success rate observed even during this initial multicenter learning curve experience. (2) 
The device appears highly effective in preventing recurrent stroke (especially in concert 
with dual antiplatelet therapy). (3) These promising results underscore the importance of 
the pivotal randomized trial of this device in patients with cryptogenic stroke.
2910-62 Transcatheter Closure of Patent Foramen Ovale in 
Patients with Paradoxical Embolism: Longitudinal Risk 
of Recurrent Stroke
Verna Harms, Mark Reisman, Jill T. Jesurum, Cindy J. Fuller, Merrill P. Spencer, John 
V. Olsen, Kimberly A. Krabill, William A. Gray, Swedish Medical Center, Seattle, WA, 
SpencerVascular Technologies, Seattle, WA
Background: Despite medical therapy, patients with patent foramen ovale (PFO) and 
paradoxical embolism are at risk for recurrence. Transcatheter PFO closure (PFO-C) has 
been shown to reduce right to left shunt (RLS) and prevent recurrent stroke. We prospectively 
and longitudinally evaluated clinical outcomes and closure status in 242 consecutive patients 
(age, 53 + 15 years; 52% women) who had PFO-C for prevention of recurrent stroke.
Methods: Criteria for PFO-C included > 1 presumed paradoxical cerebral embolism, 
echocardiography conﬁrmation of a provocable RLS, and probe patency of PFO tunnel. 
Clopidogrel and aspirin were prescribed for 3 and > 6 months, respectively. Clinical 
evaluation and power m-mode transcranial Doppler (pmTCD) were performed at 1, 6, 
12 and 24 months post-procedure. Closure status was deﬁned by the number of embolic 
tracks detected on pmTCD during calibrated Valsalva.
Results: During a mean follow-up duration of 518 days (range, 21-1467), the cumulative 
adverse event rate for death (n=8), recurrent stroke (n=7), and device explantation (n=3) 
was 7.7%, resulting in an estimated 4-year event-free survival of .92 (SE = .02). Elderly 
patients (> 65 years, n = 56) had a signiﬁcantly higher recurrent stroke rate (8.9% vs. 1.2%, 
p = .012). Estimated probability of 4-year stroke-free survival was signiﬁcantly higher for 
younger patients (.97 vs. .86, p = 0.003). Age was the only signiﬁcant univariate predictor of 
recurrent stroke (β = 0.073, p = .017). PFO size, atrial septal aneurysm, residual RLS, and 
history of >1 cerebrovascular events did not predict recurrent stroke. Final pmTCD showed 
a signiﬁcant reduction in RLS grade compared to baseline (4.6± 0.73 vs. 1.8± 1.6, p < 
.000). Complete closure or minimal residual RLS was achieved in 55% of patients, whereas 
moderate and large RLS persisted in 29% and 17% of patients, respectively.
Conclusions: In comparison to medical therapy, transcatheter PFO-C in patients < 65 
years is associated with a lower recurrent stroke rate during long-term follow-up. The 
diagnosis of PFO-mediated paradoxical embolism and the potential therapeutic beneﬁt of 
PFO-C should be cautiously considered in elderly patients with cerebrovascular risks.
2910-63 Major Complications Associated With Transcatheter 
Atrial Septal Occluder Implantation
Jeffrey W. Delaney, Jennifer Li, John F. Rhodes, Jr., Duke University Medical Center, 
Durham, NC
Background: To summarize major complications and outcome for patients receiving 
percutaneous closure of atrial septal communications. 
Methods: The Medline database and the US FDA Manufacturer and User Facility Device 
Experience databases (MAUDE) were searched for reports related to complications with atrial 
septal occluding devices. The medical literature documenting complication rates for these devices 
(AGA and NMT Medical) were reviewed and summarized. The MAUDE database complication 
reports were compared with the medical literature using national implant estimates. 
Results: The MAUDE database correlated in the type of complications most frequently 
encountered with each device. However, estimated total implant numbers indicated a 
higher incidence of major complications. AGA devices had a 0.2% erosion/perforation rate 
with a higher morbidity and mortality (25%) than previously reported, as well as a higher 
embolization rate, of at least 1%. NMT devices had a lower incidence of erosion/perforation 
rate of 0.05%. Embolization rates for the NMT devices were also lower than published 
European studies, possibly reﬂecting the U.S. restriction of the device for closure of patent 
foramen ovale. Thrombus was more frequently encountered on the NMT device. 
Conclusions: Both AGA and NMT devices have been shown to be safe and effective 
alternatives to cardiac surgery. The MAUDE database correlates, with a very low overall 
complication rate, but does show a higher estimated major complication rate than the 
medical literature. These data demonstrate the difﬁculty in quantifying rare complications 
in the pre-marketing analysis and the obligation providers have to report and evaluate 
complications throughout the life-cycle of each device.
2910-64 First Report of a Left Ventricular Implant for LV Volume 
Reduction and Improved Cardiac Performance: Initial 
Animal and Human Results
James D. Joye, Sinisa Gradinac, El Camino Hospital, Mountain View, CA
Background: The progression of systolic left ventricular dysfunction after myocardial 
infarction and its sequelae have been well-documented over time. Mechanical solutions 
to date have been cumbersome due to the need for either an open chest surgery or 
secure cannulation of the coronary sinus. We present initial animal and ﬁrst-in-man 
clinical results using a simple trans-aortic apical LV implant that is designed to reduce LV 
volume and improve cardiac output.
Methods: We studied 26 coil-induced, LAD infarcted sheep who were randomized to 
either a control arm or implantation of a VPD System (Ventricular Partitioning Device, 
CardioKinetix, Redwood City, CA). Animals underwent hemodynamic assessment of LV 
size, LV volume, cardiac output, LV ejection fraction, and LV pressures at baseline, after 
implant and at sacriﬁce. Animals were followed at various time intervals from implant out 
to 360 days. The ﬁrst two humans also received implants as a prelude to conventional 
open chest LV reduction, and similar hemodynamic measurements were recorded.
Results: Implantation of VPD devices was successful in all animals. There were no 
baseline differences in LV performance between the control and treatment arms of the 
trial. Final hemodynamic data will be presented. The initial 2 human subjects underwent 
successful implantation and their acute hemodynamic response will be reported.
Conclusions: Many complex mechanical devices have been studied in an effort to reign 
in the adverse effects of ischemic cardiomyopathy. The feasibility of achieving LV volume 
reduction and improved cardiac performance with a simple LV implantable device is 
appealing and feasible.
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2910-65 Alcohol Septal Ablation for Hypertrophic Obstructive 
Cardiomyopathy: A Systematic Review of Published 
Studies
Mahboob Alam, Hisham Dokainish, Nasser Lakkis, Baylor, Houston, TX
Objective: Alcohol Septal Ablation (ASA) for hypertrophic obstructive cardiomyopathy 
(HOCM) has emerged as a lesser invasive alternative to surgical myectomy over the past 
decade. The purpose of this study is to analyze all the published literature on outcomes 
and complications after ASA.
Methods: MEDLINE and PubMed were searched for all available published literature on 
ASA (June 1996 - June 2005) using the terms: Hypertrophic obstructive cardiomyopathy, 
HOCM, Alcohol septal ablation for hypertrophic obstructive cardiomyopathy, alcohol 
septal ablation for HOCM, alcohol septal ablation (ASA), transcoronary alcohol septal 
ablation for hypertrophic obstructive cardiomyopathy (TASH), transcoronary alcohol 
septal ablation for HOCM, NSRT (non-surgical septal reduction therapy) and PTSMA 
(percutaneous transcoronary septal myocardial ablation).
Data Synthesis and Results: A total of 42 published studies (2959 patients) were 
analyzed. Mean age was 53.5 (35.4 - 72) years with a mean male to female ratio of 
1.17. Mean follow-up was 12.7 ± 0.3 months (1.5 - 43.2). Three ml absolute ethanol was 
injected in 1.2 septal perforator arteries. On average, serum CK peaked at 964 Units. At 
12 months, there was a sustained decrease in resting and provoked LVOT gradient (65.3 
to 15.8 and 125.4 to 31.5 mmHg respectively) accompanied by reduction in basal septal 
diameter (20.9 to 13.9mm), improvement in NYHA class (2.9 to 1.2) and increase in 
exercise capacity (325.3 to 437.5 seconds). Early mortality (within 30 days) was 1.5% (0.0 
- 5.0%) and late mortality (beyond 30 days) was 0.5% (0.0 - 9.3%). Other complications 
include ventricular ﬁbrillation (2.2%), LAD dissection (1.8%), complete heart block 
requiring permanent pacemaker (10.5%) and pericardial effusion (0.6%). A repeat ASA 
was performed on 6.6% patients and 1.9% patients underwent surgical myomectomy with 
resolution of symptoms.
Conclusions: Literature to date suggests that ASA results in acute and intermediate-
term favorable clinical and echocardiographic outcomes. A randomized controlled trial 
is needed to compare ASA and myomectomy in order to determine which technique 
provides maximal beneﬁt.
2910-66 Transcatheter Patch Occlusion of Perimembranous 
Ventricular Septal Defects With Surgical Indication: 
Acute and Medium-Term Results
Eleftherios B. Sideris, Benjamin Macuil, Victor Varvarenko, Alexander Sokolov, Savvas 
Toumanidis, Athenian Institute of Pediatric Cardiology, Athens, Greece, 1er Octubre 
Hospital, Mexico-City, Mexico
Background: Large peri-membranous ventricular septal defects (VSDs) are managed 
predominently by Surgery. The transcatheter patch (TP) is a wireless device requiring 
minimal subaortic rim and has been used as an alternative to Surgery for the last 5 years. 
We are presenting our acute and medium-long term results.
Methods: Twenty ﬁve surgical candidates for VSD correction were brought to the cath-lab 
for TP occlusion. There were 4 cases of non-restrictive VSDs including 2 mal-alignment 
ones (Fallot- Tetralogy). All cases except for the Fallot Tetralogy cases which were 
cyanotic had large L-R shunts (Qp:Qs > 2:1). Patient age varied between 2-35 years 
(med.7) and VSD size between
5-20 mm (med 12). All VSDs were corrected using the femoral vein; four were crossed 
ante-grade and the rest retrograde. The patches were released in 48 hours in 15 cases, in 
24 hours in 7 (using preformed clot) and in 1 hour in 3 (using surgical adhesive).
Results: All VSDs with the exception of 3 were succesfully occluded (18 full occlusions, 
4 small residual shunts). The ﬁrst unsuccessful case had aortic valve prolapse and 
the balloon/patch was retrieved electively, because of aortic insufﬁciency; however 
in a subsequent similar case the balloon/ patch remained in place despite the aortic 
insufﬁciency with an excellent result, upon patch release. In the second case a 21mm 
balloon ruptured with the patch retrieved and in the 3rd case the long sheath could not be 
advanced from the RV to LV. Another case required deﬁbrilation during the procedure with 
excellent ﬁnal result.There was no case of aortic insufﬁciency or complete heart block 
either acutely or on follow-up.
Conclusions: Transcatheter patch occlusion of large perimembranous VSDs is effective 
and safe both acutely and on medium long term follow-up. Larger clinical trials are 
justiﬁed.
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2911-67 Prevention of Contrast Nephropathy With Allopurinol. A 
Randomized Controlled Trial
Alpay Turan Sezgin, Tuna Katircibasi, Aysegul Zumrutdal, Goknur Tekin, Tolga Kocum, 
Abdullah Tekin, Fatma Yigit, Tansel Erol, Tayfun Acil, Necip Ermis, Nurzen Sezgin, Senol 
Demircan, Haldun Muderrisoglu, Baskent university, Adana, Turkey
Background: Contrast nephropathy (CN) remains a common complication of radiographic 
procedures. Radiographic contrast agents can cause a reduction in renal function that 
may be due to reactive oxygen species. Conﬂicting evidence suggests that administration 
of the antioxidants prevents CN. This study was designed to test allopurinol, a xanthine 
oxidase inhibitor for prevention of CN. 
Methods: We prospectively randomized 82 patients with a serum creatinine concentration 
≥ 1.1 mg/dl undergoing cardiac catheterization/ intervention with iohexol, a nonionic, 
low-osmolality contrast agent to receive 300 mg allopurinol orally 24 hours before 
administration contrast agent and hydration (1mg /kg/h N/saline for 12 h pre- and post-
contrast, n=42, 63±10 years, 76% men), or hydration alone (1mg /kg/h N/saline for 12 h 
pre- and post-contrast, n= 40, 62±9 years, 77% men). Serum creatinine, urea nitrogen, 
uric acid were measured repeatedly during the week before administration of contrast 
agent and immediately before, and at 48 and 96 h thereafter. Contrast nephropathy was 
deﬁned as an increase serum creatinine concentration by 25% at either two or four days 
after contrast administration. 
Results: Contrast nephropathy occurred in 5 of the 40 patients (12,5%) in the hydration 
group and none in allopurinol group (p=0.02). In the allopurinol group, mean serum 
creatinine decreased signiﬁcantly from 1.34±0.2 to 1.17±0.2 at 48 h and to 1.14±0.2 
mg/dl at four days after post-contrast and (p=0.0001 and p=0.0001 compared to 
baseline, respectively). In the hydration group, the mean serum creatinine decreased 
nonsigniﬁcantly, from 1.42±0.3 to 1.36±0.4 and to 1.40±0.5 mg/dl (p=0.06 and p=0.3, 
respectively) at 48 h and four days after post-contrast. 
Conclusions: Prophylactic oral administration of allopurinol, along with hydration, 
may protect against contrast nephropathy in high risk patients undergoing a coronary 
procedure.
2911-68 Radiation Exposure in Patients Undergoing Elective 
Angioplasty: The Effect of Flat Panel Detection
Ananth M. Prasan, Glen Ison, David Rees, St George Hospital, Sydney, Australia
Background: Coronary angiography and interventions have been performed using 
digital angiography and ﬂuoroscopy systems which incorporate an Image Intensiﬁer 
(II). More recently Flat-Panel (FP) detectors have been introduced which are thought to 
improve spatial resolution. However, there is limited data on the effect of FP on radiation 
exposure. We sought to determine the impact of FP on total radiation exposure in patients 
undergoing elective angioplasty at our institution. 
Methods: Patients who underwent elective angioplasty in the 6 months prior to and 
following upgrade of our ToshibaTM Catheterization lab from image intensiﬁer to ﬂat panel 
were included. Demographic and radiation data were collected prospective ly and the 
same operators performed cases during the two periods.Radiation data was obtained 
from the dose area product meter intrinsic to the x-ray system.
Results: FP resulted in increased mean cumulative radiation exposure (Table). mean ± SD
Conclusions: Adoption of Flat Panel detector technology increases radiation exposure. 
This may have important safety implications for patients undergoing multiple procedures 
and laboratory staff.
Comparison of Image intensiﬁer and Flat Panel technologies
Image Intensiﬁer Flat Panel p value
No. of patients 68 69
Age (years) 68 ± 11 66 ± 12 NS
Weight (Kg) 78 ± 17 78 ± 15 NS
No. of cine acquisitions 29 ± 13 31 ± 15 NS
Radiation (cGycm) 9475 ± 7668 14261 ± 10440 <0.005
Screening time (min) 18 ± 13 19 ± 12 NS
Contrast (ml) 194 ± 79 195 ± 76 NS
 
2911-69 Methodology and Validation of Myocardial Blush Grade 
(MBG) Assessment in Patients With Acute Myocardial 
Infarction (AMI) Undergoing Mechanical Reperfusion
Ricardo A. Costa, Alexandra J. Lansky, Ecaterina Cristea, Martin Fahy, Martin B. Leon, 
Jeffrey W. Moses, Gregg W. Stone, Cardiovascular Research Foundation, New York, NY
Background: Assessment of MBG is subjective and its utility as a reliable surrogate 
endpoint in clinical trials is dependent on its reproducibility. We report the results of a 
validation study. 
Methods: 501 pts with AMI <6 hrs enrolled in the multicenter EMERALD trial underwent 
primary or rescue stenting. Off-line core lab analysis of MBG (2nd endpoint) was performed 
in 451 pts (90%), and was graded as follow: 0/1 = absence or minimal myocardial contrast 
opaciﬁcation, 2 = moderate contrast opaciﬁcation, but less than in either an ipsilateral or 
contralateral non-infarct artery, and 3 = normal MBG or contrast opaciﬁcation, comparable 
with the other coronary arteries. When MBG persisted (“staining”), MBG=0 was assigned. 
Analysis was performed by 2 experienced physicians by consensus and over-reading 
performed by experienced senior physician, all blinded to patient and clinical information. 
Validation was performed by the same personnel 4 months after the initial analysis, 
blinded to previous results. Results: Results are shown in the Table. Overall intra-observer 
agreement was 86.5% (RCA 81%, LCX 77% and RCA 92%), and 94.6% when analyzing 
“open” (MBG 0/1) versus “closed” (MBG 2/3) microcirculation. 
Conclusions: These results demonstrate that within a single core lab with a team of 
experienced readers using consistent methodology, MBG is reproducible and can be 
performed with a high degree of agreement, further validating its suitability as an endpoint 
in clinical trials.
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Variable KAPPA p value
Pre Procedure Blush Grade 0 0.94 <0.0001
Pre Procedure Blush Grade 1 0.71 <0.0002
Pre Procedure Blush Grade 2 0.79 <0.0003
Pre Procedure Blush Grade 3 0.76 <0.0004
Pre Overall 0.84 <0.0005
Final Blush Grade 0 0.80 <0.0001
Final Blush Grade 1 0.79 <0.0002
Final Blush Grade 2 0.72 <0.0003
Final Blush Grade 3 0.81 <0.0004
Final Overall 0.78 <0.0005
 
2911-70 Coronary Artery Endothelial Dysfunction and Its 
Clinical Implication into Angiographic Severity of 
Myocardial Bridge
Seung-Woon Rha, Chang Gyu Park, Hyo Won Kim, Kyung Jin Kim, Sang Ki Moon, 
Soon Yong Suh, Jin Won Kim, Hong Seog Seo, Dong Joo Oh, Cardiovascular Center, 
Korea University Guro Hospital, Seoul, South Korea
Background: Previous reports have suggested a link between myocardial bridge (MB) and 
coronary spasm. We evaluated the incidence of signiﬁcant endothelial dysfunction in patients 
(pts) with MB and clinical characteristics according to angiographic severity of MB.
Methods: A total 141 pts (82 men, Age; 54.4±11.3 years) who underwent diagnostic 
coronary angiography with typical angiographic ‘milking effects’ were selected for 
incremental acetylcholine (Ach) provocation test (A1 to A3, 20, 50 and 100µg). Qualitative 
coronary angiography (QCA) analysis was done for assessing MB severity.
Results: Ninety eight percent of the pts had MB at left anterior descending artery 
(LAD). Angiographic and clinical characteristics during Ach provocation test according 
to MB severity are shown on the table. Overall, 74.5% (105/141) of MB pts had (+) Ach 
provocation test. The proportion of (+) provocation, proportion of pt’s response to lower 
dose of Ach and ST-T change during provocation test was increased according to MB 
severity. Spasm patterns such as focal or diffuse and pt’s subjective symptoms were not 
associated with MB severity.
Conclusion: Greater than 70% of pts in MB had signiﬁcant endothelial dysfunction by 
Ach provocation test and this could be responsible for the pt’s coronary morbidty related 
to coronary spasm. The more severe MB, the more pts had (+) provocation results, (+) 
response to lower Ach dose and ST-T change in EKG during the provocation test.
 
N
MB
Severity
Criteria by 
CAG
Mean % 
Diameter 
Stenosis
Ach Provocation 
(+)
% of pt’s response 
to Ach Dose
Focal 
Spasm
*Chest 
Pain
*ST-T 
change
73 Mild(< 50%)
33.3±
10.0%
68.5%
(50/73)
<A2-60.6
A3-39.4
20.0%
(10/50)
70.0%
(35/50)
8.0%
(4/50)
57 Mod(50-70%)
57.8±
6.2%
80.7%
(46/57)
<A2-70.2
A3-29.8
43.5%
(20/46)
73.9%
(34/46)
15.2%
(7/46)
11 Severe(> 70%)
73.5±
6.9%
81.8%
(9/11)
<A2-90.9
A3-9.0
22.2%
(2/9)
44.4%
(4/9)
28.6%
(2/7)
 
2911-71 Three-Dimensional Reconstruction and Quantiﬁcation 
of Standard Coronary Angiography Improves Drug 
Eluting Stent Utilization
Raghava R. Gollapudi, Rafael Valencia, Steve S. Lee, Garrett B. Wong, Paul S. Teirstein, 
Matthew J. Price, Scripps Green Hospital, La Jolla, CA
Background: The accurate determination of the length of stent required to cover a 
target lesion is often limited by signiﬁcant foreshortening on standard, two-dimensional 
angiography. Our goal was to assess whether the use of real-time three-dimensional (3D) 
coronary reconstruction and lesion quantiﬁcation could improve drug-eluting stent (DES) 
utilization.
Methods: Consecutive coronary lesions that underwent stent implantation were analyzed 
using the CardiOp-B system (IC3D, Paieon and Siemens), an image acquisition and 
processing application that enables real-time 3D lesion visualization and quantiﬁcation. 
Operators were blinded to the analysis. The minimum number and appropriate length 
of DES to span each target lesion were calculated and compared to the number and 
length of DES selected by the operator, who was blinded to the 3D analysis. A stent 
was considered to be selected by the operator if it was removed from its packaging and 
advanced into the guide-catheter.
Results: A total of 43 target lesions were prospectively analyzed. CardiOp-B analysis 
was successful in 39 of 43 (90.7%) cases. The analysis would have changed operator 
decision-making in 7 cases (18%). In 6 cases, the DES selected by the operator was 
too short requiring an additional DES or an exchange for a DES of longer length. In 1 
case, the selected DES was too long and was exchanged for a shorter one. In each 
of these cases, 3D analysis accurately predicted the appropriate length and number of 
DES. In comparison to traditional angiography, determination of DES number and length 
by CardiOp-B would have signiﬁcantly decreased the total length of DES implanted (29.8 
mm ± 16.1 mm vs. 26.8 ± 13.3 mm, p=0.004) and would have tended to reduce the 
average number of stents per lesion (1.42 ± 0.73 vs. 1.33 ± 0.47, p=0.10).
Conclusion: Utilization of real-time 3D reconstruction and lesion quantiﬁcation can aid in 
the determination of appropriate DES length and number, and can improve the efﬁciency 
of DES use in nearly 20% of cases.
2911-72 Quantitative Angiogram Analysis to Predict 
Physiological Stenosis Severity: Comparison 
With Intracoronary Pressure and Doppler Velocity 
Measurements in Humans
Serge Zweers, Yvette Seppenwoolde, Bart-Jan Verhoeff, Joan C. Tuinenburg, Gerhard 
Koning, Johan H.C. Reiber, Jos A.E. Spaan, Jan J. Piek, Maria Siebes, Academic 
Medical Center, Amsterdam, The Netherlands, Leiden University Medical Center, 
Leiden, The Netherlands
Background:Stenosis ﬂow reserve (SFR) for standardized conditions can be predicted 
from stenosis geometry based on ﬂuid dynamic equations. It has a predictive value similar 
to that of intracoronary parameters for detection of reversible ischemia. The objective 
was to compare stenosis pressure gradients (dP) predicted from quantitative coronary 
angiography (QCA) to intracoronary measurements of dP.
Methods: Simultaneous intracoronary measurements of distal pressure and ﬂow 
velocity were obtained in 27 patients before (Pre) and after balloon angioplasty (PTCA) 
and stenting (Stent) at maximal hyperemia. Angiograms were recorded at rest in 1 or 2 
views. The target lesion (A) and a second lesion (B) if present in the same segment were 
quantitatively analyzed using QCA-CMS software (MEDIS, Netherlands). This analysis 
includes calculation of stenosis frictional and exit pressure loss coefﬁcients, which were 
used to predict dP at measured hyperemic ﬂow rates. QCA-based predictions were 
compared to dP measured over the whole segment.
Results: Target lesion (A) severity was 62 ± 11% (Pre), 35 ± 11% (PTCA), and 0.2 ± 11% 
(Stent). Stenosis B was 32 ± 8%. Minimum stenosis diameter ratio for the 2 angiographic 
views was 0.8±0.15 (Pre) and 0.9±0.1 after stenting. Predicted dP for the target lesion 
underestimated measured dP for all conditions, by 23 ± 22 mmHg (Pre), 13 ± 13 mmHg 
(PTCA), and 10 ± 9 mmHg (Stent). This result improved marginally when only the most 
severe view was used. Adding the predicted dP of stenosis B after stent placement 
reduced the underestimation to 6 ± 9 mmHg.
Conclusions: Although SFR < 2.3 is predictive of ischemia, measured dP is 
underestimated when calculated from angiograms with QCA. Likely reasons are: the 
eccentric nature of most lesions requires acquisition of the most severe angiographic 
view; QCA analysis predicts dP for a local stenosis, while intracoronary dP includes losses 
over a whole segment. In severe lesions, the guide wire may have caused additional 
dP; stenosis geometry is different during hyperemia and during contrast injection at rest. 
Future work should be carried out to integrate QCA-based pressure losses along the 
diseased vessel to improve dP prediction.
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2912-73 Sirolimus Versus Paclitaxel Eluting Stent Experience 
in an Unselected Population With Coronary Artery 
Disease (C- Versus T-REWARD Registries)
Ron Waksman, Ashesh N. Buch, Pramod K. Kuchulakanti, William W. Chu, Aamir 
Javaid, Rebecca Torguson, Kimberly Smith, Natalie Gevorkian, Zhenyi Xue, Jana 
Fournadjieva, Lowell F. Satler, Kenneth M. Kent, Augusto D. Pichard, Joseph Lindsay, 
Washington Hospital Center, Washington, DC
Background: Sirolimus- (SES) and paclitaxel-eluting stents (PES) have both been shown 
to be superior to bare metal stents in larger clinical trials. The aim of this retrospective study 
was to compare the efﬁcacy and safety of Cypher® versus Taxus® stents in unselected 
patients undergoing contemporary percutaneous coronary intervention (PCI).
Methods: All patients who have had a drug-eluting stent implanted at our institution have 
had their demographic, procedural, and subsequent follow-up data entered onto our 
databases. We analyzed the outcome data for 2518 patients with coronary artery disease 
that underwent PCI with either SES or PES for whom we have 6-month follow-up data.
Results: Baseline characteristics were similar except for more men, patients with 
unstable angina, previous history of PCI, and type C lesions in the PES group (p < 0.001). 
In-hospital, 30-day, and 6-month outcomes were similar between the two groups. (Table) 
Parameter SES (n=1749) PES (n=769) p value
1-month Outcomes
TLR-MACE, % 2.2 2.8 0.308
TVR-MACE, % 2.3 3.0 0.304
Death, % 1.7 2.1 0.572
Non-Q-wave MI, % 10.8 9.3 0.244
Subacute thrombosis, % 0.3 0 0.330
6-month Outcomes
TLR-MACE, % 6.7 8.0 0.237
TVR-MACE, % 7.5 8.7 0.277
Death, % 3.7 4.2 0.503
Non-Q-wave MI, % 10.9 9.4 0.257
Late thrombosis, % 0.4 0 0.112
Conclusion: The universal use of PES and SES in contemporary PCI is associated with 
similar 6-month clinical outcomes.
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2912-74 Direct and Indirect Comparison Meta-Analysis 
Demonstrates the Superiority of Sirolimus- Versus 
Paclitaxel-Eluting Stents Across 5854 Patients
Giuseppe Biondi-Zoccai, Marzia Lotrionte, Antonio Abbate, Marco Valgimigli, Luca 
Testa, Pierfrancesco Agostoni, Policlinico San Donato, San Donato Milanese, Italy
BACKGROUND: There is ongoing debate to identify the most effective drug-eluting stent 
between sirolimus- (SES) and paclitaxel-eluting stents (PES). In order to overcome the 
limitations and apparently conﬂicting results of single head-to-head randomized trials, we 
aimed to compare SES vs PES by both direct and indirect meta-analysis.
METHODS: We identiﬁed two recent direct and indirect comparison meta-analyses 
of SES vs PES. Results for binary angiographic restenosis (BAR) and target lesion 
revascularization (TLR) at 6-12 months were abstracted and pooled by means of ﬁxed 
effects generic inverse variance weighting, and are presented as odds ratios (OR) with 
95% conﬁdence intervals, and inconsistency (I2). Two-tailed statistical signiﬁcance was 
set at the 0.05 level.
RESULTS: The direct comparison meta-analysis pooled 6 head-to-head randomized 
trials, and the indirect comparison meta-analysis compared SES vs PES from 9 additional 
trials. Combining these studies, including a total of 5854 patients (2852 treated with SES 
and 3002 with PES), demonstrated signiﬁcant reductions in BAR (p<0.0001) and TLR 
(p=0.0008) associated with the use of SES in comparison to PES (Figure 1).
CONCLUSIONS: This study deﬁnitively establish the superiority of SES in comparison to 
PES in patients undergoing percutaneous coronary intervention, and should be taken into 
account, together with costs, in clinical decision making. 
2912-75 Drug Eluting Stents in Complex Lesions:  
A Contemporary Comparative Analysis
John Cosgrave, Rade Babic, Nuccia Morici, Cosmo Godino, Simon Corbett, Gloria 
Melzi, Tiziana Aranzulla, Alaide Chieffo, Giuseppe M. Sangiorgi, Matteo Montorfano, 
Iassen Michev, Flavio Airoldi, Mauro Carlino, Antonio Colombo, EMO Centro Cuore 
Columbus, Milan, Italy, S. Raffaele Hospital, Milan, Italy
Background: Drug eluting stents (DES) signiﬁcantly reduce MACE rates. Recent data 
have suggested a clinical advantage of sirolimus eluting stents (SES) over paclitaxel 
eluting stents (PES). We have retrospectively compared the outcomes of PES and SES 
in complex versus simpler lesions.
Methods: 2442 lesions were treated in 1434 patients between March 2003 and December 
2004. PES and SES were implanted in 676 and 758 patients respectively. Lesions were 
deﬁned as complex if one or more of the following criteria were met: 3 or more stents 
in one vessel; 5 or more stents per procedure; medically treated diabetes mellitus; 
bifurcation lesions or chronic occlusions. The end points analyzed were follow-up major 
adverse cardiac events (MACE) deﬁned as a composite of death, myocardial infarction 
and target vessel revascularization, including target lesion revascularization.
Results: There were no signiﬁcant differences in demographic and angiographic 
parameters between all groups. In the less complex group, SES were superior for late 
loss (0.22 ± 0.74 mm versus 0.42 ± 0.80 for PES, p=0.004), MACE (12.8% versus 20.1%, 
p=0.006), TLR (6.0% versus 9.9%, p=0.019) and TVR (8.0% versus 14.9%, p=000.1). In 
complex lesions MACE, TLR and TVR were similar for PES and SES although late loss 
remains superior for SES (0.37 ± 0.80 mm versus 0.64 ± 0.83 for PES, p<0.001).
Conclusions: The apparent superiority of SES over PES disappears as disease 
complexity increases with equal outcomes for both platforms. Late loss should not be 
used as a surrogate marker for clinical outcome in complex lesions.
2912-76 Differences Between Sirolimus-eluting and Paclitaxel-
eluting Stents as Assessed by Intravascular Ultrasound
Stephane Cook, Thuraia Nageh, Lorenz Räber, Peter Jüni, Peter Wenaweser, Mario 
Togni, Michael Billinger, Christian Seiler, Marco Rofﬁ, Roberto Corti, Gabor Sütsch, 
Willibald Maier, Franz R. Eberli, Otto M. Hess, Bernhard Meier, Stephan Windecker, 
Swiss Cardiovascular Center Bern, University Hospital, Bern, Switzerland
Background. As part of the angiographic follow-up protocol, we performed intravascular 
ultrasound (IVUS) examination in the ﬁrst 236 patients enrolled in the SIRTAX trial, a 
randomized trial to compare a Sirolimus-eluting (SES) with a Paclitaxel-eluting (PES) 
stent. The purpose of the IVUS substudy was to evaluate differences in neointimal 
hyperplasia and vascular remodeling between the two stent types.
Methods and Results. A total of 236 patients with eluting stent, underwent IVUS 
examination at the time of angiographic follow-up. Intravascular ultrasound imaging was 
performed using motorized pullback (0.5 mm/s) and Eagle Eye scanner. All IVUS core 
lab analyses were performed blinded to treatment arm, and adequacy of the image for 
analysis was determined before unblinding the data. After excluding 36 patients for failed 
acquisition (severe stenosis: 9 patients, 2 SES vs. 7 PES, p=0.43), inadequate pullback 
or poor image quality, volumetric analysis was possible in 200 patients and 222 segments 
(SES, n=104; PES, n=118). There were no signiﬁcant differences in baseline clinical 
and angiographic characteristics between SES and PES patients. Volumetric data are 
depicted in the Table. The rate of incomplete stent apposition was signiﬁcantly higher for 
SES than PES (p<0.001).
Conclusion.SES more effectively reduced neointimal hyperplasia as assessed by IVUS 
than PES. However, SES was associated with a higher rate of ISA than PES without a 
difference in clinical sequelae.
IVUS volumetric data at 9-month follow-up
SES group (n=104) PES group (n=118) p
Stent diameter,mm 2.94+/-0.32 2.97+/-0.34 N.S.
Stent length, mm 18.8+/-8.5 19.1+/-10.1 N.S.
Vessel volume, mm3/mm 21.8+/-6.3 22.6+/-6.4 N.S.
Stent volume, mm3/mm 7.2+/-2.0 8.0+/-2.3 <0.01
Lumen volume, mm3/mm 6.5+/-1.9 7.1+/-2.2 N.S.
Intimal hyperplasia, mm3/mm 0.68+/-0.53 0.94+/-0.57 <0.001
%Volume obstruction 9.5+/-5.8 12.0+/-6.0 <0.001
2912-77 Comparison of Sirolimus- and Paclitaxel- Eluting 
Versus Bare Metal Stenting in an Unselected Patient 
Population With Acute Myocardial Infarction
Leon I. Kupferwasser, Allen M. Amorn, Michael S. Lee, Saibal Kar, Bojan Cercek, Suhail 
Dohad, Nikhil Kapoor, Rajendra R. Makkar, Cedars-Sinai Medical Center, Division of 
Cardiology, Los Angeles, CA
Background: Drug-eluting stents (DES) have been shown to reduce the incidence of 
target vessel revascularization when compared to bare metal stents (BMS) in patients 
(pts) undergoing elective percutaneous intervention (PCI). Limited data are available in 
pts with acute myocardial infarction (STEMI). The aim of this study was to compare pts 
with STEMI treated with primary PCI using DES vs. BMS. 
Methods: 241 consecutive pts who presented with STEMI between 7/2001 and 6/2005 
were studied. The procedures and outcomes of 115 pts treated with DES were compared 
to 126 pts treated with BMS. 
Results: Signiﬁcant differences in the following parameters were noted: number of stent 
per target vessel (DES: 1.6 ± 0.9 vs. BMS: 1.38 ± 0.62, p=0.015), bifurcation PCI (DES: 
20.9% vs. BMS: 5.6%, p=0.004), crush-technique (DES: 10% vs. BMS: 0.6%, p= 0.008), 
multivessel PCI (DES: 22.6% vs. BMS: 8.7%, p=0.004). The outcomes at 30 days and 6 
months are illustrated in the table. No differences were noted between pts treated with 
Sirolimus- vs Paclitaxel-eluting stents. Pts treated with DES-multivessel stenting were 
associated with a lower death rate (Δ -12.5%; p=0.49) and reinfarction rate (Δ -18.8%; p= 
0.23) when compared to comparable pts treated with DES-single vessel stenting. 
Conclusion: The routine use of DES in STEMI yields improved outcomes at 6 months 
when compared to BMS, despite a substantially higher rate of complex PCIs and 
multivessel intervention in the pts. treated with DES. 
30-Day outcomes (n= 241) DES BMS p value
Death (%) 5.2 5.6 1.0
Reinfarction (%) 1.7 2.4 1.0
Target vessel revascularization (%) 1.7 4.8 0.29
Any event (%) 7.0 11.1 0.37
6-months outcomes (n= 218)
Death (%) 5.4 7.9 0.59
Reinfarction (%) 1.1 3.2 0.39
Target vessel revascularization (%) 1.1 9.5 0.009
Any event (%) 5.4 15.9 0.01
 
2912-78 Comparison of Vascular Response to ABT-578 Versus 
Sirolimus Eluting Stent Implantation: Intravascular 
Ultrasound Results From ENDEAVOR 3
Akiyoshi Miyazawa, Yoichiro Hongo, Seung-Ho Hur, Ichizo Tsujino, Brian K. Courtney, 
Ali H.M. Hassan, Robert Applegate, Ronald Caputo, Mark Turco, Michel Ball, Charles 
O’Shaughnessy, David E. Kandzari, Martin B. Leon, Yasuhiro Honda, Peter J. Fitzgerald, 
for the ENDEAVOR 3 Investigators, Stanford University Medical Center, Palo Alto, CA
Background ENDEAVOR 3 is a prospective, multicenter, 3:1 randomized trial to compare 
ABT-578 eluting phosphorylcholine-coated cobalt-chromium alloy DriverTM stents (AES) 
with sirolimus eluting stents (SES) in de novo coronary lesions. The purpose of this 
study was to investigate long-term vascular response to AES versus SES using serial 
volumetric intravascular ultrasound (IVUS).
Methods Serial (baseline and 8 months) IVUS was available in 258 patients (190 AES, 68 
SES). At the stent and reference segments, volume index was calculated to standardize 
volumetric IVUS data by segment length. % neointimal (NI) volume was deﬁned as NI 
volume divided by stent volume (%). Custom-designed 3-D software was used to compute 
% NI coverage over stent surface area and actual mean NI thickness.
Results At 8 months, 50.4% of AES surface was covered by NI, while only 10.3% was 
covered in SES. Differences in mean NI thickness and lumen dimensions were both 
minimal, despite the greater NI volume in AES. Although overall vessel volume indices 
were similar, SES had a signiﬁcantly higher incidence of late acquired incomplete 
apposition. No signiﬁcant difference was observed in proximal or distal reference lumens 
between the two stents.
Conclusion The relatively diffuse nature of NI within AES resulted in a clinically acceptable 
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lumen loss at 8 months. Combined with less late acquired incomplete apposition, the 
larger neointimal coverage over the stent surface area may favorably impact the safety 
proﬁle of this new stent. 
Baseline Follow up
SES AES P SES AES P
% Neointimal Coverage over Stent Surface Area 10.3±11.7 50.4±25.9 <0.01
Mean Neointimal Thickness (mm) 0.05±0.05 0.17±0.08 <0.01
Neointima Volume Index (mm3/mm) 0.2±4.1 1.1±0.8 <0.01
Lumen Volume Index (mm3/mm) 6.8±2.0 7.0±2.0 0.46 6.8±2.1 6.0±2.0 0.04
Vessel Volume Index (mm3/mm) 11.9±4.1 13.7±4.3 0.08 12.6±4.1 14.2±4.3 0.25
Late Acquired Incomplete Stent Apposition (%) 5.8 0.5 0.02
Proximal Reference Lumen Volume Index (mm3/mm) 6.4±2.9 7.8±2.6 0.07 7.2±3.1 7.2±2.6 0.67
Distal Reference Lumen Volume Index (mm3/mm) 5.7±2.4 6.5±2.5 0.11 5.7±2.5 6.1±2.2 0.44
 
2912-79 Two-Year Clinical Follow-Up of the Unrestricted Use of 
the Paclitaxel-Eluting Stent Compared to the Sirolimus-
Eluting Stent as Part of the Taxus-Stent Evaluated at 
Rotterdam Cardiology Hospital (T-SEARCH) Registry
Joost Daemen, Andrew T.L. Ong, Marco Valgimigli, Gastón A. Rodriguez-Granillo, 
Héctor M. García-García, Keiichi Tsuchida, Sophia Vaina, Shuzou Tanimoto, Carlos A. 
G. van Mieghem, Ron T. van Domburg, Patrick W. Serruys, Erasmus Medical Center, 
Thoraxcenter, Rotterdam, The Netherlands
Background: Recently Sirolimus- and Paclitaxel-Eluting stents, (respectively SES and 
PES), have shown to effectively reduce restenosis in stenotic coronary arteries compared 
to standard bare metal stents. To date, there is no data on the efﬁcacy of both stents and 
possible superiority of one of both devices over multiple years of follow-up. Furthermore a 
late catch-up phenomenon of restenosis has not been excluded yet.
Methods:  Since April 2002, 508 consecutive patients treated with SES were included. In 
February 2003, PES replaced the SES as the device of choice for every PCI in our institution. 
Until September 3th, 576 patients treated wih PES were included. Two year clinical follow-up 
is still ongoing and is already complete for 81.5% of our patients (mean 821 days).
Results: There were more males in the PES group (68% versus 74% respectively, p=0.04) 
and at presentation the incidence of cardiogenic shock and complex lesions was higher in 
the PES group. Preliminary cumulative survival was 92.1% in the SES group versus 91.8% 
in the PES group (95% CI 0.67 to 1.61; p=0.86). We will be able to present our complete 
follow-up, including the rates of Major Adverse Cardiac Events, at the meeting.
Conclusions: After 2 years of follow-up, the use of sirolimus- and paclitaxel-eluting stents 
remains safe. Our preliminary medium-term results of the unrestricted use of both devices 
show that the difference between both devices will be minimal.
POSTER SESSION
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2913-80 Association of the Polymorphism in the Drug 
Transporter Gene ABCB1 With In-Stent Restenosis of 
Paclitaxel Eluting Stents in the Korean Subjects
Chul Min Ahn, Sungha Park, Jung Ae Hong, Ji Hyun Lee, Young-Guk Ko, Donghoon 
Choi, Jong-Won Ha, Min Goo Lee, Yangsoo Jang, Namsik Chung, Won Heum Shim, 
Seung-Yun Cho, Yonsei Cardiovascular Center, Seoul, South Korea, Yonsei University 
College of Medicine, Seoul, South Korea
Background: Paclitaxel eluting stents (Taxus, Boston Scientiﬁc) are reported with 
angiographic restenosis rate of 10-15%. Neointimal hyperplasia after Taxus stent 
insertion may be mediated by increasing drug resistance involving the ATP binding 
cassette sub-family B member 1(ABCB1, also known as MDR1 and P-glycoprotein 170). 
We investigated the possibility of the association of ABCB1 C3435T gene polymorphism 
with the in-stent restenosis (ISR) in Korean subjects undergoing Taxus stent insertion. 
Methods: The study included 106 patients with symptomatic coronary artery disease 
who underwent Taxus stent insertion and 9 month followup coronary angiography. We 
screened the ABCB1 C3435T gene polymorphism in these patients. Genotyping was 
performed by Snap-shot method. 
Results: The genotype distribution for the CC:CT:TT genotype was 44(41.5%):50(47.2
%):12(11.3%). There were no signiﬁcant difference between patients homozygous for the 
C allele compared to patients with CT and TT genotypes in terms of the baseline clinical 
characteristics, coronary artery disease risk factors, stent size and baseline coronary 
artery lesion characteristics. The results showed a signiﬁcant association of the C3435T 
polymorphisms with in-segment restenosis [CC:1/44(2.3%), CT and TT:13/62(21.0%), P-
value =0.005] and ISR rate [CC:0/44(0.0%) , CT and TT:11/62(17.7%), P-value =0.003]. 
The patients homozygous for the C allele were associated with signiﬁcant decrease in late 
loss.(0.19±0.62mm vs 0.49±0.73mm, P-value: 0.026) The presence of C allele, assuming 
a codominant effect of the C allele, was independently associated with decreased risk of 
ISR when controlled for age, stent length, average reference diameter, diabetes, lesion 
complexity and smoking [OR=0.103(0.015-0.680), P-value = 0.018]. Conclusion: The 
results from this study demonstrates, for the ﬁrst time, the signiﬁcant association of C3435T 
gene polymorphism with ISR of Taxus stent. The presence of C allele was associated with 
independent protective effect from ISR in Korean subjects. This work was supported by a 
grant of Ministry of Health and Welfare, Republic of Korea (00-PJ6-PG5-23-0001)
2913-81 Sulfasalazine Reduces Neointimal Hyperplasia in Rat 
Carotid Artery Balloon Injury Model by Inhibition of NF-
κB Signaling and Activation of Nrf-2
Sir Jung-Ju, Kim Ju-Young, Kwak Jae-Jin, Kim Yong-Seok, Lee Hae-Young, Kang Hyun-
Jae, Kim Kwang-Il, Cho Young-Seok, Chung Woo-Young, Koo Bon-Kwon, Choi Dong-Ju, 
Kim Hyo-Soo, Oh Byung-Hee, Park Young-Bae, Seoul National University Hospital, 
Seoul, South Korea, Cardiovascular Research Institute, Seoul, South Korea
Background: Sulfasalazine(SSZ) has been used as anti-inﬂammatory and 
immunomodulatory drug in the treatment of inﬂammatory bowel disease and rheumatoid 
arthritis.The transcription factor NF-κB is known to play a pivotal role in the activation of 
inﬂammatory genes, thus inducing proliferative vascular disorders.In recent years, the 
transcription factor NF-E2 p45-related factor-2(Nrf-2) has been reported to regulate the 
expression of antioxidant and detoxiﬁcation genes such as heme oxygenase-1(HO-1).We 
hypothesized that SSZ might reduce neointimal hyperplasia in rat carotid artery balloon 
injury model and investigate the possible mechanism involved.
Methods: Rat vascular smooth muscle cells were cultured in the presence of SSZ(100 µM). 
Cell cycle change and degree of apoptosis was evaluated by FACS analyses. NF-κB activation 
was evaluated by electrophoretic mobility shift assay and expression of HO-1 and Nrf2 was 
evaluated by Western blot. For in vivo experiments, rat carotid artery balloon injury model 
was used to test the effects of SSZ and vehicle on neointimal growth. Rats were divided into 
2 groups(n=5/group): SSZ(86 mg/kg/d) and vehicle(normal saline). Drugs were administered 
via intraperitoneal injection from 3 days before to 2 weeks after balloon injury.
Results: In vitro, SSZ signiﬁcantly increased TNF-α-mediated apoptosis and induced 
cell cycle arrest in rat VSMCs.Apoptosis induction by SSZ was reversed by antioxidant, 
NAC, suggesting effect of SSZ was mediated by ROS.SSZ signiﬁcantly inhibited TNF-α-
mediated activation of NF-κB and increased HO-1 expression via activation of Nrf-2. In 
vivo, SSZ reduced neointimal hyperplasia after balloon-injury in rat carotid artery(p<0.05).
Tissue immunoblot showed signiﬁcant increase of caspase-3 in SSZ-treated carotid 
artery, suggesting reduced hyperplasia resulted from increased apoptosis of rat VSMCs.
Conclusions: SSZ was found to have a potent inhibiting effect of neointimal hyperplasia 
via inhibition of NF-κB signaling. This study suggests that those inhibiting effect of SSZ 
was mediated by activation of Nrf-2 and induction of HO-1 and that SSZ might be a 
potential agent in preventing restenosis after angioplasty.
2913-82 Histopathologic Features of Restenotic Lesions Within 
Drug- Eluting Stents and Bare Metal Stents in Humans
Chiara Foglieni, Alaide Chieffo, Carlo Briguori, Laura Rota Nodari, Gloria Melzi, 
Giuseppe Sangiorgi, Matteo Montorfano, Alessio Giazzon, Anton E. Becker, Antonio 
Colombo, Attilio Maseri, San Raffaele Scientiﬁc Institute, Milan, Italy, Clinica 
Mediterranea, Naples, Italy
Backgrounds: Drug-eluting stents (DES) are associated with a lower rate of in-stent 
restenosis (ISR). Features about neo-intimal tissue involved in restenosis after either 
sirolimus- (SES) or paclitaxel-eluting stent (PES) implantation are still scanty.
Methods From October 2004 to June 2005 8 pts previously treated with DES (4 PES, 
4 SES) and 7 with bare metal stent (BMS) underwent directional atherectomy for ISR 
after 4 to 13 months. Morphology was evaluated on sections from 5 pts by Movat’s stain. 
Confocal microscopy was performed in all 15 pts, assessing the proliferation rate by Ki67 
and inﬂammatory cells (lymphocytes, granulocytes, macrophages) by CD3 and CD18. 
Smooth muscle cells (SMC) were characterized by alpha-SM actin (SMA), F-actin, 
myosin heavy chain type 1 - 2 (Mhc) and Collagen type I (Coll). Endothelial cells were 
assessed by VE-cadherin, CD34 and CD31.
Results In all pts histology showed that restenotic lesions were mainly composed of 
neointimal tissue, with polymer or metal residues and ﬁbro-lipidic areas. Confocal 
microscopy conﬁrmed histology, showing prevalence of SMCs with a synthetic phenotype, 
absence of both inﬂammatory cells and endothelial lining. On serial sections sparse Ki67 
positive cells were identiﬁed as SMCs. SMCs expressed SMA and F-actin in all restenotic 
lesions. Distinctive features between SES, PES and BMS were: 1) mean proliferation 
index: 0,85 % in SES, 0,41% in PES, 0.87% in BMS; 2) Mhc and Coll expression were 
BMS> PES> SES; 3) several Mhc negative areas were observed in all PES, but not in 
SES and in BMS; 4) no endothelial cells were detected in PES, whereas clusters of CD 
31/VE-cadherin or CD31/CD34 double positive cells were present in SES far from the 
polymer and in BMS tissues, 
Conclusions: Intra-DES and -BMS restenotic tissues are mainly composed by SMCs of 
a synthetic phenotype, still proliferating up to 13-months follow-up but only in DES. These 
preliminary results suggest different mechanisms of restenosis both in BMS vs. DES and 
in SES vs. PES. These ﬁndings may have relevant implications for the optimal duration of 
anti-platelets pts therapy for different types of DES.
2913-83 Zotarolimus (ABT-578) Inhibits Monocyte 
Chemoattractant Protein-1 Production By 
Lipopolysaccharide-stimulated Human Monocytes
Matthew M. Mack, Lanlan Li, Yu Xiao, Sandra E. Burke, Abbott Vascular Devices, Abbott 
Park, IL
Background: Stent implantation induces a local inﬂammatory response, including 
monocyte (hMC) activation which can stimulate smooth muscle proliferation and 
restenosis. Agents delivered from drug-eluting stents (DES) may attenuate this 
inﬂammatory response. This study determined the effects of common DES agents, 
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including zotarolimus (formerly ABT-578), on the generation of proinﬂammatory cytokines 
by stimulated hMC in vitro.
Methods: The production of monocyte chemoattractant protein-1 (MCP-1) by 
lipopolysaccharide (LPS)-activated hMC, tumor necrosis factor-α (TNF-α)-stimulated 
human coronary artery endothelial (hCaEC) and smooth muscle cells (hCaSMC) was 
determined by immunoassay (ELISA).
Results: Zotarolimus and sirolimus dose-dependently inhibited LPS-stimulated MCP-
1 production by hMC; dexamethasone (dex) was signiﬁcantly less potent (ﬁgure). Dex 
inhibited MCP-1 production by TNF-α treated hCaSMC, but had no effect in hCaEC 
(IC50 = 43.3 ± 14.3 nM and >10µM, respectively). Both zotarolimus and sirolimus 
(1µM) attenuated TNF-α induced MCP-1 production in hCaEC (41 ± 3% and 32 ± 7%, 
respectively) but had no effect on hCaSMC MCP-1 production.
Conclusions: These data suggest that zotarolimus and sirolimus directly block hMC 
activation; dexamethasone may indirectly inhibit hMC activation by suppressing SMC-
mediated MCP-1 production. It is hypothesized that the anti-restenotic activity of these 
compounds may be partially mediated by their anti-inﬂammatory activity.
 
2913-84 Mobilization of Stem Cell into Peripheral Blood After 
Percutaneous Coronary Intervention is Abnormal in 
Patients Who Have Restenosis
Francesco Pelliccia, Christian Pristipino, Vincenzo Pasceri, Antonino Granatelli, 
Guido Meoni, David Mocini, Giacomo Menichella, Giuseppe Richichi, San Filippo Neri 
Hospital, Rome, Italy
Background: Rapid repair of the injured arterial wall after percutaneous coronary 
intervention (PCI) can prevent restenosis. To this end, circulating stem cells seem to play 
a crucial role in the repair process. Accordingly, the aim of this study was to assess the 
hypothesis that restenosis after PCI occur in patients who have an impaired stem cells 
activity after vascular injury.
Methods: We studied 25 stable angina patients (Gr. A) who underwent elective PCI and 
showed signiﬁcant binary restenosis (i.e., diameter stenosis>50% at follow-up) at 8-month 
angiography. For comparison, 25 age- and sex-matched patients (Gr. B) who had no 
restenosis at follow-up were considered. All patients had PCI with >1 bare metal stents. 
Peripheral blood samples were drawn at time of PCI. FACSCalibur ﬂow-cytometer was 
used for stem cells assay and absolute number of mononuclear cells, CD34+, CD45+, 
CD105+, and CD133+ were evaluated.
Results: Comparison of the two groups did not show any difference in risk factors, 
cardiac function, extension of coronary artery disease, and pharmacologic treatment. 
Also, there were no differences in treated vessel, quantitative coronary angiography data 
and procedural characteristics. Flow cytometry showed that the two groups had similar 
absolute numbers of mononuclear cells (6,82+1,14 vs 6,76+1,30 n/µL, NS). Compared 
with Gr.B, conversely, Gr. A patients showed signiﬁcantly lower absolute numbers of 
CD45+, a leukocyte marker, (72,28+12,32 vs 83,08+7,24 n/µL, p=0.002), and CD105+, 
a marker of neo-angiogenesis, (179,61+71,24 vs 216,57+63,96 n/µL, p=0.04). On the 
opposite, Gr. A patients had signiﬁcantly higher absolute numbers of the endothelial 
markers CD34+ (0,140+0,074 vs 0,101+0,054 n/µL, p=0.04), and CD133+ (0,063+0,022 
vs 0,034+0,026 n/µL, p=0.0001).
Conclusions: Stem cell mobilization into peripheral blood after PCI and stenting is abnormal 
in patients who experience restenosis at 6-month. Impaired stem cells response to vascular 
injury seems to contribute to delayed angiogenesis and excessive endothelialization, thus 
being a novel mechanism underlying the phenomenon of restenosis.
2913-85 Increased In-stent Stenosis in ApoE-Knockout Mice: A 
Novel Mouse Model of Angioplasty and Stenting
Ziad A. Ali, Nicholas J. Alp, Henry Lupton, Nadine Arnold, David R. Greaves, Yanhua Hu, 
Julian Gunn, Keith M. Channon, University of Oxford, Oxford, United Kingdom
Background: Greater understanding of the molecular mechanisms underlying in-stent 
stenosis could provide new therapeutic targets. We developed a novel mouse model of 
angioplasty and stenting to allow investigation of these mechanisms using genetically 
modiﬁed strains.
Methods: Thoracic aortic segments from hypercholesterolemic ApoE -/- or C57Bl/6 wild-
type mice (n=5/group) were grafted into the carotid artery of isogenic recipients using a 
cuff technique - either as untreated aortic grafts (control), following balloon angioplasty 
alone, or after stenting with a 1.0x3.0mm stainless steel stent deployed on a 1.25 mm 
balloon (10 atm). Vessels were harvested after 28 days.
Results: Balloon angioplasty caused signiﬁcant neointima formation compared to 
control (3-fold, *P<0.01). Stented animals developed reproducible in-stent stenosis, with 
signiﬁcantly greater neointimal area compared to balloon or control (Figure, **P<0.01). 
Importantly, neointimal area was 1.3 fold greater (Figure, #P<0.05) in stented ApoE -/- 
mice compared with C57Bl/6. Despite increased neointima in the stented animals, lumen 
area was increased by 71% (P<0.001) due to maintenance of vessel expansion, whereas 
balloon angioplasty reduced lumen area by 60% (P<0.01).
Conclusions: This model reproduces important features of human PCI and provides 
the potential to investigate molecular pathways and explore novel therapeutic targets for 
in-stent stenosis.
2913-86 Effect of Magnesium Alloy Stents in Porcine Coronary 
Arteries: Morphometric Analysis of a Long-Term Study
Ron Waksman, Rajbabu Pakala, Eric Wittchow, Sonja Hartwig, Claus Harder, Ronald 
Rohde, Bernd Heublein, Axel Haverich, Arnim Andreae, Karl-Heinz Waldman, 
Washington Hospital Center, Washington, DC, BIOTRONIK GmbH, Erlangen, Germany
Background: Bioabsorbable stents carry the potential to overcome the limitations posed 
by permanent metallic stents such as chronic inﬂammation and late stent thrombosis. 
This study aimed to test the long-term effects of bioabsorbable magnesium alloy stents 
(MAS) on neointima formation in porcine coronary arteries.
Methods and Results: Two MAS or 1 stainless steel stent were randomly deployed in 
coronary arteries of mini pigs. Animals were sacriﬁced at 1 (n = 6), 3 (n = 6), 6 (n = 
6), and 12 (n = 8) months, arteries ﬁxed, sections made from proximal, mid, and distal 
sections of the stent, stained, and morphometric analysis performed. Neointimal area 
in the arteries stented with MAS ranged from 1.92 ± 0.58 at 1 month to 1.27 ± 0.27 
at 12 months as compared to 1.77 ± 0.89 to 1.99 ± 1.02 in the animals deployed with 
stainless steel stents. At each time point, the neointimal area in the arteries stented with 
MAS was smaller as compared to the one in the arteries deployed with stainless steel 
stents (p< 0.01). Vessel area was smaller in the arteries stented with MAS (p< 0.01), and 
may be the result of remodeling. There is no signiﬁcant difference in the lumen area or 
% occlusion between arteries stented with MAS or stainless steel stents. In spite of the 
lesser neointima, smaller vessel area may be the reason for lack of improvement in the 
lumen area or % occlusion in the arteries stented with MAS.
Conclusion: The deployment of MAS in coronary arteries was safe and associated with 
less neointimal area as compared to stainless steel stents.
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POSTER SESSION
2914 
Computed Tomography and Mitral 
Regurgitation: Validation and New 
Applications
Monday, March 13, 2006, 9:00 a.m.-12:30 p.m.
Georgia World Congress Center, Hall B1
Presentation Hour: 10:00 a.m.-11:00 a.m.
2914-87 Discordance Between Anatomical and Functional 
Severity of Coronary Artery Disease: 16-slice Multi-
detector Computed Tomography and Fractional Flow 
Reserve
Jasper S. Wijpkema, Joost Dorgelo, Tineke P. Willems, Rene A. Tio, Gillian A. Jessurun, 
Matthijs Oudkerk, Felix Zijlstra, University Medical Center Groningen, University of 
Groningen, Groningen, The Netherlands
Background: New developments have made 16-slice Multi-Detector Computed 
Tomography (MDCT) a promising technique for detecting signiﬁcant coronary stenoses. 
At present, there is a paucity of data on the relation between fractional ﬂow reserve (FFR) 
measurement and MDCT stenosis detection. The aim of this study was to investigate the 
relation between the anatomical severity of coronary artery disease detected by MDCT 
and functional severity measured by FFR.
Methods: We studied 53 patients (39 men and 14 women, age 62.5±8.1 years) with 
single-vessel disease scheduled for percutaneous coronary intervention (PCI). All patients 
underwent MDCT scanning 1 day prior to PCI and FFR was measured before PCI in the 
target vessel. Quantitative Coronary Angiography (QCA) for conventional angiography 
and stenosis quantiﬁcation for MDCT were performed ofﬂine by two independent 
observers who met in consensus.
Results: MDCT analysis could be performed in 52 of 53 patients (98.1%) and all patients 
had adequate FFR and QCA measurements. The mean diameters of stenosis calculated 
by MDCT and QCA were 67.0±11.6% and 60.8±11.6% respectively. No signiﬁcant 
relation was found between MDCT and QCA (r=0.22, CI=-0.06 to 0.47, p=0.12) The mean 
FFR in all patients was 0.67±0.18. A relation of r= -0.46 (CI=-0.65 to -0.22, p=0.0006) 
between QCA and FFR was found. In contrast, no relation between MDCT and FFR could 
be demonstrated (r=-0.09, CI=-0.36 to 0.19, p=0.50). Furthermore, a high incidence of 
discordant ﬁndings - 3 false negative (MDCT<50% and FFR50% and FFR>0.75) - was 
present. Coronary calciﬁcation did not inﬂuence QCA, FFR or MDCT outcome.
Conclusions: No clear relation exists between anatomical and functional severity of 
coronary artery disease as deﬁned by MDCT and FFR. Therefore, functional assessment 
of coronary stenoses remains mandatory for clinical decision making.
2914-88 Evaluation of Coronary Plaques With 64-slice Computed 
Tomography Compared With Intracoronary Ultrasound
Honghua Ye, S. Saito, S. Tanaka, H. Kaneda, Y. Taketan, T. Shion, Y. Miyashita, S. 
Takahas, H. Domae, S. Sekine, Shonan Kamakura General Hospital, Kamakura, Japan
Background: Currently, the ability of multislice CT to detect coronary plaque and quantify 
plaque dimensions has not been known.
Methods: We included 12 patients of stable angina pectoris scheduled for PCI 
according to invasive coronary angiography. Contrast-enhanced 64-slice CT angiography 
(Sensation 64, Siemens Medical Solutions) was performed before percutaneous coronary 
intervention (PCI), and ICUS was performed during procedure.
Results: 88 segments in 31 vessels (LAD12, LCX 10, RCA 9) of 12 patients are 
investigated by both IVUS and CT. 68 segments (54 in proximal segments and 14 in distal 
segments) were assessable. (20 segments were excluded due to severe calciﬁcation, 
motion artifact or low opaciﬁcation ). Compared with ICUS, CT correctly detected 47 of 
the 51 segments with plaques. (Sensitivity: 92.15%), and correctly evaluated 16 of 17 
segments without plaques (speciﬁcity 94.12%). sensitivity of detecting segments with 
plaque obstruction less than 50% is 87.09% and speciﬁcity is 94.71%. CT correlated 
well with ICUS concerning gradation of segments with plaque obstruction less or more 
than 50%, (simple kappa 0.63, 95% conﬁdence limits: from 0.47 to 0.78). Measurement 
of plaque area derived by CT also correlated with ICUS (r = 0.53 p < 0.0001), but 
overestimated ( plaque area by ICUS: 6.80 ± 2.81 vs plaque area by CT : 9.09±3.89 ,p < 
0.0001). 30 of 43 hypoechoic compositions were detected as low-density compositions by 
CT (69.76%) with average CT number of 67.39 HU.
Conclusion: Contrast-enhanced 64-slice CT angiography could detect plaques in 
proximal coronary artery with high accuracy. Measurement of plaque area derived by CT 
correlated with ICUS but exact measurement was still limited.
2914-117 One-beat Whole Heart Imaging Using the 2nd Spec 256-
multislice CT: First Clinical Data
Akira Kurata, Teruhito Mochizuki, Kazuhiro Katada, Shuji Tanada, Masahiro Endo, 
Teruhito Kido, Hiroshi Higashino, Makoto Saito, Hideki Okayama, Jitsuo Higaki, Ehime 
Univarsity School of Medicine, Ehime, Japan
Background: Since the 2nd spec 256-multislice CT covers 12.8 cm along z-axis (0.5mm 
slice thickness x 256-slice), it covers whole heart within one rotation (0.5 sec). Purpose 
of this study was to evaluate the advantage of the 2nd spec 256-multislice CT, analyzing 
the ﬁrst clinical results.
Methods: Clinical materials consisted of 2 patients with old myocardial infarction (inferior 
and anterior). After test injection of contrast medium for optimal scan timing, the scan 
was obtained, using the same contrast medium at 3 to 4 ml/sec x 15 sec with a chaser 
of saline at 3ml/sec (20ml). Acquisition time was about 1.5 sec (one beat + fan angle 
[0.5 sec]). Twenty phases were extracted for coronary imaging and for 2D/3D cine (=4D) 
cardiac imaging to assess cardiac function. In the most stable phase, coronary arteries 
were evaluated. Left ventricular functional parameters and volume curve including end-
diastolic and end-systolic volumes, and ejection fraction were obtained.
Results: In all subjects, coronary arteries were assessable without stair-step artifacts. 
All left ventricular functional parameters were abnormality in two OMI lesions could 
be assessed. Image fusion of the coronary tree and left ventricular function was also 
successfully obtained.
Conclusions: The 2nd spec 256-Multislice CT seems to be a promising next generation 
CT for coronary and cardiac imaging, allowing “One-beat whole heart imaging”.
2914-118 Thrombolytic Therapy Prior to Percutaneous Coronary 
Intervention in Acute Myorcardial Infarction May 
Shorten Reperfusion Time Assessed by Cardiac 
Magnetic Resonance
Véronique Decalf, Marie Claude Morice, Bernard Noël, Jérôme Garot, Yves Louvard, 
Pierre Dumas, Thierry Unterseeh, Philippe Garot, Oscar Tavolaro, Institut Cardiovasculaire 
Paris Sud, Massy, France, Institut Cardiovasculaire Paris Sud, Quincy, France
Cardiac magnetic resonance imaging perfusion (CMR), performed early after successful 
primary angioplasty frequently shows incomplete myocardial tissue reperfusion, but is a 
very sensitive tool now used in many studies.
We investigated the effect of pre-hospital thrombolytic therapy (facilitated PCI) on tissue 
reperfusion kinetics compared to non facilitated primary PCI in Pts with ST-segment 
elevation AMI < 12 hours. Successful PCI Pts (TIMI 3 ﬂow), who had CMR within 4 
months after AMI were included (July 2002-January 2005, n=146). CMR was performed 
on a Siemens Symphony 1.5 T after injection of 0.2 mmol/kg of gadolinium (n=184). For 
ﬁrst pass analysis, each slice was divided into 8 segments which were divided into subepi 
and subendocardial layers. Normal perfusion was deﬁned by < 5% of segments involved 
by hypoperfusion. The reperfusion curve was established by plotting the percentage of 
Pts with normal perfusion in each group.
Out of these 146 Pts, 42% had facilitated PCI and the probability of normal perfusion 
increased progressively to 100% at second week. In the non facilitated group (58%), 
probability of normal perfusion reached 100% at 4 weeks. In-hospital mortality and 
complications were not signiﬁcantly different between the 2 groups. Results are 
summarized in the graph below.
Facilitated PCI by pre-hospital thrombolytic therapy prior to PCI in acute MI seems to 
shorten time to normal perfusion. This might be related to a higher initial TIMI ﬂow, which 
needs to be investigated by other studies.
 
2914-119 Study of Coronary Calcium Score by Multislice 
Computed Tomography in Relation to Endothelial 
Dysfunction, C-reactive Protein, and Interleukin-6 in 
Asymptomatic Individuals
Mahmoud M. Ramadan, Essam M. Mahfouz, Gamal F. Gomaa, Tarek A. El-Diasty, 
Division of Cardiology, Department of Medicine, Mansoura Faculty of Medicine, 
Mansoura University, Mansoura, Egypt, Division of Radiology, Mansoura Urology and 
Nephrology Center, Mansoura University, Mansoura, Egypt
Background: coronary artery calciﬁcation (CAC) and its score (CACS) has been 
correlated with the presence and extent of coronary artery disease (CAD); and can be 
estimated non-invasively by multislice spiral computed tomography (MSCT). The purpose 
of this study was to discover the association between CAC(S) and the major CAD risk 
factors, endothelial dysfunction, C-reactive protein (CRP), and interleukin (IL)-6 in 
asymptomatic individuals at risk for CAD. 
Methods: we studied 112 subjects (73 were males) with a mean age of 49.6±6.7 
years. CACS was measured by MSCT using Agatston method. Endothelium-dependent 
ﬂow-mediated dilatation (FMD) and endothelium-independent nitroglycerine-mediated 
dilatation (NGMD) were measured non-invasively by high-resolution external beam 
brachial ultrasound. Serum high-sensitive CRP and IL-6 levels were measured by 
particle-enhanced immunoturbidometric latex agglutination assay and high-sensitivity 
immunoassay respectively. 
Results: signiﬁcant positive correlations were found between CACS and age (r=0.332, 
p<0.001), total cholesterol (r=0.384, p<0.001), low-density lipoprotein cholesterol 
(r=0.378, p<0.001), triglycerides (r=0.412, p<0.001), IL-6 (0.287, 0.002), risk factor 
number [RFNo] (r=0.576, p<0.001) and metabolic score [MetSc] (r=0.303, p=0.001). 
CACS values correlated negatively with high-density lipoprotein cholesterol (r=-0.269, 
p=0.004) and FMD (r=-0.573, p<0.001). Correlations between CACS and both CRP & 
NGMD were non-signiﬁcant (r=0. 111, p=0.234; and r=-0.081, p=0.398; respectively). 
In multivariately-adjusted logistic regression analysis; age, RFNo, IL-6, and FMD were 
independently associated with CAC presence. 
Conclusions: RFNo was a more sensitive predictor for CAC presence than metabolic 
score. Age was strongly independently associated with CAC presence even before the 7th 
decade. IL-6, but not CRP, was independently associated with CAC presence, while FMD 
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was an independent inverse predictor of that event. Further studies that should not focus 
on nitric oxide alone are needed to precisely determine the released endothelial factor(s) 
implicated in CAC pathogenesis and progression.
2914-120 Correlation of Multislice CT Coronary Angiography 
Findings With the ACC/AHA and SCAI Coronary Lesion 
Classiﬁcation Systems
Kheng-Thye Ho, Axel Kuettner, Dieter Ropers, Yiong-Huak Chan, Werner G. Daniel, 
Stephan Achenbach, National University Hospital, Singapore, Singapore, University of 
Erlangen, Erlangen, Germany
Background The exact correlation of CTA with invasive coronary angiography (ICA) is 
unknown. The aims of our study were to correlate 1) CTA to ICA ﬁndings using ACC/AHA & 
SCAI classiﬁcation systems for coronary lesions 2) results of 16 & 64-slice scanners with ICA.
Methods We evaluated 202 coronary lesions, 100 & 102 on16 & 64-slice scanners 
respectively in consecutive patients scheduled for ICA between May 2004 & June 2005 
for evaluation of known / suspected CAD. 2 blinded experienced observers reviewed CTA 
datasets for signiﬁcant coronary artery stenosis (≥50%) using ACC/AHA & SCAI systems. 
ICA studies were evaluated by 2 other blinded observers. Differences were resolved by 
consensus. CTA & ICA results were compared on a segmental basis, for each vessel and 
each patient. ICA was the reference standard for detection of signiﬁcant lesions.
Results  There were 57 patients, 81% male, mean age 62 years, mean BMI 27.4 mg/
m2, diabetes 15%, hypertension 69%, dyslipidemia 87%, smoking 40%, previous bypass 
surgery 18%. On ICA, 15, 21, 16 & 4 patients had single, double, triple vessel & left-main 
disease respectively. 10 had bypass grafts. With ACC/AHA system, there were 61, 33, 45, 
3, 43 & 17 type A, B1, B2, C1, C2 & minor(<50%)/unseen lesions respectively on ICA. On 
CTA, this corresponded to 83, 24, 38, 5 & 52 type A, B1, B2, C1 & C2 lesions respectively. 
With SCAI system, there were 95, 90 & 17 type I, IV & minor lesions respectively on ICA. 
On CTA, this corresponded to 145, 2, 1 & 54 type I, II, III & IV lesions respectively.
With ACC/AHA system, κ for CTA & ICA for all lesions, for distinguishing non-C2 & C2 
lesions was 0.67 & 0.79 respectively.  κ for ICA and CTA using SCAI system was 0.76 for 
all lesions & 0.81 for distinguishing between non-type IV and type IV lesions. κ for ICA 
& CTA in identifying type IV & non-type IV lesions with 16 & 64-slice scanners was 0.81 
& 0.82 respectively. CTA detected 17 more lesions (8.4%) than ICA. These included 3 
occluded grafts not visible on ICA, and 14 classiﬁed as non-signiﬁcant by ICA.
Conclusions 1) CTA detects C2 / IV lesions accurately. 2) CTA has better κ with SCAI 
than ACC/AHA lesion classiﬁcation system. 3) κ for 16 & 64-slice results & ICA for Type 
IV & non-Type IV lesions were not signiﬁcantly different.
2914-121 Vessel Density Ratio: A Novel Approach to Identifying 
Culprit Lesions in Acute Coronary Syndrome By 
Multidetector Computed Tomography
Sze-Piaw Chin, Tiong-Kiam Ong, Chee-Khoon Liew, Wei-Ling Chan, Houng-Bang Liew, 
Annuar Rapaee, Choon-Kiat Ang, Alan Fong, Kui-Hian Sim, Department of Cardiology, 
Sarawak General Hospital, Kuching, Malaysia
Background: We hypothesized that a ‘culprit’ lesion in acute coronary syndrome (ACS) 
should have low overall lumen density on multidetector computed tomography-assisted 
coronary angiography (MDCTA) because of lower probability of calciﬁcation and larger 
burden of occlusive thrombus. Assessing lesion severity and its relation to ACS can be 
difﬁcult because calciﬁcation tend to obscure lumen while presence of occlusive thrombus 
may blur demarcation between vessel wall and lumen. However if we measured the mean 
density of a region of interest (ROI) that includes the coronary vessel wall, lumen, plaque 
and thrombus- expressed as a ratio to aortic root mean density acting as a reference 
point -such a vessel density ratio (VDR) may be more convenient, standardized and 
reproducible.We aim to test the feasibility of VDR in identifying ‘culprit’ lesions in ACS.
Methods: 64 patients (21 exertional angina; 17 unstable angina/ NSTEMI; 26 STEMI) 
provided 188 diseased segments on conventional angiography. All underwent 64-row 
MDCTA (Siemens, Germany) within a week of angiography. ROI was mapped out from 
maximum intensity projections of diseased segments in planar view. Results: 174 
lesions were evaluable. Patients presenting with acute coronary syndrome (STEMI and 
unstable angina/NSTEMI) had lower mean VDR compared to patients with exertional 
angina (0.58 vs. 0.66 vs. 0.81, p <0.001). Culprit lesions of ACS patients had lowest mean 
VDR compared to non-culprit lesions and lesions of non-ACS patients with signiﬁcant 
differences (0.51 vs. 0.68 vs. 0.81, p <0.001).
Conclusions: VDR may be a reproducible and standardized approach in identifying 
‘culprit’ lesions by MDCTA.
2914-122 Feasibility of Real-Time Magnetic Resonance-guided 
Endovascular Stent-graft Placement in a Pig Model of 
Aortic Dissection
Holger Eggebrecht, Hilmar Kühl, Gernot Kaiser, Stephanie Aker, Michael Zenge, 
Frank Breuckmann, Mark E. Ladd, Raimund Erbel, Harald H. Quick, University of 
Essen, Essen, Germany, Institute for Diagnostik and Interventional Radiology and 
Neuroradiology, Essen, Germany
Aims: To evaluate the feasibility of real-time MR imaging (rtMRI) to guide stent-graft 
placement in order to avoid the disadvantages of ionizing radiation and nephrotoxic 
contrast media. 
Methods and Results: Using a catheter-based technique, dissections of the descending 
thoracic aorta were successfully created under x-ray in 8 domestic pigs. Implantation 
of commercially available stent-grafts was performed wholly under rtMRI. By pre-
interventional MRI, the maximum aortic diameter was 2.4±0.3 cm, and the minimal 
diameter of the true lumen was 0.9±0.1 cm. rt-MRI detected that in 1 pig the stent-graft 
delivery system was inadvertently advanced within the false lumen. In the remaining 
7 pigs, rtMRI permitted 1) successful and safe device navigation to the thoracic aorta, 
2) precise positioning and 3) successful stent-graft deployment, and 4) safe catheter 
withdrawal. No complications occurred. After stent-graft placement, MRI demonstrated 
correct position of the stent-graft and complete obliteration of the false lumen which 
was conﬁrmed by necropsy. All stent-grafts were well expanded. True lumen diameter 
increased to 2.0±0.1 cm (p=0.001 vs. baseline).
Conclusions: Endovascular stent-graft placement for experimental AD using commercially 
available catheter devices is feasible and safe under rtMRI-guidance. Besides detailed 
pre-interventional evaluation and procedure guidance, MRI permits immediate post-
interventional anatomic and functional evaluation of procedure success. 
ORAL CONTRIBUTIONS
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Monday, March 13, 2006, 10:30 a.m.-11:30 a.m.
Georgia World Congress Center, Room C207
10:30 a.m.
2802-3 A New Score Assessing Programmatic PCI Case Risk: 
The ACC-NCDR Complexity Score
Lloyd W. Klein, Paul Kolm, Emir Veledar, William Weintraub, Rush University Medical 
Center, Chicago, IL, Emory University, Atlanta, GA
Catheterization laboratories and outside agencies are interested in assessing PCI quality 
on an institutional level. Evaluating clinical outcomes without a measure of case risk may 
lead to erroneous conclusions, especially by the public, without considering patient mix. 
We devised a complexity score that summates the expected risk based on all individual 
cases taken on, and then evaluated expected vs. observed outcomes in 403 hospitals 
in the US.
Methods: All PCI cases in the NCDR database from 1999 to September, 2004 were 
analyzed. The complexity score was calculated from a previously validated logistic 
regression risk adjusted model based on 28 risk factors of in-hospital mortality. The 
expected in-hospital mortality (complexity score) was calculated from predicted risk 
summed for each patient. The ratio of observed mortality rate to mean predicted mortality 
rate was then derived for each program.
Results: 448,901 PCI cases in NCDR were analyzed. The observed to predicted mortality 
ranged from 0.0 to 13.16 with mean of 1.55 and median of 1.26. The ﬁgure plots the 
distribution of observed to predicted ratios for all 403 programs. 5%(22) programs had 0% 
mortality, 27% (108) programs had ratios between 0 and 1, 52% (209) percent had ratios 
between 1 and 2, and 5% (21) had ratios greater than or equal to 3.
Conclusions: Programs with observed to expected ratios >3 have signiﬁcantly worse 
clinical outcomes than predicted based on case mix. This method of analysis may be a 
reasonable tool to evaluate overall quality.
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2802-4 Nine-Year Clinical Outcome of Coronary Stenting 
Versus Coronary Artery Bypass Grafting in Patients 
With Signiﬁcant Proximal LAD Stenosis or Multiple 
Vessel Disease
Shun Kohsaka, Vei-Vei Lee, Masashi Goto, MacArthur A. Elayda, Noriaki Aoki, Ross M. 
Reul, James M. Wilson, Texas Heart Institute, Baylor College of Medicine, Houston, TX, 
University of Texas at Houston, Houston, TX
Background: The use of stents in clinical practice has evolved to include complex lesions 
and high-risk patients. However, it has not yet been clearly shown that stent implantation 
produces outcomes comparable to those of coronary artery bypass grafting (CABG) in 
unselected patients with coronary artery disease (CAD).
Methods: We examined long-term follow-up data from 6779 patients with multivessel 
or single proximal left anterior descending CAD who underwent isolated primary 
revascularization by coronary stenting (n=3847) or CABG (n=2932) between 1995 and 
2004. Nine-year total mortality rates were calculated. Propensity score adjustment were 
used to identify signiﬁcant predictors of long-term mortality. Two case-matched groups 
of 1744 patients each (total n=3488) were created by matching the stenting and CABG 
patients on as many variables as possible.
Results: Adjusted mortality was similar between the CABG group and the stented group (OR 
0.8; 95% CI, 0.7-1.0; P=0.27). Two treatments were also associated with similar long-term 
survival in case-matched comparison (OR, 0.9; 95% CI, 0.7-1.2; Log-Rank test P=0.288) 
as well as in subgroups of patients with diabetes (OR, 1.1; 95% CI, 0.77-1.5; P=0.67) or left 
ventricular systolic dysfunction with EF<35% (OR, 0.69; 95% CI, 0.40-1.2; P=0.19).
Conclusions: In unselected patients undergoing primary coronary revascularization, 
an operator-elected strategy of stenting as opposed to CABG was not associated with 
reduced long-term survival.
 
11:00 a.m.
2802-5 The Epidemiology, Outcomes and Predictors of 
Coronary Stent Thrombosis in New York State
Daniel R. Montellese, David L. Brown, State University of New York-Stony Brook, Stony 
Brook, NY
Background: Stent thrombosis is a rare complication of coronary stent placement. 
Because of its infrequent occurrence, previous studies have been unable to identify 
clinical and angiographic factors associated with stent thrombosis. We analyzed 4 years 
of data from a statewide mandatory registry to determine the incidence, outcomes and 
predictors of stent thrombosis.
Methods: This was a retrospective analysis of demographic, clinical and angiographic 
data from all 92,043 patients from the New York State Coronary Angioplasty Reporting 
System Registry who underwent coronary stent placement from 1996-1999. Independent 
predictors of stent thrombosis were determined using multivariable logistic regression.
Results: Of the 92,043 patients undergoing stent placement, stent thrombosis occurred 
in 477 (0.5%). Patients with stent thrombosis were younger (61.7 vs. 63.0 years, P=0.011), 
more often female (69% vs. 63%, P=0.008), less often Caucasian (86% vs. 89%, 
P=0.029) and more often smokers (23% vs. 18%, P=0.005). Patients with hypertension 
(71% vs. 66%, P=0.014), a stent in the left anterior descending (LAD) (46% vs. 41%, 
P=0.046) or those in whom the stent was placed within 6 hours of an acute myocardial 
infarction (MI) (11% vs. 4.4%, P<0.001) more commonly developed stent thrombosis. 
Ejection fractions did not differ between groups. Patients with stent thrombosis more 
often required emergency bypass surgery (7.3% vs. 0.4%, P<0.001), developed Q-wave 
MI (8.8% vs. 0.3%, P<0.001) and suffered in-hospital death (6.9% vs. 0.7%, P<0.001). 
Independent predictors of stent thrombosis were female gender (OR 1.32, 95% CI 1.09-
1.60, P=0.005), hypertension (OR 1.35, 95% CI 1.09-1.65, P=0.004) stent placement 
within 6 hours of the onset of acute MI (OR 2.62, 95% CI 1.94-3.53, P<0.001) and LAD 
stented (OR 1.21, 95% CI 1.01-1.45, P=0.039).
Conclusions: This population-based study conﬁrms the infrequency of stent thrombosis 
and its association with unfavorable outcomes. It is the ﬁrst study to identify clinical and 
angiographic risk factors that are predictive of stent thrombosis. These characteristics may 
help identify patients who would beneﬁt from novel strategies to prevent stent thrombosis.
11:15 a.m.
2802-6 Relationship Between Hospital PCI Volume and In-
Hospital Major Adverse Clinical Events: The ACC-NCDR 
Results
Lloyd W. Klein, Zefeng Zhang, Liping Zhao, Emir Veledar, Jovenne Foster, Paul Kolm, 
Ralph Brindis, William Weintraub, Rush University Medical Center, Chicago, IL, Emory 
University, Atlanta, GA
Background:
The presence and strength of an inverse association between institutional procedure 
volume and patient outcomes remains controversial. The AHA/ACC Task Force concluded 
that hospitals performing fewer than 400 PCIs per year are likely to have increased 
complications, and the level of indication for PCI at these institutions downgraded.
Methods:
In-hospital adverse events (death & unplanned CABG) after PCI in 667,803 patients 
undergoing PCI at 403 sites in ACC-NCDR from 2001 to 2004 were analyzed. Institutions 
were classiﬁed by annual PCI volume (≤200: n=9,808, site=47; 201-400: n=60,044, 
site=85; >400: n=597,951, site=222). Separate analyses using hierarchical modeling 
were performed for ST elevated myocardial infarction (STEMI) (n=90,526), non-STEMI 
(n=94,587) and elective (n=482,960) PCI adjusting for baseline covariates.
Results: Overall in-hospital event rates were 5.61%, 2.54% and 0.69% for STEMI (age, 
61.2± 13.0 years), non-STEMI (64.3± 13.1) and elective PCI (65.0± 11.7), respectively. 
In STEMI and non-STEMI PCI, hospital PCI volume is not associated with in-hospital 
adverse events. In elective PCI, an increased risk of adverse events was signiﬁcant only 
for hospital volume 201-400 vs. 400 (see table). 
Hospital volume
STEMI (n=90,256)
(OR, 95% CI,
p value)
Non-STEMI (n=94,587)
(OR, 95% CI, p value)
Elective
(n=482,960)
(OR, 95% CI, p value)
≤200 vs. >400 1.015 (0.712, 1.446)0.935
0.808 (0.514, 1.272)
0.358
1.342 (0.852, 2.115)
0.204
201-400 vs. >400 1.107 (0.916, 1.337)0.293
0.934 (0.726, 1.203)
0.599
1.242 (1.010, 1.528)
0.040
Conclusions: Adverse clinical outcomes, including in-hospital mortality & unplanned 
CABG, are not strongly associated with hospital volume. Therefore, the AHA/ACC 
guideline of 400 PCI per year as a volume minimum cannot be validated as a quality of 
care indicator.
ORAL CONTRIBUTIONS
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2803-3 Frequency, Predictors, and Clinical Outcomes of Late-
Acquired Incomplete Stent Apposition in Patients 
Treated With Taxus Stents: A Volumetric Intravascular 
Ultrasound Meta-Analysis From the Taxus IV, V, and VI 
Trials
Gary Mintz, Neil J. Weissman, Keith Dawkins, Eberhard Grube, Stephen Ellis, Stephen 
Fernandez, Joel Greenberg, Michael Kutcher, Frank Zhou, Joerg Koglin, Gregg 
W. Stone, Washington Hospital Center, Washington, DC, Cardiovascular Research 
Foundation, New York, NY
Background: Late-acquired incomplete stent apposition (LA-ISA) is deﬁned as stent 
struts that are in contact with the vessel wall at implantation, but not at follow-up. The 
mechanism of LA-ISA is positive remodeling without an equal amount of abluminal intimal 
hyperplasia (IH). This study assessed whether LA-ISA is more common after TAXUS 
stent implantation and whether it has any impact on clinical outcomes.
Methods: We performed a volumetric intravascular ultrasound (IVUS) meta-analysis of 
547 pts. from TAXUS IV, TAXUS V, and TAXUS VI with paired IVUS data. Stent, lumen, 
and IH (stent - lumen) areas were measured every millimeter, and %IH (IH/stent) was 
calculated.
Results: LA-ISA frequency at 9month was greater with TAXUS moderate-release (MR) 
stents compared to BMS (p<0.0001), however, in the TAXUS slow-release (SR) stent, 
the rates of LA-ISA were comparable to BMS (p=0.37). In TAXUS SR and MR pts. with 
LA-ISA, there were no major adverse cardiac events (MACE) from 9m to 2y. Among all 
pts., Pearson correlation tests showed that LA-ISA was associated with a reduction in 
%IH (p=0.0001). Among TAXUS pts., multivariate logistic regression analysis determined 
lesion length was a predictor of LA-ISA (odds ratio=1.055, p=0.0035).
Conclusions: Compared to BMS, LA-ISA is more common after implantation of TAXUS 
MR only, but not the commercially available TAXUS SR stent. Lesion length is a predictor 
of LA-ISA in TAXUS pts. Finally, LA-ISA is not associated with an increase in clinical 
events beyond 9 months. 
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BMS/LA-
ISA
BMS/No-
LA-ISA
TAXUS
SR/LA-
ISA
TAXUS SR/No-
LA-ISA
Taxus MR/LA-
ISA
Taxus
MR/No-LA-
ISA
Late-acquired ISA
# (%)
9 
(3.5%)
251 
(96.5%)
11 
(5.3%) 198 (94.7%) 13 (16.7%)
65 
(83.3%)
%IH (9m) 21.0 ± 7.6
31.7 ± 
15.5
4.5 ± 
4.7 13.5 ± 12.7 6.2 ± 8.6
11.8 ± 
11.1
MACE (9m-2y) 0/9 (0%)
13/251 
(5.2%)
0/11 
(0%)
10/198 
(5.1%) 0/13 (0%)
5/65 
(7.7%)
Follow-up time, months 
(since procedure)
18.8 ± 
6.5
19.6 ± 
5.9
12.9 ± 
3.9 17.8 ± 6.1 24.1 ± 0.2
24.0 ± 
0.4
1:42 p.m.
2803-4 Angioscopic Findings of the Neointimal Coverage Over 
the Sirolimus-Eluting Stent: Nine-Months Follow-Up 
Study
Masaki Awata, Jun-ichi Kotani, Shinsuke Nanto, Masaaki Uematsu, Takakazu Morozumi, 
Toshinari Onishi, Osamu Iida, Fusako Oshima, Hitoshi Minamiguchi, Hirokuni Akahori, 
Seiki Nagata, Kansai Rosai Hospital, Amagasaki, Japan
Background: The sirolimus eluting stent (SES) has remarkably reduced restenosis 
by inhibiting neointimal hyperplasia. However, neointimal coverage following stent 
implantation is not well understood. Using angioscopy, we compared the degree of 
neointimal coverage following SES (CypherTM, Cordis) with the bare-metal stent of 
the identical structure (Bx VerocityTM, Cordis, BMS) at 9 months follow-up. Methods: 
Angioscopy (VecmovamTM, Clinical Supply) was performed in 32 stented segments (20 
SES and 12 BMS) 9 months (8-11 months) after stent implantation. We evaluated 1) the 
degree of neointimal coverage over the stent; 2) presence of thrombi; 3) yellow plaque 
beneath the stent. The degree of neointimal coverage was classiﬁed into two groups: 
complete / incomplete coverage, based on whether the stent struts were embedded 
by the neointima. Results: All BMS presented complete neointimal coverage, whereas 
50% of SES showed incomplete coverage (p=0.004). Strikingly, complete absence of 
neointimal coverage was observed in a SES implanted segment even after 9 months. A 
white thrombus was detected only in a SES. Red thrombi were detected in 20 % of SES 
and 8.3% of BMS (p = 0.6). Yellow plaque was not related to the presence of thrombi in 
this cohort (p=0.3), but was strongly associated with the incomplete neointimal coverage 
(p=0.007).
Conclusions: Angiscopic follow-up of patients implanted the sirolimus-eluting stent 
demonstrated the absence of neointimal coverage and the presence of yellow plaque 
beneath the stent struts even after 9 months in contrast to the bare-metal stent of the 
identical structure.
1:54 p.m.
2803-5 Patients With More Coronary Calciﬁcation Undergo 
Less Change in Atheroma Burden With Established 
Medical Therapies: Observations From Intravascular 
Ultrasound
Stephen J. Nicholls, Kathy Wolski, Ilke Sipahi, Paul Schoenhagen, Timothy Crowe, 
Samir Kapadia, Stanley L. Hazen, E. Murat Tuzcu, Steven E. Nissen, Cleveland Clinic 
Foundation, Cleveland, OH
Background: Coronary calciﬁcation correlates with the extent of atherosclerosis and 
predicts clinical outcome. It is uncertain whether altering the progression of calciﬁcation 
inﬂuences plaque burden or event rates. This study assessed the impact of baseline 
coronary calciﬁcation on plaque progression rates in response to a high rate of use of 
established medical therapies.
Methods: Atheroma volume was determined in serial intravascular ultrasound pullbacks 
in matched arterial segments of 776 patients with angiographic coronary artery disease. 
A calcium score was assigned for each measured image (total 28,876) (0=no calcium, 
1=calcium with acoustic shadowing less than 90o and 2=calcium with shadowing greater 
than 90o). A calcium index was derived by averaging the calcium scores of all measured 
images in the arterial segment studied. Patients with calcium index below and above the 
median (0.26) were compared with regard to their baseline atheroma burden and plaque 
progression rates.
Results: Patients with a high calcium index (mean 0.64) were older (58 v 55 years, 
p<0.001), more likely to be male (77.4 v 67.9%, p=0.003), smokers (28 v 22%, p=0.07) 
and have a history of hypertension (70 v 62%, p=0.03). A higher calcium index was 
associated with greater baseline percent atheroma volume (PAV, 45 v 34%, p<0.001), 
total atheroma volume (TAV, 223 v 160 mm3, p<0.001) and percent of images with 
maximal plaque thickness >0.5mm (93 v 72%, p<0.001). Patients with a lower calcium 
index (mean 0.08) were more likely to undergo plaque regression (>5% decrease in PAV, 
26 v 19%, p=0.01) or progression (>5% increase in PAV, 44 v 34%, p=0.008). A trend for 
a greater increase in PAV (1.4+/-5.2 v 0.9+/-4.2%, p=0.13) and TAV (3.6+/-27.7 v 0.3+/-
29.2%, p=0.11) was noted in patients with a lower calcium index.
Conclusion: Despite having more plaque, patients with more coronary calciﬁcation 
are less likely to undergo changes in the extent of atheroma following treatment with 
established medical therapies. As calciﬁc lesions contain smaller pools of lipidic and 
inﬂammatory material, they appear to be more resistant to undergo changes in size in 
response to systemic interventions that target atherosclerotic risk factors.
2:06 p.m.
2803-6 Aggressive Modiﬁcation of Risk Factors Promotes 
Regression of Coronary Atherosclerosis in Patients 
With Diabetes
Stephen J. Nicholls, Kathy Wolski, Thomas Wang, Adnan Chhatriwalla, Ilke Sipahi, 
Paul Schoenhagen, Timothy Crowe, Samir Kapadia, E. Murat Tuzcu, Steven E. Nissen, 
Cleveland Clinic Foundation, Cleveland, OH
Background: Diabetic patients with coronary artery disease (CAD) have a high rate of 
clinical events and diffuse disease on coronary angiography. It has been reported that 
plaque progression is dramatically inﬂuenced by aggressive lowering of risk predictors 
including LDL cholesterol, systolic blood pressure and C-reactive protein (CRP). This 
study aimed to determine whether diabetic status inﬂuenced either the extent of atheroma 
at baseline or its response to risk factor modiﬁcation in patients with CAD.
Methods: Serial intravascular ultrasound analysis of matched coronary artery segments 
was performed in 776 patients with angiographic CAD to evaluate plaque progression. 
Patients were stratiﬁed according to their diabetic status and compared with regard to 
their demographics, extent of atherosclerotic plaque at baseline and rate of regression, 
deﬁned as a reduction in percent atheroma volume (PAV) of at least 5% at followup, in 
relation to the degree of risk factor modiﬁcation.
Results: Diabetics were older (58+/-9 v 56+/-10 years, p=0.02) and more likely to be 
female (36 v 24%, p=0.01), African-American (10 v 5%, p=0.04), obese (72 v 42%, 
p<0.001), have a history of hypertension (82 v 62%, p<0.001) and had lower HDL levels 
(40+/-11 v 42+/-11 mg/dL, p=0.05). Diabetics also had a greater PAV (42+/-10 v 39+/-
11%, p=0.001) at baseline. There was a trend towards greater increases in PAV (1.7+/-4.8 
v 1+/-4.7%, p=0.13) and normalized total atheroma volume (5.5+/-31.9 v 1.1+/-27.6%, 
p=0.10) in diabetics. Diabetics were just as likely to undergo plaque regression if the 
medical therapy they received lowered LDL<80 mg/dL (24 v 32%, p=0.41), systolic blood 
pressure <130 mmHg (19 v 25%, p=0.33) and CRP <2 mg/L (21 v 22%, p=1.0).
Conclusion: In the presence of more atherogenic risk factors, the coronary arteries of 
diabetics with CAD harbor a greater extent of atheroma. Diabetics were just as likely to 
undergo plaque regression in the setting of aggressive risk factor modiﬁcation. This further 
highlights the beneﬁt of secondary prevention strategies in diabetic patients with CAD.
2:18 p.m.
2803-7 Adventitial Delivery of Liposomes Containing Complex 
Lipids and Human Derived Oxidized LDL Induces 
the Formation of Complex Coronary Atherosclerosis 
Lesions: A Prospective Intravascular/Virtual Histology 
Study in Pigs
Juan F. Granada, Carlos L. Alviar, David Wallace-Bradley, Daryl G. Schulz, Eli I. Lev, 
Albert E. Raizner, Greg L. Kaluza, The Methodist Hospital Research Institute and the 
University of Houston, Houston, TX, The Corbic Research Institute, Envigado, Colombia
Background: We aimed to follow the progression of atherosclerotic plaque formation 
after adventitial injection of a liposome-based atherogenic mixture using Intravascular 
Ultrasound-Virtual Histology (IVUS-VH).
Methods: Transluminal subintimal injections were performed in 32 coronary segments 
with a liposome based human oxidized LDL mixture using a microneedle injection 
catheter (Endobionics). IVUS/VH analysis was performed at baseline, 2 and 7 weeks. 
Animals were sacriﬁced at 7 weeks and tissue processed for histological examination and 
comparison with VH ﬁndings. 
Results: 210 IVUS/VH images were analyzed and compared to histology of corresponding 
60 coronary segments. IVUS showed that all lesions were eccentric (index, 0.76±0.07), 
non-occlusive (plaque burden, 37.6% ± 4.9%) and located in positively remodeled 
segments (index, 1.43 ± 0.23). By VH, these plaques were mainly ﬁbro-fatty (64.7% ± 
26.7%) and had a necrotic core of 24.1% ± 9.9%. Dense calcium constituted 27.2% ± 
15.9% of the plaque area. By histology, all lesions were ﬁbro-fatty, containing abundant 
lipidic deposits and macrophages in the sub-intimal layer. There was no evidence of 
signiﬁcant necrotic core formation or dense calcium deposition.
Conclusions: The adventitial delivery of liposome-based oxidized LDL induces the 
formation of eccentric, lipidic and inﬂammatory lesions by 7 weeks. VH correlates with 
the presence of ﬁbro-fatty tissue but overestimated the presence of dense calcium and 
necrotic core.
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2803-8 Distribution of Necrotic Core in Human Coronary 
Plaques Is Related to the Blood Stream: An In Vivo 
Assessment by Intravascular Ultrasound: Virtual 
Histology
Hector M. Garcia-Garcia, Gaston A. Rodriguez-Granillo, Marco Valgimigli, Wentzel J. 
Jolanda, Evelyn Regar, Pim de Feyter, Patrick W. Serruys, Thoraxcenter, Erasmus MC, 
Rotterdam, The Netherlands
Background: A bulging atherosclerotic plaque modiﬁes the coronary blood ﬂow pattern, 
resulting in local areas of high-ﬂow/high-shear stress (upstream) and low-ﬂow/low-shear 
stress (downstream). Thus, atherosclerotic plaque composition varies greatly regarding to 
tissue components between upstream and downstream parts of the plaque. We sought to 
explore the distribution of necrotic core along focal coronary atherosclerotic plaques.
Methods: The present investigation is an investigators-driven prospective study. Ninety 
consecutive patients (121 vessels) admitted for coronary catheterization and subsequent 
intervention were eligible if a non-target vessel was suitable for IVUS-Virtual Histology 
interrogation of at least 30 mm of length. The most diseased part of the vessel was 
selected and its immediate 10 mm proximal and distal were included in this analysis. 
Finally, this segment was divided in four 5 mm sub-segments, two proximal (one and two) 
to the most diseased cross-sectional area and two distal (three and four).
Results: The mean age was 57.9±10.8 years, most being male patients 68 (75.6 %). Of 
note, only 7.8% of the population were diabetic patients.
The upstream sub-segments presented signiﬁcantly larger content of necrotic core 
(11.6±10.5% in one and 11.7±9.6% in two) when compared to the downstream sub-
segment four (10.2±9.9%, p=0.004 and p=0.002, respectively). Calcium was larger in 
sub-segment two (6.5±9.7%) than in sub-segment four (5.4±9.5%, p=0.03). Conversely, 
the largest amount of ﬁbrous tissue was found in segment 3 with 63.8±9%, when 
compared with the sub-segments one and four was stastiscally signiﬁcant, p=0.037 and 
0.019 respectively.
Conclusions: The necrotic core and calcium were larger in the proximal (upstream) 
part of the coronary plaque. Conversely, the ﬁbrous tissue was mainly located in the 
downstream section of the plaque. Both ﬁndings are related to the blood ﬂow pattern that 
prevails at that site of the coronary plaque.
POSTER SESSION
2915 
Percutaneous Coronary Interventions: 
Acute and Chronic Renal Insufﬁency
Monday, March 13, 2006, 1:30 p.m.-5:00 p.m.
Georgia World Congress Center, Hall B1
Presentation Hour: 2:30 p.m.-3:30 p.m.
2915-61 Outcomes of Patients on Chronic Dialysis Undergoing 
Percutaneous Intervention in Coronary Arteries With 
Drug-eluting Stents
Salah-Eddine Hassani, Roswitha Wolfram, Zhenyi Xue, Augusto Pichard, Lowell F. 
Satler, Kenneth M. Kent, Neil J. Weissman, Ron Waksman, Washington Hospital Center, 
Washington, DC
Background: Percutaneous coronary intervention (PCI) for patients on chronic dialysis 
continues to present a challenge due to high morbidity and recurrence rates. We aimed to 
evaluate clinical outcomes of dialysis patients after coronary DES implantation.
Methods: We analyzed the data of 3442 consecutive patients who underwent PCI and 
DES implantation. Periprocedural events, 1-, and 6-month clinical outcomes were then 
compared between dialysis patients (n=72) and non-dialysis patients (n= 3370).
Results: Baseline characteristics revealed a higher prevalence of female gender (p=0.03), 
African Americans (p<0.001), acute myocardial infarction (MI) (p=0.04), hypertension 
(p<0.001), diabetes mellitus (p<0.001), number of diseased vessels (p=0.04), and lower 
ejection fraction (p<0.001) in dialysis patients. Non-dialysis patients showed more history 
of smoking (p<0.001) and obesity (p=0.02). Procedural success was higher (p=0.05), 
while there was a trend toward lower mortality rate in the non-dialysis group during 
hospitalization. At 6 months, restenosis rates were generally low and comparable, but 
mortality (19% vs. 4%, p<0.001) was higher in dialysis patients. Multivariate analysis 
revealed cardiogenic shock (p=0.04) to be an independent predictor of mortality.
Conclusions: DES implantation in chronic dialysis patients is clinically safe with low TLR 
rates at 6 months, yet it does not impact on the poor survival, which is highly inﬂuenced 
by underlying co-morbidities.
 
Events at 6-month (%) Dialysis patients (n=72)
Non dialysis patients
(n=3370) p Value
Death 7 (19) 81 (4) <0.001
MI
Q-wave
Non-Q-wave
1 (3.3)
11 (29)
28 (1.4)
404 (18)
0.35
0.09
TLR 1 (3.3) 48 (2.4) 0.52
TLR-MACE 9 (24) 157 (8) 0.002
 
2915-62 Impact of Drug-eluting Stents on Outcomes of 
Patients With End-Stage Renal Disease Undergoing 
Percutaneous Coronary Revascularization
Pranab Das, David J. Moliterno, Darell Sneed, Richard Charnigo, Debabrata Mukherjee, 
Steven R. Steinhubl, David C. Booth, Khaled M. Ziada, Gill Heart Institute, University of 
Kentucky, Lexington, KY
Background: End-stage renal disease (ESRD) patients on chronic dialysis are at higher 
risk for target vessel revascularization (TVR) after coronary stenting. However, ESRD 
patients were excluded from trials establishing the superiority of drug-eluting stents 
(DES) over bare-metal stents (BMS) in reducing TVR.
Objective: We sought to identify the impact of stent type (DES versus BMS) on TVR and 
other adverse events in ESRD patients.
Methods: The study included 89 consecutive ESRD patients who underwent coronary 
stenting and were followed for ≥9 months. TVR was the primary endpoint, and the 
secondary endpoint was a composite of death, myocardial infarction (MI), and TVR. 
Multivariate logistic regression models were used to adjust for differences in clinical and 
procedural characteristics.
Results: DES were used in 24 and BMS in 65 patients. The stent diameter was smaller 
(p=0.008), but the stent length was longer (p=0.006) in the DES group. TVR was required 
in 1 (4%) of DES and 17 (26%) of BMS patients, while 8 (33%) DES and 39 (60%) 
BMS patients met the secondary endpoint. By multivariate logistic regression, DES use 
was associated with a reduction in TVR (OR 0.10, 95% CI 0.010-1.04, p=0.054) and a 
signiﬁcant reduction in death, MI and TVR (OR 0.12, 95% CI 0.028-0.51, p=0.004).
Conclusion: A high rate of ischemic events was noted for ESRD patients, regardless of 
stent type. However, in ESRD patients undergoing coronary stenting, DES use is effective 
in reducing 9-month TVR and the composite of death, MI, and TVR.
2915-63 Volume to Clearance Ratio: A More 
Pharmacokinetically-correct Risk Factor for 
Radiographic Contrast Media-induced Nephropathy
Warren K. Laskey, Larry Osborn, Faith Selzer, Robert Wilensky, Ruchira Glaser, Oscar 
Marroquin, Howard Cohen, NHLBI Dynamic Registry, University of New Mexico, 
Albuquerque, NM, University of Pittsburgh, Pittsburgh, PA
Background: Contrast media (CM)-induced nephropathy (CIN) is a risk factor for 
adverse outcomes following radiographic procedures. Risk factors for CIN include renal 
insufﬁciency and/or factors predisposing to renal insufﬁciency. The role of the volume 
of CM given remains unclear with many conﬂicting cut-points. The area under the 
curve (AUC) of the concentration of a drug over time determines true exposure. It has 
been shown that the ratio of the volume of CM/creatinine clearance (V/Cl-Cr) is highly 
correlated with the AUC of injected CM
Methods: To determine the clinical relevance of this easily-derived ratio, we calculated 
V/Cl-Cr in 1,627 patients undergoing percutaneous coronary intervention (PCI) in wave 
4 (2004) of the NHLBI Dynamic Registry. CIN was deﬁned as a post-PCI increase in 
creatinine of, at least, 0.5 mg/dL
Results: The overall incidence of CIN was 3%. The median values of V/Cr-Cl for patients 
with and without CIN were 4.74 and 2.54, respectively (p<0.001). We found (Figure): On 
multivariable analysis, after adjusting for other known and important clinical predictors of 
CIN (diabetes, congestive heart failure, baseline renal insufﬁciency), V/Cl-Cr remained 
signiﬁcantly associated with CIN (OR 2.12; 95% CI 1.02, 4.42, p=0.04). Notably, the total 
volume of CM was not associated with CIN
Conclusions: The more pharmacokinetically-correct index of exposure-V/Cl-Cr, should be 
included, along with traditional clinical risk factors, in risk stratiﬁcation algorithms for CIN.
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2915-64 Safety and Performance of Targeted Renal Therapy for 
Prevention of Contrast-Induced Nephropathy: Data 
From the Be-Rite! Registry
Mauricio G. Cohen, Paolo Danna, William Fearon, Matthew J. Price, Giora Weisz, 
Jefferey Moses, Alan Yeung, Paul Cohen, Roxanna Mehran, Hooman Madyoon, 
Vandana Mathur, Martin B. Leon, Michael Collins, Gregg Stone, Campbell Rogers, 
Columbia University, New York, NY, Scripps Clinic, La Jolla, CA
Background: Systemic pharmacologic approaches for preventing contrast-induced 
nephropathy (CIN) have been unsuccessful most likely due to the inability to deliver 
therapeutic renal doses without causing systemic side effects. Targeted Renal Therapy 
(TRT) is intended to enhance beneﬁcial renal effects of drugs while minimizing systemic 
effects due to renal ﬁrst-pass elimination of drug. 
Methods: The FDA-cleared Benephit Infusion Systems (BIS, FlowMedica) consist of 
a bifurcated catheter for simultaneous cannulation of both renal arteries. Simultaneous 
coronary procedures can be conducted with a single femoral access via an accessory 
port in the sheath. The Benephit System Renal Infusion Treatment International Registry 
(Be-RITe!) is a retrospective, observational study intended to capture real world use 
patterns, device performance, and safety in consecutive patients given TRT with the BIS. 
Results: We enrolled 76 high-risk patients with a baseline creatinine of 2.3 mg/dl at 7 
sites. IR drug was infused in 94.7%. Bilateral renal artery cannulation was accomplished 
in 87% of patients in a mean time of 2.1 + 1.3 min. There were 3 device complications 
(2 groin hematomas and a dissection of a 3 mm accessory renal artery which required 
stenting but had no sequelae). 
Conclusions: The BIS performed well in a complex population with numerous 
comorbidities. The devices were safe and did not adversely affect procedure time or 
complexity. Further studies of TRT for prevention of CIN are warranted. 
Patient and Procedural Characteristics
Age (years) 68.9 + 1.3
Male gender (%) 75.7
Diabetes (%) 53.3
History of Congestive Heart Failure/Acutely Decompensated Heart Failure (%) 32.0/8.0
Baseline Serum Creatinine (> 2.5 (%)) 2.3 + 0.15 (30)
Baseline Creatinine Clearance (%) (% < 30) 42.0 + 2.4 (30)
Peripheral Vascular Disease (%) 18
Contrast volume required for device placement (ml) 11.4 ± 0.6
Total contrast volume (±SD) (mL) 208.6 ± 14.7
Number of devices exchanged via second port 5.6 ± 0.5
Intra-Renal Drugs Used
Fenoldopam (dose range: 0.1 - 0.8 mcg/kg/min) 78.9%
Sodium Bicarbonate (dose range: 1M @ 1 - 2 mg/kg/hr) 15.5%
Alprostadil dose (dose: 40 ng/kg/min) 5.6%
Post Procedure Creatinine
Day 1 Creatinine (mg/dL) 2.2 ± 0.10
Day 2 Creatinine (mg/dL) 2.4 ± 0.20
 
2915-65 Local Intra-Renal Delivery of Fenoldopam Improves 
Renal Function Without Hypotension in Patients 
Undergoing Cardiac Catheterization: Results of a 
Randomized, Controlled Trial
Matthew J. Price, Hooman Madyoon, Vandana S. Mathur, Neil Sawhney, Donald S. 
Baim, Paul S. Teirstein, Scripps Clinic, La Jolla, CA
Background: A novel catheter has been developed that allows local renal artery drug 
delivery. We hypothesized that selective intra-renal (IR) administration of fenoldopam(FEN) 
may lead to a greater increase in glomerular ﬁltration rate (GFR) and lower systemic drug 
levels (due to ﬁrst-pass elimination) and consequently reduce hypotension compared to 
intravenous (IV) infusion.
Methods: We used a specially designed bifurcated renal infusion catheter for local drug 
delivery. Patients (n=33) undergoing cardiac catheterization were randomized in a 2:1 
ratio, to FEN (initially IV, then crossed over to IR FEN at the same dose via the bifurcated 
renal infusion catheter), or to control dextrose infusion. GFR was measured by inulin 
clearance.
Results: Compared to IV FEN, IR FEN was associated with signiﬁcantly higher GFR 
(73.7±3.1 vs. 62.6±2.5 ml/min, p=0.0007), renal plasma ﬂow (537.2±34.0 vs. 494.0±35.5 
ml/min, p<0.01), and lower FEN plasma levels (3.3±0.3 vs. 4.8±0.3 ng/ml, p<0.0001). 
There was no change in BP with IR FEN compared to untreated controls (-12.4 ± 2.9 
mmHg vs. -18.50 ± 3.6 mmHg, p=0.21), while IV FEN signiﬁcantly decreased BP (-22.2 
± 3.2 mmHg vs, -8.4 ± 5.8 mmHg, p<0.05). Two hours following drug discontinuation after 
contrast administration, GFR in the patients receiving IR fenoldopam remained higher than 
in controls (+15.0 ml/min (+25%) vs. -8.0 ml/min (-14.0%), p<0.05). The majority of renal 
cannulations were performed within 60 seconds, with no device-related adverse events.
Conclusions: Local intra-renal infusion of fenoldopam is safe, practical, and improves 
renal function without reducing blood pressure compared to both intravenous fenoldopam 
and placebo. Local intra-renal delivery of vasodilators is a new treatment option to prevent 
contrast-induced nephropathy.
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2916-66 Cost-Effectiveness of PCI With or Without Drug-
Eluting Stents Versus Bypass Surgery for Treatment 
of Multivessel Coronary Disease Among Patients With 
Diabetes Mellitus: 1-Year Results From the ARTS Trial 
and ARTS II Registry
Brian Dulisse, Harvard Clinical Research Institute, Boston, MA, Beth Israel Deaconess 
Medical Center, Boston, MA
Background: The cost-effectiveness (CE) of drug-eluting stents relative to bare-metal 
stents (BMS) and CABG has not been evaluated among diabetic pts with multivessel 
disease.
Methods: We examined 1-yr outcomes and costs among 159 diabetic pts with 
multivessel CAD treated with sirolimus-eluting stents (SES) in the ARTS II registry and 
compared these results with 208 diabetic pts randomized to BMS or CABG in the ARTS 
trial. Procedural costs were based on measured resource use and 2004 unit costs (SES 
= $2400; BMS = $800) while other hospital costs were based on MedPAR data. Risk-
adjusted analyses were performed by stratiﬁed bootstrap resampling.
Results: Compared with CABG, SES was associated with lower rates of death/MI/stroke 
(DMS), while reducing initial hospital costs and total 1-yr costs. Compared with BMS, SES 
was associated with lower rates of repeat revascularization (RepRev) and DMS. Although 
index hospitalization costs for SES were ~$3800 greater than for BMS, reduced f/u costs 
offset ~80% of this cost after 1-yr. CE analysis demonstrated that relative to CABG, SES 
was economically dominant for the composite of DMS, while the incremental CE ratio for 
CABG vs. SES was unfavorable at $81,185/RepRev avoided. The incremental CE ratio of 
SES vs. BMS was $6170 per DMS avoided, and $3691/RepRev avoided.
Conclusions: At 1-year, SES is economically attractive compared with both BMS and 
CABG across a wide range of endpoints for diabetic patients with multivessel CAD.
1-year risk-adjusted outcomes and costs
 
SES
(n=159)
BMS
(n=112)
CABG
(n=96)
95% CI
DES - BMS
95% CI
CABG - DES
Index Procedure
Total Procedure duration (min.) 86 116 244 -44 to -15 147 to 169
# of stents 3.7 3.1 0.1 0.1 to 0.9 -3.3 to - 3.9
Gp2b3a use 22.0% 3.6% 0.0% 11.1% to 25.8% -15.7% to 28.3%
1-year outcomes
Death 2.1% 6.2% 3.3% -9.4% to 0.6% -2.8% to 5.7%
Death/MI/Stroke 2..5% 14.4% 7.4% -19.1% to -5.2% -0.6% to 10.9%
Repeat Revasc. 13.5% 28.4% 5.3% -25.1% to -4.9% -15.4 % to -0.8%
Costs
Index hospitalization $26,381 $22,549 $35,321 $2657 to $5000 $6366 to $12138
Follow-up medical care $6238 $9334 $3369 -$6022 to -$303 -$4709 to -$980
1-year
total $32,618 $31,884 $38,689 -$2438 to $3824 $2965 to $9610
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2916-67 Drug Eluting Stents in Diabetics: A Contemporary 
Comparative Analysis
Rade Babic, Nuccia Morici, Cosmo Godino, Simon Corbett, John Cosgrave, Gloria 
Melzi, Tiziana Aranzulla, Alaide Chieffo, Giuseppe M. Sangiorgi, Matteo Montorfano, 
Iassen Michev, Flavio Airoldi, Mauro Carlino, Antonio Colombo, EMO Centro Cuore 
Columbus, Milano, Italy, S. Raffaele Hospital, Milan, Italy
Background: Despite the advent of drug eluting stents, diabetes mellitus remains an 
important independent predictor of repeat revascularization. Recent data suggest an 
advantage for sirolimus eluting stents in diabetic patients. In light of this, we compared 
the outcomes of Paclitaxel eluting (PES) and Sirolimus eluting (SES) stent implantation 
in diabetic patients.
Methods: 696 lesions were treated in 367 diabetic patients between March 2003 and 
December 2004 in our institutions. Paclitaxel eluting and Sirolimus eluting stents were 
implanted in 182 and 185 patients respectively. Both groups were similar for angiographic 
and clinical variables. The end-point was: per-patient in-hospital and follow-up major 
adverse cardiac events (MACE) deﬁned as a composite of death, myocardial infarction 
(MI), and target vessel revascularization, including target lesion revascularization (TLR).
Results: Angiographic follow up was 71% in both groups. The late loss was greater for 
PES, 0.64 ± 0.77 mm versus 0.39 ± 0.87 for SES (p = 0.004). The MACE rates in PES and 
SES groups were 28.6% and 35.1% respectively (p = 0.25), and the lesion-based TLR 
rates were 14.4% and 18.8% (p = 0.125). Angiographic restenosis occurred in 25.7% of 
the PES cohort and 28.6% of the SES cohort (p = 0.54).
Conclusions: Both stent platforms perform equally well in diabetic patients, but PCI with 
DES is still associated with a signiﬁcant MACE rate in the real world. The advantage in 
late loss for SES does not translate into a measurable clinical beneﬁt in our large series.
2916-68 Taxus Neutralizes the Impact of Diabetes Mellitus 
on In-Stent Restenosis: A Volumetric Intravascular 
Ultrasound Meta-Analysis From the Taxus IV, V, and VI 
Trials
Gary Mintz, Neil J. Weissman, Keith Dawkins, Eberhard Grube, Stephen Ellis, Helen 
Fong, Louis Cannon, A.R. Zaki Masud, Lazar Mandinov, Joerg Koglin, Gregg W. Stone, 
Washington Hospital Center, Washington, DC, Cardiovascular Research Foundation, 
New York, NY
Background: In the bare metal stent (BMS) era, diabetes mellitus (DM) was a strong 
predictor of in-stent restenosis (ISR) because of exaggerated intimal hyperplasia (IH). 
This IVUS meta-analysis assessed whether this remains true after implantation of the 
paclitaxel-eluting TAXUS Express stent.
Methods: We performed a volumetric intravascular ultrasound (IVUS) meta-analysis of 730 
patients from TAXUS IV (n=218), TAXUS V (n=158), and TAXUS VI (n= 354). Stent, lumen, 
and IH (stent-lumen) areas were measured every millimeter and volumes, %IH (IH/stent), 
minimum lumen area (MLA), and % neointima-free length of stent (NFLS) were calculated.
Results: As shown in the Table, patients with medically treated DM treated with BMS had 
a greater %IH compared to non-DM patients (p=0.0207). Conversely, patients with DM 
treated with TAXUS stents had the same %IH as non-DM patients (p=0.16). The %IH in 
DM patients treated with TAXUS stents was also markedly less than DM patients treated 
with BMS (13.7% vs. 34.6%; p<0.0001). This was true across all three trials.
Conclusions: Treatment with the paclitaxel-eluting TAXUS stent neutralizes the impact 
of DM on IH and ISR. Diabetics treated with TAXUS stents have the same low neointimal 
hyperplasia response as non-diabetics. 
BMS/Non-DM BMS/DM TAXUS/Non-DM TAXUS/DM
N (#) 266 96 268 100
Stent volume 
(mm2)
206.4±102.5 
(204)
221.3±111.7 
(70)
202.9±97.7 
(208)
207.5±122.7 
(84)
IH volume (mm3) 61.2±43.4 (204) 78.9±62.4 (70) 25.2±29 (208) 29.7±33.6 (84)
% IH 30.0±13.9 (211) 34.6±16.9 (75) 11.6±11.6 (217) 13.7±12.2 (87)
% NFLS 3.4±5.5 (134) 2.8±4.9 (44) 12.4±9.1 (144) 9.8±9.5 (61)
MLA (mm2) 4.7±2.4 (266) 4.3±2.3 (96) 5.7±2.3 (268) 5.3±2.6 (100)
 
2916-69 Microvascular Complications and Outcome After 
Coronary Sirolimus-eluting Stent Implantation in 
Diabetic Patients
Carlo Briguori, Flavio Airoldi, Tiziana Aranzulla, Amelia Focaccio, Davide D’Andrea, 
Nuccia Morici, Mauro Carlino, Massimo Giuseppe Sangiorgi, Matteo Montorfano, 
Marco Boccalatte, Antonio Colombo, Laboratory of Interventional Cardiology, Clinica 
Mediterranea, Naples, Italy, Laboratory of Interventional Cardiology, San Raffaele 
Hospital, Milan, Italy
Background. We tested whether microvascular complications predict 1-year outcome after 
successful elective sirolimus-eluting stent (SES) implantation in type 2 diabetic patients
Methods. All consecutive type 2 diabetic patients who had elective SES implantation on 
native vessels at our Institution from April 2002 to June 2004 were analyzed. According 
to presence of microvascular complications, 4 groups of patients were identiﬁed: 1) group 
without microvascular complications, 2) group with nephropathy, 3) group with retinopathy 
and 4) group with both microvascular complications.
Results. Two-hundred-fourteen consecutive diabetic patients were analyzed. At 12 
months, major adverse cardiac events (MACE) occurred in 9 of the 46 patients (19.5%) in 
the group without microvascular complications, in 16 of the 96 patients (17%) in the group 
with nephropathy, in 12 of the 33 patients (36.5%) in the group with retinopathy and in 20 
of the 39 patients (51%) in the group with both microvascular complications (p<0.001). 
Independent predictors of MACE were: presence of diabetic retinopathy (hazard ratio = 
4.59 [95% conﬁdence interval 1.39-15.09]; p = 0.005; Figure), and vessel diameter <2.75 
mm (hazard ratio = 4.13; [95% conﬁdence interval 1.23-13.90]; p = 0.012).
Conclusions. Diabetic retinopathy represents a strong predictor of MACE following SES 
implantation in diabetic patients.
 
2916-70 Gender-Speciﬁc Effects of Diabetes on Adverse 
Outcomes After PCI: Trends Over Time
Kimberly P. Champney, Emir Veledar, Habib Samady, Nanette Wenger, Spencer Palmer, 
Douglas Morris, Susmita Mallik, Viola Vaccariono, Emory University, Atlanta, GA
Background: Diabetes mellitus (DM) is a stronger risk factor for adverse outcomes 
after MI in women than in men. Whether this gender-speciﬁc effect of DM also occurs 
after elective PCI, and whether it has changed in recent years with improvement in PCI 
technology and concurrent treatments, is unknown.
Methods: We examined 9465 elective PCI procedures in patients without prior 
revascularization at Emory University Hospitals between 1990 and 1999. Hazards ratios 
(HR) for 1-year major adverse cardiac events (MACE), a composite endpoint of death, 
myocardial infarction, and revascularization, were calculated comparing DM to no-DM 
patients by gender and study year. Data were adjusted for other demographic factors, 
history of MI, other comorbidity and CHD risk factors using Cox-proportional hazards 
models.
Results: In 1990-91, DM was associated with almost twofold greater MACE rate in 
women (38% vs 23%, adjusted HR=1.9, 95% CI 1.4-2.7) but little effect in men (33% vs 
29%; p=0.02 for interaction between DM and gender). The risk of MACE due to DM in 
women decreased over time (Figure). The HR became non-signiﬁcant by year 1996 and 
was close to 1 by 1998. Diabetes had no impact on the risk of MACE in men during the 
same period. 
Conclusions: DM was a substantial risk factor for adverse outcomes at 1 year after 
elective PCI in women only until approximately 1996. DM-related MACE rates in women 
have fallen dramatically in recent years. As a result, the signiﬁcant gender-DM interaction 
found in 1990-91 is no longer present.
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2917-71 Gp IIb/IIIa Inhibitors Administration in Chronic Renal 
Insufﬁciency Patients Undergoing Percutaneous 
Coronary Intervention: Results of the SHAKESPEARE 
International Registry
Luis Gruberg, Rafael Beyar, Jean-Pierre Bassand, Ricardo Seabra-Gomez, Paolo 
Fioretti, Martin Gottwik, Keith Dawkins, Andrej Cieslinski, David Hasdai, Jochen Senges, 
Anselm K. Gitt, SHAKESPEARE Study Group, Rambam Medical Center, Haifa, Israel
Background: A limited a number of studies have assessed the impact of Gp IIb/IIIa 
inhibitors during percutaneous coronary interventions (PCI) in chronic renal insufﬁciency 
(CRI) patients because of concern about an increased risk of bleeding complications. We 
assessed the impact of Gp IIb/IIIa inhibitors on the outcomes of CRI patients undergoing 
PCI in a large, prospective, multicenter, international registry.
Methods: Between 11/2001 and 12/2002, data on a total of 13,456 consecutive patients 
undergoing PCI were obtained at 30 centers in 7 countries (France, Germany, Israel, Italy, 
Poland, Portugal, UK) as part of the international SHAKESPEARE Registry.
Results: A total 393 patients had CRI (serum creatinine >2.0 mg/d); 120 (30.5%) 
were treated with Gp IIb/IIIa inhibitors and 273 were not (69.5%). Baseline clinical and 
angiographic characteristics were similar between the two groups (Table). Abciximab 
was used in 48% of patients and eptiﬁbatide in 28%. In-hospital outcomes were similar 
(Table).
Conclusions: The use of Gp IIb/IIIa inhibitors in CRI patients undergoing PCI, seems 
to be safe, with only a signiﬁcant increase in minor bleeding complications. Despite a 
signiﬁcantly higher rate of MI patients treated with Gp IIb/IIIa inhibitors (41% vs. 21%), the 
outcomes were similar between the two groups, except for a signiﬁcantly higher mortality 
rate in NSTEMI patients who were not treated with Gp IIb/IIIa inhibitors. 
Gp IIb/IIIa
n=120
No Gp IIb/IIIa
n=273 p
Age (years) 70 (64-76) 70 (62-76) 0.9
Female gender (%) 21 23 0.6
Hypertension (%) 78 73 0.37
Acute STEMI (%) 23 13 0.01
Acute NSTEMI (%) 18 9 0.009
Unstable angina (%) 33 43 0.08
In-hospital death (%) 5.8 7.3 0.59
Death in STEMI pts (%) 18.5 29.4 0.32
Death in NSTEMI pts (%) 0 17.4 <0.0001
In-hospital bleeding (%) 15.3 4.9 0.0009
Major bleeding (%) 4.2 1.8 0.18
Minor bleeding (%) 10.0 2.6 0.0015
MACCE (%) 9.2 8.1 0.72
 
2917-72 Clinical Success in 100 Consecutive Endovascular 
Occlusion Cases Using Re-Entry Catheters for Failed 
Sub-Intimal Approach
James D. Joye, Rod Serry, Frederick G. St. Goar, Patrik Zetterlund, El Camino Hospital, 
Mountain View, CA
Background. Successful recanalization of chronic total occlusions (CTO’s) in the 
peripheral vasculature has had limited success due to the advanced nature of the 
disease. Even with reﬁnement of the subintimal technique and operator experience, distal 
entrapment without true lumen re-entry is encountered in 25-50% of cases. Fluoroscopy 
and IVUS-based re-entry catheters have been developed to potentially overcome this 
problem.
Methods. We retrospectively reviewed 100 consecutive patients with peripheral vascular 
CTO’s in whom we were unable to safely pass a guide wire into the distal lumen, and in 
whom re-entry was attempted. We utilized either the Pioneer Catheter (Medtronic, Inc., 
Santa Rosa, CA) or the Outback Catheter (JJIS/Cordis, Warren, NJ ) for all cases. The 
distribution of occlusions in which re-entry was attempted included 33 aorto-iliac, 56 
femoropopliteal, and 11 subclavian cases.
Results. The patients in this study were 64M/36F, age 68+6 yrs, and length of occlusion 
was 24 + 6cm. Clinical success, deﬁned as successful re-entry into the target lumen 
distally, was achieved in 95/100 (95%) cases. In all of these cases the intended 
endovascular therapy was completed successfully. Reasons for failure to re-enter the true 
lumen despite the use of the study devices included extensive calciﬁcation, small distal 
target vessel, diffuse atherosclerotic disease, and suboptimal imaging.
Conclusion. Subintimal entrapment can be reliably overcome in the majority of cases 
that present with occlusion with the use of re-entry catheters. Attention to lesion 
morphology and target vessel caliber are important variables to factor into appropriate 
case selection.
2917-73 Incidence and Predictors of Procedure-related 
Nephropathy After Thoracic Aortic Stent-Graft 
Placement
Holger Eggebrecht, Frank Breuckmann, Christoph K. Naber, Ulf Herold, Peter 
Kienbaum, Jürgen Peters, Heinz G. Jakob, Raimund Erbel, Rajendra H. Mehta, 
University of Essen, Essen, Germany, Duke Clinical Research Institute, Durham, NC
Background: Procedure-related nephropathy (PRN) is a serious complication of 
interventional procedures using intraarterial contrast agents. In the present study, we 
assessed the incidence and predictors of PRN in patients undergoing stent-grafting.
Methods: A total of 100 patients (age: 64.5±11.5 (22.1-83.0) years, 74% male) 
undergoing technically successful thoracic aortic stent-graft placement between 07/1999 
and 10/2005 were included into. PRN was deﬁned as an increase of ≥ 25% and/or ≥ 0.5 
mg/dl in preprocedure serum creatinine at 48 hours after the procedure.
Results: Baseline glomerular ﬁltration rate (GFR) was 63.47±25.66 (6.99-144.25) ml/
min/1.73 m2. Chronic kidney disease (GFR ≤ 60 ml/min/1.73 m2) was present in 47% of 
patients. During the stent-graft procedure, patients received 312±191 (40-950) ml of non-
ionic contrast media. PRN occurred in 33 (33%) patients, requiring transient dialysis in 6 
of them. Multivariable analysis revealed that a poor clinical health status (ASA class > 3) 
preoperatively (HR=0.21, 95% CI 0.068-0.648, p=0.007) and duration of the stent-graft 
procedure (HR=1.007, 95% CI 1.001-1.014, p=0.028) were the independent predictors for 
PRN. Survival of patients with PRN was signiﬁcantly worse than that of patients without 
(1-year survival: 88.8±4.0% vs. 64.7±8.6%, p=0.0068).
Conclusion: PRN is a frequent complication of thoracic aortic stent-graft placement, 
which has signiﬁcant adverse impact on both short- and long-term survival of patients.
2917-74 Distal Embolic Protection Devices, High Intensity 
Transient Signals and Neurological Outcomes During 
Carotid Artery Stenting
Luis Gruberg, Prashant Nair, Arthur Kerner, Sirush Petchersky, Eﬁm Kouperberg, Rafael 
Beyar, Rambam Medical Center, Haifa, Israel
A major limitation of percutaneous carotid artery stenting (CAS) is the occurrence of 
distal embolization during the procedure. Transcranial Doppler (TCD) performed during 
CAS with the detection of high intensity transient signals (HITS) indicate that distal 
embolization is a universal ﬁnding. We assessed the incidence and clinical impact of HITS 
in pts undergoing CAS with different distal embolic protection devices. 154 pts underwent 
CAS at our institution, 78 had restenosis following carotid endarterectomy (CEA) and 76 
had de novo lesions. Three different types of ﬁlters were used: FilterWire®, Angioguard® 
and Spider®. The total number of HITS during the procedure is presented. An optimal 
window for TCD was available in 47 post-CEA and 42 pts with de novo lesions. A ﬁlter 
was used in 22 and in 30 pts, respectively. A total of 6 pts had a CVA, three in pts treated 
without ﬁlters (0, 63 and 63 HITS), 2 with the Angioguard® (0 and 277 HITS) and 1 with 
the Sipder® ﬁlter (0 HITS). Six pts had a TIA, 2 with the Angioguard® (15 and 90 HITS), 
2 without ﬁlter, 1 with the FilterWire® and 1 with the Spider®, these 3 pts did not have an 
appropriate window for TCD. One patient died (no ﬁlter, 72 HITS).
No Filter Angioguard® FilterWire® Spider®
S/P CEA (n=47) 25 7 11 2
De Novo (n=42) 12 11 10 8
S/P CEA and HITS 120 145 185 128
De Novo and HITS 136 142 198 161
CVA/TIA 3 / 2 2 / 2 0 / 1 1 / 1
Conclusions: HITS are a very common event during CAS and are present during different 
stages of the procedure. Neither lesion type (post-CEA or de novo) nor ﬁlter type appear to 
have an inﬂuence on the number of HITS or neurological events. The neurological outcomes 
do not seem to be related to the presence (or absence) or the number of HITS.
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2917-75 Correlations Between Hyperemic Pressure Gradient, 
Intravascular Ultrasound, Duplex Ultrasound, and 
Quantitative Aniography in Patients With Renal Artery 
Stenoses
Jai Varma, Adam Shapira, Sohail Ikram, Massoud A. Leesar, University of Louisville, 
Louisville, KY
Background: The visual estimation of a renal artery stenosis (RAS) based on angiography 
often dictates decisions regarding renal artery stenting. To date, no correlations have 
been reported between Duplex ultrasound, hyperemic peak-to-peak pressure gradients 
(HPPG), intravascular ultrasound (IVUS), and quantitative renal artery angiography 
(QRA) to assess the signiﬁcance of a stenosis in patients with RAS.
Methods: In 22 hypertensive patients with RAS based on renal angiography, Duplex 
ultrasound was performed. HPPG was performed during papaverin injection by a pressure 
wire. Subsequently, IVUS, and QRA were performed.
Results: Linear regression analysis demonstrated strong correlations between HPPG and 
area stenosis by IVUS (r = 0.75, P<0.001) as well as HPPG and minimum lumen diameter 
by IVUS (r=0.64, P<0.001). The correlations between HPPG versus Duplex ultrasound 
and QRA were moderate (r=0.43, and r=0.44, respectively; P<0.5). At HPPG cut-point 
of 25 mmHg, an IVUS area stenosis of 59% had the highest sensitivity and speciﬁcity 
(both 100%) for determining the signiﬁcance of RAS, followed by IVUS minimum lumen 
diameter of 3.0 mm (100% and 93%, respectively). By QRA, the best agreement with 
HPPG was found when a diameter stenosis was 47% (sensitivity, 87%; speciﬁcity, 92%). 
By Duplex ultrasound, the best agreement with HPPG was found when peak systolic 
velocity was 184 cm/s (sensitivity, 85%; speciﬁcity, 66%).
Conclusions: We conclude that (1) an IVUS area stenosis and minimum lumen diameter 
of 59% and 3.0 mm, respectively, strongly correlated with HPPG of 25 mmHg and (2) 
a decision-making strategy to assess the signiﬁcance of RAS predicated on the use of 
either HPPG or validated IVUS parameters are superior to Duplex ultrasound and QRA.
2917-76 Correlation of Improvement in Depression With 
Improvement in Peripheral Artery Disease Symptoms 
Following Peripheral Endovascular Revascularization
David M. Saﬂey, John A. House, Jaime E. Barberena, Steven P. Marso, Mid America 
Heart Institute, Kansas City, MO
Background: Depression is common among patients with symptomatic Peripheral 
Arterial Disease (PAD). The effect of revascularization on depressive symptoms is 
unknown. We examined changes in depression and PAD symptoms 30 days after 
Peripheral Endovascular Revascularization (PER).
Methods: Patients undergoing infra-aortic PER were prospectively enrolled in the ALEVE 
study to quantify health status recovery. The Peripheral Artery Questionnaire (PAQ) 
was used to assess PAD-related health status. Scores range from 0-100, with higher 
scores indicating better quality of life. Depression was assessed with the Patient Health 
Questionnaire (PHQ). Scores <5 were considered not depressed, 5-15 mild/moderate 
depression and >15 severe depression. Both questionnaires were administered at 
baseline and 30 days after PER by a trained interviewer.
Results: 236 patients were enrolled with baseline and follow-up depression and health 
status assessments. The average age was 68 years, 95% were Caucasian, and 62% 
were male. Within 30 days of PER, there was a 30% decrease in the prevalence of 
depression (46% vs. 32%, p<0.001). Average PAQ (30±18 vs. 70±25, p<0.001) and PHQ 
scores (5.7±6.0 vs. 3.7±4.7, p<0.001) improved signiﬁcantly following PER. Correlation of 
changes in depression and PAD symptoms is shown in the ﬁgure.
Conclusions: Depressive symptoms are common in PAD, and frequently improve 
following PER. Improvement in depression correlates well with improvement in PAD 
symptoms.
2917-77 Symptoms of Peripheral Artery Disease are Effectively 
and Persistently Improved Following Percutaneous 
Revascularization
David M. Saﬂey, Casey Stoner, John A. House, Jaime E. Barberena, William C. Daniel, 
Steven B. Laster, John A. Spertus, Steven P. Marso, Mid America Heart Institute, 
Kansas City, MO
Background: Symptomatic peripheral artery disease affects 5 million Americans. There 
are over 150,000 peripheral endovascular revascularization (PER) procedures in the 
United States yearly. However, the magnitude and durability of symptom improvement 
after PER is unknown.
Methods: Following informed consent, patients undergoing PER were prospectively 
enrolled in this study. Health status was assessed at baseline, 1, 3, 6, and 12 months 
with the disease speciﬁc Peripheral Artery Questionnaire (PAQ). The primary endpoint 
was health status recovery 12 months following PER, assessed by the PAQ summary 
score. Scores range from 0-100; higher scores represent fewer symptoms and better 
health status. PAQ Scores for Physical Limitation, Symptoms, and Quality of Life were 
also compared.
Results: There were 300 patients enrolled. The average age was 65±11 years, 62% were 
male and 96% were Caucasian. Coronary artery disease (65%), hypertension (69%), 
hypercholesterolemia (66%), diabetes mellitus (37%), and tobacco use (44%) were 
common. There were improvements in Physical Limitation (19±21 vs. 50±33, p<0.001), 
Symptoms (34±21 vs. 62± 30, p<0.001), and Quality of Life (37±21 vs. 64±28, p<0.001) 1 
year following PER. PAQ summary scores are shown in the ﬁgure. There was a decrement 
between 1 and 12 months (p=0.007), but improvements remained signiﬁcant.
Conclusions: There is a signiﬁcant improvement in PAD-related health status following 
PER. These improvements are sustained for 1 year following PER.
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2918-78 Randomized Trial Comparing Immediate Sheath 
Removal Reversing Heparin With Protamine Versus 
Late Conventional Sheath Removal After Elective 
Coronary Angioplasty
Guillermo Marchetti, Diego Lavaggi, Alejandro Salvatierra Ruiz, Juan Fernández, Juan 
Arellano, Pablo Kantor, Ricardo Iglesias, Raul Ferreyra, Antonio Pocoví, Alejandro 
Palacios, Sanatorio Mitre, Buenos Aires, Argentina
Background and Aim: Immediate sheath removal (IR) reversing heparin with protamine 
(PTM) after elective coronary angioplasty could improve the quality of the procedure, 
resulting in better patient comfort and reducing immobilization time. In order to 
demonstrate that a fast hemostasis and compression in the puncture site is safe and 
by no means inferior to late compression, we designed a prospective randomized trial 
comparing IR, reversing heparin with PTM versus late conventional sheath removal (LR), 
5 ± 1 hours after elective coronary angioplasty.
Methods: From November 2003 to September 2005, a total of 196 patients were 
randomized to IR (N= 96) versus LR (N=100). Drug-Eluting stents and IIbIIIa inhibitors 
were used in 11.2% and 2% of patients, respectively. All patients were treated by femoral 
access and sheaths were removed by a senior resident of cardiology applying manual 
compression. Our combined primary endpoint was any puncture site complication at 30 
days (major groin hematoma >5cm diameter, bleeding requiring transfusion, recurrent 
bleeding, artery occlusion, psudoaneurysm or arteriovenous ﬁstula). Our combined 
secondary endpoint was any major adverse cardiac event (MACE) at 30 days: death, 
myocardial infarction or target vessel revascularization. IR patients were controlled 
by activated clotting time (ACT) and LR patients were controlled by activated partial 
thromboplastin time. For IR patients we administered intravenous PTM according to 
ACT (seconds): 250-300, 25mg; 200-250, 20mg; 160-200, 15mg and <160, removal. We 
performed a new ACT ﬁve minutes later and repeated the same diagram when necessary, 
until getting an ACT<160 seconds.
Results: There were no signiﬁcant differences between the two groups. The primary 
endpoint was observed in 4,16% for IR vs 7% for LR, p=0,582. The secondary endpoint 
was observed in 0,74% for IR vs 1% for LR, p=0,495. No patients sustained Bare Metal 
or Drug-Eluting stent thrombosis.
Conclusions: Immediate sheath removal reversing heparin with PTM is feasible and 
safe, with a low incidence of puncture site complications. This practice could improve 
hospitalization time, reducing bed rest and achieving an earlier discharge.
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2918-79 Sheath Management in Patients Undergoing Elective 
Percutaneous Coronary Intervention in the STEEPLE 
Trial
Richard Gallo, Steven Steinhubl, Marc Cohen, Ph. Gabriel Steg, Walter Desmet, Harvey 
White, Gilles Montalescot, for the STEEPLE Investigators, the Montreal Heart Institute, 
Université de Montréal, Montréal, PQ, Canada, Centre Hospitalier Universitaire Pitié-
Salpêtrière, Paris, France
Background: Timing of sheath removal, sheath size, and use of closure devices affect 
outcomes in patients undergoing elective percutaneous coronary intervention (PCI). We 
assessed the effect of sheath management on bleeding in patients undergoing elective 
PCI in the recently completed STEEPLE trial.
Methods: STEEPLE was a prospective, open-label, randomized trial in 3,528 patients 
undergoing PCI. Patients were randomized to intravenous enoxaparin (enox) (0.5 or 0.75 
mg/kg) or activated clotting time (ACT)-adjusted unfractionated heparin (UFH), stratiﬁed 
by GP IIb/IIIa inhibitor use. Besides showing similar efﬁcacy to UFH, enox reduced major 
bleeds by 57% (P<0.01). Sheath removal was authorized with ACT 150-180 seconds in 
the UFH group, 4-6 hours after end of PCI in the enox 0.75 mg/kg group, and immediately 
after PCI in the enox 0.5 mg/kg group.
Results: Closure devices were used in 39%, a sheath size of <7F in 80%, and early 
sheath removal (<30 min) in 43% of patients. Enox was associated with reduced bleeding 
when a closure device was used and with a sheath size of <7F. Early sheath removal 
after the end of the procedure (<30 min) resulted in fewer bleeding events with enox 
than with UFH. 
Non-CABG major and minor 
bleeding n/N (%) Enox 0.5 Enox 0.75 UFH
P-value
for interaction 
enox 0.5 vs 
UFH
P-value for 
interaction enox 
0.75 vs UFH
Closure device
No 44/636 (6.9)
55/736 
(7.5)
55/731 
(7.5) 0.02 0.03
Yes 18/407 (4.4)
25/468 
(5.3)
50/478 
(10.5)
Sheath size
< 7F 40/822 (4.9)
59/979 
(6.0)
90/967 
(9.3) 0.002 0.02
≥ 7F 23/221 (10.4)
21/225 
(9.3)
15/242 
(6.2)
Time from end of PCI to sheath 
removal
0-≤30 minutes 24/489 (4.9)
24/479 
(5.0)
53/489 
(10.8)
0.03 0.0130-120 minutes 3/83(3.6)
2/20 
(10.0) 4/62 (6.5)
>120 minutes 34/459 (7.4)
53/677 
(7.8)
45/638 
(7.1)
Conclusion: Early sheath removal (<30 min) reduces bleeding in patients receiving 
enox compared with UFH. Use of a closure device and a small sheath size also reduce 
bleeding complications in elective PCI patients on enox, but not in patients on UFH. Enox 
is an effective and safer alternative to UFH in elective PCI patients.
2918-80 DNA Damage and DNA Repair Pathway in Pulmonary 
Ischemia and Reperfusion Injury
Pramod Bonde, II, Lei Chen, Liliana Moreno-Vinasco, Daquing Gao, Jeff Jacobson, Joe 
G. Garcia, Chiming Wei, Johns Hopkins University, Baltimore, MD
Background: Oxidative damage induced by reperfusion is responsible for increased 
morbidity and mortality following lung transplantation. A stable and deleterious DNA 
adduct, 8-oxogaunine (8-oxoG) results due to oxidative DNA damage. Mut-Y Homologue 
(MYH) is a DNA repair enzyme promoting DNA reconstruction through the mis-match 
repair pathway to repair 8-oxoG lesion. We investigated the role of DNA mismatch repair 
pathway mediated by MYH in the setting of lung ischemia and reperfusion.
Methods: Left lungs of the adult Sprague Dawley rats were subjected to one hour 
ischemia and two and four hour reperfusion. Un-operated animals served as controls. 
Quantiﬁcation of 8-oxoG was performed using immunohistochemistry (IHC) and MYH 
was analyzed by Western blot. Apoptosis was assessed by TUNEL staining and Caspase-
3, AIF and PARP levels.
Results: There was signiﬁcant increase in DNA damage as reﬂected by positive 8-oxoG 
staining in 2 hour (22% increase) and 4 hour reperfusion (31% increase) compared to 
control (p<0.01). MYH staining by IHC was signiﬁcantly reduced in 2 hour and 4 hour 
reperfusion compared to controls (p<0.05). Down regulation of DNA repair enzyme 
(MYH) was mirrored functionally by decreased protein levels in lung tissues subjected to 
reperfusion compared to controls. Increasing apoptosis was detected in the reperfusion 
groups as reﬂected by TUNEL staining. Both caspase-dependent pathway (caspase-3) 
and caspase-independent pathway (apoptosis-inducing factor [AIF] and PARP) levels 
were increased by IHC study and protein estimation by Western Blot analysis.
Conclusions: Reperfusion leads to increased DNA damage and down regulation of DNA 
mismatch repair pathway in a model of ischemia and reperfusion in lungs. Gene therapy 
targeted at this pathway may prove an attractive therapeutic intervention to reduce 
reperfusion injury in lung transplantation.
2918-81 Cost Effectiveness of the Angioseal Vascular Closure 
Device after Percutaneous Coronary Intervention
Nipun Arora, Michael E. Matheny, Campbell D.K. Rogers, Matthew R. Reynolds, Frederic S. 
Resnic, Brigham and Women’s Hospital, Boston, MA, Harvard Medical School, Boston, MA
Background: The Angioseal vascular closure device has been shown to be safe and effective 
in reducing the time to hemostasis following cardiac interventions. The cost effectiveness of 
routine use of Angioseal following coronary intervention (PCI) has not been explored.
Methods: A decision analysis model was constructed to evaluate routine Angioseal use 
after PCI with respect to hospital costs. Vascular event probabilities were derived from 
pooled analysis of published randomized trials. Local institutional costs were collected 
for 5,844 PCI patients between 1/02 and 12/04. A matched case control methodology 
was performed to calculate the incremental costs of vascular complications. Sensitivity 
analyses were performed on all key costs and probabilities.
Results: Vascular event rates with incremental costs are shown in the ﬁgure. The routine 
use of Angioseal for vascular closure was associated with a net cost savings of $68 
per PCI case. Sensitivity analysis showed that Angioseal had net cost savings over 
compression as long as the total cost for compression exceeded $40 per case.
Conclusion: In this study, the routine use of Angioseal following PCI was associated 
with net cost savings as compared with compression. This observed cost savings is in 
addition to the previously demonstrated advantages of Angioseal in patient comfort and 
preference.
2918-82 Vascular Access Site Complications in the 
Contemporary Practice of Percutaneous Coronary 
Interventions: Impact of Closure Devices and 
Bivalirudin
Sundeep Mishra, Roswitha M. Wolfram, Zhenyi Xue, Pramod K. Kuchulakanti, Lowell 
F. Satler, Augustus D. Pichard, William Suddath, Kenneth Kent, Ron Waksman, 
Washington Hospital Center, Washington, DC, DC
Background: Vascular complications continue to be a limitation of percutaneous coronary 
interventions (PCI). This study examined the impact of bivalirudin with an arteriotomy 
closure device (ACD) on vascular access site complications during PCI.
Methods: We compared data of 2022 patients who received periprocedural bivalirudin 
and ACD, 495 patients who received heparin and ACD, 415 patients with heparin and 
manual compression (MC), and 659 patients with bivalirudin and MC. Patients treated 
with glycoprotein IIb/IIIa inhibitors were excluded from this study. Utilized ACDs were 
Angio-seal (67%), PerClose (25%), and Duett (7%).
Results: Baseline characteristics were mostly comparable between groups. Overall ACD 
use was associated with superior vascular outcomes with both heparin and bivalirudin. 
ACD in combination with bivalirudin showed the lowest incidence of bleeding and vascular 
complications (Table).
Conclusions: In patients undergoing PCI, the combination of periprocedural bivalirudin 
and postprocedural access site closure with one of the currently available devices 
appears to be an effective strategy to minimize vascular complications.
Vascular and bleeding related outcomes
Parameters Heparin+MC (n=415)
Bivalirudin+ 
MC (n= 659)
Heparin+ACD 
(n=495)
Bivalirudin + 
ACD (n=2022)
Maximum ACT, sec 300±77 369±167¥ 308±191 357±82 χ
Vascular 
complications 26 (6.3) 42 (6.4) 12 (2.5)
 π 25 (1.2) *, χ
Major bleeding, 
n (%) 19 (4.6) 26 (3.9) 12 (2.4) 20 (1.0)
 *, χ
Hematocrit 
decrease ≥15, n (%) 14 (3.6) 19 (3.0) 7 (1.5)
 π 14 (0.7) * 
Gastrointestinal 
bleeding, n (%) 6 (1.5) 7 (1.1) 5 (1.0) 7 (0.4)
 
Transfusion, n (%) 37 (10.2) 45 (7.0) 20 (4.6) π 38 (2.1) *, χ
Hematoma >4cm, 
n (%) 33 (8.1) 50 (7.6) 19 (3.9)
 π 54 (2.7) *
ICU stay, days 1.9±4.4 1.2±3.5 0.7±1.5 π 0.4±1.8*, χ
¥ p<0.05 Heparin + MC vs. Bivalirudin + MC; χ p<0.05 Heparin + ACD vs. Bivalirudin 
+ ACD; π p<0.05 Heparin + MC vs. Heparin + ACD; * p<0.05 Bivalirudin + MC vs. 
Bivalirudin + ACD
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2918-83 Retroperitoneal Hemorrhage Following Interventional 
Cardiac Catheterization Procedures: Predictors, 
Outcomes, Association With Vascular Closure Devices, 
and Healthcare Costs
Nipun Arora, Nils Kucher, Michael E. Matheny, Campbell D.K. Rogers, Frederic S. Resnic, 
Brigham and Women’s Hospital, Boston, MA, Harvard Medical School, Boston, MA
Background: Retroperitoneal hemorrhage (RPH) is an infrequent but dangerous 
complication of cardiac catheterization. We sought to explore the costs, predictors and 
outcomes of RPH.
Methods: Using a local prospective outcomes registry of 12,083 consecutive patients 
undergoing left heart catheterization and PCI between 1/02 and 12/04, all cases of CT 
conﬁrmed RPH were identiﬁed. Demographic, clinical, and procedural variables were 
analyzed and outcomes assessed. A case control algorithm was used to generate 
random controls matched for age, gender, procedure, and use of closure device. Costs 
were assessed using total hospital inpatient costs.
Results: There were 26 cases of RPH (0.22% overall; 0.07% in diagnostic; 0.42% in 
PCI cases). PCI (OR 4.04, p=0.01), high femoral stick (OR 17.8, p<0.01) and peripheral 
vascular disease (OR 4.87, p=0.02) were found to be independent predictors of RPH. 
There was no signiﬁcant association of RPH with use of GPIIb/IIIa inhibitors, sheath size, 
intra-aortic balloon pump or vascular closure. RPH led to increased in-hospital costs of 
$8,176 (p<0.01) and increased length of stay of 2 days (p=0.01). RPH in PCI cases had 
an in-hospital mortality of 4.17%; a 4.4 fold increase over controls (p=0.1).
Univariate Analysis Multivariate Analysis
Variable
RPH 
Patients
(n= 26)
Controls
(n=98) OR (95%C.I) P value OR (95% C.I) P value
Peripheral vascular disease 12% 4% 2.76 (1.01-7.6) 0.04* 4.87 (1.24-19.03) 0.02*
Percutaneous coronary 
intervention (PCI) 88% 100% 5.95 (2.24-45.6) 0.00*
4.04 (1.31-
15.80) 0.01*
High femoral puncture 33% 3% 15.83 (3.79-66.07) 0.00*
17.82 (3.63-
87.52) 0.00*
Vascular closure device 96% 88% 3.20 (0.39-25.97) 0.25
Conclusions: PCI, high femoral arterial puncture and peripheral vascular disease are 
signiﬁcant risk factors for the development of RPH. RPH is associated with signiﬁcantly 
increased length of stay, total costs and a trend toward increased mortality.
2918-84 The Safety and Efﬁcacy of the Starclose™ Vascular 
Closure System: The Ultrasound Substudy of the Clip 
Study
Michael Jaff, Gail Hadley, James B. Hermiller, Charles Simonton, Tomoaki Hinohara, 
Louis Cannon, Mark Reisman, Greg Braden, Dana R. Fletcher, Michael Zapien, Tony M. 
Chou, Massachusetts General Hospital, Boston, MA, Abbott Vascular, Redwood City, CA
Background: The CLIP Study was a performed to assess the safety and efﬁcacy of the 
StarClose™ Vascular Closure System (Abbott Vascular, Redwood City, CA) as compared 
to standard compression (SC) following 5 to 6 French diagnostic or interventional 
percutaneous procedures. StarClose, currently an investigational device in the U.S., 
features an innovative nitinol clip that is designed to achieve closure of the femoral artery 
access site.
Methods: At 17 sites, 483 patients were randomized at a 2:1 ratio to receive StarClose 
or SC with primary endpoints of post-procedure time to hemostasis and major vascular 
complications through 30 days. A substudy of the CLIP intervational arm evaluated duplex 
ultrasound (DUS) images of the closure site at ﬁve study sites, targeting 100 subjects at 
day 30. The DUS protocol was devised and implemented by an independent core lab. 
DUS of the common femoral artery and vein, superﬁcial femoral artery and vein, and the 
saphenofemoral venous conﬂuence were evaluated approximately 6cm above and below 
the puncture site to determine absence or presence of iatrogenic injuries: hematoma, 
pseudoaneurysm (PSA), arteriovenous ﬁstula (AVF), and vessel thrombosis or stenosis 
using 2-dimensional gray scale, color enhanced, and focused Doppler images.
Results: DUS of 96 subjects randomized to StarClose (N=71) and SC (N=25) were 
performed. There was no evidence of hematoma, PSA or AVF observed. One non-
substudy SC patient was noted to have a PSA one day after the procedure requiring 
repeat thrombin injections and blood transfusion. All patients in the substudy demonstrated 
patency of the access site artery and vein without thrombosis or stenosis.
Conclusion: Independent DUS analysis, a safe and reliable method for determining the 
safety and efﬁcacy of access site closure devices, found no statistical difference between 
the StarClose and SC groups of a substudy of patients in the CLIP study. Both groups 
maintained vessel patency without stenosis, thrombosis, hematoma, pseudoaneurysm 
or AV ﬁstula.
POSTER SESSION
2919 
Catheter Based Therapy: Stroke 
Prevention
Monday, March 13, 2006, 1:30 p.m.-5:00 p.m.
Georgia World Congress Center, Hall B1
Presentation Hour: 2:30 p.m.-3:30 p.m.
2919-85 Safety and Efﬁcacy of Carotid Artery Stenting With 
Distal Embolic Protection in Octogenarians
Leonardo C. Clavijo, Lowell F. Satler, Aravinda Nanjundappa, Habeeb M. Ahmed, Tracey 
Bersnahan, Donna J. Whitman, Ron Waksman, John R. Laird, Washington Hospital 
Center, Washington
Background: Carotid stenting is an alternative to surgery for the treatment of high-risk 
patients with carotid stenosis (CAS). Data regarding safety and efﬁcacy of carotid stenting 
in patients >80 years (octogenarians) is limited.
Methods: A prospective, single-center registry including patients who underwent carotid 
stenting with distal embolic protection. Patients were divided according to two age 
groups: <80 or ≥80 years. All patients had a brain CT scan and independent neurological 
evaluation before and 24 hrs after carotid intervention. Clinical follow up was performed 
at 1, 3, & 6 months and 1 year.
Results: Between August 2003 and August 2005, 180 patients underwent carotid 
stenting, 30 patients were >80 and 150 patients <80, mean ages 83.2±3.6 and 67.1±7.3 
respectively. Baseline characteristics were comparable, except for a higher incidence of 
chronic renal insufﬁciency in the octogenarian group (33.3% vs. 8%, p=0.003). Procedural 
success was similar in both groups (99%). There were no differences in neurological 
complications in-hospital or at 1 year. In-hospital bleeding complications were more 
common in octogenarians (16.7% vs. 5.3%, p=0.045).
Conclusions: Carotid artery stenting in octogenarians is associated with high procedural 
success and a rate of neurological complications that is comparable to that of younger 
patients. Bleeding complications after carotid artery stenting are more common in 
octogenarians.
Table. Carotid Stenting in Octogenarian Patients 
Age ≥80 Age <80 P value
Prior Carotid Stent, % 8.3 1 0.09
Prior carotid endarderectomy, % 20.8 17 0.76
Symptomatic CAS, % 17.4 29.9 0.23
In-hospital CVA, % 3.3 1.3 0.42
In-hospital TIA, % 0 0.7 1
Minor Bleeding, % 6.7 0.7 0.07
Intracranial Bleeding, % 0 0.7 1
Any Bleeding, % 16.7 5.3 0.04
Death at 1 year, % 6.7 1.3 0.13
TLR, % 3.3 0.7 0.30
 
2919-86 Distal Embolic Protection Device Recovery Catheter 
Problems During Carotid Stenting: A Technical Analysis
Subbarao V. Myla, Lawrence Jacobs, Martin Kleinbart, Jim Cubelis, Carol Moore, 
Maggie Macari-Hinson, Cheryl Roland, Susan K. Goldberg, Hoag Memorial Hospital 
Presbyterian, Newport Beach, CA
Background: Carotid stenting (CS) using distal embolic protection devices (DPD) with 
either Percusurge Balloon occlusion or Carotid Filter is being performed with increasing 
frequency in clinical and post market studies for higher surgical risk patients. Difﬁculties 
and complications during recovery of DPD with retrieval catheters are being reported with 
ﬁlter detachment and embolization, stroke and surgery.
Study: We sought to analyze the technical factors causing the difﬁculty in DPD recovery 
and potential roles of stent type (Open cell design vs. closed cell design), Recovery 
catheter(RC) design (Coaxial two catheter syle or single stiff monorail style) and presence 
or absence of anatomical adversity for DPD retrieval (Tortuosity, sharp entry and exit 
angles at lesion, heavy calcium at lesion and signiﬁcant residual lesion) in carotid stenting 
(CS) during the past four years.
Methods: From a total of 238 patients, 278 vessels had CAS. Twenty ﬁve (25%) percent 
were symptomatic. All except 0.5 % of patients had either ﬁlter devices or Percusurge 
distal embolic device placed and self expanding Nitinol stents or Wallstent deployed. An 
independent neurologist examined the patient before and after the procedure and at 30 
day follow-up.
Results:Anatomical Issues- The odds for patients with anatomical adversity are 30.5 
times the odds for patients without anatomical adversity.Stent Type- The odds for patients 
with open cell design stents are 102 times the odds for patients with closed cell design 
stents.RC Type- The odds for patients with stiff RC are 57.9 times the odds for patients 
with coaxial catheters. There was no difference between soft and coaxial catheters. The 
area under the Receiver Operating Curve (ROC) (C Statistic) was 0.938. The stent type 
has the biggest impact on the development of RC problems during this procedure.
Conclusion: The Carotid Stent and recovery catheter design and adverse anatomy 
predict problems with RC during carotid stenting with DPD. The closed cell design 
appears most suited to overcome the anatomical adversity. With open cell stents optimal 
recovery catheter designs are extremely important to avoid complications.
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2919-87 Favorable Outcomes of Women Undergoing Carotid 
Stenting
Vivek Rajagopal, Hitinder S. Gurm, Alex Abou-Chebl, Samir R. Kapadia, Deepak L. 
Bhatt, Matthews Chacko, Brian K. Jefferson, Christian Simpfendorfer, Chris Bajzer, Jay 
S. Yadav, Cleveland Clinic Foundation, Cleveland, OH
Background: Women undergoing carotid endarterectomy have worse outcomes than 
men. Less is known about outcomes for women undergoing carotid stenting.
Methods: We evaluated the 30-day outcomes of 915 patients who underwent carotid 
stenting between Feb 1998 and Aug 2005 at our institution, according to gender.
Results: This cohort contained 318 women and 597 men. Men and women did not 
differ in history of hypertension, stroke, renal insufﬁciency, congestive heart failure, or 
peripheral vascular disease. Men were slightly older than women (71 vs. 68 yrs, P=0.01), 
more likely to have anemia, diabetes, history of myocardial infarction, hyperlipidemia but 
less likely to be recent smokers. The 30-day incidence of death, MI, or stroke was 5.0% for 
women compared to 6.5% for men (P=0.36). On multivariate logistic regression, gender 
was not a predictor of the composite endpoint.
Conclusions: Unlike with carotid endarterectomy, women undergoing carotid stenting 
appear to have similar short-term outcomes as men. Carotid stenting is an attractive 
alternative to carotid endarterectomy in women who require carotid revascularization.
2919-88 Percutaneous Interventions of Vertebral Artery 
Stenoses
Deval Mehta, Rohit Dhall, Ritesh Gupta, Rodney Soto, William Hillegass, Vijay Misra, 
University of Alabama, Birmingham, AL
Background:
Percutaneous endovascular interventions may be a therapeutic option for patients with 
vertobral artery disease who are symptomatic despite antiplatelet therapy. Our aim was 
to assess the safety and outcomes of percutaneous intervention in patients with vertebral 
artery disease.
Methods:
In 139 consecutive patients (94 men, median age 63), 146 stenotic segments [44% right 
(n=65), 4.8% bilateral (n=7)] were treated with angioplasty or angioplasty with stenting 
between 2001 and 2005. Of these patients, 10% (n=14) had an acute stroke (within 1 
week prior to the procedure), 36% (n=50) had an old stroke (>1 week prior), 20% (n=28) 
had a TIA, 24% (n=33) had vertebrobasilar insufﬁciency symptoms and 10% (n=14) had 
severe stenosis on non-invasive imaging. The stenosis was localized to proximal segment 
in 62% (n=91), to the mid segment and distal segment each in 18% (n=28 each).
Results:
The procedure was performed with initial technical success in 139 out of 139 patients. 
2 patients died after the procedure. In one patient, the procedure was done after an 
acute stroke, and he had a right pontine infarct, and another patient had an MI after the 
vertebroplasty and cardiac catheterization for severe CAD were done at the same time. 
4 patients had strokes post procedure. The median time to discharge after the procedure 
was 1 day (range 1-50 days). Out-patient follow up was available on 109 of the 139 
patients. The follow up evaluation included a history and detailed physical examination 
by the neurologist. The median time for follow up was 7 months (range 1-54 months). Of 
those followed, 6% (n=7) had a stroke. Twelve patients required a follow-up angiogram 
done for recurring symptoms, of these 7 had restenosis.
Conclusions:
Percutaneous endovasular revascularization of vertebral artery disease is feasible and 
can be performed safely in carefully selected patients. Mid term follow up suggests that 
endovascular revascularization along with anti- platelet therapy may be an effective and 
safe treatment option for patients with vertebral artery stenoses.
2919-89 Percutaneous Subxiphoid Left Atrial Appendage 
Obliteration With an Innovative Highly Articulated 
Teleoperated Catheter
Marco A. Zenati, Alon Wolf, Takeyoshi Ota, Amir Degani, Howie Choset, University of 
Pittsburgh, Pittsburgh, PA, Carnegie Mellon University, Pittsburgh, PA
Background: Minimally invasive obliteration of the left atrial appendage (LAA) using a 
percutaneous subxiphoid approach for stroke prevention in patients with atrial ﬁbrillation is 
currently hampered by lack of dedicated technology for intrapericardial navigation around 
the beating heart. We have developed a novel 10-millimeter diameter highly articulated 
teleoperated catheter and performed preliminary experiments in a porcine preparation.
Methods: In 5 large healthy pigs, the teleoperated catheter was introduced in the 
pericardial space through a 10mm opening. Target visualization was acquired with the on-
board camera. The operator controlled the path of the catheter using a master controller. 
The catheter was guided to the base of the LAA and, through the catheter’s working port, 
an EndoLoopTM (Ethicon) was advanced and was used to ligate the LAA.
Results: Access to the pericardial space and progression to the LAA was successfull 
in all cases without interference with the beating heart. The on-board camera provided 
adequate visualization of the anatomical landmarks and facilitated the placement of 
the EndoLoop. Post-mortem gross examination of the heart demonstrated complete 
obliteration of the LAA in all cases.
Conclusions: We have developed a dedicated highly articulated catheter for minimally 
invasive obliteration of the LAA. The size and the radius of curvature are being improved 
based on the results of these experiments. We envision this minimally invasive approach 
to become standard for stroke prevention in AF when adopted by the interventional 
cardiology community.
POSTER SESSION
2920 
Antithrombotic Therapy Pre and  
Post-Intervention
Monday, March 13, 2006, 1:30 p.m.-5:00 p.m.
Georgia World Congress Center, Hall B1
Presentation Hour: 2:30 p.m.-3:30 p.m.
2920-118 Therapeutic Strategies After Stent Placement in 
Chronic Anticoagulated Patients: Effectiveness and 
Safety in Daily Clinical Practice. MUSICA Study
Antonia Sambola, Pilar Tornos, Jose Angel, Fernando Alfonso, Jose Valencia, Hector 
Bueno, Emili Iraculis, Javier Zueco, Oriol Rodriguez, Jose Lopez-Minguez, On behalf 
MUSICA Study Group, Hospital Vall d’Hebron, Barcelona, Spain, Hospital Clinico San 
Carlos, Madrid, Spain
Background. Dual antiplatelet therapy with aspirin (AAS) and clopidogrel (CL) after stent 
coronary placement is mandatory. However, in previously-anticoagulated patients there 
are no recommendations in the guidelines.
Methods: A prospective multicenter registry was established in chronically-anticoagulated 
patients undergoing to stenting between November 2003 and January 2005 in order to 
assess which regimes were used in daily practice and the complication rate (bleeding, stent 
thrombosis and thromboembolism) during hospitalization and at 6 months of follow-up.
Results: Two-hundred and ﬁfty-nine consecutive patients were identiﬁed (205 male/54 
female 71±10 y). Reasons for anticoagulation were: prosthetic valve in 36 (14%), atrial 
ﬁbrillation in 175 (68%) and other causes in 48 (18%). After stenting, 140 patients (54%) 
were discharged on acenocumarol (AC)+AAS+CL, 64 (25%) on AAS+CL, 26 (10%) 
on low-molecular weight heparin (LMWH)+AAS+CL, 24 (9%) on AC+CL, 3 pt (1%) 
on AC+AAS and 2 pt (1%) with LMWH+AAS. The choice of therapeutic regimens was 
inﬂuenced by the indication for anticoagulation (29% of patients with atrial ﬁbrillation 
received only AAS+CL). Bleeding events occured in 25 patients (9.6%). Eight of them 
were major events (3%) including 1 death due to intracranial hemorrhage. Bleeding risk 
was signiﬁcantly higher in patients who received three drugs: OR 5.08 [95% CI: 1.33-
19.39], p=0.001. Stent thrombosis occurred in 1 patient on AC+CL at 1 month after 
discharge. Embolic episodes occurred in 2 patients on AAS+CL at 1 month and 6 months 
respectively.
Conclusions: Different therapeutic options are used in chronically anticoagulated 
patients after stent placement. The risk of bleeding is increased in patients treated with 
either AC or LMWH and AAS+CL. Our results suggest that triple therapy should be 
restricted to patients with a strong reason for anticoagulation (prosthetic valve, high risk 
atrial ﬁbrillation).
2920-119 Reduction in Major and Minor Adverse Events With 
Eptiﬁbatide-based Pharmacotherapy in Percutaneous 
Coronary Intervention: The REMOVE Trial
Rafael Valencia, Neil Sawhney, Steve S. Lee, Garrett Wong, Raghava R. Gollapudi, 
Michelle Banares, Richard A. Schatz, Matthew J. Price, Paul S. Teirstein, Scripps Clinic, 
La Jolla, CA
Background: Since the inception of percutaneous coronary intervention (PCI), anti-
thrombin (i.e. heparin) therapy has been used to prevent thrombus formation and ischemic 
complications. The addition of anti-platelet therapy has reduced ischemic events, but can 
result in increased bleeding. We hypothesized that maximal antiplatelet therapy with 
aspirin, thienopyridines, and a GP IIb-IIIa inhibitor without the addition of heparin would 
result in fewer bleeding complications without an increase in thrombotic and/or ischemic 
events.
Methods: We randomized 159 patients to either a platelet GP IIb-IIIa inhibitor (eptiﬁbatide 
[EPT]) without heparin ( i.e. no anti-thrombin) or a GP IIb-IIIa inhibitor (EPT) with heparin. 
All patients were preloaded with aspirin (325mg) and clopidogrel (300mg). All complex 
lesion subsets including left main, ostial, bifurcation, and vein graft lesions were included 
with the exception of chronic total occlusions. Procedural and in-hospital events were 
prospectively evaluated. Major bleeding was deﬁned as an intracranial hemorrhage or a 
fall in hemoglobin of >5 g/dl. Minor bleeding was deﬁned as hemorrhage associated with 
a fall in hemoglobin of 3-5 g/dl.
Results: A total of 159 patients were randomized (79 to EPT and 80 to EPT plus heparin). 
There were no deaths in either treatment arm. One patient in the EPT arm sustained 
an acute thrombosis requiring in-hospital target vessel revascularization with bailout 
anti-thrombin therapy (p= 0.3). There were 13 (16.5%) procedural myocardial infarctions 
(deﬁned as CK-MB>3x normal) in the EPT arm and 9 (11.3%) in the EPT plus heparin 
arm (p=0.5). Major and minor bleeding did not signiﬁcantly differ between the two groups. 
There was one major and one minor bleed in the eptiﬁbatide arm. There were two 
major and two minor bleeds in the eptiﬁbatide plus heparin arm. Signiﬁcant hematomas 
occurred in 4 ( 5.1%) patients treated with EPT and in 13 (16.3%) patients treated with 
EPT plus heparin (p=0.02).
Conclusions: Analysis of the REMOVE trial suggests that PCI performed using a strategy 
of anti-platelet therapy without an anti-thrombin agent can be performed safely and may 
decrease peri-procedure hematomas.
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2920-120 Anti-Xa Activity and Outcomes in Patients Undergoing 
Elective Percutaneous Coronary Intervention With 
Intravenous Enoxaparin: The STEEPLE Trial
Gilles Montalescot, Steven Steinhubl, Marc Cohen, Walter Desmet, Carlos Macaya, 
Harvey White, Richard Gallo, for the STEEPLE Investigators, Centre Hospitalier 
Universitaire Pitié-Salpêtrière, Paris, France, University of Kentucky, Lexington
Background: It has been shown that a relationship exists between subcutaneous 
enoxaparin dose, anti-Xa levels, and outcomes in ACS patients. However, minimal data 
are available for anti-Xa when intravenous (IV) enoxaparin is used in PCI. We assessed 
the correlation between anti-Xa levels and outcomes in patients scheduled to undergo 
elective PCI in the recently completed STEEPLE trial.
Methods: STEEPLE, a prospective, open-label, randomized trial in 3,528 patients 
undergoing elective PCI, showed that there was no difference in ischemic events and 
a 57% reduction ( P<0.01) in major bleeding with enoxaparin vs UFH. Patients were 
randomized to IV enoxaparin (0.5 or 0.75 mg/kg) or an activated clotting time-adjusted 
UFH regimen, stratiﬁed by the operator’s choice of GP IIb/IIIa inhibitor use. For this 
analysis, both enoxaparin doses were combined. Anti-Xa levels were measured in all 
patients prior to and at the end of PCI. For each patient, we used the highest anti-Xa for 
its relation to bleeding and the lowest anti-Xa for its relation to ischemic events.
Results: High anti-Xa levels were associated with signiﬁcantly more frequent bleeding 
(p<0.05). A multivariate logistic regression model showed that anti-Xa was independently 
associated with bleeding rate (OR 1.6 [1.1 - 2.3] for each unit of anti-Xa, p=0.01). There was 
no signiﬁcant correlation between the composite ischemic endpoint and anti-Xa levels.
Anti-Xa levels < 0.5 IU/mL
0.5-1.2 
IU/mL
1.2-1.8 
IU/mL
> 1.8 
IU/mL
P-value for 
trend
Non-CABG bleeding, n/N (%) 3/49 (6.1)
95/1584 
(6.0)
32/420 
(7.6)
7/55 
(12.7) <0.05
Non-CABG major bleeding, n/N (%) 1/49 (2.0)
18/1584 
(1.1)
8/420 
(1.9)
1/55 
(1.8) 0.34
Non-CABG minor bleeding, n/N (%) 2/49 (4.1)
78/1584 
(4.9)
24/420 
(5.7)
6/55 
(10.9) 0.10
Composite ischemic endpoint of 30-day death, 
nonfatal myocardial infarction and urgent target vessel 
revascularization, n/N (hazard rate)
22/249 
(8.8)
105/1757 
(6.0)
8/104 
(7.7)
1/7 
(14.3) 0.26
Conclusions: Higher anti-Xa levels were associated with increased bleeding in elective 
PCI patients.
2920-121 Anemia Increases Cardiovascular Mortality in Patients 
Undergoing Percutaneous Coronary Intervention
Amar D. Patel, Michele D. Voeltz, Reza Fazel, Frederick Feit, A. Michael Lincoff, Steven 
V. Manoukian, Emory University, Atlanta, GA
Background: Recent data demonstrate that anemic patients undergoing percutaneous 
coronary intervention (PCI) have a signiﬁcantly increased mortality rate when compared 
to nonanemic patients. It is unclear whether the increased mortality in anemic patients 
is due to cardiovascular or non-cardiovascular causes. We hypothesized that anemic 
patients undergoing PCI would have an increased cardiovascular mortality when 
compared to nonanemic patients. We further hypothesized that anemic patients would 
have similarly increased odds for cardiovascular (CV) and non-cardiovascular (non-CV) 
death as compared to nonanemic patients.
Methods: We reviewed the Randomized Evaluation in PCI Linking Angiomax to Reduced 
Clinical Events (REPLACE)-2 Trial, the methodology and results of which have been 
previously published. Anemia was deﬁned using the World Health Organization deﬁnition 
(hemoglobin<12.0g/dl in women and <13.0g/dl in men). Causes of death were divided 
into a cardiovascular or non-cardiovascular etiology. We calculated odds ratio (OR) for CV 
and non-CV death in anemic patients compared to non-anemic patients. The Breslow-Day 
(BD) test for homogeneity was used to assess for differences between these two ORs.
Results: Of the 6,010 patients enrolled, 1,362 (23%) were classiﬁed as anemic. At 1-year 
follow-up, 58 (4.3%) deaths in the anemic group and 65 (1.4%) deaths in the nonanemic 
group were recorded (OR=3.09, 95%CI 2.16-4.41; p<0.0001). Anemic patients had 
increased rates of CV mortality at 30 days (OR=5.99, 95%CI 1.75-20.52; p=0.004), 6 
months (OR=3.64, 95%CI 1.9-6.95; p<0.0001), and 1 year (OR=3.18, 95%CI 1.97-5.12; 
p<0.0001) when compared to nonanemic patients. There was a proportionate increase in 
the odds of CV and non-CV mortality (OR=2.98, 95%CI 1.74-5.10; p<0.0001) in anemic 
patients compared to nonanemic patients (p-value for BD test= 0.8).
Conclusions: Anemic patients undergoing PCI have a dramatically increased risk of 
short- and long-term mortality. Therefore, the overall increase in mortality in anemic 
patients is not solely due to an increase in non-cardiovascular mortality.
2920-122 Smoking Inﬂuences the Effectiveness of Dual 
Antiplatelet Therapy on Long-Term Outcomes 
Following Percutaneous Coronary Intervention
Kiran Y. Saraff, Steven R. Steinhubl, Amy P. Hsu, Eric J. Topol, for the CREDO investigators, 
Gill Heart Institute, Lexington, KY, Cleveland Clinic Foundation, Cleveland, OH
Background: Smoking increases platelet reactivity and persistent smokers have poor 
longterm outcomes after percutaneous coronary interventions compared to nonsmokers. 
Despite this, aspirin and platelet glycoprotein IIb/IIIa inhibitors have not conclusively 
demonstrated an incremental beneﬁt in smokers. Interaction of smoking status and dual 
antiplatelet therapy with aspirin and clopidogrel has not been studied.
Methods:The population (N=2116) from the clopidogrel for the Reduction of Events 
During Observation (CREDO) trial were analyzed. Patients likely to undergo PCI were 
randomly assigned to therapy with aspirin or with aspirin and clopidogrel. Outcomes 
measured were death, myocardial infarction (MI) or stroke at one year and death, MI and 
urgent target vessel revascularization at 28 days. Using Cox proportional Hazard model 
(one year end point) and multiple logistic regression analysis (28 day end point), inﬂuence 
of smoking status on outcomes and the inﬂuence of randomized therapy was analyzed.
Results: 
Out comes according to smoking status and antiplatelet therapy
Smoking 
status (N) Smoker (647) Nonsmoker (1433)
Treatment (n) Aspirin only (n=312)
Aspirin + 
clopidogrel (n=335)
Aspirin only 
(n=737)
Aspirin + 
clopidogrel 
(n=696)
28 day 
outcome
n/N
(%)
33/312 
(10.58)
18/335
(5.37)
50/737
(6.78)
47/696
(6.75)
One year 
outcome
43/312
(13.78)
21/335
(6.27)
79/737 
(10.72)
68/696
(9.77)
Smoking status signiﬁcantly inﬂuenced the beneﬁt of long term clopidogrel therapy 
(HR=0.44; 95% CI=0.23 to 0.83; P=0.01). A trend of interaction between smoking status 
and dual antiplatelet therapy was observed at 28 days (OR= 0.46; 95% CI= 0.21to1.04; 
P=0.06)
Conclusion:The beneﬁt of longterm dual antiplatelet therapy with aspirin and clopidogrel 
is especially pronounced in smokers
ORAL CONTRIBUTIONS
2804 
Acute Mydocardial Infarction: Achieving 
the Best Door to Ballon Times
Monday, March 13, 2006, 4:00 p.m.-5:00 p.m.
Georgia World Congress Center, Room C207
4:00 p.m.
2804-3 A Community-Based Transfer Protocol for Primary 
Angioplasty in Patients With Acute Myocardial 
Infarction
Giuseppe Musumeci, Giulio Guagliumi, Roberta Rossini, Laurian Mihalcsik, Maurizio 
Tespili, Angelina Vassileva, Paolo Giani, Antonio Pitì, Orazio Valsecchi, Antonello 
Gavazzi, Ospedali Riuniti di Bergamo, Bergamo, Italy
Background: Primary PCI is superior to ﬁbrinolytic therapy in the treatment of acute ST-
segment elevation myocardial infarction (STEMI), but it is available in only a minority of 
hospitals. However, there is little evidence that systematically transferring patients (pts) 
for primary PCI in routine practice is safe and feasible.
Aim of the present study was to demonstrate the safety and feasibility of interhospital 
transfer of pts with STEMI for primary PCI to a tertiary centre.
Methods: We enrolled 754 pts from 12 referral hospitals without PCI facilities. All pts 
were referred to Our Institution for primary PCI. We had interventional capabilities 
with skilled operators and on-site surgical backup. Transfer had to be completed within 
one hour. All ambulances had resuscitation equipment. Major adverse cardiac and 
cerebrovascular events (MACCE: death, acute myocardial infarction, heart failure, stroke 
and reintervention) were recorded at 30-day and at one-year follow-up.
Results: Transfer for primary PCI was well tolerated, with no deaths or serious adverse 
events. The median transfer distance was 22 km (range 5 to 43 km), with a median 
transfer time of 24 min. The in-door-out-door time (median) in the community hospitals 
was 41 mins and door-to-balloon time at our center was 23 minutes. The median door-to-
balloon time from the community hospital was 88 minutes. Mean symptom to balloon time 
was 174±63 min. The 47.6% of pts had an anterior myocardial infarction and 5.1% were 
in Killip class IV. Final TIMI 3 was obtained in 98.4% of pts. At 30-day MACCE rate was 
8.3% (death 3.8%, acute myocardial infarction 2.5%, stroke 0.4% and heart failure 1.6%), 
whereas at one year it raised up to 22.2% (death 6.1%, acute myocardial infarction 3.3%, 
stroke 0.9%, heart failure 2.8% and reintervention 9.1%).
Conclusions: In our pts, the beneﬁt of treatment with primary PCI was the same as for 
pts admitted directly to an interventional-treatment center, described in previous studies. 
Therefore, rapid transfer of STEMI pts from community hospitals for primary PCI seems 
to be feasible, safe and effective. A strategy with a proven plan for rapid access (within 60 
min) for the interhospital transfer is necessary.
4:15 p.m.
2804-4 Delayed Facilitated Percutaneous Coronary Intervention 
Versus Immediate in Reperfused Stemi
Pietro Di Pasquale, Sergio Cannizzaro, Francesco Giambanco, Sergio Fasullo, 
Giuseppe Vitale, Nicola La Manna, Filippo Ganci, Giuseppina D’Aiello, Salvatore 
Paterna, G.F. Ingrassia Hospital, Palermo, Italy, University of Palermo, Palermo, Italy
Background: There are several new strategies proposed to improve the outcome of 
patients with ST-elevation myocardial infarction (STEMI).The aim of this study was to
investigate the outcomes in patients initially successfully treated pharmacologically and 
immediate PCI < 2 hr,and in patients initially successfully treated with pharmacological 
therapy and with delayed PCI (12-72 h).
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Methods:451 reperfused STEMI patients, aged 18 to 75 years, class I-II Killip, with an 
acceptable echocardiographic window and admitted within 12 hs of the onset of symptoms 
were randomized into two groups. All patients had to have successful reperfusion, to 
receive the combination of GP IIb/IIIa inhibitors plus half dose rtPA. Thereafter,patients 
were sub-grouped as follows:group 1 (immediate PCI) patients had PCI within 2 h; and 
group 2 (delayed PCI) patients in which PCI was performed after 12 hs and within 72 hs.
Results: The 225 reperfused (immediate-PCI) and 226 reperfused (delayed-PCI) patients 
(time from randomization to PCI 165+37 min in immediate PCI versus 45.1+ 20.2 h in delayed 
PCI group) showed similar results in ejection fraction, CK release and patency of the IRA. In 
addition, the delayed PCI group showed a signiﬁcant reduction in ischemic events, restenosis 
and bleedings (P= 0.005, 0.01, 0.01 respectively) and signiﬁcant reduced angiographic 
evidence of thrombus formation in the infarction-related artery (IRA) (p=0.001).
Conclusion: Our data suggest the safety and possible use of delayed facilitated PCI in 
patients with STEMI, and that delayed PCI in patients treated with combined lytic and IIb/
IIIa inhibitors appears to be as effective and possibly superior (reduced ischemic events 
and repeat PCI) as immediate PCI.
4:30 p.m.
2804-5 Ambulance Diagnosis of ST-Elevation Myocardial 
Infarction Reduces Treatment Delays in Patients 
Referred for Primary Angioplasty
Hamza El Aidi, Hendrik-Jan Dieker, Marc A. Brouwer, Wim RM Aengevaeren, Freek WA 
Verheugt, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Introduction: Increasing time-to-treatment in primary angioplasty is related to worse 
clinical outcome. Prehospital ECG diagnosis and direct notiﬁcation of the cath lab may 
shorten treatment delays associated with transport for primary PCI.
Methods: A consecutive cohort of patients with ST-elevation MI referred to our intervention 
center for primary PCI was studied from August 2004 - August 2005. A comparison of 
treatment delays was made between patients diagnosed by nurses in the ambulance 
by means of prehospital ECG and those diagnosed in a non-intervention center by a 
physician. Our intervention center was notiﬁed by telephone directly after diagnosis from 
either site.
Results: In total 125 patients were referred for primary PCI: 61 from the ambulance and 
64 from non-intervention centers. The median call-to-balloon time was 8 min. shorter in 
patients from the ambulance as compared to patients from a non-intervention center (62 
vs. 70 min, p=0.02, see Figure). In contrast, the door-to-balloon time was signiﬁcantly 
longer in patients from the ambulance (17 min., p<0.01).
Conclusion: Despite excellent treatment times in patients transported for primary PCI, 
a strategy of prehospital ECG diagnosis by ambulance nurses and direct notiﬁcation of 
the cath lab is associated with a signiﬁcantly shorter call-to-balloon time. This strategy of 
circumvening non-intervention centers may improve the outcome of primary PCI
. 
4:45 p.m.
2804-6 Improvement in Door to Balloon Times in a Dedicated 
Primary Percutaneous Coronary Intervention Program
Christine Swanson, Rajesh A. Shah, Basil Dudar, Srinivas Prasad, Sanjaya Khanal, 
Adam Greenbaum, Abed Asfour, Mayra Guerrero, Henry Kim, W. Douglas Weaver, 
Aaron D. Kugelmass, Henry Ford Hospital, Detroit, MI
Background: Primary percutaneous intervention (PPCI) has gained popularity as the 
reperfusion strategy for ST elevation MI. Door to balloon (DTB) times of < 120 minutes 
are associated with decreased morbidity and mortality. However, consistently achieving 
this reperfusion time goal remains problematic. In an attempt to provide timely PPCI, we 
redesigned an “around the clock” PPCI program in a large urban academic medical center.
Methods: The Henry Ford Hospital Myocardial Infarction Program was designed as a 
multidisciplinary team composed of the cath lab, emergency room, cardiac care unit staff, 
and hospital administration in 2003. Systematic process improvement targets included: 1) 
early emergency room identiﬁcation 2) communication and activation 3) emergency room 
care 4) in-hospital transport and 5) cath lab procedures, and were implemented in late 
2003. Process components were reviewed frequently and results shared with program 
participants on a regular basis.
Results: Median DTB times steadily improved over the study period. 
Quarter Q4 2003
Q1 
2004
Q2 
2004
Q3 
2004
Q4 
2004
Q1 
2005
Q2 
2005
Patient (n) 16 20 19 19 19 25 18
Median door to balloon time 
(mins) 132 130 123 97 92 96 75
Conclusions: Consistent early reperfusion with PPCI can be achieved with a dedicated 
PPCI program. A multidisciplinary approach is crucial to the intial and continued 
success of such a system. Ongoing outcome review and participant feedback are critical 
components to a successful PPCI program.
POSTER SESSION
2921 
Saphenous Vein Graft Intervention:  
Distal Protection
Tuesday, March 14, 2006, 8:30 a.m.-Noon
Georgia World Congress Center, Hall B1
Presentation Hour: 10:00 a.m.-11:00 a.m.
2921-61 Predictors of 30-Day Death or Large Myocardial 
Infarction Following Percutaneous Intervention of 
Saphenous Vein Bypass Grafts: Development and 
Validation of a Simple Risk Score
Tara A. Lavelle, Alanna Coolong, Richard E. Kuntz, Donald S. Baim, Sabina A. Murphy, 
David J. Cohen, Beth Israel Deaconess Medical Center, Boston, MA, Brigham and 
Women’s Hospital, Boston, MA
Background: Embolic protection devices (EPDs) have been shown to reduce the risk 
of complications after PCI of diseased SVGs but are not uniformly applied. Reliable 
prediction of these events would allow for more informed utilization decisions.
Methods: Control patients from 3 clinical trials (SAFER, X-TRACT, and FIRE) undergoing 
SVG PCI without embolic protection were pooled for our analysis (n=738). Two-thirds 
were randomly assigned to a derivation group, and the remainder formed the validation 
group. Logistic regression was used to identify angiographic and clinical characteristics 
associated with 30-day death and large MI (CK-MB > 5X), and the resulting coefﬁcients 
were combined to develop an integer risk score (range 0-8).
Results: Four variables were independently associated with 30-day death or large MI: 
age>75, plaque volume, SVG degeneration, and presence of thrombus. In the derivation 
group, event rates increased progressively as the risk score increased (p<0.001 for trend) 
and this pattern was conﬁrmed in the validation group. Stratiﬁcation of the SAFER trial 
population on the basis of this score (3 levels) and EPD treatment demonstrated consistent 
risk reduction across the 3 strata (p=NS for interaction between risk group and treatment).
Conclusion: For patients undergoing SVG PCI without an EPD, 4 simple risk factors can 
reliably predict the risk of 30-day death or large MI. In the future, this risk classiﬁcation 
system may provide a basis for improved decision making. 
Table. Relationship between SVG Risk Score and Observed/Predicted Rates of 
Ischemic Complications after SVG PCI
Event Rates in Pooled Dataset
Risk Group Risk Score Number of pts Death or Large MI Death or Any MI
Observed Predicted Observed Predicted
Low 0-2 339 5.3% 5.2% 8.9% 8.9%
Medium 3-4 251 10.8% 12.1% 16.7% 16.9%
High >4 131 26.7% 24.5% 31.3% 30.8%
Trend test p <0.001 p <0.001
Pearson 
Correlation r = 0.994 r = 0.999
 
2921-62 Clinical and Angiographic Correlates of Long-Term 
Mortality Following Percutaneous Intervention of 
Saphenous Vein Graft
Rajendra H. Mehta, Emily Honeycutt, Robert M. Califf, Linda K. Shaw, Donald D. Glower, 
Robert A. Harrington, Michael H. Sketch, Jr., Duke Clinical Research Institute and Duke 
University Medical Center, Durham, NC
Background: Patients undergoing percutaneous coronary intervention (PCI) of 
Saphenous Vein Grafts (SVG) have been shown to be associated with poor short- and 
long-term survival. However, the clinical and angiographic factors associated with long-
term mortality after SVG interventions are currently less well known.
Methods: Accordingly, we analyzed 1019 patients undergoing PCI of SVG enrolled in 
the Duke Cardiovascular Disease Database (1986 to 2003). Cox Proportional Hazards 
Model was used to identify baseline and angiographic variables associated with long-
term mortality.
Results: At a median follow-up of 4 years, 24% undergoing SVG interventions died (IQR 
2-7 years). Independent correlate of death at follow-up on multivariable analysis are 
shown in Table in descending order of their Chi-square value. The c-index of the model 
was 0.83 suggesting good model discrimination. Bootstrap validation conﬁrmed internal 
validity of the model. A nomogram was developed using variables signiﬁcant in the model 
as a simple bedside tool to help clinicians accurately estimate risk after PCI of SVG.
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Conclusions: Long-term survival after SVG intervention is poor with one-fourth of 
patients dying at median follow-up of 4 years. The simple risk tool provides a method for 
clinicians to advice patients undergoing SVG PCI regarding their long-term prognosis, 
thereby enhancing discharge and long-term follow-up planning and setting up of realistic 
expectations and as risk-adjustment tool in outcomes research.
Independent Correlates of Long-term Mortality
Variable Hazard Ratio
95% 
Conﬁdence 
Interval
Chi-
square P value Variable
Hazard 
Ratio
95% Conﬁdence 
Interval
Chi-
square
P 
value
Diabetes Mellitus 1.82 1.45-2.29 26.19 <0.0001 Patent Internal Mammary Artery 0.68 0.53-0.88 9.06 0.0026
Peripheral Vascular 
Disease 1.83 1.44-2.32 24.54 <0.0001
Body Mass Index 
<25 Kg/m2 0.91 0.85-0.97 7.62 0.0058
Heart Rate at 
Presentation 1.02 1.01-1.03 24.48 <0.0001
Body Mass Index 
>25 Kg/m2 1.01 0.99-1.03 0.78 0.3783
Age (per 10 years) 1.31 1.15-1.49 16.89 <0.0001 History of Hypertension 1.46 1.11-1.93 7.07 0.0078
Congestive Heart Failure 
at Presentation 1.57 1.24-2.00 13.69 0.0002 S3 gallop 1.77 1.07-2.91 4.99 0.0255
Renal Insufﬁciency 1.99 1.35-2.93 11.94 0.0005 Other SVG Stenosis >75% 1.49 1.01-2.19 3.95 0.0468
 
2921-63 In-Hospital and Long-Term Outcome Following 
Percutaneous Coronary Interventions in Patients With 
and Without Prior Coronary Bypass Surgery
Mandeep Singh, Charanjit Rihal, Verghese Mathew, Ryan Lennon, Patricia Best, David 
Holmes, Jr., Mayo Clinic, Rochester, MN
Background. Data regarding the impact of recent technologic and pharmacologic 
advances on the outcome of patients with prior CABG are lacking.
Methods and Results. We compared in-hospital and long-term outcome of 1046 PCI in 
patients with prior CABG (n=666 in the native artery, n=380 in the vein grafts) from 2000- 
04 at Mayo Clinic, and compared the results with PCI in patients without prior CABG 
(N=3978) Table. The in-hospital MACE were signiﬁcantly lower in patients with prior 
CABG with native coronary intervention. After adjusting for risk factors and medication 
use, compared to patients without, patients with CABG and native vessel intervention 
have lower risk of PCI complications, mainly due to reduction in the post-procedure CK-
MB elevation (OR 0.70, 95% CI 0.52, 0.94; p=0.018). Patients with prior CABG and vein 
graft PCI have similar in-hospital complications as patients without (OR 0.96, 95% CI 
0.70, 1.34; p=0.82). During follow-up (22 months), the death/MI/TVR were 25%, 41%, and 
31% for patients without prior CABG, with intervention in vein graft, and with prior CABG 
but native vessel intervention, respectively.
Conclusions. Patients with prior CABG have similar in-hospital complications as 
compared with patients without. Native coronary interventions in patients with prior 
CABG is associated with lower PCI complications. On follow-up, patients with vein graft 
intervention had signiﬁcantly more events than patients without a history of CABG.
Variable No prior CABG(%) Prior CABGNative PCI(%)
Prior CABG
Vein-graft PCI(%) P
Age, yr. 66.2±12.4 68.9±10.2 71.5±9.5 <0.001
Diabetes 23 35 32 <0.001
Multivessel disease 69 70 77 0.017
Procedural success 95 93 94 0.17
Death 1.9 0.8 1.8 0.12
Emergency CABG 0.6 0.2 0.0 0.10
CK-MB elevation 28 13 24 <0.001
Any PCI complication 27 12 23 <0.001
2921-64 Acute and Long Term Local Vascular Effects of 
Compliant Balloon Inﬂation (percusurge System) on 
Saphenous Vein Bypass Grafts: An Angiographic 
Analysis
Tom Vydt, Jan De Brauwere, Paul Vermeersch, Pierfrancesco Agostoni, Paul Van 
den Heuvel, Frank Van den Branden, Stefan Verheye, Glenn Van Langenhove, AZ 
Middelheim, Antwerp, Belgium
Background: The GuardWire distal protection device reduces the incidence of 
periprocedural myocardial infarction and slow-ﬂow phenomenon, during percutaneous 
coronary intervention (PCI) of saphenous vein grafts. A compliant balloon is positioned 
distal to the lesion before PCI and inﬂated at low pressure during the procedure, suction 
of the stagnant blood/debris is performed just after PCI, and then the balloon is deﬂated. 
Although no safety issues have been reported up to date, no prospective evaluation of the 
potential injury to the vessel wall has been performed. We therefore evaluated angiographic 
outcomes of the segments where compliant balloon inﬂation was performed.
Methods: Consecutive patients undergoing saphenous vein graft PCI were enrolled. 
After delivery of the GuardWire system, the type of intervention was left to the operator’s 
discretion. Quantitative coronary angiography (QCA) analysis of the segment of the 
saphenous vein graft where the GuardWire balloon was inﬂated, was performed before 
procedure, after ﬁnal removal of the balloon and at 6-month follow up.
Results: 40 patients were included and all underwent follow-up angiography. The GuardWire 
was deployed effectively in all of them. The QCA results are shown in the Table.
Conclusions: This prospective study shows for the ﬁrst time the “angiographic safety” of 
low pressure inﬂations of a compliant balloon in saphenous vein grafts, demonstrating the 
absence of long-term effects on the vein graft wall.
QCA data of the 40 vein graft segments evaluated. Data are presented as 
mean +/- standard deviation.
Pre-procedure Post-procedure Follow-up P-value
Minimal luminal diameter (mm) 2.56 +/- 0.55 2.56 +/- 0.56 2.56 +/- 0.61 0.99
Reference vessel diameter 
(mm) 2.83 +/- 0.57 2.91 +/- 0.62 2.93 +/- 0.68 0.13
Diameter stenosis (%) 10 +/- 6 12 +/- 9 12 +/- 9 0.14
Late loss (mm) - - 0.003 +/- 0.19 -
2921-65 The Export Aspiration System in Patients With 
Acute Coronary Syndrome and Visible Thrombus 
Demonstrates No Remarkable Beneﬁt
Hubertus von Korn, Jiangtao Yu, Marc Ohlow, Andreas Wagner, Burckhard Huegl, 
Bernward Lauer, Clinic for Cardiology, Bad Berka, Germany
Background: A visible thrombus is a risk factor during percutaneous coronary 
intervention (PCI)
Methods: We treated 79 patients (pts) with the Export Aspiration System with acute coronary 
syndrome + visible thrombus (group 1). Retrospectively we analysed 79 pts with acute 
coronary syndrome + visible thrombus without performed thrombectomy (group 2, n= 79).
Results: See for baseline parameters table 1. TIMI ﬂow and MBG improvement directly 
after thrombosuction was observed in 54.4 % and 29.1 %, technical success was seen 
in 93.7 %. Final TIMI ﬂow 3 or MBG 3 after completing PCI in group 1 and 2 was seen in 
68.4 % vs. 72.2 % (p= 0.6) and in 57.0 % vs. 55.7 % (p= 0.9). Final TIMI ﬂow 0 or MBG 
0 in group 1 and 2 was observed in 10.1 % vs. 5.1 % (p= 0.23) and in 30.4 % vs. 20.3 % 
(p= 0.15). Angiographic complications (distal embolization, no reﬂow) were rare (13.9 % 
vs. 12.7 %, p= n.s.).
Histologic evaluation  Histologic evaluation in 61 pts revealed mostly mixed thrombotic 
material (83.6 %), the age of this material is less than 24 hours , we found no plaque 
material. Microscopic material was seen in 91.8 %.
MACE (during hospital stay)  Total MACE rate (cardiac death, myocardial infarction, 
cardiac shock, urgent CABG or new intervention) was exactly 11.4 % in both groups .
Conclusions: Using the Export Aspiration System in patients presenting with acute 
coronary syndrome and angiographic visible thrombus produced no remarkable beneﬁt.
Baseline parameters
Group 1 + thrombectomy 
(n= 79)
Group 2 (n= 
79) p
Age years (mean) 64.6 66.8 0.22
Men (%) 76.0 67.1 0.22
Initial TIMI ﬂow 0 before 
angiopalsty (%) 65.8 77.2 0.11
Target LCA (%) 46.8 60.8 0.08
Target RCA (%) 40.5 36.7 0.5
Target venous bypass graft (%) 12.7 2.5 < 0.05
EF (%) 47.5 47.4 1.0
Stent thrombosis (%) 27.9 2.5 < 0.05
GP IIb/IIIa antagonists 81.0 53.2 < 0.05
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2922-66 Final Results of Two Arm European Pivotal Trial With 
CoStar Stent (EuroSTAR): 6 and 12 Month Outcome
Keith D. Dawkins, Antonio Columbo, Stefan Verheye, Joseph Dens, Martyn Thomas, 
Helmut Schuhlen, Patrick Serruys, Wessex Cardiac Unit, Southampton, United 
Kingdom, HSR Ospedale San Raffaele, Milan, Italy
Background: The EuroSTAR study was designed to evaluate the safety, performance 
and efﬁcacy of the CoStar Stent with 10 µg and 30 µg dose formulations in native 
coronary artery lesions.
Methods: 18 clinical sites in Europe and New Zealand sequentially enrolled 282 patients 
(intention to treat) in 2 arms of the EuroSTAR study. The CoStar™ stent used in the 
study is a cobalt chromium (L605) balloon expandable coronary stent loaded with a drug/
polymer matrix of paclitaxel and a bioresorbable polymer (PLGA). Using a novel and 
unique reservoir based drug delivery system, 10 µg or 30 µg of murally released paclitaxel 
was eluted over 30 days
Results: A total of 278 patients (10 µg n=144 and 30 µg n=134) with 321 lesions were 
treated per protocol. Comparative 6 month clinical data are presented for both arms. 
Baseline demographics for the 10 µg and 30 µg arms were similar. However, there were 
less diabetic patients in the 30µg arm (11.7% to 15.9%). In the 10 µg arm direct stenting 
was 51.7%, device success 99.0%, and procedural success 97.2%. In the 30 µg arm 
direct stenting was 50.3%, device success 98.0%, and procedural success 94.2%.
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Cumulative 6 month hierarchical MACE in the 10 µg arm was 4.8% (Q-wave MI 0.0%, 
non Q-wave MI 1.4%, TLR 1.7%, cardiac death 1.4%) and in the 30 µg arm was 9.2% (Q-
wave MI 1.5%, non Q-wave MI 3.8%, TLR 3.6%, cardiac death 0.0%). Independent core 
laboratory 6 month quantitative coronary angiography (QCA) demonstrated, for the 10 µg 
arm: Reference Vessel Diameter 2.76 ± 0.47mm; Lesion Length 11.13 ± 5.23mm; In-Stent 
Late Loss 0.26 ± 0.39mm; In-segment Late loss 0.07± 0.38 mm; In-Stent Restenosis 3.4%. 
Six month QCA data and 12 month clinical follow-up for both arms will be presented.
Conclusions: These ﬁndings support the safety, performance, and efﬁcacy of the CoStar 
stent in both dose formulations as demonstrated by low observed rates of clinical events. 
CoStar 10 µg dose formulation demonstrates favorable angiographic results with low six-
month indices of late loss and binary restenosis while delivering low dose of paclitaxel to 
the tissue with fully erodable polymeric carrier system. The 10 µg dose is evaluated in the 
global pivotal, randomized COSTAR II trial, actively enrolling patients.
2922-67 Sirolimus-Eluting Stent Versus Coronary Artery Bypass 
Grafting and Bare Metal Stent for the Treatment 
of Multivessel Coronary Artery Disease Including 
Involvement of Proximal Left Anterior Descending 
Artery: Insight From Arts II and Arts I Studies
Jean Fajadet, Marco Valgimigli, J. Wouter Jukema, Ran Kornowski, Gabriel Steg, 
Amadeo Betriu, Marc De Belder, Ottmar Pachinger, Hans-Peter Stoll, Patrick W. 
Serruys, Clinic Pasteur, Toulouse, France, Erasmus University Medical Center, 
Thoraxcenter, Rotterdam, The Netherlands
Background: The efﬁcacy and safety of sirolimus-eluting stents (SES) for the treatment of 
extensive multivessel coronary artery disease (MVD), including intervention for proximal 
left anterior descending artery (pLAD, segment 6 according to ACC/AHA classiﬁcation) 
disease, is largely unknown.
Methods: The ARTS I trial was a randomized trial comparing CABG and coronary 
stenting for the treatment of patients with MVD. Three hundred ninety-six patients with 
MVD and involvement of pLAD were randomly assigned to undergo CABG (206 patients; 
CABG arm) or angioplasty with bare metal stent implantation (187 patients; BMS arm). 
ARTS II, which was designed to be an ARTS I companion trial, is a 45 centers, single arm, 
non-inferiority trial on 607 consecutive MVD patients who were exclusively treated with 
sirolimus-eluting stents, of whom 289 received treatment for pLAD (SES arm). Long-term 
outcome in patients with pLAD involvement was compared among the three groups for 
major adverse cardiac and cerebrovascular events (MACCE) at 1-year.
Results: The prevalence of patients with 3-vessel disease, including pLAD was 54% in 
the SES arm, 29.4% in the BMS arm, and 36.9% in the CABG arm. The prevalence of 
patients with diabetes was 24.9%, 11.2% and 14.6% in the SES, BMS and CABG arm, 
respectively. The cumulative incidence of death at 1-year was 1.0% in the SES arm, as 
compared to 3.7% in the BMS, and 3.4% in the CABG arm (p=0.054 vs. BMS and p=0.10 
vs. CABG). The myocardial infarction (MI) rate was 0.7% in the SES arm, as compared 
to 4.8% in the BMS (p=0.009), and 3.4% in the CABG group (p=0.038). The incidence 
of cerebrovascular accidents (CVA) was 0.7% in the SES group, 0.5% in the BMS and 
1% CABG group (p=n.s. for both comparisons). One-year cumulative incidence of the 
composite of death, MI, CVA and TVR (MACCE) rate was 10.4% in the SES arm, which 
was signiﬁcantly lower than in the BMS group (20.3%) (p=0.003), and statistically similar 
to the CABG group (10.2%) (p=1).
Conclusions: The use of SES for the treatment of MVD, including pLAD may signiﬁcantly 
reduce the cumulative event rate as compared to conventional BMS, while equalizing 
outcome with respect to patients allocated to CABG group enrolled in ARTS I study.
2922-68 Long-Term Clinical Outcome in Patients Treated With 
Sirolimus-Eluting Stent in Small Coronary Arteries. 
Results From the SES-SMART Trial
Alberto Menozzi, Emilia Solinas, Piera Angelica Merlini, Ezio Bramucci, Claudio 
Cavallini, Ciro Indolﬁ, Antonio Manari, Antonio Marzocchi, Luigi Vignali, Enrico Aurier, 
Diego Ardissino, for the SES-SMART Investigators, Ospedale Maggiore - Università 
degli Studi di Parma, Parma, Italy
Background: The SES-SMART trial demonstrated that the use of Sirolimus-Eluting 
Stents (SES) reduces the incidence of angiographic restenosis in highly challenging 
conditions such as small coronary arteries. The aim of this study was to determine 
whether the lower rate of angiographic restenosis observed in the SES-SMART study 
is associated with a reduced incidence of Major Cardiac and Cerebrovascular Events 
(MACCE) during long-term follow-up.
Methods: The SES-SMART trial is a multicenter, single-blind, prospective trial, 
randomising 257 patients undergoing PCI in a previously untreated lesion located in a 
small coronary artery (2.75 mm or less) to receive a SES or an uncoated stent (BMS) of 
identical structure. Mean reference vessel diameter and mean lesion length were 2.20 
mm and 11.84 mm respectively. Patients were prospectively followed-up for 24 months.
Results: Baseline patients characteristics and medical treatment during follow-up were 
comparable between the two groups. The 24-month follow-up was completed in 238 
patients (92.6%). The incidence of MACCE is shown in the table.
Conclusions: In patients with small coronary arteries, the use of SES leads to a signiﬁcant 
reduction of MACCE, expecially myocardial infarction and target lesion revascularization. 
The reduction of myocardial infarction in patients with small coronary arteries treated with 
SES deserves further investigation in a prospective and speciﬁcally-designed trial.
24-Month Follow-up Cumulative MACCE
Variable SES BMS Odds Ratio 95% C.I.
Death 1 (0.8%) 5 (3.9%) 0.19 0.0-1.72
Myocardial Infarction 2 (1.6%) 13 (10.1) 0.14 0.0-0.67
Target Lesion Revascularization 11 (8.5%) 33 (25.8%) 0.27 0.12-0.59
Cerebrovascular Accident 2 (1.6%) 4 (3.1%) 0.49 0.01-3.17
Any MACCE 16 (12.5%) 55 (42.9%) 0.20 0.10-0.39
Stent thrombosis 1 (0.8%) 4 (3.1%) 0.24 0.0-2.34
 
2922-69 The Sisr Trial: 12-Month Outcomes of Sirolimus Eluting 
Stents for the Treatment of in-stent Restenosis
David R. Holmes, Jr., Jeffrey Popma, Richard Kuntz, Peter J. Fitzgerald, Paul S. 
Teirstein, Lowell Satler, Michael Sketch, Sidney A. Cohen, Mayo Clinic, Rochester, MN, 
Cordis Corporation, Johnson & Johnson, Warren, NJ
Background: Intravascular brachytherapy is the only approved treatment for in-stent 
restenosis (ISR). Marked beneﬁt of the simolimus-eluting BX-VELOCITY stent (CYPHER®) 
in reducing target lesion revascularization by inhibition of neointimal hyperplasia has led 
to the hypothesis that treatment of ISR with CYPHER® will lead to either equivalent or 
superior clinical and angiographic outcomes compared to brachytherapy (Brachy).
Methods: 384 patients were randomized 2:1 (259 CYPHER®: 125 Brachy) at 26 sites 
in the US from February 2003 to July 2004. Patients enrolled had ISR lesions in native 
coronary arteries that were >15mm to < 40mm in length and > 2.5mm to < 3.5mm in 
diameter. Bayesian methods were utilized to include additional Brachy control data from 
the Gamma I & II studies. The primary endpoint of target vessel failure (TVF), deﬁned 
as cardiac death, MI or TVR at 9 months was evaluated for non-inferiority and then 
superiority of Cypher® vs. Brachy.
Results: Nine month data is presented below. There were no signiﬁcant differences 
in demographic or procedural characteristics. Signiﬁcant differences were seen in the 
angiographic and clinical outcomes, which are presented in the table below. 
Demographics /Procedural Characteristics Cypher® Brachytherapy
Age (years) 62.7 + 10.7 63.5 + 11.7
Gender (male %) 68.2% 65.6%
Diabetes Mellitus % 33.3% 29.6%
Insulin Dependent % 9.3% 8.8%
Angina Status (unstable) % 46.9% 50.9%
Lesion Length >20 mm % 27.0% 32.8%
Total Occlusion % 6.7% 1.6%
Bifurcation % 28.2% 34.7%
Lesion Length (Mean + SD, mm) 17.22+7.97 16.76+8.55
9 Month Clinical Outcomes
TVF (cardiac death, MI, or TVR) - primary endpoint 12.4% 21.6%
MACE 10.0% 19.2%
MI (Q wave or non-Q wave) 2.3% 0.0%
TLR 8.5% 19.2%
Stent Thrombosis 0.0% 0.0%
6 Month Angiographic Outcomes 
Minimal Lumen Diameter (mm) - Within Analysis 1.80 + 0.63 1.52 + 0.63
Percent Diameter Stenosis % - Within Analysis 32.35 + 20.62 40.97 + 21.08
Net Gain (mm) - Within Analysis 1.00+0.61 0.68+0.60
Binary Restenosis (%) - Within Analysis 19.8% 29.5%
Conclusions: The 6/9 month data suggests that the sirolimus eluting stent is non-inferior 
and superior to brachytherapy in this ISR population. The results of the twelve month 
clinical follow-up will be presented.
2922-70 Twelve-Month Intravascular Ultrasound Results 
From STEALTH-1: A Randomized First in Man Trial of 
Biolimus A9 Eluting Stents
Sanda Jegere, Tomomi Koizumi, Masao Yamasaki, Yoshihisa Shimada, Ali H.M. Hassan, 
Paul G. Yock, Karl-Eugen Hauptmann, Eberhard Grube, Yasuhiro Honda, Alexandre 
Abizaid, Peter J. Fitzgerald, The STEALTH Investigators, Stanford University, Stanford, CA
Background: The Biolimus A9 eluting coronary stents (A9-ES) use a bioabsorbable 
polylactic acid polymer for sustained local release of Biolimus A9, a highly lipophilic 
sirolimus derivative. The purpose of this study was to evaluate the long-term vessel 
response to A9-ES, compared to bare metal stents (BMS) in de novo coronary lesions.
Methods: The STEALTH-1 trial enrolled 120 patients in a prospective, multicenter, double-
blind, and 2:1 randomized fashion (A9-ES 80, BMS 40). Serial IVUS was performed at 
baseline and 6 months. To further evaluate longer-term effects, a subset of 28 patients 
underwent 12-month IVUS follow-up as well. Volume index (volume/length) was computed 
to standardize volumetric IVUS data by segment length.
Results: Overall, A9-ES showed signiﬁcantly less neointimal hyperplasia than BMS both 
at 6 and 12 months (neointimal volume index: 0.2±0.3 vs. 1.9±1.3 mm3/mm, p<0.001 
at 6 months; 0.5±0.4 vs. 2.5±1.0 mm3/mm, p<0.001 at 12 months, for A9-ES vs. BMS, 
respectively). Serial comparison showed minimal neointimal increase (p=0.033) in A9-ES 
between 6 and 12 months (Figure). Both groups had similar rates of late incomplete stent 
apposition at 6 months (3% vs. 3%) with no additional cases at 12 months.
Conclusion: In this ﬁrst-in-man experience, A9-ES with a bioabsorbable polymer 
demonstrated equivalent safety and superior efﬁcacy compared to BMS, as evidenced 
by signiﬁcant reduction of neointimal hyperplasia with no increased risk of adverse vessel 
response up to 12 months.
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2922-71 Three-Year Clinical Follow-Up of the Unrestricted Use 
of the Sirolimus-Eluting Stent Compared to the Use of 
a Standard Bare Metal Stent as Part of the Rapamycin-
Eluting-Stent Evaluated at Rotterdam Cardiology 
Hospital (RESEARCH) Registry
Joost Daemen, Andrew T.L. Ong, Sophia Vaina, Héctor M. García-García, Keiichi 
Tsuchida, Marco Valgimigli, Gastón A. Rodriguez-Granillo, Shuzou Tanimoto, Ron T. van 
Domburg, Patrick W. Serruys, Erasmus Medical Center, Thoraxcenter, Rotterdam, The 
Netherlands
Background: Recently Sirolimus-Eluting Stents (SES) have shown to effectively reduce 
restenosis in constricted coronary arteries. To date, there is no data on the rate of 
superiority above standard Bare Metal Stents (BMS) after multiple years of follow-up.
Methods: Since April 2002, 508 consecutive patients were treated exclusively with 
sirolimus-eluting stents. Prior to this, from October 2001 to April 2002, 450 consecutive 
patients were treated with standard bare metal stents and form the control group. Three-
year follow-up is still ongoing and already complete for 67.5% of our patients (mean 1033 
days). We will be able to present the complete follow-up at the meeting.
Results: Patients treated with SES had signiﬁcantly more multivessel disease and more 
type C lesions, furthermore more stents per patient were implanted. There were more 
previous myocardial infarctions in the BMS group. Diabetes was present in 15% of the BMS 
population versus 18% in the SES population. Preliminary cumulative survival percentages 
are 91.5% in BMS population versus 92.1% in the SES population (95% CI 0.58 to 1.47; 
p=0.74). Major Adverse Cardiac Event (MACE) rates will be presented at the meeting.
Conclusions: Our results show that even after 3 years of follow-up the use of Sirolimus-
Eluting stents in an unselected patient population remains safe. Preliminary results of 
MACE rates look auspicious.
2922-72 Pooled Analysis of the Endeavor Abt-578-eluting Stent 
System for the Treatment of Coronary-artery Stenosis 
in 1,317 Patients
David Kandzari, William Wijns, Martin B. Leon, Jean Fajadet, Ian Meredith, Duke 
University, Raleigh Durham, NC, Columbia University, New York, NY
Background: The Endeavor drug-eluting coronary stent (Medtronic, Inc. Santa Rosa, 
CA) is a cobalt-based alloy stent with a phosphorylcholine polymer and zotarolimus dose 
concentration of 10µg/mm stent length. We evaluated the collective safety and efﬁcacy 
among patients treated with the Endeavor stent from four randomized clinical trials.
Methods: Clinical and angiographic outcomes were analyzed in systematic overview of four 
trials: Endeavor I ﬁrst-in-human study; Endeavor II randomized controlled study (comparison 
with bare metal stent); Endeavor II continued access (CA) registry; Endeavor III randomized 
trial (comparison with sirolimus-eluting stents). Protocol-speciﬁed follow-up angiography 
was performed at 8 months for a subset of patients in the Endeavor II, II CA, and III trials, 
and clinical follow-up was performed at 9 months following the index procedure.
Results: A total of 1,317 patients with de novo coronary lesions were treated with the 
Endeavor stent. Diabetes mellitus was present in 22.5% of patients, the mean reference 
vessel diameter was 2.73 mm, and the mean lesion length was 22.67 mm. The acute 
device-deployment and procedural success rates were 98% and 96.4%, respectively. At 8 
months, mean in-stent late lumen loss was 0.60 mm and was consistent across patient and 
lesion subgroups (0.61 mm, <2.5 mm vessels; 0.62 mm, diabetics; 0.66 mm, >16 mm lesion 
length). The overall 9-month rate of stent thrombosis was 0.3%. No case of stent thrombosis 
occurred after 14 days postprocedure. At 9 months, the incidence of major adverse cardiac 
events was 7.6%; death, 0.9%; and target lesion revascularization, 4.9%.
Conclusion: Despite varied clinical and angiographic characteristics, treatment with the 
Endeavor stent is associated with consistently low rates of target lesion revascularization 
and overall major adverse events. In particular, the occurrence of both early stent 
thrombosis is very low with no late stent thrombosis. These ﬁndings further support 
evaluation of the Endeavor stent in higher clinical-risk patients and lesion complexities
2922-73 First Report of the Descover U.S. Multicenter 
Percutaneous Coronary Intervention Registry
David O. Williams, J. Dawn Abbott, Helen A. Vlachos, Kevin E. Kipp, DEScover Intestigators, 
Rhode Island Hospital, Providence, RI, University of PIttsburgh, Pittsburgh, PA
Background: How drug-eluting stents are being used in clinical practice in the United 
States (US) is unknown. We therefore analyzed the baseline, procedural and in-hospital 
outcomes of 7187 patients (pts) consecutively enrolled in the DEScover PCI registry. 
Methods: DEScover is an observational prospective study that was conducted at 140 
medical centers in the United States with enrollment from December 2004 to June 2005. 
An electronic case-report form was competed for each consenting pt. by trained data 
coordinators and analyzed by a central data coordinating center. 
Results: Stent implantation was performed in 6936/7187 (96.5%) of pts and few 
360/6936 (5.2%) received only a bare-metal stent (BMS). Of DES treated pts, 3598 
(54.7%) received sirolimus stent(s) (SS) alone, 2463 (37.5%) paclitaxel stent(s) (PS) 
alone while 515 (7.8%) received combinations of SS, PS and BMS. Among pts who did 
not receive a stent, there was a greater prevalence of prior PCI or CABG and a higher 
incidence of unsuccessful PCI. For pts treated with stents, BMS pts more often presented 
with AMI with the circumstances of PCI considered emergent. Compared to SS pts, PS 
pts were similar in terms of age, gender, cardiovascular history, procedural indications 
and circumstances, extent of CAD, lesions attempted and procedural success. Pts 
receiving combined SS/PS more often had multi-vessel disease, multiple lesion attempts. 
Initial cumulative, unadjusted 90-day follow-up of pts discharged from hospital indicates 
a mortality rate of 1.4%, MI 1.7%, stent thrombosis (ST) 0.5% and repeat PCI 3.3%. 
Rates of ST according to type of stent used were BMS: 0.7%, SS :0.3%, PS: 0.6%, SS/
BMS:0.9% and PS/BMS: 2.7%. 
Conclusions: DEScover indicated that in the US stents were used in nearly all PCI 
procedures and the majority were DES (95%). There were no differences in SS compared 
to PS use according to pt or lesion features and procedural success rates were similar. 
In short-term follow-up, overall adverse event rates were low and DES ST rates were not 
higher than BMS.
2922-74 A Contemporary Approach to Drug-eluting Stent 
Practice: Six-Month Outcomes for Arrive 2, a 
Prospective, Multicenter Us Safety Surveillance 
Registry Evaluating All-comers Use of the Taxus 
Express Paclitaxel-eluting Stent System
John M. Lasala, David A. Cox, Mary E. Russell, Washington University School of 
Medicine, St. Louis, MO, Mid-Carolina Cardiology Presbyterian Hospital, Charlotte, NC
Background: ARRIVE 2 is the second, larger, of two multicenter US surveillance 
programs designed to compile safety and clinical outcomes data for the TAXUS® 
Express2™ Paclitaxel-eluting Coronary Stent System as used in real world, routine clinical 
practice and to identify low frequency TAXUS-related clinical events.
Methods: Community-based physicians at up to 60 US sites will each enroll through a 
web-based registry up to 100 consecutive consenting patients treated with TAXUS stents 
(maximum of 5,000). Baseline characteristics, stent use and outcomes are collected. 
Clinical or telephone follow-up at 30 days and at 6 months, 1 and 2 years collect data on 
TAXUS-related death, myocardial infarction (MI), stent thrombosis, re-intervention, and 
hypersensitivity events.
Results: Interim 30-day analysis (22 July 2005) indicates that in the ARRIVE 2 registry 
4,066 patients with 5,639 lesions in 4,733 vessels received 6,380 stents. Mean age was 
65 years; 67% were male; 32% had diabetes mellitus. Lesion types included long (>20 
mm, 17.3%), bifurcation (7.1%), in-stent restenosis (6.1%) and graft (5.9%). Treatments 
included multivessel (15.3%), 2 lesions (22.7%), and ≥3 lesions (7.2%). Adjudicated 
outcomes are presented in the table below.
Conclusions: Early data from ARRIVE 2 show similar usage patterns to that of ARRIVE 
1 and illustrate the expanded use of the TAXUS stent in higher risk patients with complex 
lesions in contemporary clinical practice. Six-month follow-up data will be available in 
March 2006. 
ARRIVE 2 (%)
TAXUS stent related events at 30 days (Interim Data)
ST-angiographically documented 0.5
ST-presumed* 0.2
TAXUS-related cardiac event 1.6
Cardiac death 0.6
Q-wave MI 0.2
Non-Q-wave MI 0.7
TAXUS-related re-intervention 0.7
* Presumed ST includes sudden death and MI in region of vessel.
 
2922-75 Twelve Month Clinical Results from Endeavor III: 
A Randomized Comparison of the Endeavor Drug 
(Zotarolimus) Eluting Stent System versus Cypher in 
De Novo Native Coronary Lesions
David Kandzari, Ian Meredith, William Wijns, Martin B. Leon, Jean Fajadet, O.L.V. 
Hospital, Aalst, Belgium, Monash Medical Center, Clayton, Australia
Background_ A recently completed randomized trial (436 patients) comparing a cobalt 
alloy stent coated with a phosphorylcholine polymer eluting Zotarolimous (a tetrazole-
containing macrocyclic immunosuppressant @10mcg/mm), (Endeavor stent, Medtronic, 
MN) vs. bare metal stent controls indicated markedly reduced target vessel failure 
(the primary endpoint) and ischemia-driven target lesion revascularization. However, 
the relative safety and efﬁcacy of the Endeavor stent has not been conﬁrmed in a US 
patient population. The ENDEAVOR III trial was designed as a conﬁrmatory trial vs the 
commercially approved drug-eluting stent Cypher, in a US population.
Methods_ ENDEAVOR III trial is a prospective, multi-center trial evaluating the safety 
and efﬁcacy of the Endeavor stent in 436 patients undergoing elective percutaneous 
revascularization of de novo native coronary lesions with reference vessel diameters 
between 2.5 mm and 3.5 mm and lesion length ≥14 mm and ≤27 mm. Patients were 
randomized in a 3:1 fashion to the Endeavor or sirolimus-eluting Cypher stent to examine 
the primary endpoint of in-segment late lumen loss at 8-month angiographic follow-up. 
Secondary efﬁcacy endpoints included major adverse cardiac events at 30 days and 
9 months, in-stent late loss 8 months post-procedure, target lesion revascularization 
9 months post-procedure, 8-month neointimal hyperplastic volume by intravascular 
ultrasound, and 8-month angiographic binary restenosis. With clinical follow up at 1, 2, 
3, 4 and 5 years
Results_ Trial enrollment was completed in September 2004. Analysis of procedural 
outcomes, 30-day results, primary endpoint angiographic and IVUS follow-up, and clinical 
follow-up will be presented for the ﬁrst time at TCT. The twelve month clinical results for 
the ENDEAVOR III trial will be available for presentation at ACC 2006.
Conclusions_A randomized, multicenter trial has been performed to (1) provide further 
information regarding the sustained safety and efﬁcacy of a cobalt alloy stent with a 
phosphorylcholine polymer eluting ABT-578, and (2) conﬁrm the sustained efﬁcacy 
of the Endeavor stent vs the Cypher stent regarding angiographic, IVUS, and clinical 
endpoints.
ACC_2006_A_i2Summit B.indd   40 1/6/06   10:51:41 AM
JACC February 21, 2006 ABSTRACTS - Innovation in Intervention: i2 Summit 2006  41B
Innovation in Intervention: i2
 S
um
m
it 2
0
0
6
2922-76 Safety and Effectiveness of the Biomatrix™ Biolimus 
A9™-eluting Stent in Non-selected Patients (Early 
Results for the BEACON Registry)
Teguh Santoso, on behalf of the BEACON Study Group, Medistra Hospital, Jakarta, 
Indonesia
Background: Randomized trials have demonstrated that drug-eluting stents decrease 
the risk of restenosis, and their use is rapidly expanding from lower-risk, single-lesion 
procedures to include a variable population of high-risk patients and complex lesions. 
The Biolimus Eluting A-9 Coronary Stent Obviating Luminal Narrowing (BEACON) 
study is a prospective, multicenter, non-selected, all comers registry with patients 
stratiﬁed into deﬁned populations. BEACON is designed to evaluate clinical outcomes 
of the BioMatrix™ stent (Biosensors International, Singapore) in a larger and more 
diverse patient population. The safety and efﬁcacy of the device in this real-world clinical 
population are largely unknown.
Methods: To date (December 2004 through September 2005), BEACON has enrolled 310 
patients (518 treated lesions with 573 stents). Data were collected on patients meeting 
protocol criteria (Group I, low to moderate risk; median follow-up 3.5 months; n=165) 
and high-risk, real-world patients (Group II; median follow-up 5.0 months; n=144). Group 
stratiﬁcation was based on protocol-deﬁned lesion length, vessel diameter, left ventricular 
ejection fraction, calciﬁcation, ostial lesions, severe calciﬁcation, and signiﬁcant left main 
disease. One or more BioMatrix stents were used in 99.4% of all patients.
Results: Patients in Group II were older (62.5±11.3 years versus 59.8±11.8 years), had 
more diseased vessels (mean per patient 2.2 versus 1.6), more treated lesions (mean 
per patient 1.87 versus 1.45), more diabetes (50.7% versus 37.6%) and prior PCI (41.7% 
versus 26.7%), lower LVEF (61.6% versus 67.6%), and longer lesions (19.6 mm versus 
16.4 mm). Group II had 11.8% ostial lesions, 14.6% severe calciﬁcation, and 67.4% AHA 
class B2 or C lesions. Preliminary major adverse cardiac events (MACE) rates to median 
follow-up were 0.6% (1/165) for Group I and 6.3% (9/144) for Group II. Preliminary TLR 
rates to follow-up were 0% for Group I and 1.4% (2/144) for Group II.
Conclusions: Preliminary early results from the BEACON registry suggest that the 
BioMatrix Biolimus A9-eluting stent is safe and effective in diverse, non-selected patients 
undergoing percutaneous coronary intervention.
2922-77 Long-Term Clinical Beneﬁt of Cypher® Sirolimus-eluting 
Coronary Stent: Four-Year Follow-Up of the Sirius 
Study
Martin B. Leon, Columbia University, New York City, NY, Cordis Corporation, Warren, NJ
Background: The SIRIUS Study is a multi-center, double-blind, randomized study 
comparing the Sirolimus-eluting stent (CYPHER®) to a bare metal Bx VELOCITY™ 
control (BX) in the treatment of patients with de novo native coronary artery lesions. 
Analysis of the primary endpoint of target vessel failure (TVF) at 9 months demonstrated 
the safety and effectiveness of the CYPHER® stent. Long-term follow-up is planned 
annually out to 5 years.
Methods: 4 years clinical follow-up for surviving patients who were enrolled at 53 centers is 
currently underway. Target lesion revascularization (TLR), TVF and major adverse cardiac 
events (MACE) continue to be adjudicated by an independent clinical events committee.
Results: TLR, TVF and MACE rates reported at 1, 2 and 3 years are summarized below. 
1 Year 2 Year 3 Year
CYPHER®
(n=533)
BX
(n=525) p-value
CYPHER®
(n=533)
BX
(n=525) p-value
CYPHER®
(n=533)
BX
(n=525) p-value
TLR 4.9% 20.0% <0.0001 5.8% 21.3% <0.0001 6.8% 23.2% <0.0001
TVR 9.8% 24.8% <0.0001 12.0% 26.7% <0.0001 15.6% 30.1% <0.0001
MACE 8.3% 22.3% <0.0001 10.1% 24.4% <0.0001 12.6% 27.4% <0.0001
Conclusions: Data up to the 3-year follow up of the SIRIUS study demonstrates 
maintenance of the highly signiﬁcant differences in clinical outcomes between CYPHER® 
and BX, with a trend for an increase in this difference over time. Increments in target 
vessel revascularization and MACE are similar in both arms, reﬂecting non-target lesion 
atherosclerotic disease progression. Completed 4-year follow-up clinical data will be 
presented.
2922-78 Four-Year Clinical Results of the Taxus III Trial: A 
Feasibility Study of the Polymer-based, Paclitaxel-
coated Stent for the Treatment of In-Stent Restenosis
Eberhard Grube, Patrick W. Serruys, Mary E. Russell, Heart Center Siegburg, Siegburg, 
Germany, Erasmus University Medical Center, Rotterdam, The Netherlands
Background: The slow-release, polymer-based, paclitaxel-eluting TAXUS stent has been 
shown to reduce clinical and angiographic restenosis in de novo lesions. Paclitaxel-eluting 
stents may also provide a mechanism for the treatment of in-stent restenosis. The primary 
objective of TAXUS III was to evaluate the feasibility of the TAXUS NIRx paclitaxel-coated 
stent to treat and reduce recurrent restenosis in previously implanted stents. The results 
presented herein are outcomes of 4-year clinical follow-up of TAXUS III.
Methods: TAXUS III is a non-randomized, prospective, single-arm clinical trial designed 
to evaluate the safety of the NIRx slow-release 1 ug/mm2 paclitaxel-coated stent in 28 
patients (2 sites) with in-stent restenosis (ISR) within a previously implanted stent. Two 
stent sizes (nominal balloon diameters of 3.0 and 3.5 mm) and a stent length of 15 mm 
were used. The primary endpoint was the Major Adverse Cardiac Event rate (MACE, 
consisting of cardiac death, myocardial infarction, and target vessel revascularization) 
at 30 days after placement of the study stent. Angiographic and intravascular ultrasound 
parameters were assessed at 6 months and MACE rate was measured at 6 and 12 
months and annually thereafter out to 5 years.
Results: As reported previously, procedural success was achieved in 96% of patients. 
Thirty-day and 6-month MACE rates were 4% and 25% respectively, with a 6-month 
target lesion revascularization (TLR) rate of 17.9%. One new TLR at 217 days increased 
the 1-year TLR rate to 21.4%. Two new MACE occurred in one patient at 688 days, a non-
Q-wave MI in a non-target vessel and cardiac death, resulting in a 2-year MACE rate of 
32.1% with a maintained TLR rate of 21.4%. PCI in the target lesion at day 883 resulted 
in a 3-year TLR rate of 25.0% with a MACE rate of 35.7%. There has been no reported 
stent thrombosis to date.
Conclusions: The results of the TAXUS III trial demonstrate that the paclitaxel-eluting 
NIRx stent is safe in the treatment of ISR. In the TAXUS III patients, progressive coronary 
artery disease is evident based on an increasing MACE rate, however, the beneﬁt in 
TLR is durable out to 3-years. Four-year clinical results will be available at the time of 
presentation.
2922-79 Stent Thrombosis and Target Vessel Revascularization 
Following Primary Percutaneous Coronary Intervention 
With Drug-eluting Stents Versis Bare Metal Stents for 
ST Elevation Myocardial Infarction: Results From the 
Stent Registry
Bruce Brodie, Thomas Stuckey, Mark Pulsipher, William Downey, Angela Humphrey, 
Barbara Bradshaw, Chris Metzger, James Hermiller, Fred Krainin, Stanley Juk, John 
McPherson, Barry Cheek, Charles Simonton, LeBauer Cardiovascular Research 
Foundation and Moses Cone Heart and Vascular Center, Greensboro, NC
Background: The incidence of stent thrombosis (ST) and target vessel revascularization 
(TVR) following primary PCI with DES for STEMI is unknown.
Methods: The STENT Registry is a prospective, multi-center database, initiated May 
2003 to assess “real world” outcomes by enrolling >90% of all PCI procedures at 
participating centers. 9 month clinical follow-up was obtained in 95% of patients. The 
frequency of ST and TVR was evaluated in patients treated with DES vs. BMS both for 
STEMI and Elective/Urgent (E/U) PCI.
Results: In all patients (n = 4599), ST occurred more often with STEMI than E/U PCI 
(1.9% vs. 0.6%, p=0.002) and more often with BMS than DES (1.5% vs. 0.6%, p=0.005). 
TVR occurred with similar frequency in STEMI and E/U PCI (3.9% vs. 4.5%, p=0.56) 
and more often with BMS than DES (6.3% vs. 3.9%, p=0.002). Multivariable analysis 
showed STEMI and BMS were independent predictors of ST, and BMS an independent 
predictor of TVR.
STEMI patients treated with DES (n=330) vs. BMS (n=240) were younger (59.0 vs. 61.4 
yrs, p=0.02), had less prior CABG (9% vs. 17%, p=006), less 3V CAD (15.8% vs. 30.0%, 
p=0003), and more initial TIMI 3 ﬂow (24% vs. 15%, p=0.048). In STEMI patients, ST and 
TVR were reduced with DES compared with BMS, similar to E/U PCI (Table).
Conclusion: ST occurs more frequently with STEMI than U/E PCI, and surprisingly 
occurs more frequently with BMS than DES. Our preliminary data suggest that DES 
reduce ST and TVR in pts with STEMI similar to that of E/U PCI. We expect 9 month f/u 
data on an additional 350 STEMI pts by 3/06. 
ST* TVR**
STEMI
DES (n=330) 1.2% 3.0%
BMS (n=240) 2.9% 5.0%
p value 0.25 0.32
Elective/Urgent PCI
DES (n=3287) 0.5% 4.0%
BMS (n=742) 1.1% 6.7%
p value 0.13 0.002
* p = 0.002 for STEMI vs. E/U PCI
p = 0.005 for DES vs. BMS
** p = 0.002 for DES vs. BMS
 
2922-80 Safety and Effectiveness of Paclitaxel-eluting Stent 
Implantation in Over 1000 Very High-Risk Patients. 
Insights From the Prospective Multicenter Taxus in 
Real-life Usage Evalutation (TRUE) Study
Giuseppe Biondi-Zoccai, Giuseppe Sangiorgi, Pierfrancesco Agostoni, Eberhard 
Grube, David Antoniucci, Bernard Reimers, Corrado Tamburino, Carlo Di Mario, Antonio 
Colombo, San Raffaele Hospital and EMO Centro Cuore Columbus, Milan, Italy
BACKGROUND: The Taxus stent has been proved safe and effective in selected patients 
undergoing PCI. However, there is still uncertainty on the performance of Taxus in 
real-world patients at higher risk for major adverse cardiovascular events (MACE) or 
restenosis.
METHODS: 1065 consecutive high-risk patients undergoing Taxus stenting were enrolled 
at 7 European high-volume centers, provided that the target lesion was an unprotected 
left main (N=113), a bifurcation (N=219), a chronic total occlusion (N=183), a long lesion 
(> 28 mm, N=283), in a small vessel (<2.75 mm, N=417), or the patient had diabetes 
mellitus (N=315). Clinical events were adjudicated at 1, 7 and 12 months, with mandatory 
angiographic follow-up at 4-7 months.
RESULTS: Across the 1065 included patients, 1865 lesions were treated with a total 
of 2113 implanted Taxus (2.0±1.1 per patient, 1.2±0.6 per lesion, total Taxus length 
per patient 46±31 mm, preprocedural reference vessel diameter 2.59±0.52 mm, lesion 
length 18±13 mm). One-month MACE occurred in 5.5% of patients, with 0.7% death, 
3.5% myocardial infarction (MI), 0.1% coronary artery bypass grafting (CABG), and 
1.2% target vessel revascularization (TVR). Seven-month events were as follows: MACE 
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26.8%, death 2.5%, MI 4.7%, CABG 1.2%, TVR 18.4% and target lesion revascularization 
(TLR) 12.8%. Angiographically adjudicated stent thrombosis (ST) was uncommon, with 
a cumulative 1.2% at 7 months (0.4% periprocedural ST, 0.4% subacute ST, and 0.4% 
late ST). Comprehensive rates of ST (including sudden death) was instead 1.6%, with 
events predicted independently by bifurcation lesion treatment (odds ratio 4.2 [95%CI 
1.6-11.6], p=0.005).
CONCLUSIONS: In the present 1065-patient study selecting high-risk subjects and/or 
lesions, the performance of the Taxus stent was very satisfactory, especially given the 
overall proﬁle of enrolled subjects and the limited number of stent thromboses.
POSTER SESSION
2923 
Myogenesis: Effects and Remodeling on 
Myocardial Function
Tuesday, March 14, 2006, 8:30 a.m.-Noon
Georgia World Congress Center, Hall B1
Presentation Hour: 10:00 a.m.-11:00 a.m.
2923-81 Intracoronary Injection of Autologous Mesenchymal 
Stem Cells (MSCs) Improves Regional Function by 
Recruiting Endogenous Cell Repair Mechanisms in 
Hibernating Myocardium
Gen Suzuki, Te-chung Lee, John M. Canty, Jr., University at Buffalo, Buffalo, NY, VAMC, 
Buffalo, NY
Background: MSCs improve function following MI but their effects in hibernating 
myocardium are unknown.
Methods: Swine (n=20) with hibernating myocardium from a chronic LAD occlusion 
were studied 4-months after instrumentation in the closed-chest sedated state (propofol). 
Autologous MSCs expanded ex vivo (44x106 cells, n=10) were injected into the major 
coronary arteries. MSCs were transfected with AdvEGFP to assess in vivo differentiation. 
Responses before and 15 days after MSCs were compared to untreated controls (n=10). 
We assessed the frequency of myocytes in the growth phase of the cell cycle (Ki-67), 
myocyte nuclear density and cell size.
Results: LAD wall thickening (ΔWT) increased from 2.4 ± 0.3 to 3.6 ± 0.5 mm (p<0.05) 
after i.c. MSCs. There was no change in ﬂow at rest or adenosine vasodilation. MSCs 
increased LV mass (27%) and increased the number of Ki-67 positive myocytes 
(Table). This was accompanied by a 20% increase in myocyte nuclear density. Despite 
anatomic hypertrophy, there was a reduction in myocyte diameter after MSCs. EGFP 
demonstrated MSC differentiation into vascular smooth muscle, endothelium and rare 
cardiac myocytes.
Conclusions: We conclude that intracoronary MSCs improve function and stimulate 
myocyte hyperplasia but do not alter perfusion in hibernating myocardium. The 
increase in myocyte nuclear density exceeds the low frequency of EGFP positive MSCs 
differentiating into myocytes and raises the possibility that MSCs amplify endogenous 
cardiac repair mechanisms.
LV mass/Body 
weight (g/kg)
LAD Myocyte 
diameter 
(µm)
LAD Ki-67 positive 
myocytes (nuclei/106 
myocytes)
LAD Myocyte 
Nuclear density 
(nuclei/mm2)
Untreated control 2.2 ± 0.1 16.1 ± 0.4 417 ± 73 698 ± 38
MSCs 2.8 ± 0.1* 13.5 ± 0.4* 1930 ± 233* 835 ± 40*
Mean ± SEM, *p<0.05 Untreated vs. MSCs
 
2923-82 Quantitative Evaluation of Sex Mismatch Cell 
Transplantation Using Real-Time Polymerase Chain 
Reaction Is Efﬁcacious for Determining Myocardial Cell 
Delivery Efﬁciency
Todd J. Brinton, Kitch D. Wilson, Erik T. Price, Sally X. Zhang, Manickam Krishnan, 
Joseph C. Wu, Alan C. Yeung, Paul G. Yock, Stanford University, Stanford, CA
Background: Cell-based myocardial regeneration is an emerging treatment option for 
both acute myocardial infarction and chronic cardiomyopathy. However, quantitative 
methods for evaluating cell transplant efﬁciency are lacking. We sought to develop and 
evaluate a new molecular technique for accurately measuring the number of viable 
transplanted cells in a pig model based on tracking the Y chromosome in a male cell 
transplanted into female hosts.
Methods: Custom probes and primers were designed and manufactured from the SRY 
gene sequence (Applied Biosystems, Foster City, CA) of male Yorkshire swine. To validate 
the ability to count male cells in female tissue, ex-vivo myocardial samples obtained from 
the LV of a female swine were mixed with known quantities (107,106,105,104, etc) of male 
porcine peripheral mononuclear cells (pMNCs). Samples were subjected to DNA isolation 
and real-time polymerase chain reaction (PCR). To determine the accuracy of analyzing 
sub-fractions of myocardial samples to aid in processing, 106 or 104 male pMNCs were 
added to female ex-vivo myocardial samples. Subsequently, sub-fractional analysis 
(100%, 50%, 30%, 20%, 10%) was performed from homogenized samples. To determine 
the feasibility of the method to quantify in-vivo delivery efﬁciency, 24 million male pMNCs 
were directly injected into the anterior lateral LV of a female swine in an open chest model. 
Following euthanasia, target zone tissue was subjected to similar processing using 10% 
sub-fractional analysis.
Results: Ex-vivo experiments demonstrated a highly signiﬁcant correlation between 
known cell counts obtained by hemocytometry and results obtained using real-time PCR 
(r=0.994). Sub-fraction analysis of myocardial samples had a coefﬁcient of variation 
of 1-3% for cell counting using fractional samples as low as 10%. In-vivo target zone 
myocardial delivery efﬁciency was 46%.
Conclusions: The results of this study demonstrate the feasibility of this molecular 
technique for evaluating cellular transplant efﬁciency. The method should be useful for 
evaluating different modes of cell delivery and validating new non-invasive platforms for 
assessing cell transplant location and viability.
2923-83 Percutaneous Delivery of Engineered Transcription 
Factor 32E-ZFP Improves Ventricular Remodeling in a 
Porcine Model of Acute Myocardial Infarction
Jennifer Lyons, Fumiaki Ikeno, Sascha Emami, Christian Leutenegger, Yoriyaso Suzuki, 
Christine Nolasco, Joseph Rokovich, Frank K. Giordano, Patrice Tremble, Mehrdad 
Rezaee, Stanford University, Palo Alto, CA, Edwards Lifesciences, Irvine, CA
Background: In this study, the percutaneous delivery efﬁciency and efﬁcacy of adenoviral 
vectors encoding a marker (DSRed) or a transgene regulating expression of VEGFA 
(ZFP-32E) were examined in a porcine model of acute myocardial infarction (AMI). Even 
after successful re-establishment of coronary perfusion after AMI, unfavorable myocardial 
remodeling occurs. Percutaneous delivery of vectors for ZFP-32E, a transcription factor 
that modulates angiogenic and cardioprotective factors as well as progenitor cell signaling 
in hypoxic tissue, may improve outcome after AMI.
Methods: AMI was induced in swine by a 60 minute total occlusion of the mid-LAD. 
Adenovirus (1012 vp) was delivered by catheter within 24 h of infarct. AdDSRed was 
used to determine delivery efﬁciency by histology 5 d post delivery. AdZFP-32E was 
used in a blinded efﬁcacy study (saline (8) vs ZFP-32E (17)), and functional parameters 
were measured at baseline, prior to and14 d post-delivery by echocardiogram and left 
ventricular angiogram.
Results: Histological analysis showed consistent endomyocardial infarct in 27% of 
the LAD territory. No expression of AdDSRed marker was detected with intracoronary 
injection, as opposed to high levels after either intramyocardial injection (IMD) or 
retrograde coronary venous delivery (RCVD). Marker expression was focal with IMD 
and distributed throughout the peri-infarct region with RCVD. At 2 days post RCVD, RT-
PCR showed ZFP-32E expression in the peri-infarct region to be a median of 1.2 x 106 
copies/106 cells. Functional measures 14 d post-treatment showed signiﬁcant differences 
in end systolic and diastolic volumes (ESV 43.9±2.6 vs, 59±8.5 (p=0.02); EDV 84±2.6 vs. 
120±21 (p=0.02); treated vs controls).
Conclusions: Acute post MI delivery of ZFP-32E via RCVD is well tolerated and may 
decrease in ventricular remodeling.
2923-84 Intermediate Follow-Up of a Phase 1 Study of Skeletal 
Myoblasts for Congetsive Heart Failure
Warren Sherman, Nicholas Chronos, Stephen Ellis, Timothy Henry, David Holmes, 
Patrick Whitlow, Damita Carryer, Diana Crisan, Lisa Mowatt, Kelly Brezina, Betsy 
Wilson, Mount Sinai Hospital, New York, NY, Columbia University Medical Center, New 
York, NY
Background: Preliminary studies of autologous skeletal myoblast (ASM) implantation 
combined with CABG, for chronic myocardial disease suggest improvement in clinical 
indices and left ventricular (LV) function, with little potential risk. These hybrid studies 
do not permit the evaluation of ASM administration alone. We report the early results 
MYOHEART, a multicenter, Phase 1 study of ASM monotherapy in patients with 
congestive heart failure (CHF).
Methods: MYOHEART is an open label, dose escalation study of ASM implanted with a 
percutaneous endoventricular catheter. Patient with NYHA Class 2-3 CHF from post-MI 
(> 3 months) systolic left ventricular dysfunction (SLVD), EF 20-40%, pre-existent ICD 
insertion and without reversible myocardial ischemia were eligible. Primary objectives 
were feasibility and safety of ASM procurement and injection, including a rigorous 
arrhythmia detection program. Secondary objectives measured clinical and noninvasive 
parameters of LV function.
Results: As of 10.05.05, ten subjects were implanted: age 58+11 yrs, M/F 10/0, CHF 
Class 2.3+/-.1, baseline EF 29+5, 5 into each of the ﬁrst two dosing ranges: 25 x 106 and 
75 x 106 cells. There were no procedural-related adverse events. In follow-up (1-12 mo) 1 
subject had brief runs of nonsustained VT (8 wks) and 2 had VT responding to either burst 
pacing (10 months) and or ICD shock (7 wks). One death (10 wks) is under review.
Conclusions: Preliminary results from this Phase 1 study demonstrate the feasibility and 
safety of ASM procurement and catheter-based administration in patients with post-MI 
SLVD. The frequency of serious ventricular arrhythmias at appears to be low. 3-month 
follow-up data on all 3 Cohorts (15 subjects) will be presented.
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POSTER SESSION
2924 
Clinical Approach to Coronary Artery 
Restenosis
Tuesday, March 14, 2006, 8:30 a.m.-Noon
Georgia World Congress Center, Hall B1
Presentation Hour: 10:00 a.m.-11:00 a.m.
2924-86 Does Size Really Matter? A Comparison of Drug-eluting 
Versus Bare-metal Stents at Different Stent Diameters
Douglas L. Kosmicki, Kent G. Meredith, Heidi Thomas, Benjamin D. Horne, Robert R. 
Pearson, Tami Bair, Rodney S. Badger, William H. Barry, Jeffrey L. Anderson, Joseph B. 
Muhlestein, LDS Hospital, Salt Lake City, UT, University of Utah, Salt Lake City, UT
Background: Since the approval of drug-eluting stents (DES) in April 2003, there has 
been widespread and rapid adoption, accounting for approximately 80% of all stents 
implanted in the United States. However, the expanded utilization of DES has increased 
the costs associated with a coronary intervention. Previous observations have shown 
lower restenosis rates with larger diameter stents. We assessed whether DES-associated 
beneﬁts for restenosis persist in larger diameter stents when compared to bare metal 
stents (BMS).
Methods: Patients (N=4419) enrolled into the Intermountain Heart Collaborative Study 
Registry from 2002-2005, who received either a DES (n=2279) or BMS (n=2140), and had 
6 months of follow up were assessed. Stent diameter was categorized as <3 (n=3482) or 
>3 (n=937). Univariate and multivariate logistic regression was used to determine risk of 
target lesion revascularization (TLR) for BMS and DES in each stent diameter category. 
Multivariate models adjusted for traditional cardiac risk factors and presentation.
Results: Age averaged 63.9 years, 74.7% were male, and 27.6% had diabetes. When 
compared with DES, BMS ≤3 mm were associated with higher frequency of TLR (8.0% 
versus 3.1%, Odds Ratio (OR) =2.69, 95% CI: 1.93-3.75, p<0.0001), which effect remained 
after multivariate adjustment (OR=2.77, 95% CI: 1.98-3.87, p<0.0001). At diameters >3 
mm, TLR for BMS compared to DES did not differ statistically in both univariate (5.7% 
versus 4.4%, OR=1.33, 95% CI 0.67-2.63, p=0.41) and multivariate (OR=1.34, 95% CI: 
0.67-2.74, p=0.39), although the frequency of TLR continued to be lower for DES.
Conclusion: This analysis of a real-world, unselected population conﬁrms the highly 
beneﬁcial effect of DES on 6 month-TLR rates in stents with diameters ≤3 mm. For 
stents with diameters > 3 mm the difference in TLR was not signiﬁcant. The comparable 
performance of BMS vs. DES at diameters >3 mm suggests that speciﬁc trials are needed 
to compare the cost-beneﬁt ratio of using BMS for routine, low-risk lesions with larger 
diameters. 
2924-87 Relevance of Restenosis Pattern in the Drug-eluting 
Stent Era
John Cosgrave, Gloria Melzi, Flavio Airoldi, Giuseppe Biondi-Zoccai, Matteo 
Montorfano, Mauro Carlino, Alaide Chieffo, Iassen Michev, Giuseppe M. Sangiorgi, 
Cosmo Godino, Simon Corbett, Antonio Colombo, S. Raffaele Hospital, Milan, Italy, 
EMO Centro Cuore Columbus, Milan, Italy
Background: The angiographic pattern of in-stent restenosis (ISR) in the bare metal stent 
era conveys prognostic information. Whether the same is true in cases of drug eluting 
stent (DES) restenosis is unknown and may have important therapeutic implications. Our 
hypothesis was that the pattern of restenosis would be a signiﬁcant predictive factor for 
subsequent angiographic restenosis and target lesion revascularization (TLR).
Methods: We identiﬁed all patients undergoing treatment of DES restenosis in our 
institution. We divided these lesions into 2 groups: focal (<10 mm) and non focal. The end 
points analyzed were angiographic restenosis and TLR.
Results: We identiﬁed a total of 250 restenotic lesions (203 patients). Focal restenosis was 
found in 163 (65.2%) of cases and non focal in 87 (34.8%); of these 24.3% were diffuse, 
2.4% proliferative and 8% obstructive. Diabetes was the only clinical variable associated 
with the pattern of restenosis (25.4% in the focal and 47.9% in the non focal group, 
p=0.002). In the non focal group the mean stent lenght of the lesion that restenosed was 
greater (29.56±12.6 vs 35.74±18.25, p=0.002) and there were more occlusions at initial 
DES implantation (7.4% vs 25.3%, p=0.0001). Both TLR and the rate of angiographic 
restenosis were signiﬁcantly more frequent in the non focal group (8% in the focal vs 23% 
in the non focal, p=0.001 and 16.2% vs 51.1%; p=0.0001, respectively).
Conclusions: Diabetes remains a signiﬁcant predictor of the pattern of restenosis in the 
DES era. Similar to bare metal stent data, the angiographic pattern of restenosis following 
DES implantation is prognostically important.
2924-88 Intravascular Brachytherapy Versus Repeat Drug-
eluting Stenting for the Treatment of Patients With 
Drug-eluting Stent Restenosis
Rebecca Torguson, Regina Deible, Kimberly Smith, William W. Chu, Kenneth M. Kent, 
Augusto D. Pichard, William O. Suddath, Lowell F. Satler, Ron Waksman, Washington 
Hospital Center, Washington, DC
Background: Intravascular radiation (IRT) is an effective treatment for patients (pts) with 
in-stent restenosis (ISR) of bare metal stents. This study evaluates and compares the 
safety and efﬁcacy of IRT versus repeat drug-eluting stents (DES) for the treatment of 
ISR of DES.
Methods: RESCUE is an international, internet registry of pts who presented with 
ISR of a DES and assigned to IRT following percutaneous coronary intervention 
(PCI). Commercial available IRT systems were utilized. These pts were compared to a 
consecutive series of pts who presented with ISR of a DES and were assigned to repeat 
DES (rDES). The antiplatelet regimen for both groups was life-long aspirin and at least 
12 months of clopidogrel. Pts were followed up by telephone contact or clinical visit at 6 
months.
Results: Sixty-one pts (71 DES) were enrolled into the IRT arm and 50 pts (50 DES) 
were enrolled into the rDES arm. Baseline clinical and angiographic characteristics were 
similar between both groups. The Cypher stent was used more frequently in the rDES 
group than in the IRT group for the initial DES implantation, 88.5% vs. 69% (p = 0.01), 
respectively. All pts have completed 6-month follow-up. There has been no report of 
subacute thrombosis in either group. (Table)
Conclusions: IRT as adjunct therapy to PCI for pts presenting with ISR of a DES is safe 
and should be considered a superior therapeutic option for this difﬁcult subset of pts when 
compared with repeat DES implantation.
 
n (%)
IRT Group
Pt n=61,
Vessel n=62
rDES Group
Pt n=50,
Vessel n=50
p value
All MACE 2 (3.3) 11 (22) 0.002
All Death 0 (0) 2 (4) 0.2
Q Wave Myocardial Infarction 0 (0) 1 (2) 0.45
TVR 2 (3.3) 8 (16) 0.04
TLR 2 (3.3) 4 (8) 0.24
 
2924-117 Maximum Clot Strength is a Novel and Highly Predictive 
Indicator of Restenosis: A Potential Future Measure to 
Determine Who Needs Antiproliferative Therapy and 
How Much
Paul A. Gurbel, Kazi Zaman, Kevin P. Bliden, Udaya Tantry, Sinai Center for Thrombosis 
Research, Baltimore, MD
Background: Platelets play a fundamental role in the genesis of stent restenosis by 
mediating inﬂammation and smooth muscle proliferation. Thrombi with high tensile 
strength may facilitate growth factor release to the adjacent vessel wall resulting in 
neointimal hyperplasia.
Methods: We measured pretreatment ex vivo maximum thrombin-induced clot strength, 
time to ﬁbrin formation, and the combined clotting index by thrombelastography (TEG) in 
25 healthy controls and 178 consecutive elective stent patients followed for 6 months for 
the development of symptomatic restenosis.
Results: Patients with restenosis (n = 12, 8 drug-eluting) had greater clot strength 
(mm)(75.0 ± 4.0 vs. 67.1 ± 6.6, p = 0.0001), and higher combined clotting indices 
(relative index) (3.4 ± 1.6 vs. 2.3 ± 2.1, p = 0.05) than patients without restenosis and 
healthy controls (p < 0.001 for all measurements). The risk for restenosis was ~7 times 
greater for patients with clot strength in the highest quartile vs. the lowest two quartiles 
(Figure). Multivariate analysis demonstrated the independent predictive value of this 
measurement. 
Conclusions: The prothrombotic state highlighted by high tensile clot strength, is 
independently predictive of the development of in-stent restenosis irrespective of stent 
type and may serve as a new marker targeting antiproliferative therapy for those at 
greatest risk rather than uniform use of drug-eluting stents.
 
2924-118 To Stent or Not to Stent? Focal Sirolimus-eluting Stent 
Restenosis: A Therapeutic Dilemma
Gloria Melzi, John Cosgrave, Matteo Montorfano, Mauro Carlino, Alaide Chieffo, Flavio 
Airoldi, Iassen Michev, Giuseppe M. Sangiorgi, Altin Palloshi, Rade Babic, Antonio 
Colombo, S. Raffaele Hospital, Milan, Italy, EMO Centro Cuore Columbus, Milan, Italy
Background: Sirolimus-eluting stents (SES) signiﬁcantly reduce restenosis and the need 
for repeat revascularization compared with bare metal stents. Despite this, restenosis still 
occurs with target lesion revascularization (TLR) approaching 5% in large randomized 
trials. Preliminary observations in a small cohort of SES restenoses showed suboptimal 
results, especially in high-risk subsets. Our aim was to compare the outcomes of 
POBA and repeat drug-eluting stent (DES) implantation in the treatment of focal SES 
restenosis.
Methods: Our study population comprised all consecutive patients (pts) who underwent 
reintervention for focal (<10 mm) SES restenosis between September 2002 and 
September 2004. The end points analyzed were MACE and per lesion TVR and TLR.
Results: Ninety-ﬁve pts (114 lesions) were included: 52 (45.6%) lesions were treated with 
POBA and 62 (54.4%) with repeat DES implantation. No pts were lost to clinical follow-
up. Fifty-ﬁve (57.9%) pts underwent angiographic follow-up and the rate of angiographic 
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follow-up was similar in the two groups. At follow-up (mean 13.6±6.5 months) there were 
no cases of myocardial infarction and 3 (3.1%) cardiac deaths, 2 (5.4%) in the POBA and 
1 (1.7%) in the DES treatment group (p=0.33). TVR occurred in 10 (19.2%) lesions in the 
POBA group and in 8 (12.9%) in the DES group (p=0.25) and TLR in 7 (13.5%) and 5 
(8.1%) lesions respectively (p=0.26). When the outcome was analysed according to the 
type of DES subsequently implanted, SES or paclitaxel-eluting stent (PES), TLR occurred 
in 4 (9.5%) lesions in the SES group and in 1 (5.0%) in the PES group (p 0.55).
Conclusions: Overall the treatment of focal SES restenosis is associated with favorable 
early and mid-term results in this challenging cohort of pts. These preliminary data 
demonstrate no clear advantages for any of the modalities analysed. Furthermore, the 
treatment of SES-restenosis with the placement of an additional DES, either SES or PES, 
is safe, with no documented complications related to re-exposure to local antiproliferative 
agents.
2924-119 Impact of Previous Clinical Recurrence on Outcome 
After Percutaneous Coronary Intervention
Jasper S. Wijpkema, Rutger L. Anthonio, Gillian A. Jessurun, Rene A. Tio, Felix Zijlstra, 
University Medical Center Groningen, University of Groningen, Groningen, The 
Netherlands
Background: Identifying risk factors for restenosis is important in selecting patients who 
will beneﬁt most from drug-eluting stents (DES). We hypothesized that a history of Clinical 
Recurrence (CR) in one coronary artery increases the risk of CR after Percutaneous 
Coronary Intervention (PCI) of a de novo lesion in a different coronary artery. If true, this 
could be an indication for the use of DES.
Methods: We retrospectively analyzed all patients who underwent PCI between 1993 
and 2004 and selected patients with 2 or more interventions in 2 different native vessels. 
Patients were divided into patients without CR (group 1) and with CR (group 2) after the 
ﬁrst PCI. CR was deﬁned as repeated PCI or Coronary Artery Bypass Grafting within 1 
year after PCI. Clinical and procedural characteristics as well as CR rates of subsequent 
interventions were obtained and analyzed.
Results: A total of 1,010 patients were entered into the ﬁnal analysis, 727 in group 1 and 
283 in group 2. Major risk factors were comparable between both groups. Lesion and 
procedural characteristics differed only in number of balloons/procedure (0.83 vs. 0.98, 
p=0.017) and stents/procedure (1.18 vs. 1.34, p=0.009) used. Patients in group 2 had a 
much higher risk of CR after their second PCI (RR = 2.8, CI = 2.0-3.9). This effect was 
even more pronounced after a third PCI (table). 
CR after PCI in vessel 1
No
(n=727)
Yes 
(n=283) p-value
Incidence of CR after PCI in vessel 
2 (n) 9 % (62) 24 % (67) <0.001 
No. of patients with PCI in a 3rd 
vessel 78 34
CR after PCI in vessel 2 No (n=70) Yes (n=8)
No 
(n=22) Yes (n=12)
Incidence of CR after PCI in vessel 
3 (n) 3% (2) 13% (1) 18% (4) 50 % (6) <0.001 
Conclusions: Patients with a history of CR have an increased risk of CR after a second 
or third PCI in a different vessel. Therefore, DES are likely to be beneﬁcial in these 
patients.
2924-120 Paclitaxel-Eluting Stents Are More Effective in Treating 
Focal Patterns of Sirolimus-Eluting Stent Restenosis 
Compared to Non-Focal Patterns of Sirolimus-Eluting 
Stent Restenosis
Samir B. Damani, Steve S. Lee, Neil Sawhney, Garrett Wong, Raghava Gollapudi, 
Rafael Valencia, Richard A. Schatz, Matthew Price, Paul S. Teirstein, Scripps Clinic / 
Green Hospital, La Jolla, CA
Background: Implantation of paclitaxel-eluting stents (PES) is a previously untested 
treatment option for patients with in-stent restenosis (ISR) of sirolimus-eluting stents 
(SES). For bare metal stents, treatment of focal restenosis results in less need for target 
lesion revascularization (TLR) compared to treatment of non-focal restenosis patterns 
(i.e. diffuse, proliferative, and total occlusive). This study evaluated the impact of ISR 
pattern on 6 month clinical outcome following PES implantation for SES restenosis.
Methods: All patients (pts) at Scripps Clinic with ISR of SES treated with PES were 
analyzed using quantitative coronary angiography (QCA, Medis). Lesions were classiﬁed 
as focal (≤ 10mm) or non-focal (> 10mm). Non-focal lesions were subgrouped into diffuse 
intrastent (>10mm), proliferative (>10mm extending beyond stent margins), and totally 
occlusive (TIMI ﬂow 0). Clinical follow-up was obtained at 6 months.
Results: To date, 137 pts have undergone PES implantation for 150 SES ISR lesions, 
and 6 month clinical FU was obtained in 96 of the 102 (94%) eligible pts (106 of 114 
lesions). Focal restenosis was present in 105 of 150 lesions (70%). There were 45 (30%) 
non-focal lesions, including 24 (16%) diffuse, 6 (4%) proliferative, and 15 (10%) totally 
occlusive lesions. Baseline clinical characteristics were similar for focal vs non-focal ISR 
pts. Diabetes was present in 32% of focal ISR pts vs. 40% of non-focal ISR pts (p=0.3). 
TLR was signiﬁcantly higher for non-focal restenotic lesions compared to focal lesions 
(30% vs. 11%, p=0.014). A composite endpoint of death, myocardial infarction, and target 
vessel revascularization was also higher for non-focal vs focal lesions (35% vs. 16%, p< 
0.05). Two episodes of non-fatal subacute thromboses occurred, one each in focal and 
diffuse subtypes (both pts were receiving dual anti-platelet therapy).
Conclusions: At 6 months, paclitaxel-eluting stent implantation is more effective for the 
treatment of focal sirolimus-eluting stent restenosis compared to non-focal patterns of 
SES restenosis. Complete follow-up and quantitative coronary angiography data of the 
entire cohort will be presented.
2924-121 Treatment of In-stent Restenosis in Drug Eluting Stents: 
Have Stent Sandwiches Solved the Problem?
Marc Shelton, Anna Moore, M. Coleman Shelton, Robert Ligon, Gregory Mishkel, 
Prairie Heart Institute, Springﬁeld, IL, Prairie Education & Research Cooperative, 
Springﬁeld, IL
Background: No studies to date have reported outcomes of interventional treatment for 
in-stent restenosis (ISR) in DES. We evaluated treatment strategies and acute and long 
term clinical outcomes of our large series of DES ISR.
Methods: We retrospectively analyzed all interventional procedures between May 1, 2003 
and December 31, 2004 utilizing our facility’s ACC-NCDR and adjunct DES data registry. 
Major adverse cardiac events (MACE), deﬁned as death, myocardial infarction (MI), 
and target lesion revascularization (TLR), were determined both in-hospital and at one 
year. All angiograms were reviewed and the morphology of restenosis analyzed. Three 
interventional treatment strategies were examined: homogenous DES sandwich (restent 
with same DES; “homo-stent”), heterogenous DES sandwich (restent with different DES; 
“hetero-stent”), or other.
Results: A total of 4912 lesions had a DES placed; 108 lesions required revascularization 
for clinical presentation of ISR (2.2%). Of those, 86 received a stent sandwich; 64 homo-
stent (61 sirolimus-sirolimus, 3 paclitaxel-paclitaxel) and 22 hetero-stent (19 paclitaxel in 
sirolimus, 3 sirolimus in paclitaxel). The remaining 22 lesions were treated as “other” (19 
balloon angioplasty, 2 bare metal stent, 1 brachytherapy). Lesion morphology of ISR at 
presentation was: 40.7% focal, 18.5% diffuse, 33.3% edge (5mm proximal or distal from 
edge of previous stent), 0.9% proliferative and 6.5% thrombotic occlusion. Demographics 
were similar between groups, with the exception of congestive heart failure and age >65. 
There were 3 in-hospital adverse events: 1 peri-procedural MI and 2 deaths. Clinical 
follow-up was available on 99% of patients, with an average follow-up of 257 days. The 
crude event rates were: mortality 5.6%, MI 2.2%, TLR 26.0%, and MACE 30.0%. Life table 
analysis at 1 year revealed a MACE rate of 38.5% (95% CI 24.3%-52.7%) and TLR of 
24.5% (95% CI 15.0%-34.0%). There were no differences between treatment groups.
Conclusions: Although there was no difference in outcomes among the 3 groups studied, 
it is clear that the interventional treatment of DES ISR remains extremely problematic 
both in the short and long term, with a very high long-term MACE rate.
2924-122 Stented Length-to-diameter Ratio Predicts Complexity 
of Bare-metal In-Stent Restenosis After Adjustment for 
Effects of Diabetes Mellitus, Clinical and Angiographic 
Covariates
Sandeep Nathan, Atul R. Chugh, Amit P. Amin, Raed Al Dallow, Justin Haynie, Francis 
Q. Almeda, Rush University Medical Center, Chicago, IL, Cook County Hospital, 
Chicago, IL
Background: In-stent restenosis (ISR) of bare-metal stents (BMS) is associated with 
speciﬁc clinical and angiographic predictors. An angiographic grading system developed 
by Mehran, et al. [Circ 1999; 100(18)] links higher ISR lesion complexity with diabetes 
mellitus (DM), prior ISR and smaller vessel diameter but not stented length. It remains 
unclear if ISR complexity is related to DM when adjusted for stented dimensions and if 
stented length to diameter (L/D) ratio is more predictive of ISR complexity than either 
metric alone.
Methods: Data from 288 consecutive patients (pts) with symptomatic BMS ISR were 
collected at 2 institutions. ISR morphology was adjudicated and multiple averaged 
stent measurements obtained using Centricity AI 1000 GEMnet GeQCA 2.0 software. 
Univariate predictors of ISR complexity and a priori hypothesis variables were entered into 
a multivariate logistic regression model with ISR complexity dichotomized as simple (Type 
I) vs. complex (II, III, IV) to conserve discriminant power. Receiver operator characteristic 
(ROC) curves were constructed for each parameter and compared.
Results: In 288 pts (39% DM, 300 lesions, 60% complex ISR) DM [OR 1.91, 95% CI 1.13 
- 3.23, p=0.015] and L/D ratio [OR 1.37, 95% CI 1.21-1.54, p<0.001] were independently 
associated with complex ISR. Between DM and non-DM pts no differences were seen in 
stented length [17.7 ± 9.2 mm vs 19.3 ± 11.7 mm], diameter [3.14 ± 0.59 mm vs 3.22 ± 
0.55 mm] or L/D ratio [5.9 ± 3.3 vs 6.1 ± 3.9, p=NS for all]. ROC analysis suggested L/D 
ratio [AUC 0.74, 95% CI 0.68-0.79] confers greater predictive power than length [AUC 
0.71, 95% CI 0.65-0.77, p=0.049]. Both L/D ratio and length offered better predictive power 
than diameter [AUC 0.43, 95% 0.36-0.49, p<0.0001 for diameter vs. L/D or length].
Conclusions: DM and L/D ratio were independent predictors of complex ISR while stent 
length, diameter, lesion location and cardiac risk factors were not. L/D ratio was more 
predictive of ISR complexity than any other angiographic parameter studied. A 37% 
increase in odds of complex ISR was seen per unit increase in L/D ratio. Development of 
a predictive model may help guide selective use of drug-eluting stents.
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ORAL CONTRIBUTIONS
2805 
Safety and Efﬁcacy of Antiplatet 
and Antithrombin Therapy During 
Percutaneous Coronary Interventions
Tuesday, March 14, 2006, 9:00 a.m.-10:00 a.m.
Georgia World Congress Center, Room C207
9:00 a.m.
2805-3 Safety and Efﬁcacy of Glycoprotein IIb/IIIa Inhibitors 
With Intravenous Enoxaparin in Patients Undergoing 
Elective Percutaneous Coronary Intervention: Findings 
From the STEEPLE Trial
Steven Steinhubl, Harvey White, Stephen King, Richard Gallo, Gilles Montalescot, for 
the STEEPLE Investigators, University of Kentucky, Lexington, KY, Centre Hospitalier 
Universitaire Pitié-Salpêtrière, Paris, France
Background: Efﬁcacy and safety data for glycoprotein (GP) IIb/IIIa inhibitors come from 
studies with adjunct unfractionated heparin (UFH). The effect of GP IIb/IIIa inhibitor as an 
adjunct to enoxaparin compared with UFH has not previously been assessed in PCI.
Methods: STEEPLE is a prospective, open-label, randomized trial of 3,528 patients 
undergoing a non-emergent PCI who were randomized to intravenous enoxaparin (0.5 
or 0.75 mg/kg) or an ACT-adjusted UFH regimen. Randomization was stratiﬁed by the 
operator’s choice of GP IIb/IIIa inhibitor use. The effect of GP IIb/IIIa inhibitor use on non-
CABG-related bleeding and the composite ischemic endpoint was assessed.
Results: Overall, a 57% reduction in major bleeding was found with enoxaparin (P<0.01), 
with no difference in ischemic events compared with UFH. GP IIb/IIIa inhibitors were used 
in 40% of patients and were associated with increased bleeding (10.3% with vs 5.0% 
without GP IIb/IIIa inhibitors, p<0.001), and ischemic events (8.1% vs 5.2%, p<0.001). 
After multivariate analysis, use of GPIIb/IIIa inhibitors was independently correlated to 
bleeding (OR 2.3 [1.7-3.0]; p<0.001), but not to ischemic events. These results were 
independent of the randomized therapy.
Enoxaparin 0.5 
mg/kg
Enoxaparin 0.75 
mg/kg UFH
GP IIb/IIIa 
inhibitor use no yes no yes no yes
Major and minor 
bleeding, n/N (%)
26/616 
(4.2)
37/430 
(8.6)
26/709 
(3.7)
54/497 
(10.9)
50/725 
(6.9)
55/487 
(11.3)
Composite 
ischemic end 
point of 30-day 
death, nonfatal 
myocardial 
infarction 
and urgent 
target vessel 
revascularization, 
n/N (hazard rate)
30/637 
(4.8)
36/433 
(8.3)
42/729 
(5.9)
42/499 
(8.5)
35/739 
(4.8)
37/491 
(7.6)
Conclusions: Use of GP IIb/IIIa inhibitors in operator-selected patients is associated with 
a signiﬁcant increase in bleeding irrespective of the randomized anticoagulation regimen. 
The greater ischemic event rate is likely confounded by baseline patient characteristics.
9:15 p.m.
2805-4 Mortality Beneﬁt With Concomitant Clopidogrel Therapy 
and GP IIb/IIIa Antagonists at the Time of Ad Hoc 
Percutaneous Intervention
Richard J. Gumina, Eric H. Yang, Gurpreet S. Sandhu, Abhiram Prasad, John F. 
Bresnahan, Ryan J. Lennon, Charanjit S. Rihal, David R. Holmes, Jr., Mandeep Singh, 
Mayo Clinic College of Medicine, Rochester, MN
Background: There are limited data on the clinical outcomes in patients administered 
clopidogrel at the time of ad hoc percutaneous coronary interventions (PCI) concomitantly 
with a glycoprotein (GP) IIb/IIIa antagonist.
Methods: Thirty-day and long-term outcomes were stratiﬁed based on administration of a 
GP IIb/IIIa antagonist at the time of PCI. We identiﬁed 6,587 patients undergoing elective 
or urgent PCI from March 1, 1998 and December 31, 2003, who received clopidogrel at 
the time of ad hoc PCI.
Results: The mean age was 66.1±11.7 years in the 3,474 patients receiving compared 
to 67.6±11.7 years in the 3,113 patients not receiving a GP IIb/IIIa antagonist (P<0.001). 
Thirty-day unadjusted mortality was signiﬁcantly lower in those patients who received 
a GP IIb/IIIa antagonist (0.8% vs. 1.3%; P=0.03). Following application of propensity 
analysis to adjust for the likelihood of receiving GP IIb/IIIa inhibitors based on clinical, 
angiographic, and procedural characteristics, this signiﬁcant association with improved 
30-day mortality persisted (HR: 0.46, [95% CI 0.26-0.81] P=0.007). Kaplan-Meier analysis 
(median follow-up: 36 months) revealed a signiﬁcant improvement in long-term survival in 
those patient receiving a GP IIb/IIIa antagonist (P<0.001) at the time of ad hoc PCI that 
persisted following propensity adjustments (HR: 0.73 [95% CI, 0.61-0.88] P=0.001).
Conclusions: These data from a single-center following an unselected consecutive 
series of patients demonstrate that in patients undergoing elective or urgent ad hoc 
PCI, the addition of a GP IIb/IIIa antagonist to dual antiplatelet therapy is independently 
associated with a beneﬁcial effect on 30-day and long-term mortality.
9:30 p.m.
2805-5 Increased Risk in Patients With High Platelet 
Aggregation on Chronic Clopidogrel Therapy 
Undergoing Repeat PCI: Is the Current Antiplatelet 
Therapy Adequate?
Kittane Vishnupriya, Mulugeta Fissha, Kevin P. Bliden, Udaya S. Tantry, Paul A. Gurbel, 
Sinai Center for Thrombosis Research, Baltimore, MD
Background: We hypothesized that patients on chronic clopidogrel therapy who undergo 
repeat elective PCI continue to be higher risk for post-PCI ischemic events and that the 
risk is much higher if they have high pre-procedure platelet aggregation measured by 
standard light transmittance aggregometry (LTA)
Methods: LTA (arachidonic acid and ADP )was performed prior to PCI in 75 consecutive 
patients undergoing elective repeat PCI who were on chronic anti-platelet therapy with 
ASA (325 mg qd) and clopidogrel (75 mg qd). Patients were followed for 6 months for the 
occurrence of adverse ischemic events (death, MI, stent thrombosis, stroke, ischemia 
requiring hospitalization).
Results: All patients were aspirin responsive. Patients with ischemic events (11/75,15%) 
within 6 months had greater pre-PCI ADP-induced platelet aggregation than patients 
without ischemic events (p=0.004)(Figure). Sixty-four percent of patients with ischemic 
events had greater than 50% platelet aggregation by ADP measured pre-PCI.vs.16% 
of patients without ischemic events (p < 0.01) There was no signiﬁcant difference in the 
baseline demographic characteristics and angiographic success between the groups.
Conclusions: Patients undergoing repeat elective PCI who exhibit high ADP-induced 
platelet aggregation while on chronic clopidogrel therapy are at increased risk for post 
procedure ischemic events. Alternative antiplatelet strategies should be studied in these 
patients to reduce post-PCI adverse ischemic events. 
9:45 p.m.
2805-6 The Safety and Efﬁcacy of Elective Percutaneous 
Coronary Intervention Using Bivalirudin Versus Heparin 
and Glycoprotein IIb/IIIa Inhibitors: Insight From the 
Blue Cross Blue Shield of Michigan Cardiovascular 
Consortium
Hitinder Gurm, Dean E. Smith, Sanjaya Khanal, Arthur Riba, Andrew J. Carter, Thomas 
LaLonde, Eva M. Kline-Rogers, Mauro Moscucci, for The Blue Cross Blue Shield of 
Michigan Cardiovascular Consortium, University of Michigan Medical Center, Ann Arbor, MI
Background: The REPLACE II trial demonstrated the noninferiority of a strategy of 
bivalirudin compared with heparin and GP IIbIIIa inhibition in patients undergoing PCI. 
There is a paucity of outcome data with bivalirudin use in the setting of real-world PCI 
practice.
Methods: We evaluated the outcome of 11,350 patients who underwent elective PCI for 
stable coronary artery disease (CAD) from 2002 to 2004 in a large regional consortium 
(BMC2), and who were treated with bivalirudin (n=1869) or with heparin and GP IIbIIIa 
inhibitors (n=9481). The primary endpoints were transfusion and in-hospital major 
adverse cardiovascular events (MACE) deﬁned as the composite of death, MI, stroke, 
and any CABG or target lesion revascularization.
Results: Compared with patients who received heparin plus GP IIbIIIa inhibitors, patients 
who received bivalirudin alone had a similar incidence of post procedural MI, stroke, 
in-hospital death, MACE (2.62 versus 2.46, P = 0.67), or transfusion (2.46% versus 
2.39%, P = 0.86). After adjusting for the propensity to receive Bivalirudin and for baseline 
comorbidities, there was no difference in the odds of MACE or the need for transfusion 
between the two groups.
Conclusion: Compared with Heparin plus GP IIbIIIa inhibition, use of bivalirudin in 
patients undergoing PCI for stable CAD is associated with similar ischemic and bleeding 
complications. Given the ease of administration and lower cost, bivalirudin provides an 
attractive treatment option in this patient population.
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ORAL CONTRIBUTIONS
2806 
Drug Eluting Stents: Patients and Lesion 
Speciﬁc Subsets
Tuesday, March 14, 2006, 10:30 a.m.-Noon
Georgia World Congress Center, Room C207
10:30 a.m.
2806-3 Left Main Taxus Pilot Study: Mid-Term Follow-Up
Thierry Lefevre, Olivier Darremont, Marie-Claude Morice, Marc Silvestri, Yves Louvard, 
Philippe Garot, Jean-Louis Leymarie, Véronique Decalf, Andres Ramos, Thierry 
Unterseeh, Pierre Dumas, On behalf of the Left Main Taxus Pilot Study Investigators, 
Institut Cardiovasculaire Paris Sud, Massy, France
Background: CABG is the gold standard treatment of unprotected left main (LM) 
stenosis. Percutaneous coronary intervention (PCI) has been proposed as an alternative 
treatment in some centers with excellent in-hospital results. 
Methods: A pilot feasibility and safety study using the TAXUS stent was set up in 4 
French centers with a wide previous experience in LM stenting. PCI was proposed as an 
alternative to CABG in patients with de novo unprotected LM stenosis. The main technical 
recommendations were to systematically cover the LM ostium with the stent and use a 
provisional T stenting approach in the presence of distal LM lesion with systematic ﬁnal 
kissing balloon inﬂation (Kiss). Acute MI and cardiogenic shock were the only exclusion 
criteria. Prospective 1, 7 and 12 months as well as 2, 3, 4 and 5 years clinical follow-up 
was set up with a recommended angiogram at 6 to 8 months.
Results : Between March 2003 and December 2004, 216 Pts were included (Age 
69+11 years, diabetes 28.4%, previous MI 20%, 3 Vessel disease 27%, ejection fraction 
61+12%, distal LM 74%, Euroscore 4.8+3.4,). The number of other treated lesions was 
1.2+0.9 and total stent length 42+22 mm. Reference LM diameter was 3.71+0.49 mm.. In 
patients with distal LM, a second stent (T stenting) was used in 39% of cases and Kiss in 
95%. Angiographic success was obtained in 99.5% (1 procedural stent thombosis) and 
in-hospital MACCE rate was 4.6% (death 0.9%, Q-wave-MI 0%, non-Q-wave MI 3.2%, 
emergency CABG 0.5%, stroke 0%). Six-eight month clinical follow-up was obtained in 
98% of cases and coronary angiogram performed in 126 (58%) at 7.1+1.8 months. Total 
MACCE rate was 10.2% (Cardiac death 2.3% including 2 sudden death: 0.9%, Q-wave MI 
0%, non-Q-wave MI 3.4%, stroke 0.5%, TVR 3.4%). Coronary angiogram was performed 
in 98 patients (59%). Among 8 patients with LM resténoses, 3 were at the level of the 
ostium which was unstented, 3 were at the level of the proximal Circ (stented), 1 was 
diffuse in stent and 1 was distal to a stented ostium.
Conclusion: Unprotected LM PCI using the TAXUS stent provided excellent angiographic 
results and in-hospital outcomes. Mid-term follow-up is very promising.
10:42 a.m.
2806-4 Obesity Is a Protective Factor for Percutaneous 
Coronary Intervention With Drug-Eluting Stents: The 
Overweight Paradox
Salah-Eddine Hassani, Roswitha Wolfram, Zhenyi Xue, Natalie Gevorkian, Augusto 
Pichard, Neil J. Weissman, Lowell F. Satler, Kenneth M. Kent, Ron Waksman, 
Washington Hospital Center, Washington, DC
Background: The effect of body mass index (BMI) on outcomes after percutaneous 
coronary intervention (PCI) remains controversial. We aimed to determine the impact of BMI 
on clinical outcomes after contemporary PCI with drug-eluting stent (DES) implantation.
Methods and Results: 3819 patients who underwent PCI with DES were analyzed and 
divided into 3 groups according to their BMI: <25 (n=831), 25-30 (n=1448), and >30 
kg/m² (n=1540). In-hospital, 30-day, and 1-year outcomes were then compared among 
groups. Obese patients were signiﬁcantly younger (p=0.004) with a higher incidence 
of hypertension, diabetes, hypercholesterolemia, and positive family history (p <0.001, 
respectively) than BMI <25 and BMI 25-30 patients. Patients with BMI <25 had a higher 
incidence of heart failure (p=0.002) and lower ejection fraction (p=0.005). Despite similar 
angiographic success rates among the groups, BMI <25 patients had more major in-
hospital complications (Table). Outcomes at 1 year showed comparable restenosis rates 
but a signiﬁcantly higher mortality in the BMI <25 group. Multivariate analysis revealed 
age (p<0.001), diabetes (p=0.0002), Q-wave MI (p=0.0002), acute renal failure (p=0.006), 
and BMI <25 (p=0.008) to be independent predictors of 1-year mortality.
Conclusions: DES implantation in overweight and obese patients is associated with a 
low rate of target lesion revascularization at 1 year and paradoxically an overall lower 
complication rate when compared with normal BMI patients. 
In-hospital BMI < 25(n=831) BMI 25-30 (n=1448) BMI >30 (n=1540) P value
Q-wave MI (%) 8 (0.9) 2 (0.1) 3 (0.2) 0.007
Acute renal failure (%) 31 (3.6) 34 (2.3) 31 (1.9) 0.04
1 year
SAT 7 (0.8) 1 (0.1) 4 (0.2) 0.01
Death (%) 42 (17) 35 (9.4) 25 (5.7) <0.001
Q-wave MI (%) 12 (5.4) 13 (3.6) 16 (3.8) 0.53
TLR (%) 22 (9.6) 36 (10) 33 (7.6) 0.47
TLR-MACE (%) 70 (27) 80 (20) 66 (14) <0.001
Late thrombosis (%) 2 (0.2) 2 (0.1) 3 (0.2) 0.89
10:54 a.m.
2806-5 Sirolimus: Versus Paclitaxel-Eluting Stents in the 
Treatment of Coronary Artery Disease in Patients With 
Diabetes Mellitus
Ashesh N. Buch, Pramod K. Kuchulakanti, William W. Chu, Aamir Javaid, Petros 
Okubagzi, Kimberley Smith, Zhenyi Xue, Natalie Gevorkian, Kenneth M. Kent, Augusto D. 
Pichard, Lowell F. Satler, Ron Waksman, Washington Hospital Center, Washington, DC
Background: Drug-eluting stents (DES) are associated with better clinical outcomes in 
diabetic patients compared to bare metal stents. The relative merits of the two available 
DES, sirolimus-eluting (SES) and paclitaxel-eluting stents (PES) were compared.
Methods: Records of 1320 consecutive diabetic patients treated in our institution with 
SES and PES from our prospective registries were analyzed. In-hospital, 1- and 6-month 
clinical outcomes were compared.
Results: Baseline characteristics were similar except for more men, lower body mass 
index and previous coronary revascularization in the PES group (p<0.05). Procedural 
characteristics were similar except for a higher rate of left anterior descending artery lesions 
and glycoprotein IIb-IIIa in the SES group (p<0.01) and more type C lesions (p<0.003), 
predilatation, and stents per patient in PES group (p<005). In-hospital complications, 1- and 
6-month subacute thrombosis rates were similar between the groups (Table). 
Parameter SES (n=804) PES (n=412) p value
1-month Outcomes
TLR-MACE, % 3.1 3.8 0.62
TVR-MACE, % 3.1 3.8 0.62
Death, % 2.8 3.1 0.74
Non-Q-wave MI, % 12.8 12.6 0.9
Subacute thrombosis, % 1.4 0.9 0.71
6-month Outcomes
TLR-MACE, % 9.8 11.4 0.53
TVR-MACE, % 10.7 12.3 0.52
Death, % 7.0 7.0 0.99
Non-Q-wave MI, % 15.9 19.0 0.29
Late thrombosis, % 0.3 0 -
Conclusions: Treating diabetic patients with sirolimus- or paclitaxel-eluting stents is 
associated with similar 6-month outcomes regardless of insulin therapy.
11:06 a.m.
2806-6 Comparison of Clinical Outcomes of Implantation of 
Drug-Eluting Stents With Bare Metal Stents in Large 
Coronary Arteries
Sundeep Mishra, Roswitha M. Wolfram, Zhenyi Xue, Natalie Gevorkian, Augustus D. 
Pichard, Lowell F. Satler, William Suddath, Kenneth Kent, Ron Waksman, Washington 
Hospital Center, Washington, DC
Background: Large reference vessel diameter (RVD) has been found co-relative of lower 
risk of repeat revascularization with bare metal stents (BMS). The objective of this study 
was to assess whether there is any additional beneﬁt in clinical outcome of stenting of 
large coronary vessels with drug-eluting stents (DES) as compared with BMS.
Methods: Outcomes of 352 consecutive patients undergoing single vessel angioplasty 
with DES implantation of large vessels were compared with 352 patients who received 
BMS for vessels with similar RVD. Patients were matched by propensity score 
methodology. Large vessel was deﬁned as a vessel with reference diameter ≥3.5 mm. 
Thirty-day and 6-month clinical outcomes were compared between groups.
Results: Baseline characteristics were comparable between groups except for a higher 
prevalence of prior bypass surgery (23% vs. 14%, p=0.003) in the BMS group. More 
saphenous vein graft lesions (13% vs. 8%, p=0.02) and restenotic lesions (14% vs. 8%, 
p=0.01), but fewer right coronary artery lesions (34% vs. 42%, p=0.02), were treated 
with BMS. Target lesion revascularization (TLR) rate and the incidence of major adverse 
cardiac events (MACE) were generally low and comparable between groups at 30 
days and 6 months (Table) .There was no episode of subacute stent thrombosis or late 
thrombosis in either group.
Conclusions: Stenting of large coronary arteries with DES appears to confer no additional 
beneﬁt as compared to BMS and both are associated with equally favorable outcomes.
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Clinical Outcomes at 30 days and 6 months
Events BMS (n=352) DES (n=352) p value
Death % at 30 days 3 (2.0) 1 (0.3) 0.08
Q-wave myocardial infarction % at 30 days 0 (0.0) 0 (0.0) -
TLR-MACE % at 30 days 3 (2.0) 2 (0.6) 0.16
Sub acute thrombosis % at 30 days 0 (0.0) 0 (0.0) -
Death % at 6 months 4 (3.0) 5 (1.4) 0.27
Q-wave myocardial infarction % at 6 months 2 (1.5) 2 (0.6) 0.30
TLR-MACE % at 6 months 8 (5.9) 10 (2.8) 0.11
TLR % at 6 months 2 (1.5) 4 (1.1) 0.66
Late Thrombosis % at 6 months 0 (0.0) 0 (0.0) -
11:18 a.m.
2806-7 Impact of Gender Difference Following Drug-Eluting 
Stent Implantation
Gloria Melzi, John Cosgrave, Ghada Mikhail, Alaide Chieffo, Tiziana Aranzulla, Nuccia 
Morici, Davide Tavano, Cosmo Godino, Altin Palloshi, Simon Corbett, Antonio Colombo, 
S.Raffaele Hospital, Milan, Italy, EMO Centro Cuore Columbus, Milan, Italy
Background: Prior studies have suggested that women are at higher risk for morbidity 
and mortality following coronary interventions. Gender differences in outcomes may be 
explained by the differences in reference vessel diameter and risk factor proﬁles. Whether 
the advent of drug-eluting stent (DES) has altered this scenario is currently unknown. The 
aim of the study was to examine the role of gender in outcomes after DES implantation.
Methods: The study population consisted of all patients (pts) electively treated with 
DES implantation from March 2003 to December 2004. The end points analyzed were 
in-hospital major adverse cardiac events (MACE) and myocardial infarction (MI), cardiac 
death (CD), target lesion revascularization (TLR), target vessel revascularization (TVR) 
and MACE at 9 months follow-up.
Results: 1383 pts were analysed: 187 (13.5%) women with 307 lesion and 1196 men 
with 2135 lesions. The 2 groups were well matched for clinical and lesion characteristics 
apart from age (66.3±10.5 in women and 62.8±10.6 in men, p=0.0001), diabetes (38.3% 
and 26.3% respectively, p=0.001) and the reference vessel diameter (2.62±0.6 and 
2.71±0.6 respectively, p=0.04).
There were no gender differences in in-hospital events, nor at 9 months follow-up: 
9-month FU Women (pt=187) Men (pt=1196) p-value
-MACE 34 (18.1%) 255 (21.3%) 0.45
-Death 3 (1.6%) 36 (3.0%) 0.35
-MI 2 (1.0%) 19 (1.5%) 0.44
-TLR 28 (14.9%) 171 (14.3%) 0.82
-TVR 31 (16.6%) 210 (17.5%) 0.83
Women (les=307) Men (les=2135)
-TLR 37 (12.1%) 228 (10.7%) 0.49
-TVR 47 (15.0%) 326 (15.3%) 0.93
Conclusions: Contrary to prior data, DES implantation in women is associated with 
comparable results to men. Perhaps these results are explained by the improve in 
outcomes seen in smaller vessels and diabetic patients.
11:30 a.m.
2806-8 Drug-Eluting Stents for Coronary Artery Bypass Graft 
Lesions: Low Recurrence Rates at 6-Months
Garrett B. Wong, Steve S. Lee, Raghava R. Gollapudi, Rafael Valencia, Matthew J. Price, 
Richard A. Schatz, Paul S. Teirstein, Scripps Clinic, La Jolla, CA
Background: Percutaneous coronary intervention (PCI) with drug eluting stents (DES) of 
native coronary arteries is associated with low clinical event rates. However, the safety and 
efﬁcacy sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) to treat de novo 
lesions within coronary artery bypass graft lesions have still not been thoroughly studied.
Methods: All patients (pts) at Scripps Clinic who underwent placement of SES or PES for 
a de novo bypass graft lesion were identiﬁed. Patients were considered eligible for clinical 
follow-up (FU) if at least 6 months had passed since the procedure. Clinical outcomes 
including major adverse cardiac events (MACE) were determined through review of the 
medical record or by telephone interview.
Results: To date 165 pts have undergone 234 DES implantations (188 SES, 46 PES) for 
168 de novo graft lesions, and clinical FU has been obtained in 140 (85%) eligible pts 
(mean FU of 225 + 68 days). The mean pt age was 68 + 14 years, the mean graft age 
10 + 6 years, diabetes was present in 41 pts (29%), and LV function was < 40% in 40 pts 
(28%). The bypass graft ostium was involved in 34 lesions (20%), the body in 97 (58%), 
and the distal anastomosis in 37 (22%). The majority of the lesions were saphenous 
vein grafts (94%). Arterial conduit lesions comprised 6%. In-hospital MACE (myocardial 
infarction [MI, deﬁned as CK-MB > 3x normal], target vessel revascularization [TVR], 
thrombosis, or death) occurred in 28 pts (17%), driven entirely by post-procedural MI. Out 
of hospital MACE occurred in 35 pts (21%), MI in 12 pts (7%) and TVR in only 13 pts (8%). 
There were 2 deaths: one non-cardiac at 3 months, and one cardiac at 6 days presumed 
to be due to stent thrombosis. Non-TVR occurred in 30 pts (18%).
Conclusions: Our clinical experience indicates that PCI with drug eluting stents for de 
novo coronary artery bypass graft lesions are safe and have a low (8%) rate of clinically 
driven 6 month TVR. By 6 months FU, major adverse cardiac events are driven primarily 
by disease in non-target vessels.
POSTER SESSION
2925 
Rotational Atherectomy
Tuesday, March 14, 2006, 12:30 p.m.-4:00 p.m.
Georgia World Congress Center, Hall B1
Presentation Hour: 1:30 p.m.-2:30 p.m.
2925-61 Effect of Rotational Atherectomy on the Outcomes 
of Patients With Heavily Calciﬁed Coronary Lesions 
Treated With Sirolimus-eluting Stenting
Leonardo C. Clavijo, Daniel H. Steinberg, Rebecca Torguson, John R. Laird, Lowell 
F. Satler, William O. Suddath, Kenneth M. Kent, Ron Waksman, Augusto D. Pichard, 
Washington Hospital Centerw, Washington, DC
Background: Previous studies have shown that the use of rotablator in calciﬁed coronary 
lesions prior to balloon angioplasty is associated with a high rate of restenosis and target 
lesion revascularization (TLR). Bare metal stenting after rotational atherectomy reduces 
restenosis, but rates remain high. The effect of drug-eluting stenting after rotational 
atherectomy is unknown.
Methods: One hundred and ﬁfty consecutive patients with angiographic evidence 
of heavily calciﬁed coronary lesions who underwent sirolimus-eluting stent (SES) 
implantation were included in the study. Group 1 included 71 patients with heavily calciﬁed 
lesions who underwent SES implantation without the need of rotablator (SES); Group 2 
included 79 patients with heavily calciﬁed lesions in whom rotablator was required to 
modify the plaque and facilitate the delivery of the stent (SES + rotational atherectomy).
Results: Baseline characteristics were similar between the treated groups. Clinical 
success was equivalent in both groups (>98%) and there were no in-hospital outcome 
differences. Post-procedure CK-MB elevation >3x normal occurred in 24.6% and 20.5% 
of patients in the SES and SES + rotational atherectomy groups, respectively (p=0.55). At 
6 months the TLR rate was 4.8% in SES vs. 1.6% in SES + rotational atherctomy groups, 
p=0.62. The death rate at 6 months was 6.3% in the SES vs. 9.5% in the SES + rotational 
atherectomy groups, p=0.51.
Conclusions: SES continues to perform well with a relative low event ratet in patients 
with heavily calciﬁed coronary lesions. The use of rotablator to facilitated deployment of 
SES is safe and associated with similar outcomes when compared to the treatment of 
balloon for predilatation of calciﬁed lesion prior to SES implantation.
2925-28 The Safety and Efﬁcacy of the Starclose™ Vascular 
Closure System: The Ultrasound Substudy of the Clip 
Study
Michael Jaff, Gail Hadley, James B. Hermiller, Charles Simonton, Tomoaki Hinohara, Louis 
Cannon, Mark Reisman, Greg Braden, Dana R. Fletcher, Michael Zapien, Tony M. Chou, 
Massachusetts General Hospital, Boston, MA, Abbott Vascular, Redwood City, CA
Background: The CLIP Study was a performed to assess the safety and efﬁcacy of the 
StarClose™ Vascular Closure System (Abbott Vascular, Redwood City, CA) as compared 
to standard compression (SC) following 5 to 6 French diagnostic or interventional 
percutaneous procedures. StarClose, currently an investigational device in the U.S., 
features an innovative nitinol clip that is designed to achieve closure of the femoral artery 
access site.
Methods: At 17 sites, 483 patients were randomized at a 2:1 ratio to receive StarClose 
or SC with primary endpoints of post-procedure time to hemostasis and major vascular 
complications through 30 days. A substudy of the CLIP intervational arm evaluated duplex 
ultrasound (DUS) images of the closure site at ﬁve study sites, targeting 100 subjects at 
day 30. The DUS protocol was devised and implemented by an independent core lab. 
DUS of the common femoral artery and vein, superﬁcial femoral artery and vein, and the 
saphenofemoral venous conﬂuence were evaluated approximately 6cm above and below 
the puncture site to determine absence or presence of iatrogenic injuries: hematoma, 
pseudoaneurysm (PSA), arteriovenous ﬁstula (AVF), and vessel thrombosis or stenosis 
using 2-dimensional gray scale, color enhanced, and focused Doppler images.
Results: DUS of 96 subjects randomized to StarClose (N=71) and SC (N=25) were 
performed. There was no evidence of hematoma, PSA or AVF observed. One non-
substudy SC patient was noted to have a PSA one day after the procedure requiring 
repeat thrombin injections and blood transfusion. All patients in the substudy demonstrated 
patency of the access site artery and vein without thrombosis or stenosis.
Conclusion: Independent DUS analysis, a safe and reliable method for determining the 
safety and efﬁcacy of access site closure devices, found no statistical difference between 
the StarClose and SC groups of a substudy of patients in the CLIP study. Both groups 
maintained vessel patency without stenosis, thrombosis, hematoma, pseudoaneurysm 
or AV ﬁstula.
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POSTER SESSION
2926 
Intracoronary Imaging: Part II
Tuesday, March 14, 2006, 12:30 p.m.-4:00 p.m.
Georgia World Congress Center, Hall B1
Presentation Hour: 1:30 p.m.-2:30 p.m.
2926-62 Impact of Optical Coherence Tomography (OCT) and 64-
slice Multidetector Computed Tomography (MDCT) on 
the Assessment of Acute Coronary Syndrome (ACS)
Yukio Ozaki, Masanori Okumura, Junichi Ishii, Shigeru Matsui, Hiroyuki Naruse, Shigeru 
Kato, Takahisa Sato, Yu Nakamura, Kaori Inoue, Sada Nakano, Sino Kan, Shinya 
Hiramitsu, Takeshi Kondo, Tevﬁk F. Ismail, Hitoshi Hishida, Division of Cardiology, Fujita 
Heath University, Toyoake, Japan, Northwick Park Hospital, London, United Kingdom
Recent pathological studies suggest that ACS can be initiated by the disruption of thin-
cap (<65µm) ﬁbroatheroma (TCFA). While optical coherence tomography (OCT; Lightlab, 
Boston, MA) provides a novel high-resolution image (10µm), 64-slice MDCT would offer 
precise quantitative density measurements of coronary plaque morphology (Hounsﬁeld 
units; HU). We prospectively performed MDCT with a slice thickness of 0.5mm (Aquilion 
64, Toshiba, Japan) and OCT prior to coronary intervention (PCI) in 20 patients (18 
males, mean age 63±10 years) with 44 lesions (19 ACS lesions and 25 stable lesions). 
No difference was found in age, gender and coronary risk factors including hypertension, 
diabetes and hyperlipidemia between the two groups. Quantitative coronary angiography 
(QCA) was performed by CAAS II system (Pie Medical, Maastricht, NL).
Results: While OCT revealed that ACS lesions had thinner ﬁbrous-cap (p<0.001) and 
greater lipid-pool (p<0.05) associated with thrombus formation (p<0.001) in comparison 
with stable lesions, MDCT indicated signiﬁcantly lower HU-values in ACS lesions than 
stable lesions. No difference was seen in the stenosis severity between the two groups 
in MDCT and QCA.
Conclusions: The diagnostic sensitivity and speciﬁcity at <40-HU for the prediction 
of ACS-lesion were 70% and 95%, respectively. While OCT could provide precise 
quantiﬁcation of plaque morphology in ACS, 64-slice MDCT could be useful to predict the 
high-risk vulnerable plaque in the noninvasive manner.
ACS lesion (n=19) Stable lesion (n=25) P
OCT
Cap thickness (µm) 46±20 295±113 <0.001
Lipid pool angle (degree) 245±97 182±95 <0.05
Thrombus angle (degree) 217±116 0 <0.001
64-slice MDCT
Plaque density (HU*) 37±53 98±67 <0.01
% Diameter stenosis 71±21 60±18 ns
QCA
% Diameter stenosis 62±4 62±6 ns
2926-63 Evaluation of Coronary Plaque Rupture and Thrombus 
Using Optical Coherence Tomography: Comparison to 
Intravascular Ultrasound
Yoshihiro Takeda, Tatsuya Itoh, Yoshihisa Kinoshita, Kenya Nasu, Jean Francois 
Surmely, Akira Murata, Mariko Ehara, Etsuo Tsuchikane, Mitsuyasu Terashima, Tetsuo 
Matsubara, Osamu Katoh, Takahiko Suzuki, Toyohashi Heart Center, Toyohashi, Japan
Background: Acute coronary syndromes (ACS) mainly result from plaque rupture and 
subsequent thrombosis. Several IVUS studies have reported that the percentages of 
rupture at the culprit site of ACS lie between 16% and 66%. However, compared with 
OCT, the resolution of IVUS (100 µm) limits its ability to detect rupture and thrombus.
Methods: Sixty patients undergoing PCI for native coronary artery diseases were enrolled 
and categorized according to their clinical presentation: ACS (n=33) or stable angina 
(n=27). Preinterventional OCT and IVUS imaging were performed. Using OCT, lipid-rich 
plaque was deﬁned as lipid occupying ≥1 quadrant of the cross-sectional area. In the 
culprit lesion with plaque rupture detected by OCT, the minimum thickness of “intact” 
ﬁbrous cap overlying lipid-rich plaque within 5 mm adjacent to the rupture site was also 
measured by OCT.
Results: As shown in Table, in both the ACS and stable angina patients, the percentages 
of plaque rupture and thrombus detected by OCT were higher than those detected by 
IVUS. All ruptures and thrombi diagnosed by IVUS were detected by OCT. In lesions with 
rupture, the ﬁbrous cap was signiﬁcantly thinner in the ACS compared to the stable angina 
patients (63±27 µm vs. 124±79 µm, P=0.018). Conclusions: OCT provides additional 
information about plaque morphology such as rupture and thrombus, compared to IVUS. 
Within a short distance adjacent to the rupture site, the cap thickness overlying plaque 
may vary and is correlated to the clinical presentation.
Frequency of Plaque Rupture and Thrombus Identiﬁed by IVUS and OCT
ACS (n=33) Stable angina (n=27) P value
Identiﬁed by IVUS
Plaque rupture, n (%) 7 (21) 6 (22) NS
Thrombus, n (%) 15 (45) 4 (15) 0.01
Identiﬁed by OCT
Plaque rupture, n (%) 22 (67) 8 (30) <0.005
Thrombus, n (%) 27 (82) 4 (15) <0.0001
Thickness of ﬁbrous cap, mean±SD µm 63±27* 124±79** 0.018
*n=22 **n=8
2926-64 Oxygenated Hemopure Offers Clear Visualization 
of Coronary Arteries During OCT Imaging Without 
Ischemia
Stephane Carlier, Jie Qian, Joe Schmitt, Jie Wang, Marty B. Leon, Cardiovascular 
Research Foundation, New York, NY, LightLab Imaging, Westford, MA
Background: Optical coherence tomography (OCT) utilizes near-infrared light to 
generate tomographic in vivo high resolution images of coronary arteries better than 
IVUS. It is however necessary to temporarily interrupt coronary blood ﬂow in order to 
image the vessel wall because of the scattering effects of the ﬂowing red blood cells. 
Flushing of the vessel with saline is necessary but can only be performed for a limited 
time (<30 seconds) because of the induced ischemia. Hemopure (Biopure Corporation) is 
a hemoglobin-based oxygen carrier that can enhance oxygen transport by promoting both 
the convective and diffusive components of transport in the microcirculation. We sought to 
evaluate the use of Hemopure during OCT imaging to reduce ischemia.
Methods: In vitro, attenuation experiments were performed using an OCT microscope 
(LightLab Imaging) and a tilted diffuse reﬂector (Spectralon plastic) as a depth reference 
in H2O, D2O and 8g/dl Hemopure. In pigs, we performed imaging of coronary segments 
with and w/o stents and followed ST depression during up to 2 min occlusion with 0.5 ml/s 
ﬂushing of saline or Hemopure.
Results: (see graph): Hemopure attenuation was similar to saline (< 0.15 mm-1 at 1300 
nm). Refractive index was 1.357. Perfectly clear visualization of coronary wall and stent 
was possible without ischemia related events with Hemopure, whereas 2 min ﬂushing of 
saline induced ventricular ﬁbrillation.
Conclusions: The use of Hemopure to perform OCT appears a safe alternative to 
saline ﬂush. 
2926-65 Safety and Feasibility of a Novel Intravascular Optical 
Coherence Tomography Image Wire System in a 
Clinical Setting: Japanese Multicenter Study
Shigeru Nakamura, Takahiko Suzuki, Mitsuyasu Terashima, Takashi Akasaka, Takahiro 
Hayashi, Kyoichi Mizuno, Toshiya Muramatsu, Masato Nakamura, Tadateru Takayama, 
Junichi Yoshikawa, Tetsu Yamaguchi, Kyoto-Katsura Hospital, Kyoto, Japan, Toranomon 
Hospital, Tokyo, Japan
Background: Optical coherence tomography (OCT) is a novel imaging technique with a 
high resolution. This Japanese multi-center study was designed to evaluate the safety and 
feasibility of a novel intravascular OCT imaging system in a clinical setting.
Methods: The OCT system (ImageWire®) consists of 0.016 inch image wire. OCT 
imaging is performed under the condition of vessel occlusion by a compliant balloon 
and continuous ﬂushing. In this study, 76 cases from 8 centers were enrolled; diagnostic 
coronary angiogram (CAG): 36 cases, coronary intervention (PCI): 40 cases. We assessed 
the safety and feasibility of this system, compared with those of IVUS.
Results: Vessel occlusion time was 48.3 ± 13.5 sec, and occlusion balloon pressure was 
0.4 ± 0.1 atmosphere. Flushing of lactated Ringer’s solution was performed at a rate of 
0.6 ± 0.4 ml/s. No signiﬁcant adverse events, including vessel dissection, signiﬁcant CK 
elevation and fatal arrhythmia, were observed. Procedural success rates are shown in the 
table. OCT was available in 5 of 6 tight lesions in which IVUS catheter could not cross. 
On the 98 lesions in which both OCT and IVUS were successfully performed, entire 
circumferential image of lumen border was obtained at the minimum lumen site in 88 
lesions by OCT, and in 81 lesions by IVUS.
Conclusions: This multi-center study demonstrates the safety and feasibility of the OCT 
image wire system for visualizing coronary lesions in a clinical setting. This OCT system 
also allows the visualization of tight lesions.
Procedual Success Rates
CAG (36 cases) before PCI (40 cases) after PCI (34 cases)
OCT 100 % 92.5 % 100 %
IVUS 100 % 85.0 % 100 %
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2926-66 Differences in Plaque Composition of the Target Lesion 
Between Acute Coronary Syndrome and Stable Angina 
Pectoris
Kenya Nasu, Etsuo Tsuchikane, Osamu Kato, Jean-Francois Surmely, Hiroshi Fujita, 
Yoshihiro Takeda, Tatsuya Itoh, Mariko Ehara, Yoshihisa Kinoshita, Mitsuyasu Terashima, 
Tetsuo Matsubara, Takahiko Suzuki, Toyohashi Heart Center, Toyohashi, Japan
Background: A rupture of vulnerable plaque is one of the major mechanisms for acute 
coronary syndrome (ACS) onset. However, there is little data evaluating the differences of 
plaque morphology between ACS and stable angina pectoris (AP) patients.
Methods: One hundred and twenty two signiﬁcant native coronary lesions underwent 
Virtual Histology - intravascular ultrasound (IVUS) with a 20 MHz phased-array IVUS 
catheter. In vivo tissue histology sections were reconstructed by radiofrequency 
data analysis and evaluated from distal to proximal references of the target lesion. 
Radiofrequency signals were classiﬁed into four component types: Dense Calcium; 
Fibrous; Fibro-fatty; and Necrotic Core. The average of the value from all the image slices 
for one lesion was calculated. Patients were divided into two groups, an ACS group (32 
lesions in 32 patients) and a stable AP group (90 lesions in 90 patients).
Results: Plaque composition was different between the two groups (Table) with more 
Necrotic Core (ACS; 14.1% vs. stable AP; 10.9%, respectively, p = 0.02), and less Fibrous 
(ACS; 57.1% vs. stable AP; 63.4%, respectively, p =0.03) in ACS groups. Other plaque 
components as well as the percent plaque were similar between the two groups.
Conclusions: Compare to stable AP patients, coronary plaque compositions in ACS 
patients showed an increased amount of Necrotic Core and a decrease of Fibrous. This 
could possibly indicate an increased frequency of vulnerable plaque in ACS patients
Virtual Histology Analyses
ACS (n = 32) Stable AP (n = 90) p value
Plaque area, % 34.2±11.9 36.8±10.1 NS
Fibrous area, % 57.1±13.5 63.4±13.8 0.03
Fibro-fatty area, % 19.1±9.4 17.9±9.2 NS
Necrotic Core area, % 14.1±7.8 10.9±6.4 0.02
Dense Calcium area, % 9.6±10.0 7.6±5.5 NS
 
2926-67 New Method for Intravascular Ultrasound Evaluation of 
Coronary Plaque With Ultra-low Proﬁle Imaging Device: 
Application of Elastography Combined With Integrated 
Backscatter Tissue Analyses
Tsuyoshi Yoshimuta, Masakazu Yamagishi, Mahoto Kato, Yu Kataoka, Satoshi 
Yasuda, Isao Morii, Atsushi Kawamura, Shunichi Miyazaki, Tsuyoshi Shiina, National 
Cardiovascular Center, Osaka, Japan
Background:At the time coronary interventional procedure, determination of plaque 
characteristics is important to prevent the occuerence of complication. Although 
intravascular ultrasound (IVUS) has been used for examining plaque morphology, 
few data exist regarding determination of plaque characteristics in terms of tissue 
composition and elasticity. Therefore, new IVUS system in which strain power imaging 
(SPI) and integrated backscatter (IB) tissue analyses were combined, was developed for 
clinical evaluation. Method: After conversion of radio frequency (RF) signal of ultrasound 
obtained from newly developed ultra-low proﬁle transducer (40 MHz, 2.4 Fr, Terumo), 
strain distribution of plaque induced by blood pressure changes during cardiac cycle 
was calculated by comparing RF signals of the same scan line. Under these conditions, 
we used originally developed two-dimensional searching algorithm using time series 
analysis of strain distribution. Plaque compostion was simultaneously determined by IB. 
Results: In 128 coronary sites from 21 patients, the different types of lesions such as 
lipid-rich (n=34), ﬁbrous (n=52) and calciﬁed (n=42) plaque can be distincted based on 
the strain power image.Interestingly, elastography can determine tissue elasticity even 
in the presence of calciﬁcation (Fig ). Conclusion: These results demonstrate that the 
present IVUS imaging system with SPI and IB gives possibility for determining coronary 
plaque chracteristics.
2926-68 Tissue Characterization of Transplant Coronary 
Vasculopathy by Virtual Histology
Jang-Ho Bae, Charanjit S. Rihal, David R. Holmes, Greg W. Barseness, Abhiram 
Prasad, Amir Lerman, Mayo Clinic, Rochester, MN
Background: Tissue characterization of this process in humans in vivo has not been 
previously described. We assessed the tissue characterization of transplant coronary 
vasculopathy (TCV) using virtual histology (VH) intravascular ultrasound (IVUS).
Methods: 61 consecutive patients (mean 52 years old) underwent IVUS examination of 
the left anterior descending coronary artery 55±51months after transplantation. Ofﬂine 
spectral analysis of IVUS radiofrequency data was performed with IVUS-VH software.
Results: The ﬁbrous, ﬁbrofatty, dense calciﬁed and necrotic core volume/examined length 
(mm3/mm) of plaque was 0.9±1.1 (57%), 0.2±0.3 (18%), 0.18±0.3 (12%), and 0.18±0.2 
(13%), respectively. Age (current or at transplantation) and the causes of transplantation 
were not associated with any speciﬁc plaque component. Total cholesterol and low 
density lipoprotein (LDL) cholesterol were negatively associated with ﬁbrous plaque and 
positively with necrotic core plaque. LDL cholesterol and time after heart transplantation 
were independent predictors of necrotic core and dense calciﬁed plaque constituents. 
Plaque volume was independently associated with a greater degree of ﬁbrous and fewer 
ﬁbrofatty plaques.
Conclusions: This is the ﬁrst study to evaluate the tissue characterization of TCV using 
VH. This study suggests that necrotic core, an important characteristic of vulnerable 
plaques, is associated with LDL-cholesterol and time after heart transplantation.
The results of univariate (r) and multivariate (β) analysis
% of ﬁbrous 
plaque
% of ﬁbrofatty 
plaque
% of necrotic 
core plaque
% of dense 
calciﬁed plaque
Total Cholesterol r=-0.509 (p=0.022) NS
r=0.607 
(p=0.005) NS
LDL Cholesterol r=-0.488 (p=0.034) NS
r=0.520 
(p=0.022) NS
LDL Cholesterol NS β=-0.691 (p<0.05)
β=0.948 
(p<0.001) β=0.651 (p<0.01)
Time after 
Transplantation NS NS
β=0.666 
(p<0.001) β=0.663 (p<0.01)
Plaque Volume β=1.093 (p<0.001)
β=-0.510 
(p=0.001) NS NS
2926-69 Intravascular Ultrasound-Virtual Histology 
Detects Vascular Structural Changes Observed in 
Atherosclerosis Progression and Regression in 
Hypercholesterolemic Rabbits: Clinical Implications for 
Longitudinal Evaluation of Atherosclerosis
Juan F. Granada, Catalina Granada, David Wallace-Bradley, Carlos L. Alviar, Eli I. Lev, 
Pedro Abad, Ana M. Rivas, Ana M. Oviedo, Albert E. Raizner, Greg L. Kaluza, The 
Methodist Hospital Research Institute and the University of Houston, Houston, TX, The 
Corbic Research Institute, Envigado, Colombia
Background: Virtual Histology (VH), the spectral analysis of radio-frequency signals 
backscattered from the atherosclerotic plaque during Intravascular Ultrasound (IVUS) 
imaging aims to provide a detailed analysis of the plaque composition in vivo. However, 
its ability and accuracy to monitor the landmark vascular features of progression and 
regression of atherosclerosis has not been evaluated. 
Methods: 20 rabbits were mantained in high cholesterol diet for 4 months and then 
randomized into a progression (PG, 10 rabbits, 1% cholesterol feed) or a regression group 
(RG, 10 rabbits, normal feed for a total) for a total of 8 months. Animals were longitudinally 
sacriﬁced at 4 (n=3+3), 6 (n=3+3) and 8 months (n=4+4). IVUS/VH imaging was performed 
ex-vivo in the thoracic aorta using a 20MHz IVUS catheter (Volcano Therapeutics). Tissue 
was harvested for histological evaluation and correlation with IVUS ﬁndings.
Results: A total of 920 IVUS/VH frames were analyzed in the PG and 644 frames in 
the RG. At 8 months of follow-up, the mean EEL area (PG= 16.4± 1.35mm2 versus 
RG=13.7±2.36 mm2 (p<0.001) and plaque area (PG= 8.8±1.19 mm2 versus RG= 8.1± 
1.59 mm2, p<0.05) were larger in the PG. VH analysis showed that the plaques formed in 
the PG contained more ﬁbro-fatty tissue (PG=45% versus RG=31%, p<0.001) and less 
dense calcium (PG=29% versus RG=42%, p<0.001). The percentage of ﬁbro-fatty tissue 
increased over time in the PG (4 months= 25% versus 8 months= 45.5%, p<0.001) and 
decreased in the RG (4 months= 43.7% versus 8 months= 32%, p<0.001). Conversely, the 
percentage of dense calcium increased in the RG (4 months= 29.6% versus 8 months= 
39.3%, p<0.001) compared to the PG (4 months= 45% versus 8 months= 29%, p<0.001). 
Histological veriﬁcation demonstrated agreement with VH in the proportion of ﬁbro-fatty 
tissue but not of the presence of dense calciﬁcation.
Conclusions: IVUS-VH reliably documented plaque progression and regression in 
atherosclerotic rabbits. In the PG, plaque composition showed increasing proportion of 
less dense tissue (ﬁbro-fatty), while maturation of the plaque into a denser tissue (ﬁbrotic) 
in the RG was analized as dense calcium by VH.
2926-70 Endothelial-dependent Vasodilation and Cardiovascular 
Events in Postmenopausal Women
Rosario Rossi, Annachiara Nuzzo, Giorgia Origliani, Maria G. Modena, University of 
Modena and Reggio Emilia, Modena, Italy, Centro “Bene Essere Donna”. Azienda 
Policlinico, Modena, Italy
Background: Cardiovascular events are the primary cause of death and inability 
in all industrialized countries. Conventional cardiovascular risk factors (cigarette 
smoking, hypercholesterolemia, hypertension and diabetes) fail to explain nearly 50% 
of cardiovascular events. This study examines the association between endothelial-
dependent vasodilation and cardiovascular events in a population of initially asymptomatic 
postmenopausal women.
Methods: We conducted a prospective study on 2,159 postmenopausal women, aged 
54 ± 5 years (range: 48-60 years). Endothelial function was measured as ﬂow-mediated 
dilation (FMD) of the brachial artery, using high-resolution ultrasound. The lenghts of 
the follow-up was 42 ± 12 months (range: 6-60 months). Cardiovascular events were 
deﬁned as the occurrence of one of the following: death, myocardial infarction (MI), 
revascularization (catheter-based or surgical), transient ischemic attack (TIA), and 
ischemic stroke.
Results: During observation, 81 cardiovascular events were recorded: 45 TIA; 18 ischemic 
stroke; 8 acute myocardial infarction; 8 hospitalization for coronary revascularization; 2 
cardiac-related deaths. Among patients with events, FMD resulted 3.4% ± 1.7[SEM], 
compared with 9.5% ± 1.9[SEM] recorded in women event-free (p<0.0001). The events 
rate among patients in the lowest tertile of FMD (FMD 8.3% (highest tertile, reference): 
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The RR, adjusted for age and conventional risk factors, resulted 4.55 (95% CI: 3.55-
6.32). When added to age and other risk factors, the presence of FMD% contributed 
signiﬁcantly to model predicting cardiovascular events (Likelihood Ratio �2 change: 9.16; 
p<0.0001)
Conclusions: In postmenopausal women, knowledge of FMD% provides incremental 
information regarding the risk of developing cardiovascular events in addition to that 
deﬁned by conventional cardiovascular risk assessment.
2926-71 First in Human Implanted Device in Pulmonary Artery 
Using Acoustic Telemetry Based on Noninvasive 
Ultrasound Activation and Communication
Keyur H. Parikh, Hetal D. Shah, Milan C. Chag, Urmil G. Shah, Hemang A. Baxi, Anish 
H. Chandarana, Ajay M. Naik, Joyal N. Shah, Yoseph Rozenman, The Heart Care Clinic, 
Ahmedabad, India, Remon Medical Technologies Inc., Israel
Background: The left ventricular end diastolic pressure (LVEDP) is a critical hemodynamic 
parameter, which is the basis for decompensation events in Congestive Heart failure(CHF).
The LVEDP correlates with the Pulmonary Artery diastolic pressure (PADP). RemonCHF 
Implant (Remon technologies,Israel) measures the pressure waveform in the pulmonary 
artery(PA) based on non-invasive acoustic activation and communication, as frequently 
as necessary and non-invasively. The objective of the study was to determine safety and 
functionality of the Remon Implant(RI) and its ability to accurately measure PADP in CHF 
patients. 
Methods:10 NYHA class III/IV patients were included in this First in Man study. Baseline 
PA Hemodynamics measurement was performed using a Millar Catheter. The RemonCHF 
implant (3mm x3mm x16mm) , made of Titanium case, encapsulating an energy 
exchanger, control chip, pressure sensor and energy reservoir with ultrasonic capabilities 
was percutaneously implanted, using a delivery system (internal jugular approach) in the 
Right Main PA. A self-expandable nitinol anchor for positioning of the implant is attached 
to the implant. When interrogated by the desktop system, through a handheld transducer, 
in contact with the chest, RI is activated.The energy exchanger (piezoelectric transducer) 
converts applied external ultrasonic pressure to electrical energy.Once energized, the 
control chip interrogates the pressure sensor and ultrasonically transmits the digital 
reading to an external receiver.
Results:The RemonCHF implant was deployed in 10 patients. By placing the transducer 
on the patient’s chest , high quality accurate (compared to Millar catheter placed 
simultaneously in the PA) pressure waveforms were obtained using the RI. At 3 months of 
follow up, there has been no adverse events.
Conclusions: Continuous noninvasive monitoring of PA pressure by an implantable 
device may improve management and prognosis of CHF. As opposed to the Chronicle 
Implantable Hemodynamic Monitor, which measures the right ventricular pressure and 
derives an estimated PADP by an algorithm, the RemonCHF Implant measures the PADP 
directly and non invasively from its location in the Right PA.
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Acute Mydocardial Infarction: Achieving 
the Best Results
Tuesday, March 14, 2006, 12:30 p.m.-4:00 p.m.
Georgia World Congress Center, Hall B1
Presentation Hour: 1:30 p.m.-2:30 p.m.
2927-72 Early and Late Survival in Patients with Shock Due 
to Right Ventricular Versus Left Ventricular Infarction 
Following Primary Percutaneous Coronary Intervention 
for ST Elevation Myocardial Infarction
Bruce Brodie, Thomas Stuckey, Charles Hansen, Barbara Bradshaw, Mark Pulsipher, 
William Downey, LeBauer Cardiovascular Research Foundation and Moses Cone Heart 
and Vascular Center, Greensboro, NC
Background: Previous studies have shown similarly high in-hospital mortality in patients 
with cardiogenic shock due to RV and LV infarction, but there are little data comparing 
survival following primary PCI.
Methods: Consecutive pts with STEMI treated with primary PCI (n=2496) were 
prospectively enrolled in a registry from 1984-2005 and followed for 6.5 years. Cardiogenic 
shock occurred in 189 pts (7.6%). Shock was attributed to RV infarction when there was 
proximal RCA occlusion with preserved LVEF with elevation of RA pressure or ECG/Echo 
evidence of RV infarction.
Results: Pts with RV (n=30) vs. LV shock (n=136) had less prior MI (10% vs. 29%, 
p=0.03), more current smoking (62% vs. 37%, p=0.01) less 3V CAD (20% vs. 47%, 
p=0.007), higher RA pressure (21mm vs. 16mm, p=0.003), and better LVEF (57% vs. 
32%, p<0.001). In-hospital mortality was signiﬁcantly lower with RV vs. LV shock (23.3% 
vs. 50.0%, p=0.01), and late cardiac survival was signiﬁcantly better (Figure), with only 
one post-hospital cardiac death. Signiﬁcant predictors of late cardiac mortality by Cox 
regression were age and RV infarction.
Conclusion: In contrast to prior reports, we found signiﬁcantly better survival in pts with 
shock due to RV vs. LV infarction following primary PCI. Better survival is likely related to 
lower risk proﬁle, including preserved LV function, and known substantial recovery of RV 
function following primary PCI. These data should encourage treatment of pts with shock 
due to RV infarction with primary PCI.
2927-73 In Vivo Detection of CD68 Positive Macrophages, TNF-
alpha, COX-II, and CRP in Harvested Thrombi Support 
a Local Inﬂammatory Process in Acute Thrombotic 
Coronary Occlusion
Lukas Andreas ALTWEGG, Michel Neidhart, Roberto Corti, Marco Rofﬁ, Franz Eberli, 
Steffen Gay, Thomas Felix Luescher, Willibald Maier, Cardiology University Hospital 
Zurich, Zurich, Switzerland, Institute for Experimental Rheumatology University Hospital 
Zurich, Zurich, Switzerland
Background: Multiple histological studies have illustrated the critical role of inﬂammation 
in the pathogenesis of atherothrombosis. However these observations mainly relate to 
postmortem specimens. In the present study we analyzed the inﬂammatory cell and marker 
content of freshly harvested thrombi from patients with acute myocardial infarction (AMI).
Methods: Distal protection devices used in acute percutaneous coronary intervention (PCI) 
provide the possibility of collecting material from the immediate site of coronary occlusion. With 
the PercuSurge GuardWire System we obtained local thrombotic material from 16 patients 
with acute myocardial infarction, which was ﬁxed in formaldehyde, embedded in parafﬁn and 
stained using antibodies against CD68, TNF-alpha, cyclooxygenase-II (COX-II), and CRP.
Results: Nineteen patients (mean age 55+/-2 SEM years) underwent primary PCI for AMI 
with a mean duration of 573+/-102 minutes from the onset of chest pain to GuardWire 
placement. TIMI ﬂow after the wire passage prior to inﬂation of the distal occlusion 
balloon was 0-1 in the majority (61%) of patients indicating stasis of local blood ﬂow. 
In all 19 thrombi immunohistochemistry revealed widely positive staining for CD68 
positive macrophages, TNF-alpha and COX-II. CRP, however, was found exclusively in 
the cytoplasm of singular phagocyting white blood cells suggesting phagocytosis of the 
acute phase reactant.
Conclusions: Detection of CD68 positive cells expressing TNF-alpha and COX-II in all 
locally harvested thrombi from patients with acute coronary thrombosis strongly support 
inﬂammation as a crucial pathway leading to plaque rupture and thrombus formation. 
Phagocytosis of CRP points to a mainly systemic origin of this important marker of 
inﬂammation.
2927-74 Final Results of the Typhoon Study: A Multicenter 
Randomized Trial Comparing the Use of Sirolimus-
Eluting Stents to Bare Metal Stents in Primary 
Angioplasty for Acute Myocardial Infarction
Christian Spaulding, Patrick Henry, Emmanuel Teiger, Keavin Beatt, Ezio Bramucci, Didier 
Carrie, Michel Slama, Bela Merkely, Andrejs Erglis, Massimo Margheri, Ana Cebrian, 
Christopher Bode, AP-HP, Paris, France, Universitatsklinik Freiburg, Freiburg, Germany
Background : Sirolimus-Eluting Stents (SES) have been proven to reduce restenosis and 
reintervention compared to bare metal stents (BMS). However, their safety and efﬁcacy in 
acute myocardial infarction (AMI) have not yet been demonstrated in a large randomized 
trial with clinical end-points.
Methods: TYPHOON (Trial to Assess the Use of the CYPHERTM stent in Acute Myocardial 
Infarction Treated with Balloon Angioplasty) is a multi-center randomized single-blind 
trial comparing SES to BMS in primary PTCA for AMI. Patients were included if they 
presented with AMI (deﬁned as prolonged chest pain with ST segment elevation) of less 
than 12 hours of duration and a culprit lesion in a native coronary artery suitable for 
stenting. Exclusion criteria were: Prior myocardial infarction, Kilip class > 2, bifurcation 
lesion with a diseased side branch requiring treatment, unprotected left main coronary 
disease with > 50% stenosis, signiﬁcant (>50%) stenosis proximal or distal to the artery 
requiring revascularization, severe multi-vessel disease of the non-culprit artery requiring 
CABG. Patients were randomized after the culprit lesion was visualized to receive either 
SES (Cypher™ or Cypher Select™) or BMS. The primary end-point was target vessel 
failure at one year post-procedure deﬁned as target vessel revascularization, recurrent 
myocardial infarction or cardiac death that could not be clearly attributed to a vessel other 
than the target vessel. Secondary end-points included in-hospital, 1, 6, and 12 months 
major adverse cardiac events. Based on sample size estimation, enrollment of 700 
patients was planned. An 8-month follow-up angiographic sub-study was programmed in 
200 patients from selected centers.
Results : Between October 2003 and September 2004, 715 patients from 48 centers 
were enrolled. Mean age was 59 ±12 years, 78% were men, AMI location was anterior 
in 45% of cases. One-year follow-up data will be available in November 2005, and ﬁnal 
results, including the angiographic sub-study, will be presented at the meeting.
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2927-75 Systemic Review on Long-term Mortality in the 
Randomized Trials on Elective Recanalization of 
Occluded Arteries After ST-Elevation Myocardial 
Infarction
Freek W. A. Verheugt, Marc A. Brouwer, Hendrik-Jan Dieker, RUN Medical Centre, 
Nijmegen, The Netherlands, Nijmegen, The Netherlands
Background: There is still considerable doubt, whether elective recanalization of 
occluded infarct arteries after the acute phase of ST-elevation MI may be beneﬁcial. 
Results from randomized trials so far were inconclusive due to small patient numbers 
and, by the necessarily open design MI and revascularization/recurrent ischemia are 
relatively weak endpoints. Since MI is both an entry criterion and an endpoint, it is difﬁcult 
to evaluate, since it may be induced by intervention and, therefore, its deﬁnition in the 
trials is cumbersome. Thus, long-term mortality is the best outcome parameter.
Methods and Results The 8 randomized trials were published between 1992 and 2005 
and included 684 patients with proven occluded infarct arteries after ST-elevation MI. They 
were randomized to recanalization (n = 355, almost exclusively PCI) or a conservative 
strategy (n = 329) one to 26 (median 8) days after the index event. All-cause mortality 
at a median of 6 months (ﬁgure) was 5.6% for elective recanalization and 10.0% for a 
conservative strategy (OR 0.56, 95% CI 0.33 - 0.97, p = 0.04). The overall results seem 
consistent and the test for heterogeneity is not signiﬁcant.
Conclusions: Although the trials of elective recanalization of occluded arteries after 
ST-elevation MI were too small to be conclusive, this meta-analysis suggests a nearly 
50% reduction of long-term mortality. These data support the open artery hypothesis, but 
deﬁnite proof can only be obtained from large ongoing randomized trials, like OAT.
2927-76 Pharmacological Evaluation of a Novel, Rapidly 
Reversible Intravenous Platelet P2Y12 ADP Receptor 
Antagonist, INS50589, in Healthy Volunteers
Fred L. Johnson, José L. Boyer, Philip T. Leese, Todd Durham, Christopher S. Crean, 
Ramesh Krishnamoorthy, Donald J. Kellerman, Inspire Pharmaceuticals, Inc., Durham, NC
Background: Inhibition of platelet ADP P2Y12 receptors has been demonstrated to be 
an effective treatment to reduce morbidity and mortality in patients with acute coronary 
syndrome (ACS) or recent myocardial infarction. Irreversible P2Y12 receptor antagonists 
(thienopyridines) are often administered to such patients anticipating stent placement. 
However, thienopyridine treatment has been demonstrated to produce inconsistent levels of 
platelet inhibition and has the risk of excessive bleeding in the event that the patient requires 
urgent graft surgery. INS50589 is a novel, selective, reversible antagonist of the platelet 
P2Y12 ADP receptor being developed by Inspire Pharmaceuticals, Inc. to temporarily 
modulate platelet function in settings in which platelet function must be tightly controlled. 
Methods: A phase 1, escalating-dose clinical trial was conducted to evaluate the 
pharmacology, pharmacokinetics, tolerability, and safety of INS50589 in 36 healthy male 
and female volunteers. Subjects were administered INS50589 at 0.1, 0.3, 1, and 3 mg/
kg/h or placebo by continuous intravenous infusion for four hours. Platelet function was 
monitored by ADP-induced whole blood aggregometry. 
Results: Over the dose range studied, INS50589 demonstrated dose-proportionality for 
Cmax and AUC, with an average alpha phase half-life from a two-compartment model of 
28 min (range=11-36 min). About 60% inhibition of 5 µM ADP-induced platelet aggregation 
was achieved at the lowest dose tested, and full inhibition was achieved within 15 minutes 
at 0.3 mg/kg/h and higher doses. Discontinuation of dosing was followed by a rapid return 
to normal aggregation and normal bleeding time in the two lowest doses tested, whereas 
return to normal platelet function was delayed at higher doses. No signiﬁcant treatment-
related changes were observed in vital signs, physical examination, ECG, hematology, 
or blood chemistry. 
Conclusion: INS50589 provided rapid, controlled modulation of platelet function with 
preservation and return of normal function shortly following discontinuation of dosing.
2927-77 Combination Therapy by Resveratrol and Statin Induces 
Cardioprotection in Ex-vivo Hypercholesterolemic Rats
Suresh V Penumathsa, Mahesh Thirunavukkarasu, Bela Juhasz, Lijun Zhan, Zhenwu 
Zhuang, Ebo D.de Muinck, Nilanjana Maulik, University of Connecticut Medical Center, 
Farmington, CT
Background: Hypercholesterolemia is a common health problem that signiﬁcantly 
increases risk of cardiovascular disease, which is one of the major health risks in civilized 
world. Both resveratrol and statin demonstrated cardioprotection through nitric oxide 
mechanism. Statin antagonizes Rho kinase, and thereby increases phosphorylation of 
eNOS via PI-3Kinase. 
Method: We treated Sprague-Dawley hypercholesterolemic rats (which were fed a 2% 
cholesterol diet for 8 weeks) with statin (1mg/kg/daily) and resveratrol (20mg/kg/daily) 
for two weeks orally. The rats were randomly assigned to one of the following groups: 
1) Control (C) 2) Hypercholesterolemia (HC) 3) HC+Resveratrol (HC+R) 4) HC+Statin 
(HC+S) 5) HC+Resveratrol+Statin (HC+R+S). The Langendorff’s working perfused rat 
heart, subjected to 30 min global ischemia followed by 120 min reperfusion were used 
as experimental model. 
Result: The left ventricular functional recovery and infarct size were found to be 
signiﬁcantly better in the resveratrol + statin (dp/dt= 1927±106) and resveratrol group 
(1573±390) compared to the HC group (1128±39). The infarct size in the combination and 
resveratrol groups were found to be 31±4.7 and 35±6.2 respectively compared to 54±6.6 
in the HC group. Signiﬁcant decrease in the extent of apoptosis was also observed in 
the combination group compared to all other groups may be due to signiﬁcant increase 
in beta-catenin translocation and reduction of Rho-kinase activity. VEGF expression was 
found to be increased in HC (1.19 fold), HC+R (1.67 fold), HC+S (1.39 fold), HC+R+S 
(1.27 fold) when compared to control group. However resveratrol treatment alone 
signiﬁcantly increases VEGF expression compared to any other treatment as well as HC 
group. In-vivo rat myocardial infarction model subjected to two weeks of permanent LAD 
occlusion followed by angiogram analysis demonstrated signiﬁcant abnormal increase in 
micro vessel formation in HC group compared to all other treatment groups. 
Conclusion: we hypothesize that the acute protection may be caused by anti-apoptotic 
effects, and long term effects may be caused by increased neo-vascularization of the MI 
zone leading to less ventricular remodeling.
2927-78 Door-to-Balloon Time Does Not Predict Outcomes 
Following Primary Angioplasty
Robert M. Minutello, Linda J. Cuomo, Manish Parikh, Mun K. Hong, Srihari S. Naidu, 
Geoffrey Bergman, S. Chiu Wong, Weill Cornell Medical College, New York, NY
Background: Reduced door-to-balloon time (DBT) in primary angioplasty in the setting 
of an ST elevation myocardial infarction (MI) has been shown to reduce peri-MI mortality 
rates. Whether DBT is a surrogate of institutional volume and expertise rather than an 
independent predictor of mortality is unclear.
Methods: Using single center data from a high volume PCI institution, we analyzed all 
patients who underwent primary angioplasty for STEMI from January 2004 through June 
2005. Patients who received thrombolytics prior to PCI were excluded. We sought to 
determine whether there was an inverse relationship between DBT and in-hospital major 
adverse events (MAE), peak troponin levels, and pre-discharge left ventricular ejection 
fraction (LVEF).
Results: 116 patients ﬁt inclusion criteria for the study. The median DBT was 117 minutes. 
Baseline characteristics and in-hospital outcomes were compared between patients with 
DBTs less than 90 (LT90, n=41) or greater than 90 (GT90, n=75) minutes. The mean age 
(64y vs. 61y) and percentage of male patients (61% vs. 61%) were similar between the 
LT90 and GT90 groups, respectively (p=NS). There were similar rates of GP IIb/IIIa usage 
(93% vs. 88%), peripheral vascular disease (7% vs. 13%), congestive heart failure (32% 
vs. 28%), and chronic renal failure (2.4% vs.1.3%) between resp. groups (p=NS). Patients 
with lower DTB were less likely to be diabetic (12% vs. 24%, p=0.09) and more likely to be 
within 6 hours of the onset of symptoms (66% vs. 39%, p=.004). There was no signiﬁcant 
difference in MAE (4.9% vs. 2.7%), death (7.3% vs. 6.7%), peak troponin levels (197 vs. 
222), or LVEF (44% vs. 48%), p=NS. When analyzed as a continuous variable and using 
propensity score analysis, DTB was not a signiﬁcant predictor of MAE, mortality, peak 
troponin levels, or pre-discharge ejection fraction.
Conclusion: When analyzing data from a single high volume PCI center (thereby 
eliminating the confounding variable of the institution), reduced DBT does not correlate 
with reduced in-hospital events. The reduction in in-hospital events with lower DBT seen 
in multi-center trials may be driven more by institutional expertise in MI management than 
the direct effects of reduced DBT.
2927-79 Platelet Monocyte Aggregates Determine Efﬁcacy 
of Reperfusion Following Primary Percutaneous 
Intervention (PPCI) for ST Segment Elevation 
Myocardial Infarction (STEMI), and Are Reduced by 
Early Anti-platelet Therapy
Elliot J. Smith, Roxana Mo, Rebecca Anthony, Ajay K. Jain, Thomas R. Keeble, Melanie 
A. Preston, Kerry D. McConnell, Marion Macey, Martin T. Rothman, Anthony Mathur, The 
London Chest Hospital, London, United Kingdom, Queen Mary University of London, 
London, United Kingdom
Background: Platelet monocyte aggregates (PMA) and CD40 ligand possess thrombo-
inﬂammatory properties that may impair reperfusion, and could be therapeutic targets in 
STEMI. This study investigated the inﬂuence of PMA and CD40L on reperfusion following 
PPCI, and the effect of early anti-platelet therapy on their response to PPCI.
Methods: 17 STEMI patients received clopidogrel and abciximab prior to PPCI. 11 
received early therapy (ET), 6 late (LT). Time from therapy to balloon was 76 min [66-94] 
ET vs. 38 [23-52] LT, p=0.001. Ischaemia duration (pain to balloon) was similar (216 min 
ET vs. 222 LT). PMA and CD40L were measured by ﬂow cytometry on arrival (t=0), 2 and 
24 hours post PPCI. Creatine kinase (CK) was measured for infarct size. TIMI ﬂow and 
Myocardial Blush (MBG) were graded pre and post PPCI.
Results: PMA < 20% (median) at t=0 was associated with TIMI 3 ﬂow (9/9 vs. 4/8, 
p=0.029), MBG 3 (7/9 vs. 2/8, p=0.044), and lower CK (500 [283-1015], 1462 [837-1945] 
p=0.046) post PPCI. There was no association with CD40L. PMA and CD40L at t=0 were 
similar with ET and LT. PMA fell by 34% at t=2 with ET, but remained elevated in the LT 
group, falling at t=24 (ﬁgure). CD40L was unaffected.
Conclusions: PMA determine efﬁcacy of reperfusion and infarct size following PPCI. 
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Early anti-platelet therapy results in a more rapid reduction of PMA post PPCI. These 
data may suggest that PMA mediate microvascular dysfunction, and provide a novel 
mechanism of beneﬁt for early anti-platelet therapy prior to PPCI.
 
2927-80 Late Recovery of Myocardial Blush 24-Hours After a 
Primary PCI Predicts Left Ventricular Function (LVF) 
Improvement
Miguel A. Riccitelli, Jorge Szarfer, Alejandro Garcia Escudero, Luis A. Vidal, Hospital 
Argerich, Buenos Aires, Argentina
bBackground: The lack of Myocardial Blush immediately after a primary PCI predicts 
worst long term outcomes. It’s unknown if 24 hours recovery of Myocardial Blush improves 
LVF. The aim of the study is to evaluate if Late Myocardial Blush recovery (LR) affects LVF 
evaluated 24 hours (hs.) after the procedure.
Methods: End diastolic (EDV), end systolic (ESV) volumes and Ejection Fraction (EF) 
angiographicaly assessed through the area-length method, were prospectively evaluated 
pre procedure and 24 hs. after a Primary PCI, in 234 consecutive p. performed <12 hs. 
of symptoms onset. The corrected Timi Frame Count (cTFC) and Myocardial Blush (MB) 
according to the 0-3 grades described by Gibson were evaluated immediately and 24 hs. 
after. Patients were allocated to 3 groups according to the post procedure and 24 hs. MB: 
No perfusion Group (NP): MB 0-1 immediately after and 24 hs.; Late Perfusion Group 
(LP) MB 0-1 immediately after and 2-3 at 24 hs.; Early Perfusion Group (EP) MB 2-3 
immediately after and 2-3 at 24 hs..
Results: *p<0,05 for Intra group Basal vs. 24 hs. differences; a, b, c, d, e, f, g p<0,05 for 
inter groups differences
Conclusions: Late Reperfusion improves LVF to similar levels achieved by the Early 
Reperfusion group. Therefore the development of late MB related to a restoration of 
microcirculation could be a determinant of LVF amelioration through the recovery of 
stunned myocardial areas. The Lack of MB at 24 hs. shows a lower cTFC and is associated 
with an absence of LVF recovery.
NP (n=18) 
Basal
NP (n=18) 
24 hs
LP (n=32) 
Basal
LP (n=32) 
24 hs
EP (n=184) 
Basal
EP (n=184) 
24 hs
EDV 
ml/m2 82.9±31.6 77.7±21.8 73.8±20 * 70.1±16.9* 75.8±19.4* 74.1±19.1*
ESV 
ml/m2 52.1±27.8 44.5±22.6 42.8±16.1* 36.2±14.6* 40.6±13.3* 35.6±14.6*
EF % 39.7±11.7 a 34.7±16.9 c 41.3±14.5 *b
48.6±13.3 
*d
46.3±12.7*a 
b
52.5±12.2 
*c d
cTFC 
frames 39.3±19.2 e 34.7±16.9 f
41.1±16.9 
*f
26.6±11.8 
*g
23.4±12.2 
*e f 19.9±8.6* f g
 
2927-81 Improvement in Door to Balloon Times in a Centralized 
Primary Percutaneous Coronary Intervention System
Rajesh A. Shah, Christine Swanson, Sanjaya Khanal, Adam Greenbaum, Abed Asfour, 
Henry Kim, W. Douglas Weaver, Aaron D. Kugelmass, Henry Ford Hospital, Detroit, MI
Background: Primary percutaneous intervention (PPCI) has gained popularity as the 
reperfusion strategy for ST elevation MI. Door to balloon (DTB) times of < 120 minutes 
are associated with decreased morbidity and mortality. However, consistently achieving 
this reperfusion time goal remains problematic. In an attempt to provide timely PPCI 
we developed an “around the clock” centralized 6-site PPCI referral system in a large 
metropolitan area.
Methods: Henry Ford Health System Myocardial Infarction Program includes 6 
independent emergency rooms and one hospital performing PPCI. A multidisciplinary 
team composed of staff of the cath lab, emergency rooms, cardiac care units, ambulance 
companies and hospital administration was formed in 2003. Systematic process 
improvement for 1) early patient identiﬁcation 2) communication and activation 3) 
transport and pre cath lab care and 4) cath lab procedures were implemented in late 
2003. Process components were reviewed frequently and results shared with program 
participants on a regular basis.
Results: Median DTB times (presentation @ any participating emergency room to 
balloon inﬂation in the central cath lab) steadily improved over the study period.
Quarter Q4 2003
Q1 
2004
Q2 
2004
Q3 
2004
Q4 
2004
Q1 
2005
Q2 
2005
Patient (n) 33 53 43 47 59 39 39
Median door to balloon time 
(mins) 139 139 126 118 118 113 93
Conclusions: Consistent early reperfusion with PPCI can be achieved with an integrated 
PPCI transfer system. A multidisciplinary approach is crucial to the success and 
maintenance of such a system. Ongoing outcome review and participant feedback are 
critical components to a successful PPCI program.
2927-82 Impact of Staged Non-target Vessel Revascularization 
on Clinical Outcomes Following Primary Stenting for 
Acute Myocardial Infarction (AMI): Results From the 
Emerald Trial
Ricardo A. Costa, Alexandra J. Lansky, Ken Mori, Roxana Mehran, Bahran Sahid, 
Ecaterina Cristea, Eduardo C. Silva, Bruce R. Brodie, Daniel Dulas, David A. Cox, 
Anna Kalynych, Mansoor Qureshi, Barry Rutherford, Heinz-Peter Schultheiss, Mark 
Turco, John Webb, Mitch Krucoff, Raymond Gibbons, Gregg W. Stone, Cardiovascular 
Research Foundation, New York, NY
Background: Primary percutaneous coronary intervention (PCI) in AMI is generally 
recommended to be performed in the target vessel (TV) only; patients requiring 
multivessel PCI generally undergo staged procedures. The outcomes of this approach 
have not been examined. 
Methods: In the multicenter, prospective EMERALD trial, 501 patients with ST-segment 
elevation AMI undergoing primary stenting were randomized to distal protection with 
the GuardWire vs. control. Multivessel PCI required during the index procedure was an 
exclusion criterion but patients requiring staged intervention were actively enrolled. Six-
month outcomes were examined as a function of the performance of staged intervention. 
Patients requiring TV revascularization (TVR) for recurrent ischemia within 6 months were 
excluded from analysis. 
Results: Staged procedures were performed in 11.2% of patients. Baseline clinical 
characteristics were similar, including age (mean 59.2 years), male gender (78.6%), and 
diabetes (12.3%); multivessel disease was more common in patients undergoing staged 
procedures (Table). Patients with staged procedure presented with more Killip class ≥2 
(21.4% vs. 11.8%, p=0.04) and had longer hospital stays (3.6 vs. 2.8 days, p=0.01). 
Angiographic and clinical outcomes are in the Table. 
Conclusions: Patients with multivessel coronary artery disease undergoing primary PCI 
can be safely staged. However, strategies to reduce the higher reinfarction rate beyond 
30 days should be further investigated. 
Variable Staged procedures (N=56)
No repeat 
revascularization
(N=414)
P value
1 Vessel Disease, % 1.8 57.7 <0.0001
2 Vessel Disease, % 55.4 30.2 0.0002
3 Vessel Disease, % 42.9 12.1 <0.0001
Target Vessel (index 
procedure)
LAD, % 29.8 37.6 0.25
LCX, % 15.8 11.1 0.30
RCA, % 54.4 50.6 0.59
SVG, % 0.0 0.7 0.53
In-Hospital Clinical 
Outcomes
Reinfarction, % 0.0 0.2 0.71
Death, % 0.0 1.0 0.46
30 Days Clinical 
Outcomes
Reinfarction, % 1.8 0.5 0.27
Death, % 0.0 3.0 0.20
6 Months Clinical 
Outcomes
Reinfarction, % 3.7 0.5 0.02
Death, % 0.0 3.9 0.15
 
2927-83 Gender Differences in Outcomes After Primary Stenting 
for Acute Myocardial Infarction: A Substudy From the 
EMERALD Trial
Ken Mori, Alexandra J. Lansky, Ricardo A. Costa, Roxana Mehran, Ecaterina Cristea, 
Bahran Sahid, Zorica Filipovic, Bruce R. Brodie, David A. Cox, Daniel Dulas, Anna 
Kalynych, Mansoor Qureshi, Barry Rutherford, Heinz-Peter Schultheiss, Mark Turco, 
John Webb, Mitch Krucoff, Raymond Gibbons, Gregg W. Stone, Cardiovascular Research 
Foundation, New York, NY, Colombila University Medical Center, New York, NY
Background: Previous studies reported that women with AMI undergoing 1ary PCI have 
higher rates of morbidity and mortality compared to men. Whether contemporary PCI 
improve outcome in women is unknown. 
Methods: In the prospective, randomized EMERALD trial, 501 pts with ST-segment 
elevation AMI<6 hrs of symptom onset underwent 1ary or rescued PCI and were 
randomized to PCI w/ stenting vs. PCI w/ distal protection device+stenting. ST-resolution 
(STR) was measured 30’ after PCI by continuous Holter, infarct size was measured by 
Tc-99m sestamibi, and MACE within 30 days and at 6 months was compared between 
men and women. 
Results: Women were older (63.8 vs. 57.9; p<0.0001), had smaller BMI (2.58 vs. 3.88; 
p=0.0009), had more hypertension (49.5 vs. 33.6%; p=0.0032) and less prior MI (2.8 vs 
13.2%; p=0.0014) and PCI (1.9 vs. 11.7%; p=0.0008), but similar LAD infarct (33.6 vs. 
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38.3%, p=0.38) and time to reperfusion (227 vs. 215 mins, p=0.20) compared to men. 
By QCA, women had smaller RVD (2.9 vs. 3.1mm; p=0.0005), and lower ﬁnal %DS (15.9 
vs. 18.2%; p=0.015). STR at 30’ was 72.8% for women vs. 59.8% for men, p=0.20, and 
infarct size was smaller in women (12.2±19.6 vs. 18.4±18.5, p=0.01). Clinical outcomes 
are shown in the Table. 
Conclusions: Despite being older and with more co-morbidities, women with AMI 
treated with primary stenting had similar early and late outcome compared to men. These 
favorable results may be related to the fact that women had similar time to reperfusion and 
smaller infract size compared to men. 
Outcome, % Female (n=108) Male (n=393) P Value
30 Days
Death 3.7 2.1 0.31
Re-infarction 1.9 2.6 0.70
Target Vessel Revascularization 1.9 3.5 0.45
Cerebral Vascular Accident 0.0 1.6 0.20
6 Months
Death 3.7 3.3 0.73
Re-infarction 3.9 2.9 0.61
Target Vessel Revascularization 6.9 6.6 0.82
Cerebral Vascular Accident 2.0 1.6 0.82
 
2927-84 A Regional, Rapid, Interventional Approach to Shorten 
Time to Infarct Artery Patency in ST Segment Elevation 
Myocardial Infarction: The ASSET Group
Brian W. Gross, Kent W. Dauterman, Mark G. Moran, Todd S. Kotler, Stephen J. Schnugg, 
Paul S. Rostykus, W. Douglas Weaver, Rogue Valley Medical Center, Medford, OR
Background: Multiple ST Segment Elevation Infarction (STEMI) randomized trials and 
meta-analyses have demonstrated the superiority of Percutaneous Coronary Intervention 
(PCI) compared to thrombolytic therapy. A problem remains, even at the best of centers, 
with the inherent time delays to PCI. We designed a regional program that directly triages 
STEMI patients from the ﬁeld, as well as expediting transfers from 5 local emergency 
departments, to a single pre-alerted interventional center in an attempt to address this 
problem.
Methods: The time from initial hospital entry to PCI open artery was assessed among 
233 consecutive STEMI patients presenting with < 6 hours of infarct symptoms. These 
patients arrived from various sources within a cooperative regional program designed to 
rapidly triage all STEMI patients for emergent PCI. Mortality was compared to local and 
international historical standards.
Results: Paramedic identiﬁed STEMI with direct triage to the pre-alerted PCI center 
achieved PCI infarct artery patency in less than 90 minutes of hospital arrival in 58% of 
patients. For “walk-ins” to the interventional center Emergency Department (ED) it was 
38%, but averaged only 3% for patients transferred from another referring ED. Overall 
hospital mortality was 3.4%. Mortality for direct paramedic STEMI triages was 0%.
Conclusions: Paramedic diagnosis of STEMI, with direct triage to a pre-alerted 
interventional hospital for PCI lead to the shortest time to a patent artery, especially when 
compared to inter-hospital transfers. Acute ST Segment Elevation Taskforce (ASSET) 
protocols were associated with low overall STEMI mortality and morbidity. Substantial time 
delays to PCI remained for those STEMI patients who arrived initially at a referring ED.
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2928-85 Impact of Timing of Early Intervention on In-Hospital 
Mortality in Patients With Acute Coronary Syndromes 
Adjusted for Acuity of Presentation: Insights From the 
TRACS Registry
Sandeep Nathan, Patricia Vassallo, Amit P. Amin, Ronald Berger, James E. Calvin, Rush 
University Medical Center, Chicago, IL
Background: Current recommendations for an early invasive strategy in patients (pts) 
with acute coronary syndromes (ACS) are based on decreased composite morbidity/
mortality in selected high-risk subsets. It is unclear if mortality alone is impacted by timing 
of early revascularization (ERV) with PCI in the setting of platelet glycoprotein inhibition.
Methods: The Registry of Acute Coronary Syndromes (TRACS) comprises 3,468 
consecutive pts presenting with ACS to 9 U.S. hospitals over 21 months. We assessed 
in-hospital mortality in patients divided by ERV (< 72 hrs) vs. conservative (> 72 hrs or 
no catheterization (cath)) management with pts undergoing ERV further subdivided by 
timing (<24 vs 24-72 hrs). Logistic regression was used to adjust for the effects of TIMI 
Risk Score (TRS), pre-cath glycoprotein inhibition and ERV timing on overall in-hospital 
mortality hazard.
Results: Of 3,468 pts, 1,994 (57.5%) pts underwent cath with 1,552 (44.75%) pts 
undergoing PCI. Of PCI pts, 1,315 (84.7 %) had PCI in ≤ 72 hrs (ERV group). Mean 
TRS in the ERV group was 3.95 ± 0.96 versus 3.43 ± 1.21 in the conservative group 
(p<0.0001). There were 24 (1.83%) deaths in the ERV group vs. 93 (4.33 %) in the 
conservative group (unadjusted OR=2.43 (95% CI 1.54 - 3.83, p<0.001, TRS-adjusted 
OR=2.71, 95% CI 1.72 - 4.28, p<0.001). In ERV pts, a trend towards higher mortality was 
seen in pts undergoing PCI in < 24 hrs vs. 24-72 hrs (2.13% vs 0.92%, p=0.159) with no 
difference in TRS but more pts with recent MI (7.9% vs 4.0%, p=0.016) or early biomarker 
release (53.6% vs 45.4%, p=0.017) in the < 24 hr group. Pre-cath use of glycoprotein 
inhibition was associated with improved survival even after adjustment for baseline risk 
(TRS) and ERV (OR=0.4, 95% CI 0.19-0.84, p=0.015).
Conclusions: ERV in <72 hrs of ACS presentation was associated with reduced in-
hospital mortality vs. a conservative approach despite higher mean TRS in ERV pts. The 
suggestion of differential mortality between the PCI<24 hrs and 24-72 hrs patient subsets, 
while unrelated to baseline differences in TRS, may have been inﬂuenced by selection 
bias. Early use of platelet glycoprotein inhibition was associated with improved survival 
after controlling for ERV and baseline risk.
2928-86 Vulnerable Lesion Characteristics Assessed by 
Optical Coherence Tomography (OCT), Intracoronary 
Ultrasound (IVUS), Angioscopy and Quantitative 
Coronary Angiography (QCA)
Yukio Ozaki, Masanori Okumura, Junichi Ishii, Shigeru Matsui, Hiroyuki Naruse, Shigeru 
Kato, Takahisa Sato, Yu Nakamura, Kaori Inoue, Sada Nakano, Sino Kan, Shinya 
Hiramitsu, Takeshi Kondo, Tevﬁk F. Ismail, Hitoshi Hishida, Division of Cardiology, Fujita 
Heath University, Toyoake, Japan, Northwick Park Hospital, London, United Kingdom
Postmortem-derived ﬁndings support that lipid-rich-plaques with thin-cap (<65µm) 
ﬁbroatheroma (TCFA) are prone to rupture and superimposed thrombosis can be the 
primary mechanisms causing acute coronary syndromes (ACS). While optical coherence 
tomography (OCT; Lightlab Imaging, Boston, MA) provides a novel high-resolution 
image (10µm), several in-vivo intracoronary imaging modalities including OCT, IVUS and 
angioscopy would provide clues to which plaques may rupture and whether thrombosis 
plays a role. We prospectively performed OCT, IVUS, angioscopy and QCA prior to 
coronary intervention (PCI) in 20 patients (18 males, 2 females, average age 63±10 
years) with 44 lesions (19 vulnerable lesions and 25 stable lesions). No difference was 
found in age, gender and coronary risk factors including hypertension, diabetes and 
hyperlipidemia between the two groups. Quantitative coronary angiography (QCA) was 
performed using CAAS II system (Pie Medical, Maastricht, NL).
Conclusions: IVUS and QCA differentiated poorly between vulnerable and stable lesions. 
While angioscopy could reveal plaque rupture or thrombosis in some vulnerable lesions 
(67%), in-vivo OCT clearly demonstrated vulnerable plaque having thinner ﬁbrous-cap 
[TCFA] (p<0.001), greater lipid-pool (p<0.05) associated with superimposed thrombosis 
(P<0.001) than stable lesions. Currently available OCT could discriminate vulnerable 
lesions from stable lesions.
RESULTS
Vulnerable lesions (n=19) Stable lesions (n=25) P
OCT
Cap thickness (µm) 46±20 295±113 <0.001
Lipid pool angle (degree) 245±97 182±95 <0.05
Thrombus angle (degree) 217±116 0 <0.001
IVUS
Soft/ Mixed/ Calciﬁed (%) 54/23/23 60/10/30 ns
Calcium angle (degree) 56±68 39±104 ns
Angioscopy;
Thrombus or Rupture (%) 66 14 ns
QCA;
% Diameter Stenosis 62±4 62±6 ns
2928-87 Platelet Aggregation Inhibition in Patients With Non 
ST Segment Elevation Acute Coronary Syndromes 
Pretreated With Dual or Triple Antiplatelet Therapy and 
Relationship With Angiographic and Clinical Outcome
Jaap Jan J. Smit, Isala Klinieken, Zwolle, The Netherlands
Background: The relationship between the level of platelet aggregation inhibition in 
patients with non ST segment elevation acute coronary syndromes (NSTE-ACS) and 
clinical outcome is unknown.
Methods: In patients with NSTE-ACS included in the ELISA-2 trial in our hospital, who were 
randomized to dual (600mg clopidogrel, 250mg acetylsalicylic acid) or triple antiplatelet 
therapy (10µg/kg bolus and 0.15µg/kg/min maintenance aggrastat, 300mg clopidogrel, 
250mg acetylsalicylic acid), platelet inhibition was assessed before percutaneous coronary 
intervention (PCI) using the Sysmex K4500 platelet aggregation measurement. The level of 
platelet inhibition was compared to angiographic and clinical outcome.
Results: In 178 of 328 (54%) patients platelet inhibition was measured at a median of 23 
hours after study drug administration. In patients treated with triple antiplatelet therapy, 
platelet inhibition was signiﬁcantly higher than in patients treated with dual antiplatelet 
therapy (61.1% ± 24.9% vs. 34.0% ± 26.6%, p<0.001). There was no difference with 
regard to angiographic and clinical outcome between patients with a higher versus lower 
than median level (50.1% ± 29.5%) of platelet inhibition (table 1).
Conclusions: Although platelet inhibition was signiﬁcantly better in patients pretreated 
with triple as compared to dual antiplatelet therapy, no correlation was found between 
the level of platelet inhibition and angiographic or clinical outcome in patients before PCI 
for NSTE-ACS.
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Platelet aggregation inhibition and relationship with angiographic and 
clinical outcome
platelet aggregation 
inhibition≥median
platelet aggregation 
inhibition<median p-value
TIMI-3 ﬂow pre-PCI (%) 67.6 55.6 0.139
thrombus pre-PCI (%) 9.8 18.0 0.191
distal embolization post-PCI 
(%) 2.0 3.6 1.000
TIMI-3 ﬂow post-PCI (%) 94.4 93.4 1.000
LDHQ48 (U/L, 25-75%) 148 (63.25 - 353.5) 183.5 (55.5 - 417.75) 0.891
30-day mortality (%) 1.1 1.1 1.000
2928-88 In Acute Coronary Syndromes, Should Patients with 
Multivessel Coronary Artery Disease Undergo Culprit 
Lesion or Multivessel Stenting?
Mehdi Shishehbor, Derek Chew, Inder Singh, Juhana Karha, Michael Lauer, Sorin 
Brener, David Moliterno, Stephen Ellis, Deepak Bhatt, The Cleveland Clinic Foundation, 
Cleveland, OH
Background: The invasive approach is preferred in patients presenting with acute 
coronary syndromes (ACS). However, in this setting the beneﬁt of culprit vessel versus 
multivessel stenting is not clear.
Methods: Patients with unstable angina or non-ST segment acute myocardial infarction 
undergoing PCI that were prospectively followed for at least 12 months were included. 
Culprit lesion was deﬁned by reviewing angiographic report, electrocardiogram, 
echocardiogram, and if available nuclear stress tests. A lesion was considered culprit if 
an obvious thrombus or ruptured plaque were present, or if two of the above diagnostic 
tests pointed to the same coronary territory. All patients had at least 2 vessels with ≥ 50% 
stenosis on diagnostic angiography. Patients with chronic total occlusion and those with 
unidentiﬁable culprit lesion were excluded. Our primary endpoint was 30-day death or MI 
and one year composite endpoint of death, MI, or any revascularization.
Results: From 01/2000 to 01/2003, 1099 patients with ACS and multivessel disease 
underwent PCI with bare metal stenting. Of these, 628 underwent culprit only and 471 
underwent multivessel stenting. Both in univariable and multivariable propensity matched 
analysis, adjusting for age, gender, weight, diabetes, baseline renal insufﬁciency, peripheral 
vascular disease, blood pressure, number of vessels with stenosis ≥ 50%, left ventricular 
ejection fraction, lesion classiﬁcation, glycoprotein IIb/IIIa, and medication use there were 
no differences between the two groups for the 30-day composite endpoint of death or 
myocardial infarction (MI) (HR, 1.31; 95% CI, 0.87-1.96; P=0.192). However, multivessel 
stenting was associated with increased one year death, MI, or revascularization (HR, 
1.34; 95% CI, 1.08-1.65; P=0.007), which was mainly driven by an increased rate of 
revascularization in this group (HR, 1.38; 95% CI, 1.08-1.78; P=0.010).
Conclusions: In patients with multivessel coronary artery disease presenting with ACS 
there seem to be no short term differences in myocardial infraction or death, though there 
is an increased rate of revascularization at 1 year in those undergoing multivessel PCI 
with bare metal stenting.
POSTER SESSION
2929 
Recanalization of Chronic Total 
Occlusions: Technique, Complications, 
and Long-Term Results
Tuesday, March 14, 2006, 12:30 p.m.-4:00 p.m.
Georgia World Congress Center, Hall B1
Presentation Hour: 1:30 p.m.-2:30 p.m.
2929-117 Detectability And Applicability Of Multi-slice Computed 
Tomography For Percutaneous Coronary Intervention 
For Chronic Total Occluded Lesions.
Satoru Sumitsuji, Madoka Ihara, Hajime Nakaoka, Makoto Satou, Keita Yamazaki, 
Masaaki Okutsu, Yuhei Nojima, Ken Kishida, Yuhei Nagai, Rinku General Medical 
Center, Izumisano, Japan
Background: Percutaneous Coronary Intervention for chronic occluded lesion (CTO-
PCI) is one of still remained big problem in PCI ﬁeld. Multi-slice computed tomography 
(MSCT) has ability to visualize occluded segment and potential to support CTO-PCI. 
The aim of this study is to clarify the detectability of occluded segment by MSCT and 
applicability of MSCT for CTO-PCI.
Methods: For the detectability of CTO segment, we assessed 45 CTO lesions in 40 cases 
by 16 slices MSCT. In these cases, 34 CTO lesions were attempted to revascularize by 
PCI. The applicability of MSCT for CTO-PCI was evaluated by acute success rate of 
CTO-PCI with MSCT which compared with CTO-PCI without MSCT in this 1.5 years. In 
this comparison, the disadvantage of MSCT use; radiation exposure and used contrast 
volume were also assessed.
Results: The detectability of CTO segment by MSCT was 95.6%, 43 CTO lesions were 
well visualized and only 2 CTO lesions were not detected. Success rate was better in 
CTO-PCI with MSCT than without MSCT in 1st procedure success rate and ﬁnal lesion 
success rate (see table).
Radiation exposure was less in CTO-PCI with MSCT than without MSCT, but used 
contrast volume was same in those two groups.
Conclusions: MSCT can detect occluded segment in 95% or more of cases. MSCT 
shows anatomical and calcium information of occluded segment. With MSCT information, 
success rate of CTO-PCI improved with less radiation exposure.
Results
with MSCT without MSCT
1st procedure success 88.2% (30/34) 69.2% (19/26)
Final lesion success 94.1% (32/34) 82.6% (19/23)
Radiation exposure (ﬂuoro time; median) 32.4min 49.6min
Used contrast volume (median) 258ml 287ml
2929-118 Subintimal Tracking and Reentry (STAR) Technique Is a 
Feasible and Safe Approach to Treat Coronary Chronic 
Total Occlusions
Altin Palloshi, Mauro Carlino, Iassen Michev, John Cosgrave, Flavio Airoldi, Nuccia 
Morici, Cosmo Godino, Alaide Chieffo, Gloria Melzi, Matteo Montorfano, Antonio 
Colombo, EMO Centro Cuore Columbus, Milan, Italy, San Raffaele Hospital, Milan, Italy
Background: The treatment of chronic total occlusions (CTO) using the STAR technique 
has been proposed for the recanalization of difﬁcult CTO.
Purpose: To evaluate the feasibility and safety of the STAR technique in the treatment 
of CTO.
Methods: 51 pts (5 females, mean age 60±10yrs) treated with STAR following failure of 
attempts with conventional wires, since 2003, were reviewed.
Results: 51 coronaries (RCA 39, OM 6, LCX 3, LAD 2, diagonal branch 1) underwent 
STAR procedure. Baseline CTO lesion’s characteristics were: blunt morphology (82%), 
mild to severe calciﬁcation (76%) and length >20mm (66%). Side branches were present 
at the occlusion site in 82% and bridging collaterals in 69% of cases. Controlateral 
injection was used in 25% of cases. Frontrunner was employed in 5 cases, Crosser in 4 
ones while over the wire balloons in almost all cases (98%). Procedural success deﬁned 
as successful restoration of lumen (less than 30% of residual stenosis) of the occlusion 
with TIMI ﬂow 2 or more in at least one major branch was obtained in 88% of the CTO. 
Mean stent length was 53±27mm (bare metal stents 48%), mean number of stent/lesion 
was 1.8±0.9. More than 1 distal vessel salvage (≥2) was achieved in 63% while 1 vessel 
in 30% of cases. Coronary perforation occurred in 7 patients (in 3 of them it was then 
decided to stop the procedure). No procedural tamponade, death or by-pass surgery 
occurred during the hospital stay. 5 patients had MI (CK-MB≥2 fold normal value). Stent 
thrombosis was documented in one patient 3 hours after the procedure. During a mean 
follow up of 11.5±7.8 months one non-cardiac death occurred. No by-pass surgery or 
MI were observed. 40 pts were eligible for angiographic follow-up (11 had the procedure 
recently). 4 of them refused angiographic control since in good clinical conditions. In the 
36 pts, who completed angiographic follow-up at a mean of 7±4 months, restenosis rate 
was 61% (22 pts), occlusive 22% (8 pts). Target vessel revascularization (most of the time 
to treat focal restenosis) was 48% (25 pts).
Conclusions: In patients with selected CTO, The STAR technique represents a feasible 
and relatively safe interventional approach. Furthermore, it offers an acceptable long-term 
clinical outcome.
2929-119 Procedural Implications for the Intravascular 
Ultrasound Morphologic Features of Chronic Total 
Coronary Occlusions
Kenichi Fujii, Masahiko Ochiai, Gary S. Mintz, Yoshifumi Kan, Kojiro Awano, Motomaru 
Masutani, Kazuhiro Ashida, Mitsumasa Ohyanagi, Shinobu Ichikawa, Sachiko Ura, 
Hiroshi Araki, Gregg W. Stone, Jeffrey W. Moses, Martin B. Leon, Stephane G. Carlier, 
Cardiovascular Research Foundation, New York, NY
Background: Although the success rates of percutaneous coronary intervention (PCI) 
of chronic total occlusions (CTO) have improved, morphologic features are still not well 
assessed.
Methods: We analyzed the experience at 4-centers where intravascular ultrasound 
was performed in 67 native artery CTO lesions just after the lesion was crossed with a 
guidewire (n=7) or after dilation with a 1.5-mm (n=46) or 2.0-mm (n=14) balloon. CTO 
was deﬁned as angiographic interruption of vessel continuity for >4 weeks. Calcium was 
assessed every 1mm through the entire length of lesion, and a calcium index (CI) was 
calculated as the arc grade (1: <90, 2: 91-180, 3: 181-270, and 4: >271º) multiplied by the 
length grade (1: <6, 2: 6-10, and 3: ≥10mm) for each calcium deposit. Inadequate reﬂow 
was deﬁned as post-PCI corrected TIMI frame count >40.
Results: Median CTO duration was 6.3 mos. Calcium, which may limit guidewire 
penetration of the CTO, was found somewhere in the lesion in 96%, at the proximal end in 
78%, and at the distal end in 59%. The number, maximum arc, and length of calcium, and 
total CI were 3.6±1.9, 145±85º, 5.2±3.8mm, and 7.0±5.0, respectively. However, 68% had 
only mild calcium (CI=1). In lesions with SBs at the proximal and distal ends of the CTO, 
calcium was located opposite the SB in 74% and 57%. An intramural hematoma was 
observed in 34% of CTOs, suggesting that the guidewire frequently entered the medial 
space during successful recanalization. When the hematoma was located within the CTO 
segment (65%), calcium was observed in 73% at the largest hematoma site. CTOs were 
longer, vessel area was smaller, and total CI was larger in lesions with hematoma than 
in lesions without hematoma (p=0.003, 0.05, and 0.03, respectively). Inadequate reﬂow 
post-PCI was observed in 9% and was associated with longer lesion length, larger plaque 
burden at the reference segment and larger intralesional calcium.
Conclusions: CTO lesions had multiple small calcium deposits. Intramural hematomas 
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were common and were indicative of guidewire penetration into the medial space during 
the CTO procedure, especially in long, calciﬁed lesions in smaller vessels. Post-PCI, 
inadequate reﬂow correlated with more complex CTO morphology.
2929-120 Complications During Procedure and Mid-Term Results 
After Recanalization of Chronic Total Occlusion With 
Drug Eluting Stents
Hiroshi Fujita, Yoshihisa Kinoshita, Akira Murata, Kenya Nasu, Nobuyoshi Tanaka, 
Jean-Francois Surmely, Yoshihiro Takeda, Mariko Ehara, Etsuo Tsuchikane, Mitsuyasu 
Terashima, Tetsuo Matsubara, Osamu Katoh, Takahiko Suzuki, Toyohashi Heart Center, 
Toyohashi, Japan
Background: There are few reports about differences of complications during procedure 
and mid-term outcomes after revascularization between chronic total occlusion (CTO) 
and non-CTO lesions.
Methods: From August 2003 to July 2005, we compared the incidence of complications 
(coronary perforation, cardiac tamponade, emergency CABG and death) and MACE 
(cardiac death, MI, target lesion revascularization: TLR) within 6 months following 
treatment for CTO lesions (Group C, n=292) with non-CTO with type C lesions (Group 
NC, n=744). Moreover the incidence of MACE was compared between 2 groups before 
and after the introduction of Sirolimus-eluting stent (SES).
Results: Incidence of coronary perforation in group C was higher than group NC (8.6% vs 
2.6%, p<0.05). There were no signiﬁcant difference in other complications. Group C had 
higher incidence of MACE and TLR (Table).
Conclusions: Complications of group C were not fatal but specﬁc. The mid-term outcomes 
of group C was improved by using of SES, but it was inferior to that of group NC.
MACE and TLR
Overall MACE TLR
CTO vs. non CTO 54 (38.0%) vs. 95 (24.4%), P<0.05 52 (39.4%) vs. 90 (23.4%), P<0.05
CTO pre SES vs. post SES 42 (46.2%) vs. 12 (23.5%), P<0.05 40 (49.4%) vs. 12 (23.5%), P<0.05
non CTO pre SES vs. post SES 77 (33.6%) vs. 18 (11.2%), P<0.05 74 (33.2%) vs. 16 (9.9%), P<0.05
pre SES CTO vs. non CTO 42 (46.2%) vs. 77 (33.6%), P<0.05 40 (49.4%) vs. 74 (33.2%), P<0.05
post SES CTO vs. non CTO 12 (23.5%) vs. 18 (11.2%), P<0.05 12 (23.5%) vs. 16 (9.9%), P<0.05
 
2929-121 Successful Prevention of Lesion Recurrence in Chronic 
Total Coronary Occlusions Treated With a Paclitaxel-
eluting Polymer-based Stent: 2-Year Results and Long-
Term Secondary Patency
Gerald S. Werner, Michael Fritzenwanger, Markus Ferrari, Hans R. Figulla, Medizinische 
Klinik I, Klinikum Darmstadt, Darmstadt, Germany, Klinik Innere Medizin I, Friedrich-
Schiller-University, Jena, Germany
Background: The recurrence rate after percutaneous coronary intervention (PCI) for 
chronic total coronary occlusions (CTO) is high even with routine stenting. The present 
study should assess the safety and efﬁcacy of a paclitaxel-eluting stent (Taxus) in real-
world CTOs characterized by long lesions requiring multiple long stents.
Methods: In 95 consecutive patients a CTO (duration >2 weeks) was successfully 
recanalized with implantation of Taxus stents (Boston Scientiﬁc Corp.). Each patient 
was matched to a patient drawn from a pool of 148 patients treated consecutively with 
bare metal stents (BMS) in the preceding 3 years. The matching was done at the entry 
of the Taxus patients in the study. Criteria were lesion characteristics (vessel diameter, 
stent length, location), and clinical parameters (diabetes, previous myocardial infarction). 
Angiographic results after 6 months and major clinical adverse events (MACE: death, 
MI, periprocedural CK increase >2 times, target vessel revascularization (TVR)) were 
compared between the two groups at 12 and 24 months, as well as the secondary 
angiographic patency 6 months after TVR.
Results: There was a high rate of diabetes of 33%. About 70% of all CTOs were older 
than 3 months (range 1-306 months). The number of stents was 1.7±0.9 in both groups. 
The mean stented segment length was similar with BMS and Taxus (36±17 mm vs. 40±20 
mm). After 6 months all patients underwent repeat angiography. The target vessel failure 
was signiﬁcantly lower with Taxus than with BMS (10.7% vs. 58%; p<0.001). Notably, 
the rate of late reocclusion was lower with Taxus in 1.3% vs. 21.4% (p<0.001). The 
clinical MACE rate at 12 months was 16% with Taxus and 56% with BMS (p<0.001), and 
remained similar at 2 years (18 vs. 66%). All but one restenotic lesions in Taxus were 
focal and underwent succesful repeat PCI with additional Taxus stent implantation. The 
subsequent repeat angiography showed freedom of restenosis in all cases leading to a 
secondary patency of 99%.
Conclusions: The use of Taxus stents in CTOs lead to an absolute reduction of the 
MACE rate by 70-80% which persisted after 2 years. By repeat PCI with an additional 
Taxus stent, a secondary patency of 98% in Taxus stens was be achieved.
2929-122 Chronic Total Occlusions: The Final Frontier for Drug-
eluting Stents
Gloria Melzi, John Cosgrave, Lee Ge, Alaide Chieffo, Giuseppe M. Sangiorgi, Flavio 
Airoldi, Iassen Michev, Mauro Carlino, Matteo Montorfano, Tiziana Aranzulla, Rade 
Babic, Antonio Colombo, S. Raffaele Hospital, Milan, Italy, EMO Centro Cuore 
Columbus, Milan, Italy
Background: Percutaneous intervention in chronic total occlusions (CTO) using bare 
metal stents is associated with high rates of restenosis (50%). There is some initial 
encouraging data available utilizing drug eluting stents (DES). Our aim was to compare 
the outcomes of CTO treatment with the two currently available DES platforms.
Methods: We identiﬁed all patients successfully treated with a DES in a CTO between 
March 2003 and December 2004. Lesions located in vein grafts and restenotic lesions 
were excluded. The end points analyzed were MACE and per lesion TVR and TLR.
Results: 105 lesions in 97 patients were treated with paclitaxel-eluting stents (PES) and 
111 lesions in 107 patients underwent sirolimus-eluting stent (SES) implantation. The 
two groups were well matched for clinical and lesion characteristics. Angiographic follow 
up was available in 76.3% of the PES group and 73.8% of the SES group (p=0.75). Both 
angiographic restenosis and reocclusion rates were comparable in the two groups: 23.5% 
in PES vs 24.3% in SES (p=1.0) and 7.5% vs 6% (p=0.84) respectively. Angiographic late 
loss was 0.68±1.35 vs 0.47±1.12 (p=0.36). During a median follow up of 11.7 months 
there were a total of 3 deaths, 2 in PES both non cardiac and 1 from a cardiac arrest in the 
SES group (p=0.61). Myocardial infarction occurred in 3 PES patients and 1 SES patient 
(p=0.35). Nineteen lesions (18.1%) underwent a TVR in the PES cohort and 19 (17.1%) 
in SES (p=0.86). Similarly there was no difference in the occurrence of TLR, 15 (14.3%) 
and 16 (14.4%) respectively (p=1).
Conclusions: DES implantation in CTO is safe and associated with favorable results 
when compared to historical data on bare metal stents. When comparing the two currently 
available DES platforms there are no signiﬁcant differences in the clinical outcomes.
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